[
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "mRNA-1273",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinicaltrials@modernatx.com",
        "name": null,
        "notes": "The study will start enrolling July 27th",
        "phone": "855-663-6762",
        "website": "https://www.coronaviruspreventionnetwork.org/clinical-study-volunteer/"
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 13 Jan 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 04 Mar 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 29 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 11 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "mRNA-based vaccine",
    "numSites": "87",
    "otherPartners": "CEPI,Lonza,BARDA",
    "phase": "3",
    "preferredName": "mRNA-1273",
    "primaryCompletionDate": "Thu, 27 Oct 2022 00:00:00 GMT",
    "productId": 1,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Savannah",
        "country": "USA",
        "lat": 32.0090943,
        "lng": -81.1066159,
        "locationId": "0e441452ead57648ac481688c5cd44edc095bb45",
        "name": "340 Eisenhower Dr Suite #1200, Savannah, GA 31406, USA",
        "state": "GA"
      },
      {
        "city": "Norfolk",
        "country": "USA",
        "lat": 42.0488645,
        "lng": -97.4258863,
        "locationId": "d466b5f1fe0f657d40ebf0eb5275c6694c1f2164",
        "name": "1410 N 13th St, Norfolk, NE 68701, USA",
        "state": "NE"
      },
      {
        "city": "Omaha",
        "country": "USA",
        "lat": 41.289367,
        "lng": -96.079509,
        "locationId": "1eede35428e6723220156cc69a69d61271f47e10",
        "name": "3319 N 107th St, Omaha, NE 68134, USA",
        "state": "NE"
      },
      {
        "city": "Omaha",
        "country": "USA",
        "lat": 41.289367,
        "lng": -96.079509,
        "locationId": "f29b07b1d0c04688b27c2f284a9c449cb808515c",
        "name": "3319 N 107th St, Omaha, NE 68134, USA",
        "state": "NE"
      },
      {
        "city": "Dakota Dunes",
        "country": "USA",
        "lat": 42.5024172,
        "lng": -96.4935587,
        "locationId": "7e1b2e9f3900fd562aeecd77fa6d593010221b92",
        "name": "330 Dakota Dunes Blvd #400, Dakota Dunes, SD 57049, USA",
        "state": "SD"
      },
      {
        "city": "Wilmington",
        "country": "USA",
        "lat": 34.2033756,
        "lng": -77.9272178,
        "locationId": "1e6e4acc9d6acb406be2fc787308a1eb43cf8978",
        "name": "1442 Military Cutoff Rd Suite 30, Wilmington, NC 28403, USA",
        "state": "NC"
      },
      {
        "city": "Austin",
        "country": "USA",
        "lat": 30.290713,
        "lng": -97.72794139999999,
        "locationId": "04c0ffc088140eea36154e6ca668cb9c2754b26b",
        "name": "3100 Red River St #1, Austin, TX 78705, USA",
        "state": "TX"
      },
      {
        "city": "San Angelo",
        "country": "USA",
        "lat": 31.4165254,
        "lng": -100.4703926,
        "locationId": "ec609e00c75d088ad12a9bea7150adb8b530fce1",
        "name": "3605 Executive Dr, San Angelo, TX 76904, USA",
        "state": "TX"
      },
      {
        "city": "Fort Worth",
        "country": "USA",
        "lat": 32.8222237,
        "lng": -97.4190954,
        "locationId": "5a669513d2cb1193996cc2fa7705555a95e692c6",
        "name": "4504 Boat Club Rd #400a, Fort Worth, TX 76135, USA",
        "state": "TX"
      },
      {
        "city": "Birmingham",
        "country": "USA",
        "lat": 33.5076708,
        "lng": -86.7883292,
        "locationId": "6d685ab5c5e365e271832f3cfd64e37935348888",
        "name": "810 St Vincents Dr, Birmingham, AL 35205, USA",
        "state": "AL"
      },
      {
        "city": "Phoenix",
        "country": "USA",
        "lat": 33.5108568,
        "lng": -111.9975147,
        "locationId": "d33e6d3e0f5407398c7ce503541afb61a3c1c2f8",
        "name": "3900 E Camelback Rd # 125, Phoenix, AZ 85018, USA",
        "state": "AZ"
      },
      {
        "city": "Peoria",
        "country": "USA",
        "lat": 33.609154,
        "lng": -112.2614705,
        "locationId": "99a1d1c1f7c69f8e8a4c533da86f8042b5cae0c2",
        "name": "9401 W Thunderbird Rd, Peoria, AZ 85381, USA",
        "state": "AZ"
      },
      {
        "city": "Phoenix",
        "country": "USA",
        "lat": 33.5108568,
        "lng": -111.9975147,
        "locationId": "63017a1accba017da5a012239b219e7a7c67caf5",
        "name": "3900 E Camelback Rd # 125, Phoenix, AZ 85018, USA",
        "state": "AZ"
      },
      {
        "city": "Tucson",
        "country": "USA",
        "lat": 32.2491286,
        "lng": -110.8777838,
        "locationId": "f2d52c6721f6dd16cb60ca81a1bf4a9889b42e53",
        "name": "5390 E Erickson Dr, Tucson, AZ 85712, USA",
        "state": "AZ"
      },
      {
        "city": "Little Rock",
        "country": "USA",
        "lat": 34.7453286,
        "lng": -92.3816214,
        "locationId": "787fe64c810cdc2f7e1a04d7fdb20e55b4061bee",
        "name": "9601 Baptist Health Dr suite 310, Little Rock, AR 72205, USA",
        "state": "AR"
      },
      {
        "city": "Banning",
        "country": "USA",
        "lat": 33.9305885,
        "lng": -116.9454506,
        "locationId": "7e23523cefb22c900a98f5c56ae08e821969ac47",
        "name": "264 N Highland Springs Ave #4, Banning, CA 92220, USA",
        "state": "CA"
      },
      {
        "city": "La Jolla",
        "country": "USA",
        "lat": 32.8800604,
        "lng": -117.2340135,
        "locationId": "91ac1b6ffe33ec524782b98b9af1c0025a7f26b0",
        "name": "9500 Gilman Dr, La Jolla, CA 92093, USA",
        "state": "CA"
      },
      {
        "city": "La Mesa",
        "country": "USA",
        "lat": 32.7804422,
        "lng": -117.0094774,
        "locationId": "fe803739d933f174ccd032599e1fff283f22d4df",
        "name": "5565 Grossmont Center Dr building 2 suite, La Mesa, CA 91942, USA",
        "state": "CA"
      },
      {
        "city": "Los Angeles",
        "country": "USA",
        "lat": 34.0875048,
        "lng": -118.3261271,
        "locationId": "9469a2d752864f29da1bd57f421ffa1be54d1814",
        "name": "910 Vine St, Los Angeles, CA 90038, USA",
        "state": "CA"
      },
      {
        "city": "Redding",
        "country": "USA",
        "lat": 40.5843387,
        "lng": -122.4255441,
        "locationId": "9bd8ed478b4c71f83c5e258acb2242053b6f393d",
        "name": "3652 Eureka Way, Redding, CA 96001, USA",
        "state": "CA"
      },
      {
        "city": "Sacramento",
        "country": "USA",
        "lat": 38.5965254,
        "lng": -121.3629186,
        "locationId": "cc36fb02fe9a5f4e097ec3915ffd65cb11e65099",
        "name": "4345 Arden Way, Sacramento, CA 95864, USA",
        "state": "CA"
      },
      {
        "city": "San Diego",
        "country": "USA",
        "lat": 32.779466,
        "lng": -117.135437,
        "locationId": "6c4cdc13c104b942544338197cb8e481a0165462",
        "name": "9040 Friars Rd Suite #540, San Diego, CA 92108, USA",
        "state": "CA"
      },
      {
        "city": "Aurora",
        "country": "USA",
        "lat": 39.7419295,
        "lng": -104.8411592,
        "locationId": "10840bd5db8192e1635ff5c4364e1c8463320c82",
        "name": "12605 E 16th Ave, Aurora, CO 80045, USA",
        "state": "CO"
      },
      {
        "city": "Colorado Springs",
        "country": "USA",
        "lat": 38.9257493,
        "lng": -104.7727594,
        "locationId": "141b833a1166126706e29c25fb257ded81404d93",
        "name": "2855 Dublin Blvd, Colorado Springs, CO 80918, USA",
        "state": "CO"
      },
      {
        "city": "Washington",
        "country": "USA",
        "lat": 38.8997145,
        "lng": -77.0485992,
        "locationId": "57deda10ce121700ce30dec0acb81e0614c31389",
        "name": "2121 I St NW, Washington, DC 20052, USA",
        "state": "DC"
      },
      {
        "city": "DeLand",
        "country": "USA",
        "lat": 29.0446615,
        "lng": -81.31497069999999,
        "locationId": "b4ffbaf7a009b29eb83e07433dbe6a240a427803",
        "name": "860 Peachwood Dr, DeLand, FL 32720, USA",
        "state": "FL"
      },
      {
        "city": "Hollywood",
        "country": "USA",
        "lat": 26.03195,
        "lng": -80.23431,
        "locationId": "c2772cbb5573a13a48fccbae3a1c10ae08f7af34",
        "name": "7261 Sheridan St #210, Hollywood, FL 33024, USA",
        "state": "FL"
      },
      {
        "city": "Jacksonville",
        "country": "USA",
        "lat": 30.282953,
        "lng": -81.601697,
        "locationId": "03617a7412ebeb64a85821d476cdb0926cc247f3",
        "name": "4085 University Blvd S #1, Jacksonville, FL 32216, USA",
        "state": "FL"
      },
      {
        "city": "Miami",
        "country": "USA",
        "lat": 25.7725061,
        "lng": -80.2298857,
        "locationId": "da9c58e7e84b20f5a7f375c3807d115de5f0f2ea",
        "name": "2128 W Flagler St # 201, Miami, FL 33135, USA",
        "state": "FL"
      },
      {
        "city": "Coral Gables",
        "country": "USA",
        "lat": 25.7178924,
        "lng": -80.2746368,
        "locationId": "32e53a3e65ab0418321960db747a4e2959853d5c",
        "name": "1320 S Dixie Hwy, Coral Gables, FL 33146, USA",
        "state": "FL"
      },
      {
        "city": "West Palm Beach",
        "country": "USA",
        "lat": 26.709321,
        "lng": -80.098945,
        "locationId": "74eb9073bd325dfc09a0ca452df21520ec05385e",
        "name": "2277 Palm Beach Lakes Blvd, West Palm Beach, FL 33409, USA",
        "state": "FL"
      },
      {
        "city": "Atlanta",
        "country": "USA",
        "lat": 33.751785,
        "lng": -84.3820071,
        "locationId": "796f4e4e2e2f476fa5cf9a3ad8613f73f52dea01",
        "name": "80 Jesse Hill Jr Dr SE, Atlanta, GA 30303, USA",
        "state": "GA"
      },
      {
        "city": "Atlanta",
        "country": "USA",
        "lat": 33.7934917,
        "lng": -84.3195325,
        "locationId": "45c1b0521e70dd033bf48a31810ce939a4138f5c",
        "name": "1405 Clifton Rd, Atlanta, GA 30322, USA",
        "state": "GA"
      },
      {
        "city": "Atlanta",
        "country": "USA",
        "lat": 33.803532,
        "lng": -84.318361,
        "locationId": "92ce03694c782cd165ce37ce7c5d3ef47302f8eb",
        "name": "33\u00b048'12. 84\u00b019'06., 7 1st Ave, Atlanta, GA 30317, USA",
        "state": "GA"
      },
      {
        "city": "Savannah",
        "country": "USA",
        "lat": 32.0090943,
        "lng": -81.1066159,
        "locationId": "ab3a3690d84604e2362b14350fac33fe57d9dd0d",
        "name": "340 Eisenhower Dr Suite #1200, Savannah, GA 31406, USA",
        "state": "GA"
      },
      {
        "city": "Stockbridge",
        "country": "USA",
        "lat": 33.5055533,
        "lng": -84.2252365,
        "locationId": "288c0a787e33524a88888e90de1992aaa214cf9d",
        "name": "175 Country Club Dr # 100A, Stockbridge, GA 30281, USA",
        "state": "GA"
      },
      {
        "city": "Chicago",
        "country": "USA",
        "lat": 41.8711357,
        "lng": -87.67169349999999,
        "locationId": "d2c22e9d5a5987b70499b70e34473442cfaea702",
        "name": "840 S Wood St, Chicago, IL 60612, USA",
        "state": "IL"
      },
      {
        "city": "Lenexa",
        "country": "USA",
        "lat": 38.9278708,
        "lng": -94.7750937,
        "locationId": "d40288722df62a3230875cc073d3c69e09f4829f",
        "name": "16300 College Blvd, Lenexa, KS 66219, USA",
        "state": "KS"
      },
      {
        "city": "Newton",
        "country": "USA",
        "lat": 38.0231753,
        "lng": -97.33389659999999,
        "locationId": "9bc3132e9c691ed7be070a5bb8b85a79188ef1a5",
        "name": "700 Medical Center Dr STE 210, Newton, KS 67114, USA",
        "state": "KS"
      },
      {
        "city": "Wichita",
        "country": "USA",
        "lat": 37.6619807,
        "lng": -97.2451316,
        "locationId": "45f6d6a9003499a1b19b9bb8623a4184f124edf7",
        "name": "1709 S Rock Rd, Wichita, KS 67207, USA",
        "state": "KS"
      },
      {
        "city": "Baton Rouge",
        "country": "USA",
        "lat": 30.4028557,
        "lng": -91.11409370000001,
        "locationId": "f74bf4a06ed2161a8a75391132e4b7d1bb11391d",
        "name": "5326 O'Donovan Dr, Baton Rouge, LA 70808, USA",
        "state": "LA"
      },
      {
        "city": "Metairie",
        "country": "USA",
        "lat": 30.0055977,
        "lng": -90.1843475,
        "locationId": "2c6eec9afb4f0db2321b2b237cbb6fa42501ce83",
        "name": "4517 Veterans Blvd, Metairie, LA 70006, USA",
        "state": "LA"
      },
      {
        "city": "Baltimore",
        "country": "USA",
        "lat": 39.2889604,
        "lng": -76.625715,
        "locationId": "dcd0f3772d6fec8a4b8c1b889268a75a78db8b60",
        "name": "655 W Baltimore St S, Baltimore, MD 21201, USA",
        "state": "MD"
      },
      {
        "city": "Rockville",
        "country": "USA",
        "lat": 39.0642542,
        "lng": -77.1601101,
        "locationId": "dce9e385f21236c5d0258b3a65b017ee659a635e",
        "name": "1201 Seven Locks Rd ste 101, Rockville, MD 20854, USA",
        "state": "MD"
      },
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3361091,
        "lng": -71.1074884,
        "locationId": "8b290d5cafca06931709a6f1713c4d07c0495ffd",
        "name": "75 Francis St, Boston, MA 02115, USA",
        "state": "MA"
      },
      {
        "city": "Detroit",
        "country": "USA",
        "lat": 42.3635022,
        "lng": -83.07581019999999,
        "locationId": "ec71c4ce224c923ca8350fe0686ddef714e31d85",
        "name": "1 Ford Pl, Detroit, MI 48202, USA",
        "state": "MI"
      },
      {
        "city": "Petal",
        "country": "USA",
        "lat": 31.3482091,
        "lng": -89.2541821,
        "locationId": "49010cbfa2590b229d98997414e0e8a02a4ceb54",
        "name": "206 Old Corinth Rd, Petal, MS 39465, USA",
        "state": "MS"
      },
      {
        "city": "St. Louis",
        "country": "USA",
        "lat": 38.6346955,
        "lng": -90.23405869999999,
        "locationId": "4aede01e3407692e7b19d7c70c156f74bd81f335",
        "name": "1 N Grand Blvd, St. Louis, MO 63103, USA",
        "state": "MO"
      },
      {
        "city": "St. Louis",
        "country": "USA",
        "lat": 38.6685688,
        "lng": -90.4389032,
        "locationId": "2b96d0f7211025823a1c8eff00982e199b6c91be",
        "name": "711 Old Ballas Rd # 105, St. Louis, MO 63141, USA",
        "state": "MO"
      },
      {
        "city": "Las Vegas",
        "country": "USA",
        "lat": 36.145174,
        "lng": -115.140671,
        "locationId": "ade2d326304dd01bb6a3ff0ffcfaae1640c224e2",
        "name": "1012 E Sahara Ave, Las Vegas, NV 89104, USA",
        "state": "NV"
      },
      {
        "city": "Las Vegas",
        "country": "USA",
        "lat": 36.1155615,
        "lng": -115.1228613,
        "locationId": "ffe2556c4af800ae273d25646977a72f65f565a5",
        "name": "2110 E Flamingo Rd Suite 103, Las Vegas, NV 89119, USA",
        "state": "NV"
      },
      {
        "city": "Hackensack",
        "country": "USA",
        "lat": 40.8840343,
        "lng": -74.05648819999999,
        "locationId": "32dda84f004d57a83a5b8ebf7ff60ffd948cb591",
        "name": "30 Prospect Ave, Hackensack, NJ 07601, USA",
        "state": "NJ"
      },
      {
        "city": "Newark",
        "country": "USA",
        "lat": 40.7400804,
        "lng": -74.189656,
        "locationId": "a863facef4a253d55aee1d920912ad3e3c52ea5c",
        "name": "185 S Orange Ave, Newark, NJ 07103, USA",
        "state": "NJ"
      },
      {
        "city": "Omaha",
        "country": "USA",
        "lat": 41.289367,
        "lng": -96.079509,
        "locationId": "c9b691ca802b6e4850394f346d8ee34f2002f94c",
        "name": "3319 N 107th St, Omaha, NE 68134, USA",
        "state": "NE"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7441606,
        "lng": -73.9932413,
        "locationId": "c78794fbd18b3e13f16667e0898a56b5b17bbcf6",
        "name": "119 W 24th St, New York, NY 10011, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7649151,
        "lng": -73.954897,
        "locationId": "befb2e039916d6c976fd5ee4d460983c53614722",
        "name": "1300 York Ave, New York, NY 10065, USA",
        "state": "NY"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 35.9049122,
        "lng": -79.0469134,
        "locationId": "62ddcfb5e17251b678c91f5f1488909c9da7ab33",
        "name": "Chapel Hill, NC, USA",
        "state": "NC"
      },
      {
        "city": "Charlotte",
        "country": "USA",
        "lat": 35.1483788,
        "lng": -80.8406333,
        "locationId": "a54dc8894f4418cf2983b189726d82bf90da90c6",
        "name": "6060 Piedmont Row Dr S, Charlotte, NC 28210, USA",
        "state": "NC"
      },
      {
        "city": "Fayetteville",
        "country": "USA",
        "lat": 35.0291834,
        "lng": -78.9239623,
        "locationId": "7e8bbcace3c02484ac7a2927fa73ec09556b6a94",
        "name": "1841 Quiet Cove Suite 2, Fayetteville, NC 28304, USA",
        "state": "NC"
      },
      {
        "city": "Raleigh",
        "country": "USA",
        "lat": 35.8238254,
        "lng": -78.70605359999999,
        "locationId": "1fbc59b66b78609e3943dda32ff39da84fb15c5d",
        "name": "3100 Duraleigh Rd #304, Raleigh, NC 27612, USA",
        "state": "NC"
      },
      {
        "city": "Winston-Salem",
        "country": "USA",
        "lat": 36.1002069,
        "lng": -80.2399434,
        "locationId": "92bbdd00dd8e69685ac99296c01f513014d5a20f",
        "name": "Bowman Gray Center for Medical Education, 475 Vine St, Winston-Salem, NC 27101, USA",
        "state": "NC"
      },
      {
        "city": "Cincinnati",
        "country": "USA",
        "lat": 39.2261454,
        "lng": -84.3798238,
        "locationId": "360fad23f09c380bb39fabf327a231eb6095298a",
        "name": "9395 Kenwood Rd UNIT 101, Cincinnati, OH 45242, USA",
        "state": "OH"
      },
      {
        "city": "Cincinnati",
        "country": "USA",
        "lat": 39.1041997,
        "lng": -84.5191878,
        "locationId": "3e2e97f39510b6583aac40a861e8957a51d178aa",
        "name": "801 Plum St # 240, Cincinnati, OH 45202, USA",
        "state": "OH"
      },
      {
        "city": "Beachwood",
        "country": "USA",
        "lat": 41.4618221,
        "lng": -81.49290169999999,
        "locationId": "8a039a8bf6c35ffc0e1b00f1ac1683f5751db53e",
        "name": "3619 Park E Dr, Beachwood, OH 44122, USA",
        "state": "OH"
      },
      {
        "city": "Oklahoma City",
        "country": "USA",
        "lat": 35.5305938,
        "lng": -97.58305449999999,
        "locationId": "07b9c91c9cc1ed20f4f29a9415608d4e6b4d080b",
        "name": "3555 NW 58th St # 800, Oklahoma City, OK 73112, USA",
        "state": "OK"
      },
      {
        "city": "Medford",
        "country": "USA",
        "lat": 42.3722258,
        "lng": -122.8548778,
        "locationId": "f9907031fb9fc5e163ab60e4b36a059e686f67db",
        "name": "3860 Crater Lake Ave, Medford, OR 97504, USA",
        "state": "OR"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9522188,
        "lng": -75.1932137,
        "locationId": "9ccd038dd564f1dbcd7855fb6af6148cb5c739a7",
        "name": "Philadelphia, PA 19104, USA",
        "state": "PA"
      },
      {
        "city": "Pittsburgh",
        "country": "USA",
        "lat": 40.446151,
        "lng": -79.95465279999999,
        "locationId": "10e02ad0d2e7c16dd33e9916197ba0ba8b82b2bf",
        "name": "120 Lytton Ave, Pittsburgh, PA 15213, USA",
        "state": "PA"
      },
      {
        "city": "Greenville",
        "country": "USA",
        "lat": 34.8450053,
        "lng": -82.39984489999999,
        "locationId": "db7553fbdc0c0f674a4bb0b1e0b76b300b9e9bbb",
        "name": "55 E Camperdown Way, Greenville, SC 29601, USA",
        "state": "SC"
      },
      {
        "city": "Greenville",
        "country": "USA",
        "lat": 34.8450053,
        "lng": -82.39984489999999,
        "locationId": "c94a020d1f0d34a0930ed103ce70ea67d196b189",
        "name": "55 E Camperdown Way, Greenville, SC 29601, USA",
        "state": "SC"
      },
      {
        "city": "Mt Pleasant",
        "country": "USA",
        "lat": 32.8098126,
        "lng": -79.8505758,
        "locationId": "d3640db2bf3e691578f0434ca0c4fbe4e5c678d3",
        "name": "1156 Bowman Rd #102, Mt Pleasant, SC 29464, USA",
        "state": "SC"
      },
      {
        "city": "Spartanburg",
        "country": "USA",
        "lat": 34.9495672,
        "lng": -81.9320482,
        "locationId": "958058e33bb2342bf99ae779b5f3020c92734ed1",
        "name": "Spartanburg, SC, USA",
        "state": "SC"
      },
      {
        "city": "Chattanooga",
        "country": "USA",
        "lat": 35.0534759,
        "lng": -85.1822423,
        "locationId": "0d3d6ec3841736d3a3e90b011f4a032a6247a0bf",
        "name": "6035 Shallowford Rd Suite #109, Chattanooga, TN 37421, USA",
        "state": "TN"
      },
      {
        "city": "Knoxville",
        "country": "USA",
        "lat": 35.93967689999999,
        "lng": -83.9443699,
        "locationId": "73f5c90fd355b0e312dce398d993b2a51ef3585e",
        "name": "1928 Alcoa Hwy, Knoxville, TN 37920, USA",
        "state": "TN"
      },
      {
        "city": "Nashville",
        "country": "USA",
        "lat": 36.1425227,
        "lng": -86.80140089999999,
        "locationId": "1c8d6f7da05f2020286cdd06473e287aab17f920",
        "name": "1211 Medical Center Dr, Nashville, TN 37232, USA",
        "state": "TN"
      },
      {
        "city": "Austin",
        "country": "USA",
        "lat": 30.230871,
        "lng": -97.802988,
        "locationId": "881a897ff93526d661411dd1c5ff8b6010bd0474",
        "name": "4534 West Gate Blvd #110, Austin, TX 78745, USA",
        "state": "TX"
      },
      {
        "city": "Cedar Park",
        "country": "USA",
        "lat": 30.4805136,
        "lng": -97.8272944,
        "locationId": "8c3fe384c3656b2f9ab5ff03fa3f5f635ae5dc4d",
        "name": "1905 S Lakeline Blvd #4, Cedar Park, TX 78613, USA",
        "state": "TX"
      },
      {
        "city": "DeSoto",
        "country": "USA",
        "lat": 32.645854,
        "lng": -96.880297,
        "locationId": "aebf6a118ac93adcccfbcfcf751058aecf52e39d",
        "name": "951 York Dr Ste 102, DeSoto, TX 75115, USA",
        "state": "TX"
      },
      {
        "city": "Galveston",
        "country": "USA",
        "lat": 29.3113238,
        "lng": -94.7781311,
        "locationId": "0ab82faa875c52270204e2cd7b5f49aeb41978db",
        "name": "301 University Blvd, Galveston, TX 77555, USA",
        "state": "TX"
      },
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.71052959999999,
        "lng": -95.39649899999999,
        "locationId": "924f488ee9bb0411da2899e19fd86945deaded61",
        "name": "1 Baylor Plaza, Houston, TX 77030, USA",
        "state": "TX"
      },
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.7098598,
        "lng": -95.4746682,
        "locationId": "61f3761f93e2b60dbfec63faa61524da98e9c032",
        "name": "6550 Mapleridge St #201, Houston, TX 77081, USA",
        "state": "TX"
      },
      {
        "city": "Laredo",
        "country": "USA",
        "lat": 27.5772352,
        "lng": -99.4625281,
        "locationId": "4a35e2046730bac9e7397bb3bc273de387f1ec89",
        "name": "2344 Laguna Del Mar Ct Ste 104, Laredo, TX 78041, USA",
        "state": "TX"
      },
      {
        "city": "McAllen",
        "country": "USA",
        "lat": 26.2506973,
        "lng": -98.22294169999999,
        "locationId": "80b5c3b254db73e419e4b05dd577efa0a1c3db49",
        "name": "1020 Zinnia Ave, McAllen, TX 78504, USA",
        "state": "TX"
      },
      {
        "city": "San Antonio",
        "country": "USA",
        "lat": 29.5073566,
        "lng": -98.56287379999999,
        "locationId": "05bdf6dbcff5912d503cdcc5f3938af946e63366",
        "name": "5430 Fredericksburg Rd Ste 200, San Antonio, TX 78229, USA",
        "state": "TX"
      },
      {
        "city": "Tomball",
        "country": "USA",
        "lat": 30.0849793,
        "lng": -95.6235351,
        "locationId": "a28429e9c25ae43998130a026a3dee62661e5d0d",
        "name": "13406 Medical Complex Dr Suite 53, Tomball, TX 77375, USA",
        "state": "TX"
      },
      {
        "city": "Salt Lake City",
        "country": "USA",
        "lat": 40.7216458,
        "lng": -111.8112585,
        "locationId": "723738a9ad48579840821ebdf69e7e8df7b89829",
        "name": "2295 S, Foothill Dr, Salt Lake City, UT 84109, USA",
        "state": "UT"
      },
      {
        "city": "Salt Lake City",
        "country": "USA",
        "lat": 40.6339676,
        "lng": -111.8067275,
        "locationId": "66bfb9f46a263919cdd56ccbca71bcbb87ad0b3f",
        "name": "6360 S 3000 E STE 100, Salt Lake City, UT 84121, USA",
        "state": "UT"
      },
      {
        "city": "Seattle",
        "country": "USA",
        "lat": 47.6193665,
        "lng": -122.3125725,
        "locationId": "4c8bd80282206004bdefba36f7d0056ce81b89a8",
        "name": "201 16th Ave E, Seattle, WA 98112, USA",
        "state": "WA"
      }
    ],
    "sources": [
      "https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins",
      "https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19",
      "https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "375ad6c4b12a03acefcf5e9b052423279351910a",
        "sponsorName": "Moderna"
      },
      {
        "sponsorId": "69301ed353817a1eb80b77b32f82e5809965a871",
        "sponsorName": "National Institute of Allergy and Infectious Diseases"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 27 Oct 2022 00:00:00 GMT",
    "studyStartDate": "Mon, 27 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "NVX-CoV2373",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "B.Georgievska@nucleusnetwork.com.au",
        "name": null,
        "notes": "",
        "phone": "61 3 8593 9817",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 25 May 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "not totally clear that it is prophylactic vaccine. P1 expected late spring,Trial is technically Phase I/II but they have only started phase 1 work",
    "numSites": "2",
    "otherPartners": "CEPI",
    "phase": "1",
    "preferredName": "Novavax Vaccine",
    "primaryCompletionDate": "",
    "productId": 2,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04368988",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Herston",
        "country": "AUS",
        "lat": -27.4451489,
        "lng": 153.0206887,
        "locationId": "4fac02fa508178636dd7d897f43ef70935b72739",
        "name": "Herston QLD 4006, Australia",
        "state": "QLD"
      },
      {
        "city": "Melbourne",
        "country": "AUS",
        "lat": -37.8136276,
        "lng": 144.9630576,
        "locationId": "a9fb13011c3b3c952657a6257446535844feb4b9",
        "name": "Melbourne VIC, Australia",
        "state": "VIC"
      }
    ],
    "sources": [
      "https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=",
      "http://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine",
      "https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development",
      "https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "605f6647f1bdd3849bac0626225a6effc774a373",
        "sponsorName": "Novavax Inc"
      },
      {
        "sponsorId": "f4d20a236175ba7e1926d1e68974b9e499bd94ed",
        "sponsorName": "Emergent BioSolutions Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 31 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 25 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "BNT-162,BNT162a1,BNT162b1,BNT162b2,BNT162c2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 23 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 23 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Expect clinical testing in late april. Note this drug is also being developed in china with fosun pharma. Assumed this is in discovery as no explicit statements aboit preclinical found",
    "numSites": "",
    "otherPartners": "Polymun",
    "phase": "",
    "preferredName": "BNT162",
    "primaryCompletionDate": "",
    "productId": 3,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine",
      "https://biontech.de/",
      "https://www.fiercebiotech.com/biotech/weeks-to-go-to-covid-19-vaccine-trial-biontech-lands-135m-deal-and-advances-pfizer-talks",
      "https://clinicaltrials.gov/ct2/show/NCT04380701",
      "https://biontech.de/node/159"
    ],
    "sponsors": [
      {
        "sponsorId": "7c4d34cd18acefd9b97f8b918fe356fec61f94d6",
        "sponsorName": "Pfizer Inc"
      },
      {
        "sponsorId": "633c14412c5bdb1e419eeef95aef4fe8eb93e2a1",
        "sponsorName": "BioNTech SE"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "LNP-nCoVsaRNA",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "covactrials@imperial.ac.uk",
        "name": null,
        "notes": "",
        "phone": "",
        "website": "https://www.imperial.ac.uk/covid-19-vaccine-trial/participants-info/"
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 23 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Expect clinical testing in summer",
    "numSites": "1",
    "otherPartners": "Maravai Lifesciences Inc.,Trilink Biotechnologies Inc.",
    "phase": "1/2",
    "preferredName": "Imperial College London Vaccine",
    "primaryCompletionDate": "",
    "productId": 4,
    "registryLink": "http://www.isrctn.com/ISRCTN17072692",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "GBR",
        "lat": 51.49879970000001,
        "lng": -0.1748772,
        "locationId": "da013c4395007eda32ac7bd3e52922898fb57a8d",
        "name": "South Kensington, London SW7 2BU, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/",
      "https://www.imperial.ac.uk/news/198533/first-volunteers-receive-imperial-covid-19-vaccine/",
      "https://www.imperial.ac.uk/covid-19-vaccine-trial/"
    ],
    "sponsors": [
      {
        "sponsorId": "1a693dd5acf9f3ae07a65241da0b2f2102ed1377",
        "sponsorName": "Imperial College London"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 23 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "INO-4800,CELLECTRA\u00ae 20000",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Anh.Wartel@ivi.int; clinical.trials@inovio.com",
        "name": null,
        "notes": "",
        "phone": "82 2 881 1274",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 03 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 22 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 23 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "2",
    "otherPartners": "US DoD,Bill and Melinda Gates Foundation,Coalition for Epidemic Prepardness Innovations Funding",
    "phase": "1/2a",
    "preferredName": "INO-4800",
    "primaryCompletionDate": "Tue, 22 Feb 2022 00:00:00 GMT",
    "productId": 5,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04447781",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "KOR",
        "lat": 37.57870820000001,
        "lng": 126.9975506,
        "locationId": "0fe89efab05a8d34b6e6d0bdf3ed8ee0bbd9198c",
        "name": "South Korea, Seoul, Jongno-gu, Ihwa-dong, \ub300\ud559\ub85c 101",
        "state": "Seoul"
      },
      {
        "city": "Seongnam-si",
        "country": "KOR",
        "lat": 37.3520673,
        "lng": 127.1231772,
        "locationId": "d0733ef2cdfa148dbd2203d450a663c99d0b5262",
        "name": "South Korea, Gyeonggi-do, Seongnam-si, Bundang-gu, Jeongja-dong, Gumi-ro 173(baekchilsipsam)beo, 82 KR",
        "state": "Gyeonggi-do"
      }
    ],
    "sources": [
      "https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine",
      "https://clinicaltrials.gov/ct2/show/NCT04336410"
    ],
    "sponsors": [
      {
        "sponsorId": "a28cb988e230163b5e185750856269de4f3cd2eb",
        "sponsorName": "Inovio Pharmaceuticals Inc"
      },
      {
        "sponsorId": "2534fc505ec4a7e9f4871746ebd7fe5a84b18af8",
        "sponsorName": "Beijing Advaccine Biotechnology"
      },
      {
        "sponsorId": "09820e27323251c097da890722d6b1060e453555",
        "sponsorName": "US Department of Defense"
      },
      {
        "sponsorId": "8b02e4cb59e0603882788f6b09eece49a6f530e2",
        "sponsorName": "Ology Bioservices Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 22 Feb 2022 00:00:00 GMT",
    "studyStartDate": "Mon, 22 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Ad26.COV2-S,Ad26 SARS-CoV-2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Gene therapies",
    "notes": "Expect clinical testing no later than fall 2020",
    "numSites": "",
    "otherPartners": "BARDA",
    "phase": "",
    "preferredName": "Ad26 SARS-CoV-2",
    "primaryCompletionDate": "",
    "productId": 6,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html",
      "https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/",
      "https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push"
    ],
    "sponsors": [
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      },
      {
        "sponsorId": "75dac04b368bcbb069fe03277a3ace5533a8d1cb",
        "sponsorName": "Jansssen Pharmaceutical"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Recombinant vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 18 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "they are repurposing vaccines that have been preclinically tested for SARS - hence I have put the current status as preclinical,No plans for a phase I trial until July at the earliest",
    "numSites": "",
    "otherPartners": "BARDA",
    "phase": "",
    "preferredName": "Sanofi Vaccine",
    "primaryCompletionDate": "",
    "productId": 7,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine",
      "https://www.google.com/search?q=sanofi+pasteur+headquarters&rlz=1C5CHFA_enGB854GB854&oq=sanofi+pastuer+head&aqs=chrome.1.69i57j0l7.7080j1j9&sourceid=chrome&ie=UTF-8",
      "https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00"
    ],
    "sponsors": [
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      },
      {
        "sponsorId": "b0667c7bd3f77f09b501f5439a15d5af327ec17f",
        "sponsorName": "GSK"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "REGN-COV2,REGN10933+REGN10987",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "COVID19SiteInterest@regeneron.com",
        "name": null,
        "notes": "",
        "phone": "844-734-6643",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 16 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 16 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 16 Jun 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 04 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "25",
    "otherPartners": "",
    "phase": "1/2/3",
    "preferredName": "Regeneron Therapeutic",
    "primaryCompletionDate": "Wed, 25 Nov 2020 00:00:00 GMT",
    "productId": 8,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04425629",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Chandler",
        "country": "USA",
        "lat": 33.3061605,
        "lng": -111.8412502,
        "locationId": "7d6e9c97cf06bcdc5a5742cf207960d7532b88e5",
        "name": "Chandler, AZ, USA",
        "state": "AZ"
      },
      {
        "city": "Tucson",
        "country": "USA",
        "lat": 32.2226066,
        "lng": -110.9747108,
        "locationId": "007709a71990db2befb2006df983e687be9b2f38",
        "name": "Tucson, AZ, USA",
        "state": "AZ"
      },
      {
        "city": "Long Beach",
        "country": "USA",
        "lat": 33.7700504,
        "lng": -118.1937395,
        "locationId": "e938da3981121c60b09cdcc3f4105ffeb2bda89f",
        "name": "Long Beach, CA, USA",
        "state": "CA"
      },
      {
        "city": "Santa Monica",
        "country": "USA",
        "lat": 34.0194543,
        "lng": -118.4911912,
        "locationId": "db84a661b43445fd8968450bfac3786f5a87e3f6",
        "name": "Santa Monica, CA, USA",
        "state": "CA"
      },
      {
        "city": "Aurora",
        "country": "USA",
        "lat": 39.7294319,
        "lng": -104.8319195,
        "locationId": "44bf2625f83c438a88832f58abe6b384adc61533",
        "name": "Aurora, CO, USA",
        "state": "CO"
      },
      {
        "city": "Washington",
        "country": "USA",
        "lat": 38.9071923,
        "lng": -77.0368707,
        "locationId": "202f42fdd9a9350f555f4e4ccf105ec153405ec2",
        "name": "Washington, DC, USA",
        "state": "DC"
      },
      {
        "city": "DeLand",
        "country": "USA",
        "lat": 29.028318,
        "lng": -81.3031179,
        "locationId": "ed5778430f0ef1c7285cd58244be5748380b2dfa",
        "name": "DeLand, FL, USA",
        "state": "FL"
      },
      {
        "city": "Fort Pierce",
        "country": "USA",
        "lat": 27.4467056,
        "lng": -80.3256056,
        "locationId": "7c9289323cbd396507969efca3843be716a69139",
        "name": "Fort Pierce, FL, USA",
        "state": "FL"
      },
      {
        "city": "Miami",
        "country": "USA",
        "lat": 25.7616798,
        "lng": -80.1917902,
        "locationId": "8f248209db7155b10aeb0d4298aeae510a1f533f",
        "name": "Miami, FL, USA",
        "state": "FL"
      },
      {
        "city": "West Palm Beach",
        "country": "USA",
        "lat": 26.7153424,
        "lng": -80.0533746,
        "locationId": "2935e428bd1bd4765c79158419fdd34b51a5f74b",
        "name": "West Palm Beach, FL, USA",
        "state": "FL"
      },
      {
        "city": "Atlanta",
        "country": "USA",
        "lat": 33.7489954,
        "lng": -84.3879824,
        "locationId": "6b1de99138d2c4fcc15ce789cecfc6a4978dec6a",
        "name": "Atlanta, GA, USA",
        "state": "GA"
      },
      {
        "city": "New Orleans",
        "country": "USA",
        "lat": 29.95106579999999,
        "lng": -90.0715323,
        "locationId": "c6a18874480ba660d6b13f301d769ec4b43f1de7",
        "name": "New Orleans, LA, USA",
        "state": "LA"
      },
      {
        "city": "Teaneck",
        "country": "USA",
        "lat": 40.8932469,
        "lng": -74.0116536,
        "locationId": "2662b08b3e95491d63d2ec596900374882860376",
        "name": "Teaneck, NJ, USA",
        "state": "NJ"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 40.8447819,
        "lng": -73.8648268,
        "locationId": "f1b2e6d668f7f0408ba133626f6eb469d263f51b",
        "name": "The Bronx, NY, USA",
        "state": "NY"
      },
      {
        "city": "Columbus",
        "country": "USA",
        "lat": 39.9611755,
        "lng": -82.99879419999999,
        "locationId": "e9a3ed9a861c4a5056c81e940ea8d394bf9c04c2",
        "name": "Columbus, OH, USA",
        "state": "OH"
      },
      {
        "city": "Dayton",
        "country": "USA",
        "lat": 39.7589478,
        "lng": -84.1916069,
        "locationId": "3208d93722df8151fff37416acd48af2abd1a7b5",
        "name": "Dayton, OH, USA",
        "state": "OH"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9525839,
        "lng": -75.1652215,
        "locationId": "f21bbf56ade9d901998767c4fd5a15d1ee6ab404",
        "name": "Philadelphia, PA, USA",
        "state": "PA"
      },
      {
        "city": "Charleston",
        "country": "USA",
        "lat": 32.7764749,
        "lng": -79.93105120000001,
        "locationId": "331cdbb9f35c12af5a2c13de4cea4b51b95a7323",
        "name": "Charleston, SC, USA",
        "state": "SC"
      },
      {
        "city": "Amarillo",
        "country": "USA",
        "lat": 35.2219971,
        "lng": -101.8312969,
        "locationId": "da8a72f5fea183be4d9bfd2e45599acf9ec18b16",
        "name": "Amarillo, TX, USA",
        "state": "TX"
      },
      {
        "city": "Dallas",
        "country": "USA",
        "lat": 32.7766642,
        "lng": -96.79698789999999,
        "locationId": "1e8fa3b8a8681e5f6d68a350729c12360e0165c0",
        "name": "Dallas, TX, USA",
        "state": "TX"
      },
      {
        "city": "San Antonio",
        "country": "USA",
        "lat": 29.4241219,
        "lng": -98.49362819999999,
        "locationId": "b6663fdded13e6c649c4aeb336c7eb5f50b4c88a",
        "name": "San Antonio, TX, USA",
        "state": "TX"
      },
      {
        "city": "Tyler",
        "country": "USA",
        "lat": 32.3512601,
        "lng": -95.30106239999999,
        "locationId": "693fc97a03d72595a22a189e9d565dbd9c00e3bf",
        "name": "Tyler, TX, USA",
        "state": "TX"
      }
    ],
    "sources": [
      "https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody",
      "https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody",
      "https://www.regeneron.com/covid19"
    ],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      },
      {
        "sponsorId": "fc75c1a3f384fb950104d48eeee9665cc126614f",
        "sponsorName": "HHS"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 25 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Tue, 16 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaxart Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Oral tablet. Recombinant vaccine. Plan to initiate Phase I trial in second half of 2020.",
    "numSites": "",
    "otherPartners": "Emergent",
    "phase": "",
    "preferredName": "Vaxart Vaccine",
    "primaryCompletionDate": "",
    "productId": 9,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions"
    ],
    "sponsors": [
      {
        "sponsorId": "80a6767f041a7aef5269023e2f54d91aa27066da",
        "sponsorName": "Vaxart"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "University of Queensland Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "p.griffin@nucleusnetwork.com.au",
        "name": null,
        "notes": "",
        "phone": "61 402077302",
        "website": ""
      }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 14 Jul 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Plans for clinical trials in July in Queensland.",
    "numSites": "1",
    "otherPartners": "CEPI,The Queensland Government,Paul Ramsay Foundation,a2 Milk Company",
    "phase": "1",
    "preferredName": "University of Queensland Vaccine",
    "primaryCompletionDate": "",
    "productId": 10,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Herston",
        "country": "AUS",
        "lat": -27.4495898,
        "lng": 153.0277778,
        "locationId": "77f8887065f46b2621ef2da1e0e23370e247396b",
        "name": "Level 5 Clive Berghofer Cancer Research Centre (CBCRC, 300C Herston Rd, Herston QLD 4006, Australia",
        "state": "QLD"
      }
    ],
    "sources": [
      "https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine",
      "https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html",
      "https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true"
    ],
    "sponsors": [
      {
        "sponsorId": "83489a1277ddc5cf37050ab7342ac914748abdc2",
        "sponsorName": "University of Queensland"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 14 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VIDO-InterVac Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Canadian Federal Government",
    "phase": "",
    "preferredName": "VIDO-InterVac Vaccine Candidate",
    "primaryCompletionDate": "",
    "productId": 11,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506",
      "https://www.cbc.ca/news/health/coronavirus-covid-19-vido-intervac-saskatchewan-vaccine-1.5508114?__vfz=medium%3Dsharebar"
    ],
    "sponsors": [
      {
        "sponsorId": "52a54b2f0746508531714d16ee2993cb5ff764a5",
        "sponsorName": "International Vaccine Centre"
      },
      {
        "sponsorId": "7ffe768f0f9cf49a08e526fad894319b1b874d64",
        "sponsorName": "University of Saskatchewan"
      },
      {
        "sponsorId": "00779c5db9466de70c91f79cb8ce78836132058d",
        "sponsorName": "VIDOInterVac"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "AZD1222,ChAdOx1 nCoV-19",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "vaccinetrials@ndm.ox.ac.uk",
        "name": null,
        "notes": "For South African sites: +27-11-983-4283 cutlandc@rmpru.co.za        ",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 23 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 28 May 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "20",
    "otherPartners": "University of Oxford",
    "phase": "2/3",
    "preferredName": "ChAdOx1 nCoV-19",
    "primaryCompletionDate": "Sun, 01 Aug 2021 00:00:00 GMT",
    "productId": 12,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04400838",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "GBR",
        "lat": 50.9326083,
        "lng": -1.4331552,
        "locationId": "a5edf2b463f33a1ae12bee928b41fba2000b3158",
        "name": "Tremona Rd, Southampton SO16 6YD, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.42656299999999,
        "lng": -0.1752284,
        "locationId": "6b8c3ce22944f73fb9d3fdc847294afc6e108f02",
        "name": "Blackshaw Rd, Tooting, London SW17 0QT, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 52.4508168,
        "lng": -1.9305135,
        "locationId": "cc5261ee7bacebcaf61d1c022475b4f5138dc0e1",
        "name": "Birmingham B15 2TT, UK",
        "state": "England"
      },
      {
        "city": "Bristol",
        "country": "GBR",
        "lat": 51.454513,
        "lng": -2.58791,
        "locationId": "c1feb4b6c1584d2bdc3de939886c23a018b47154",
        "name": "Bristol, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.4765399,
        "lng": -3.1694072,
        "locationId": "0ca311d5035e41303326d38b3ddef9ef1d97a4b3",
        "name": "Public Health Wales 2 Capital Quarter, Tyndall St, Cardiff CF10 4BZ, UK",
        "state": "Wales"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 53.7788201,
        "lng": -0.4438447,
        "locationId": "721c58a706e75b5128ef154c9e94c5d2d595b563",
        "name": "Castle Rd, Cottingham HU16 5JQ, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 55.9623266,
        "lng": -3.2350851,
        "locationId": "ac86580b53dc29967e61904efa4e6bf048b2a77b",
        "name": "Crewe Rd S, Edinburgh EH4 2XU, UK",
        "state": "Scotland"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 55.87212109999999,
        "lng": -4.288200499999999,
        "locationId": "ff079874fe23b79a9b68765233ce3e317030b2c8",
        "name": "Glasgow G12 8QQ, UK",
        "state": "Scotland"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 53.40855440000001,
        "lng": -2.969074,
        "locationId": "7f64a01fb3a295b88395daf6f5b028baa395a55c",
        "name": "Pembroke Pl, Liverpool L3 5QA, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.57544230000001,
        "lng": -0.322738,
        "locationId": "b35671b24fc2d0da47a6f841b9307f328e38c250",
        "name": "Northwick Park Hospital, Watford Rd, Harrow HA1 3UJ, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.5250834,
        "lng": -0.1363551,
        "locationId": "1e16b945df69383700715d88f3d8254ca0e90075",
        "name": "235 Euston Rd, Bloomsbury, London NW1 2BU, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.49284189999999,
        "lng": -0.1086417,
        "locationId": "42858a85446897f64fb266e1f7a01068579b4020",
        "name": "Lambeth Community Care Centre, Monkton Street, Prince's, London SE11 4TX, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.5178108,
        "lng": -0.1743487,
        "locationId": "3a7d8dda22084af64fc545d314b964673f103311",
        "name": "The Bays, S Wharf Rd, Paddington, London W2 1NY, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 55.0025829,
        "lng": -1.593291,
        "locationId": "6e6cb0266f4d0d959e0ffac4fa55b253bba12587",
        "name": "Freeman Rd, High Heaton, Newcastle upon Tyne NE7 7AH, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 52.943135,
        "lng": -1.1968012,
        "locationId": "db56985b91bf5f4f2461b8f2d495d6401beae9e4",
        "name": "University Park, Nottingham NG7 2QW, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.7489638,
        "lng": -1.210777,
        "locationId": "9c0fdf43cf6ce12aba542910d11ceb98296df097",
        "name": "Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE, UK",
        "state": "England"
      },
      {
        "city": "Headington",
        "country": "GBR",
        "lat": 51.764391,
        "lng": -1.2188774,
        "locationId": "67f7c2367379b223624f6f469f3a9624c849f252",
        "name": "Headley Way, Headington, Oxford OX3 9DU, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 53.379171,
        "lng": -1.4923035,
        "locationId": "4ca33f0c1f9a09677633ca38070a6896704076bf",
        "name": "Royal Hallamshire Hospital, Glossop Rd, Broomhall, Sheffield S10 2JF, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -23.5968124,
        "lng": -46.6442101,
        "locationId": "87d13a212e6beb1af97dde50ab379054995367f7",
        "name": "R. Borges Lagoa, 770 - Vila Clementino, S\u00e3o Paulo - SP, 04038-001, Brazil",
        "state": "SP"
      }
    ],
    "sources": [
      "https://economictimes.indiatimes.com/news/international/world-news/oxford-university-begins-enrolling-over-500-volunteers-for-coronavirus-vaccine-trial/articleshow/74864754.cms",
      "https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development",
      "https://www.clinicaltrials.gov/ct2/show/NCT04324606",
      "https://www.jackfm.co.uk/news/oxfordshire-news/oxford-uni-clinical-trials-for-covid-19-vaccine-could-begin-next-month/"
    ],
    "sponsors": [
      {
        "sponsorId": "b91bf90d7d04e343ba36d6ff216e09bcbdf60f8f",
        "sponsorName": "Jenner Institute"
      },
      {
        "sponsorId": "d1cf38e4f7d70b602814433c015565b664ba5fa5",
        "sponsorName": "Oxford Vaccine Group"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 01 Aug 2021 00:00:00 GMT",
    "studyStartDate": "Thu, 28 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "NIV Pune Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "NIV Pune Vaccine Candidate",
    "primaryCompletionDate": "",
    "productId": 13,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html"
    ],
    "sponsors": [
      {
        "sponsorId": "db62a75311d8473967f358928e8460e901771f76",
        "sponsorName": "National Institute of VirologyPune"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Chinese CDC Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Animal Testing",
    "numSites": "",
    "otherPartners": "Stermirna Therapeutics Co. Ltd",
    "phase": "",
    "preferredName": "Chinese_CDC_Vaccine",
    "primaryCompletionDate": "",
    "productId": 14,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm"],
    "sponsors": [
      {
        "sponsorId": "52d02c14b6240aabfbdc4ded5640e554e55e2ca1",
        "sponsorName": "Chinese Center for Disease Control and Prevention"
      },
      {
        "sponsorId": "5f73dfa644e6480f6632298372551fe30f6bfc70",
        "sponsorName": "Tongji University School of Medicine"
      },
      {
        "sponsorId": "3020404bf63cebc77d8c10a2cc920657b5249ee2",
        "sponsorName": "Stermirna Therapeutics Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DelNS1-SARS-CoV2-RBD LAIV",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Live-attenuated vaccine. Plans for clinical trials in July. Proof of concept testing done using MeRS-CoV and various animal models.",
    "numSites": "",
    "otherPartners": "CEPI,Xiamen University,Changchun-Baike,Hualan-Bio,Beijing Wantai,Sinovac,CNBG",
    "phase": "",
    "preferredName": "DelNS1-SARS-CoV2-RBD LAIV",
    "primaryCompletionDate": "",
    "productId": 15,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://fightcovid19.hku.hk/hku-state-key-laboratory-for-emerging-infectious-diseases-joins-global-effort-to-develop-covid-19-vaccine/",
      "https://www.hku.hk/press/news_detail_20788.html"
    ],
    "sponsors": [
      {
        "sponsorId": "6b014b07406a291e8e325b2a212ac65562a16644",
        "sponsorName": "University of Hong Kong"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "CureVac Vaccine,CVnCoV",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinicaltrials@curevac.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 15 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Not named yet,2 products currently undergoing animal studies,plan to start a clinical trial in early summer",
    "numSites": "4",
    "otherPartners": "CEPI",
    "phase": "1",
    "preferredName": "CureVac_Vaccine_CVnCoV",
    "primaryCompletionDate": "Sun, 01 Aug 2021 00:00:00 GMT",
    "productId": 16,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04449276",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Gent",
        "country": "BEL",
        "lat": 51.0243757,
        "lng": 3.7261488,
        "locationId": "b21056252cc0cdaefbeb5860ca1dc3660d68651d",
        "name": "Corneel Heymanslaan 10, 9000 Gent, Belgium",
        "state": "Vlaanderen"
      },
      {
        "city": "M\u00fcnchen",
        "country": "DEU",
        "lat": 48.1483061,
        "lng": 11.5729663,
        "locationId": "1df32ea8e27ea00103b09126c613370e3de7df2f",
        "name": "Theresienstra\u00dfe 39, 80333 M\u00fcnchen, Germany",
        "state": "BY"
      },
      {
        "city": "Hannover",
        "country": "DEU",
        "lat": 52.3829641,
        "lng": 9.7196989,
        "locationId": "1d73a4f439c9fbf36fd847c6fb526da996b48109",
        "name": "Welfengarten 1, 30167 Hannover, Germany",
        "state": "NDS"
      },
      {
        "city": "T\u00fcbingen",
        "country": "DEU",
        "lat": 48.5274189,
        "lng": 9.0621355,
        "locationId": "d893aa247bc08fc4d1b7f5f6f3fcb7e449f0139b",
        "name": "Wilhelmstra\u00dfe 27, 72074 T\u00fcbingen, Germany",
        "state": "BW"
      }
    ],
    "sources": [
      "https://www.curevac.com/our-pipeline",
      "https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide",
      "https://www.youtube.com/watch?v=1ZMWJJyoK7A"
    ],
    "sponsors": [
      {
        "sponsorId": "40795cb229b892237d8be44830cd652481d40676",
        "sponsorName": "CureVac AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 01 Aug 2021 00:00:00 GMT",
    "studyStartDate": "Thu, 18 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Ad5-nCoV",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "drluisbarreto@gmail.com",
        "name": null,
        "notes": "",
        "phone": "416-294-5840",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 12 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Gene therapies",
    "notes": "Vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein,Immunogenic action,Current study is assessing evaluate the safety reactogenicity and immunogenicity,Active but not recruiting",
    "numSites": "1",
    "otherPartners": "Institute of Biotechnology-Academy of Military Medical Sciences-PLA of China,Jiangsu Province Centers for Disease Control and Prevention,Hubei Provincial Center for Disease Control and Prevention,Tongji Hospital",
    "phase": "1",
    "preferredName": "Ad5-nCoV",
    "primaryCompletionDate": "",
    "productId": 17,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04398147",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Halifax",
        "country": "CAN",
        "lat": 44.6374778,
        "lng": -63.58356850000001,
        "locationId": "e77e74ae1269fb53c3fb37eca52bb79b486ad46c",
        "name": "5980 University Ave #5850, Halifax, NS B3K 6R8, Canada",
        "state": "NS"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1",
      "https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials  https://www.youtube.com/watch?v=1ZMWJJyoK7A",
      "http://www.cansinotech.com/homes/article/show/56/153.html"
    ],
    "sponsors": [
      {
        "sponsorId": "ae6d6a42f1f04b04f866b7d03b344389efca16ee",
        "sponsorName": "CanSino Biologics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sat, 01 Aug 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "GeoVax Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Using existing vaccine platform called GV-MVA-VLP,3 candidates have been identified,animal trials soon to begin",
    "numSites": "",
    "otherPartners": "BravoVax",
    "phase": "",
    "preferredName": "GeoVax_Vaccine",
    "primaryCompletionDate": "",
    "productId": 18,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program",
      "https://www.geovax.com/technology-pipeline/pipeline-summary"
    ],
    "sponsors": [
      {
        "sponsorId": "f5413cebc2f1a8871f47600364147dc47dbb9ad1",
        "sponsorName": "GeoVax Labs Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Intramuscular Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "julie.daigle@syneoshealth.com",
        "name": null,
        "notes": "",
        "phone": "418-527-4000",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 10 Jul 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 21 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Company developed a virus-derived plant-like particle of SARS-COV-2 that mimics the structure but lacks genetic material",
    "numSites": "2",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "Intramuscular Vaccine",
    "primaryCompletionDate": "Sat, 12 Sep 2020 00:00:00 GMT",
    "productId": 19,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04450004",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Montr\u00e9al",
        "country": "CAN",
        "lat": 45.4841213,
        "lng": -73.6309757,
        "locationId": "afbcd355b477d703e529f629e32bb2a7798af0c3",
        "name": "5160 Boulevard D\u00e9carie bureau 800, Montr\u00e9al, QC H3X 2H9, Canada",
        "state": "QC"
      },
      {
        "city": "Qu\u00e9bec",
        "country": "CAN",
        "lat": 46.7939825,
        "lng": -71.2982547,
        "locationId": "606cfb4884222c3e4983f380b7f9c653934407db",
        "name": "2500 Rue Einstein, Qu\u00e9bec, QC G1P 0A2, Canada",
        "state": "QC"
      }
    ],
    "sources": [
      "https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/",
      "https://www.biospace.com/employer/541504/medicago-inc-/",
      "https://www.medicago.com/en/pipeline/",
      "https://clinicaltrials.gov/ct2/show/NCT04450004",
      "Date calculated from: https://www.businesswire.com/news/home/20200312005345/en/.",
      "https://www.businesswire.com/news/home/20200312005345/en/"
    ],
    "sponsors": [
      {
        "sponsorId": "e59212c9eed9f476dcb441a9645267e5e6b915c2",
        "sponsorName": "Medicago"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 30 Apr 2021 00:00:00 GMT",
    "studyStartDate": "Fri, 10 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AdCOVID (based on NasoVax)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Gene therapies",
    "notes": "This is a repurposing of the NasoVax technology (recombinant intranasal) for a COVID-19 vaccine,It should be noted that the provided source on Atimmune's Nasovax-based COVID-19 vaccine was published on February 28. Since then there has been no news on the vaccine until March 30 which is when a new article was published stating that Altimmune will collaborate with UAB to develop AdCOVID. Because AdCOVID possesses the same characteristics as the NasoVax analog (recombinant vaccine - single-dose - and intranasal) I believe that this entry should be reclassified as AdCOVID. NasoVax is still currently in a Phase 2a trial so I have opted to classify AdCOVID as a repurposed-not approved product. Currently working on preclinical animal studies and characterization of vaccine immunogenicity,aims to receive IND approval and enable phase 1 by Q3 2020",
    "numSites": "",
    "otherPartners": "University of Alabama at Birmingham (UAB)",
    "phase": "",
    "preferredName": "NasoVax Analog (Not Currently Specified)",
    "primaryCompletionDate": "",
    "productId": 20,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine",
      "https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate",
      "https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single",
      "https://altimmune.com/nasovax/ https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate"
    ],
    "sponsors": [
      {
        "sponsorId": "e97fb449c577795bfb9ae1692146c17455a06ef8",
        "sponsorName": "Altimmune"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IBV,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Adaption of Avian CoronaVirus Infectious Bronchitis Virus Vaccine for Human Use. This is an adaptation of the IBV vaccine (against poultry coronavirus) for use in humans against COVID-19,IBV vaccine was based on a protein expression vector and the COVID vaccine will likely work in a similar manner,the Israeli ministries plan to accelerate the approval process to bring the vaccine to the market ASAP,MIGAL believes the vaccine could enter Phase 1 by June 1,it is still in the final stages of development due to delays in receiving the genetic construct,MIGAL has begun trials in mice",
    "numSites": "",
    "otherPartners": "Israel Innovation Authority,Health Ministry and the Headquarters of the National Digital Israel Initiative",
    "phase": "",
    "preferredName": "Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine",
    "primaryCompletionDate": "",
    "productId": 21,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.trialsitenews.com/israel-government-announces-13m-covid-19-research-funds-while-migals-claims-a-covid-19-breakthrough/",
      "https://migal.org.il/en/node/7010",
      "https://www.jpost.com/health-science/israeli-scientists-active-component-of-coronavirus-vaccine-days-away-623228"
    ],
    "sponsors": [
      {
        "sponsorId": "83dd887c3fd8789867722d2edd6b259ee645f1a3",
        "sponsorName": "MIGAL Research Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "TNX-1800",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "Modified horsepox virus designed to express the SARS-CoV-2 spike protein,currently in the pre-clinical stage of development and Tonix expects preliminary data from animal experiments in Q3 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "TNX-1800",
    "primaryCompletionDate": "",
    "productId": 22,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.tonixpharma.com/",
      "https://www.tonixpharma.com/news-events/press-releases/detail/1199/tonix-pharmaceuticals-reports-first-quarter-2020-financial",
      "https://www.tonixpharma.com/contact",
      "https://www.tonixpharma.com/news-events/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year",
      "https://www.tonixpharma.com/news-events/press-releases/detail/1191/tonix-pharmaceuticals-announces-research-collaboration-with"
    ],
    "sponsors": [
      {
        "sponsorId": "40e82256fff7abb570316aa4f46cf693fc0c6c98",
        "sponsorName": "Tonix Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Recombinant subunit vaccine,S-Trimer",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "min.dong@cloverbiopharma.com",
        "name": null,
        "notes": "",
        "phone": "86 010 82022300",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 19 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Glaxosmithkline,Dynavax",
    "phase": "1",
    "preferredName": "Recombinant subunit vaccine",
    "primaryCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "productId": 23,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04405908",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Nedlands",
        "country": "AUS",
        "lat": -31.96652,
        "lng": 115.815571,
        "locationId": "4113b776921dbea7a03f69b4c3c988629ebc5952",
        "name": "1 Hospital Avenue, B-Block, 1st Floor, Nedlands WA 6009, Australia",
        "state": "WA"
      }
    ],
    "sources": [
      "https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus",
      "https://www.clinicaltrialsarena.com/comment/clover-biopharmaceuticals-covid-19-vaccine/",
      "http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=42",
      "http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=51",
      "https://clinicaltrials.gov/ct2/show/NCT04405908",
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1"
    ],
    "sponsors": [
      {
        "sponsorId": "2ad3e27aa56a9275005c084d1c2ca3c71cc945a1",
        "sponsorName": "Clover Biopharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 30 Mar 2021 00:00:00 GMT",
    "studyStartDate": "Fri, 19 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Linear DNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "PCR produced linear DNA vaccine",
    "numSites": "",
    "otherPartners": "Applied DNA Sciences,Takis Biotech",
    "phase": "",
    "preferredName": "Linear DNA Vaccine",
    "primaryCompletionDate": "",
    "productId": 24,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/",
      "https://adnas.com/coronoavirus-applied-dna-linearx-takis-biotech-vaccine/",
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1"
    ],
    "sponsors": [
      {
        "sponsorId": "35a1314de34e0181bb072a8ab28865c9f1cdecc1",
        "sponsorName": "Applied DNA Sciences"
      },
      {
        "sponsorId": "3d80bed6c0a0fd89072a0112ae97d02303dc1b5e",
        "sponsorName": "Takis Biotech"
      },
      {
        "sponsorId": "ea1f0842312281e699947cd442445fd782ddde1c",
        "sponsorName": "Linearx Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "NVX-CoV2373",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "B.Georgievska@nucleusnetwork.com.au",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 25 May 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 25 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "prefusion protein made using nanoparticle technology combined with Matrix-M adjuvant",
    "numSites": "2",
    "otherPartners": "Novavax,Emergent BioSolutions Inc,CEPI",
    "phase": "1/2",
    "preferredName": "NanoFlu",
    "primaryCompletionDate": "",
    "productId": 25,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04368988",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "AUS",
        "lat": -20.9175738,
        "lng": 142.7027956,
        "locationId": "b60ccf0aa9f014b5b73722ad6bd5764ad8efe5f2",
        "name": "Queensland, Australia",
        "state": "QLD"
      },
      {
        "city": null,
        "country": "AUS",
        "lat": -37.4713077,
        "lng": 144.7851531,
        "locationId": "a3f0f599de985719af7b2c65d5a06914a5d0978d",
        "name": "Victoria, Australia",
        "state": "VIC"
      }
    ],
    "sources": [
      "http://ir.novavax.com/news-releases/news-release-details/novavax-nanoflu-achieves-all-primary-endpoints-phase-3-clinical",
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1",
      "http://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine",
      "https://www.msn.com/en-us/finance/companies/will-novavax-make-investors-a-fortune/ar-BB12uimK",
      "http://ir.novavax.com/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine",
      "https://ir.novavax.com/news-releases/news-release-details/novavax-identifies-coronavirus-vaccine-candidate-accelerates",
      "https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&draw=4&rank=23",
      "https://clinicaltrials.gov/ct2/show/record/NCT04368988?term=novavax&draw=4&rank=23",
      "https://clinicaltrials.gov/ct2/show/study/NCT04368988?term=novavax&draw=4&rank=23"
    ],
    "sponsors": [
      {
        "sponsorId": "b83afd40b4f01cc1236b6df8d6a2476e04cb0bac",
        "sponsorName": "Novavax"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 25 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Predictive Oncology Vaccine AI Platform",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "Vaccine will be based on a new self-assembling nanoparticle technology called Non Specific Protein (NSP)-10",
    "numSites": "",
    "otherPartners": "Soluble Therapeutics",
    "phase": "",
    "preferredName": "Predictive Oncology Vaccine AI Platform",
    "primaryCompletionDate": "",
    "productId": 26,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug",
      "https://www.pharmaceutical-technology.com/news/predictive-oncology-covid-19-vaccine/",
      "https://www.globenewswire.com/news-release/2020/05/06/2028420/0/en/Predictive-Oncology-and-Dr-Daniel-Carter-Collaborating-to-Develop-a-Potential-COVID-19-Vaccine-Utilizing-Novel-Nanoparticle-Vaccine-Platform-Based-on-NSP-10.html"
    ],
    "sponsors": [
      {
        "sponsorId": "5e5fd3a94173dbc6792d6963099af3d35fffc59a",
        "sponsorName": "Predictive Oncology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AJ Vaccines,S protein Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "the vaccine being developed is an S protein vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AJ_Vaccines_S_protein_Vaccine",
    "primaryCompletionDate": "",
    "productId": 27,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1",
      "https://ajvaccines.com/news/"
    ],
    "sponsors": [
      {
        "sponsorId": "f3d84a99a68fdd7ad327bbc8ce41458fc29dec50",
        "sponsorName": "AJ Vaccines"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "GS-5734",
    "chemicalName": "remdesivir",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "GileadClinicalTrials@gilead.com",
        "name": null,
        "notes": "",
        "phone": "1-833-445-3230",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 15 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Other trials undertaken by NIAD-USA,INSERM-France,China Japanese friendship hospital,No of study is increasing rapidly",
    "numSites": "184",
    "otherPartners": "Gilead Sciences",
    "phase": "3",
    "preferredName": "remdesivir",
    "primaryCompletionDate": "Wed, 20 May 2020 00:00:00 GMT",
    "productId": 28,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04292730",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w",
      "https://www.gilead.com/purpose/advancing-global-health/covid-19",
      "https://www.drugbank.ca/drugs/DB14761",
      "https://www.gilead.com/utility/contact",
      "https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials#",
      "https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials",
      "https://clinicaltrials.gov/ct2/show/NCT04292730",
      "https://clinicaltrials.gov/ct2/show/record/NCT04292730"
    ],
    "sponsors": [
      {
        "sponsorId": "cbb34f9aed92e21ff89501b842a385faabf9c8c6",
        "sponsorName": "Gilead Sciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sun, 15 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Kaletra,Aluvia",
    "chemicalName": "lopinavir,ritonavir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "qning@vip.sina.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. Some studies are published: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. Note that for the highest study there were multiple phase 4 so I picked the largest one that had already started recruiting",
    "numSites": "1",
    "otherPartners": "AbbVie",
    "phase": "4",
    "preferredName": "lopinavir,ritonavir",
    "primaryCompletionDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "productId": 29,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04255017",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "4018bff9870d041afd8a070c4f4e507816980b66",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf",
      "https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf",
      "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true",
      "https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601",
      "https://www.kaletra.com/",
      "https://www.clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2",
      "https://www.clinicaltrials.gov/ct2/show/record/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "69e116d4f9df799550df0e74438d37589994fb45",
        "sponsorName": "AbbVie"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sat, 01 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Kevzara",
    "chemicalName": "Sarilumab",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "clinicaltrials@regeneron.com",
        "name": null,
        "notes": "",
        "phone": "844-734-6643",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "63",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Sarilumab",
    "primaryCompletionDate": "Tue, 09 Mar 2021 00:00:00 GMT",
    "productId": 30,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.drugbank.ca/drugs/DB11767",
      "http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19",
      "https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical",
      "https://www.google.com/search?rlz=1C5CHFA_enGB854GB854&sxsrf=ALeKk022og2HFqxgB2OGNk6Vdmns2VRRhQ%3A1585861871624&ei=71SGXuTZJYKvggfAjrv4BA&q=regeneron+&oq=regeneron+&gs_lcp=CgZwc3ktYWIQAzIICAAQgwEQkQIyBAgAEEMyBQgAEIMBMgUIABCDATIFCAAQgwEyBQgAEIMBMgIIADICCAAyBQgAEIMBMgUIABCDAToECAAQRzoECCMQJzoFCAAQkQI6BwgAEBQQhwJQ2U1Y2ltgp1xoAHABeACAAYYBiAGSB5IBAzYuM5gBAKABAaoBB2d3cy13aXo&sclient=psy-ab&ved=0ahUKEwikjZXs08roAhWCl-AKHUDHDk8Q4dUDCAs&uact=5",
      "https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2",
      "https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1",
      "https://www.clinicaltrials.gov/ct2/show/NCT04315298"
    ],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      },
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 01 Apr 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 16 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Plaquenil,Hydroquin,Axemal,Dolquine,Quensyl,Quinoric",
    "chemicalName": "hydroxychloroquine",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "javiercrespo1991@gmail.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla",
    "phase": "4",
    "preferredName": "hydroxychloroquine",
    "primaryCompletionDate": "Fri, 06 Nov 2020 00:00:00 GMT",
    "productId": 31,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf",
      "https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html; https://www.npr.org/sections/coronavirus-live-updates/2020/03/31/824572119/clinical-trials-set-to-determine-if-anti-malaria-drug-effective-against-covid-19",
      "https://www.drugbank.ca/drugs/DB01611",
      "https://www.drugbank.ca/drugs/DB01612",
      "https://www.drugbank.ca/drugs/DB01613",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=3",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=4",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=5",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=6",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=7",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=8",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=9",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=10",
      "https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=11"
    ],
    "sponsors": [
      {
        "sponsorId": "a5091ee00972baec20a88b0bfc29cf8df11fc10e",
        "sponsorName": "Sanofi SA"
      },
      {
        "sponsorId": "11f8e68d5ce8289f7c1254157f73a6429006ed8c",
        "sponsorName": "Amneal Pharmaceuticals INc"
      },
      {
        "sponsorId": "a951d8e8824303ff34be3adad3b714181ce40092",
        "sponsorName": "Rising Pharma Holdings Inc"
      },
      {
        "sponsorId": "d49e1350f4c21eef623eb4e22b9709b13ac08f82",
        "sponsorName": "University of Minnesota"
      },
      {
        "sponsorId": "38652628acf1b84b92cad2bea1a82015a920b0c3",
        "sponsorName": "University of Oxford"
      },
      {
        "sponsorId": "c6596b3fee7a992d790e288b27e50edfb07b5974",
        "sponsorName": "IHUM\u00e9diterran\u00e9e Infection"
      },
      {
        "sponsorId": "de07adc682970664b17a2475d74c5691cd707ef6",
        "sponsorName": "Sandoz Inc"
      },
      {
        "sponsorId": "67da3aa3718d35ed721af558ab42d840a58dfdbe",
        "sponsorName": "Bayer AG"
      },
      {
        "sponsorId": "00a23d14d5c43daa469abd0a9c6a20c98de6e086",
        "sponsorName": "University of Washington"
      },
      {
        "sponsorId": "d0b12c5f18dc027ada9bc28c72459c2e0d798809",
        "sponsorName": "PatientCenterede Outcomes Research Institute"
      },
      {
        "sponsorId": "03fdeb1f847122b01435c2cc44a82112b2f1e5c9",
        "sponsorName": "World Health Organization"
      },
      {
        "sponsorId": "f87860860d12518378b68c8b4c2d0d61407eac5a",
        "sponsorName": "New York State Department of Health"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 06 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 06 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antimalarial drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "VTP-500",
    "chemicalName": "",
    "conditionOrDisease": "MERS",
    "contact": [
      {
        "email": "vaccinetrials@ndm.ox.ac.uk",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 1",
    "indication": "Other",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 14 Mar 2018 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "MERS",
    "numSites": "1",
    "otherPartners": "UNIVERSITY OF OXFORD,JANSSEN,CEPI",
    "phase": "1",
    "preferredName": "VTP500",
    "primaryCompletionDate": "Tue, 21 Jul 2020 00:00:00 GMT",
    "productId": 95,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03399578",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Oxford",
        "country": "GBR",
        "lat": 51.7520209,
        "lng": -1.2577263,
        "locationId": "f4afd02b264a450cb9b9726f3db2ce1267389e66",
        "name": "Oxford, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://www.vaccitech.co.uk/pipeline/",
      "https://clinicaltrials.gov/ct2/show/study/NCT03399578"
    ],
    "sponsors": [
      {
        "sponsorId": "3539cc93ae38ac97613e91267777269795073379",
        "sponsorName": "Vaccitech"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 21 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 14 Mar 2018 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "TJM2",
    "chemicalName": "TJ003234",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "US.Info@I-MabBiopharma.com",
        "name": null,
        "notes": "",
        "phone": "240-767-6981",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 11 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "AntiBody against GM-CSF. Previously passed a phase 1 trial. INDs submitted for phase II clinical trials in China USA and South Korea.",
    "numSites": "8",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "TJ003234",
    "primaryCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "productId": 32,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04341116",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Washington",
        "country": "USA",
        "lat": 38.9068754,
        "lng": -77.04376289999999,
        "locationId": "a3b942ccd1a0de717a874445c1ea4e06f5b73f8e",
        "name": "1234 19th St NW, Washington, DC 20036, USA",
        "state": "DC"
      },
      {
        "city": "Peoria",
        "country": "USA",
        "lat": 40.7031614,
        "lng": -89.5904178,
        "locationId": "20e41d8f52f55128db5aace071b8eb9c91e4927f",
        "name": "530 NE Glen Oak Ave, Peoria, IL 61637, USA",
        "state": "IL"
      },
      {
        "city": "Indianapolis",
        "country": "USA",
        "lat": 39.7764529,
        "lng": -85.9945985,
        "locationId": "2abe28028f432b717afed9b80edb78860bcff072",
        "name": "9650 E Washington St #245, Indianapolis, IN 46229, USA",
        "state": "IN"
      },
      {
        "city": "Metairie",
        "country": "USA",
        "lat": 30.01050529999999,
        "lng": -90.18101709999999,
        "locationId": "7307d5b0dc232a4a0c12c7e43487ce3503062350",
        "name": "3800 Houma Blvd #335A, Metairie, LA 70006, USA",
        "state": "LA"
      },
      {
        "city": "New Orleans",
        "country": "USA",
        "lat": 29.9376843,
        "lng": -90.10432109999999,
        "locationId": "2615f305f68f4b23c9f13654e68f7c77269140a2",
        "name": "2700 Napoleon Ave, New Orleans, LA 70115, USA",
        "state": "LA"
      },
      {
        "city": "Jackson",
        "country": "USA",
        "lat": 32.3282527,
        "lng": -90.17365459999999,
        "locationId": "e62ff37334186e8f18c70ee114b4abd04ef2c213",
        "name": "Emergency Room, 2500 N State St, Jackson, MS 39216, USA",
        "state": "MS"
      },
      {
        "city": "Portland",
        "country": "USA",
        "lat": 45.4992017,
        "lng": -122.6867232,
        "locationId": "2f22bba6c4943ebd02846988a5b2c76eaf76cdda",
        "name": "3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA",
        "state": "OR"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 40.0050435,
        "lng": -75.1507582,
        "locationId": "3f59525caea187bbd25a2626144f57f2e3aa2568",
        "name": "3401 N Broad St, Philadelphia, PA 19140, USA",
        "state": "PA"
      }
    ],
    "sources": [
      "http://www.i-mabbiopharma.com/en/article-491.aspx",
      "https://clinicaltrials.gov/ct2/show/NCT03794180",
      "https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70"
    ],
    "sponsors": [
      {
        "sponsorId": "4d5fc82efed329adf6897a54f395828e900a3a4d",
        "sponsorName": "IMab Biopharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 11 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AT-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Recombinant surfactant protein developed to treat bronchopulmonary dysplatia. No timeline for clinical trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AT-100",
    "primaryCompletionDate": "",
    "productId": 33,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.airwaytherapeutics.com/at-100/",
      "https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/"
    ],
    "sponsors": [
      {
        "sponsorId": "cce5891ec7c3582e4abbb8a5a1675065288b051b",
        "sponsorName": "Airway Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "TZLS-501",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Tiziana Life Sciences,Novimmune",
    "phase": "",
    "preferredName": "TZLS-501",
    "primaryCompletionDate": "",
    "productId": 34,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.marketwatch.com/story/uk-biotech-tiziana-life-sciences-says-its-tzls-501-may-be-of-use-in-treating-coronavirus-2020-03-11"
    ],
    "sponsors": [
      {
        "sponsorId": "2a18b405cfddff30dc89c827294ce141e1078ed6",
        "sponsorName": "Tiziana Life Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OYA1",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "OyaGen",
    "phase": "",
    "preferredName": "OYA1",
    "primaryCompletionDate": "",
    "productId": 35,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "09c1011fb00f7f2c97e9b4ebc1373e23f10f3703",
        "sponsorName": "OyaGen"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "BPI-002",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Also being considered as a vaccine adjuvant to stimulate long term immunity,Very little information is available on development stages - A patent has been filed for it by the company but it is not clear what that translates to,Information in column T was seen on just one website",
    "numSites": "",
    "otherPartners": "BeyondSpring Inc",
    "phase": "",
    "preferredName": "BPI-002",
    "primaryCompletionDate": "",
    "productId": 36,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/",
      "https://www.beyondspringpharma.com/otherpipeline/index.aspx",
      "https://adisinsight.springer.com/drugs/800049541",
      "https://www.beyondspringpharma.com/pipelineoverview/index.aspx"
    ],
    "sponsors": [
      {
        "sponsorId": "bdc58d6b3c51adacec8fd2e5f71d1d5d71046d8d",
        "sponsorName": "BeyondSpring Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "NP-120",
    "chemicalName": "Ifenprodil",
    "conditionOrDisease": "Idiopathic Pulmonary Fibrosis",
    "contact": [
      {
        "email": "nstewart@gvicds.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Therapeutic approach - receptor antagonist,Drug originally evaluated for treatment of Idiopathic Pulmonary Fibrosis",
    "numSites": "5",
    "otherPartners": "Cascade chemistry",
    "phase": "2",
    "preferredName": "NP-120 (Ifenprodil)",
    "primaryCompletionDate": "Sat, 20 Mar 2021 00:00:00 GMT",
    "productId": 37,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04318704",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Brookvale",
        "country": "AUS",
        "lat": -33.7661083,
        "lng": 151.2683365,
        "locationId": "ed87224b228be90fd01a31a0c66910801af0c58a",
        "name": "1 Brookvale House, 1A Cross St, Brookvale NSW 2100, Australia",
        "state": "NSW"
      },
      {
        "city": "Concord",
        "country": "AUS",
        "lat": -33.8374705,
        "lng": 151.0925689,
        "locationId": "5e9a10dbc14e35c64858c4b9e646344b41c03ee9",
        "name": "Hospital Rd, Concord NSW 2139, Australia",
        "state": "NSW"
      },
      {
        "city": "Cairns City",
        "country": "AUS",
        "lat": -16.91244,
        "lng": 145.768365,
        "locationId": "d61558748e35c1b03a3a9504b52c84f3880c9c3c",
        "name": "165 Esplanade, Cairns City QLD 4870, Australia",
        "state": "QLD"
      },
      {
        "city": "Christchurch",
        "country": "NZL",
        "lat": -43.5345531,
        "lng": 172.6258391,
        "locationId": "add91dcdd8a7c244ad3328f15fda3b9c7bb4775e",
        "name": "2 Riccarton Avenue, Christchurch Central, Christchurch 8011, New Zealand",
        "state": "Canterbury"
      },
      {
        "city": "Hamilton",
        "country": "NZL",
        "lat": -37.804897,
        "lng": 175.282056,
        "locationId": "787c39f239fad73a7e5cb1e12befdc49fd4274cc",
        "name": "Pembroke Street, Hamilton West, Hamilton 3204, New Zealand",
        "state": "Waikato"
      }
    ],
    "sources": [
      "https://algernonpharmaceuticals.com/ipf-np-120/",
      "https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "4ec6ff9fa7840783f9d6a9a99ce82cc52a732239",
        "sponsorName": "Algernon Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Jun 2021 00:00:00 GMT",
    "studyStartDate": "Sat, 20 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "APN01",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "sonja.hoeller@apeiron-biologics.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "9",
    "otherPartners": "Austrian government",
    "phase": "2",
    "preferredName": "APN01",
    "primaryCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "productId": 38,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04335136",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Innsbruck",
        "country": "AUT",
        "lat": 47.2692124,
        "lng": 11.4041024,
        "locationId": "349a50ac4e8614dc4e04ff2d1fd414ab757d8a7a",
        "name": "Innsbruck, Austria",
        "state": "Tyrol"
      },
      {
        "city": "Vienna",
        "country": "AUT",
        "lat": 48.2081743,
        "lng": 16.3738189,
        "locationId": "0b8d625882889750788aada97084c055551e9121",
        "name": "Vienna, Austria",
        "state": "Vienna"
      },
      {
        "city": "Vienna",
        "country": "AUT",
        "lat": 48.2081743,
        "lng": 16.3738189,
        "locationId": "0b8d625882889750788aada97084c055551e9121",
        "name": "Vienna, Austria",
        "state": "Vienna"
      },
      {
        "city": "Copenhagen",
        "country": "CNK",
        "lat": 55.6760968,
        "lng": 12.5683372,
        "locationId": "50f0180418e819621e0d414f9942577dc36634db",
        "name": "Copenhagen, Denmark",
        "state": null
      },
      {
        "city": null,
        "country": "CNK",
        "lat": 55.736943,
        "lng": 12.4215514,
        "locationId": "80e09000b562e506649b5de2fb1d8eea9f437813",
        "name": "Herlev Municipality, Denmark",
        "state": null
      },
      {
        "city": "Hiller\u00f8d",
        "country": "CNK",
        "lat": 55.927909,
        "lng": 12.300806,
        "locationId": "5fce627723a9a9dc0590799271c7049a493f6a8e",
        "name": "3400 Hiller\u00f8d, Denmark",
        "state": null
      },
      {
        "city": "Hvidovre",
        "country": "CNK",
        "lat": 55.64252200000001,
        "lng": 12.4753859,
        "locationId": "d61afcebb8e48be956026a9e3282e5638fb8765f",
        "name": "2650 Hvidovre, Denmark",
        "state": null
      },
      {
        "city": "Hamburg",
        "country": "DEU",
        "lat": 53.5510846,
        "lng": 9.9936819,
        "locationId": "56283cd9ffd16ac1845f9da8c6a5be73605a0258",
        "name": "Hamburg, Germany",
        "state": "HH"
      },
      {
        "city": "Munich",
        "country": "DEU",
        "lat": 48.1351253,
        "lng": 11.5819805,
        "locationId": "c61c4d03fbb24be1065ecc56523f31f98757fe6a",
        "name": "Munich, Germany",
        "state": "BY"
      }
    ],
    "sources": [
      "https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf",
      "https://clinicaltrials.gov/ct2/show/NCT00886353",
      "https://www.google.com/search?q=apeiron+biologics&rlz=1C5CHFA_enGB854GB854&oq=apeir&aqs=chrome.0.69i59j69i57j0l2j46j69i60l3.1226j0j7&sourceid=chrome&ie=UTF-8",
      "https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "6f60b15593583caa5a157b68e379e898ed540bfe",
        "sponsorName": "University of British Columbia"
      },
      {
        "sponsorId": "135275cdf7dd39808bf7b9ddb4115db4750d3cdc",
        "sponsorName": "APEIRON Biologics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 20 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Brilacidin",
    "chemicalName": "Brilacidin Tetrahydrochloride",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Innovation Pharamaceuticals",
    "phase": "",
    "preferredName": "Brilacidin Tetrahydrochloride",
    "primaryCompletionDate": "",
    "productId": 39,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e5c0bbea72c2f71ab0978ee/1583090668780/IPIX+Brilacidin+Defensin+Mimetics+-+COVID-19+Overview+March+1+2020+update.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "d74b3bc88aff79062ddc7572f048d10a2f1b7254",
        "sponsorName": "Innovation Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "PRO-140",
    "chemicalName": "leronlimab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "kushd@amarexcro.com",
        "name": null,
        "notes": "",
        "phone": "301-956-2536",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Patient treatment underway via Emergency IND,Phase 2 trial protocol filed",
    "numSites": "11",
    "otherPartners": "RedChip companies",
    "phase": "2",
    "preferredName": "leronlimab",
    "primaryCompletionDate": "",
    "productId": 40,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04347239",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Los Angeles",
        "country": "USA",
        "lat": 34.068921,
        "lng": -118.4451811,
        "locationId": "3ef9fc696390189f0367e14f7a14fbe85a799b07",
        "name": "Los Angeles, CA 90095, USA",
        "state": "CA"
      },
      {
        "city": "Rancho Mirage",
        "country": "USA",
        "lat": 33.7634956,
        "lng": -116.4054165,
        "locationId": "ec3ebb1c7cdd27973331070bb0adc4926e59ec4e",
        "name": "39000 Bob Hope Dr, Rancho Mirage, CA 92270, USA",
        "state": "CA"
      },
      {
        "city": "New Haven",
        "country": "USA",
        "lat": 41.3044229,
        "lng": -72.93556629999999,
        "locationId": "22fffac92fbf24a100d1a8187c011d10fa5444ac",
        "name": "20 York St, New Haven, CT 06510, USA",
        "state": "CT"
      },
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3396063,
        "lng": -71.10498199999999,
        "locationId": "2e66b28f12806729f756f5730757a80aae5b41a3",
        "name": "330 Brookline Ave, Boston, MA 02215, USA",
        "state": "MA"
      },
      {
        "city": "Livingston",
        "country": "USA",
        "lat": 40.7727997,
        "lng": -74.35566709999999,
        "locationId": "6d15be60e2c7deccbdd9271e256c04bf3f51c5eb",
        "name": "200 S Orange Ave, Livingston, NJ 07039, USA",
        "state": "NJ"
      },
      {
        "city": "Morristown",
        "country": "USA",
        "lat": 40.7888312,
        "lng": -74.4662803,
        "locationId": "d523ae888004001c55bded8f172ded89a77c0a5a",
        "name": "100 Madison Ave, Morristown, NJ 07960, USA",
        "state": "NJ"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 40.8804291,
        "lng": -73.88004099999999,
        "locationId": "1fe5ebae0d3b21a35f6b7f42257c719ab5973919",
        "name": "111 E 210th St, The Bronx, NY 10467, USA",
        "state": "NY"
      },
      {
        "city": "Winston-Salem",
        "country": "USA",
        "lat": 36.0765703,
        "lng": -80.2962649,
        "locationId": "3b69038002fa6a77d17496b0643334e9547a5b57",
        "name": "3333 Silas Creek Pkwy, Winston-Salem, NC 27103, USA",
        "state": "NC"
      },
      {
        "city": "Columbus",
        "country": "USA",
        "lat": 40.0063879,
        "lng": -83.045577,
        "locationId": "3f731edfd8d4d8592f2b62b52e21f41b71fabeb5",
        "name": "1315 W Lane Ave, Columbus, OH 43221, USA",
        "state": "OH"
      },
      {
        "city": "Portland",
        "country": "USA",
        "lat": 45.4992017,
        "lng": -122.6867232,
        "locationId": "b1dba12553b197c924e1783f2357cf77ade515fc",
        "name": "3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA",
        "state": "OR"
      },
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.7031663,
        "lng": -95.4032312,
        "locationId": "545a7a2dfa1b77dd4ba11eada32096a4c9440b75",
        "name": "7000 Fannin St #1200, Houston, TX 77030, USA",
        "state": "TX"
      }
    ],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "a5c509d28e5944d0d7121691e82a49f47e20f7ef",
        "sponsorName": "CytoDyn"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 01 Apr 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "BTX-025",
    "chemicalName": "Novel Viral Inhibitor",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Novel galectin inhibitor for use in COVID-19. Currently pre-clinical.",
    "numSites": "",
    "otherPartners": "Bioxytran",
    "phase": "",
    "preferredName": "Novel Viral Inhibitor",
    "primaryCompletionDate": "",
    "productId": 41,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html"
    ],
    "sponsors": [
      {
        "sponsorId": "6e5983b2fe019c343dfaeb0ad2e7419f3dfaa118",
        "sponsorName": "BIOXYTRAN"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Actemra",
    "chemicalName": "tocilizumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA).",
    "numSites": "Not disclosed",
    "otherPartners": "Roche",
    "phase": "3",
    "preferredName": "tocilizumab",
    "primaryCompletionDate": "",
    "productId": 42,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04320615",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Port Washington",
        "country": "USA",
        "lat": 40.8087324,
        "lng": -73.66136519999999,
        "locationId": "2d450fbc1d5fac98fb5c2f76802a2413550f0b95",
        "name": "11 Harbor Park Dr, Port Washington, NY 11050, USA",
        "state": "NY"
      }
    ],
    "sources": ["https://www.roche.com/media/releases/med-cor-2020-03-19.htm"],
    "sponsors": [
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Fri, 03 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Galidesivir",
    "chemicalName": "BCX4430",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinicaltrials@biocryst.com",
        "name": null,
        "notes": "",
        "phone": "919-859-1302",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Neucleoside analogue for Yellow Fever broad spectrum.",
    "numSites": "1",
    "otherPartners": "NIAID,BARDA-NIH",
    "phase": "1",
    "preferredName": "BCX4430",
    "primaryCompletionDate": "",
    "productId": 43,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03891420",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "S\u00e3o Paulo",
        "country": "BRA",
        "lat": -23.5505199,
        "lng": -46.63330939999999,
        "locationId": "5c01f70f9af90860b9f72602b9216187c2df77e0",
        "name": "S\u00e3o Paulo, State of S\u00e3o Paulo, Brazil",
        "state": "SP"
      }
    ],
    "sources": [
      "http://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-phase-1-clinical-trial-galidesivir",
      "https://www.drugbank.ca/drugs/DB11676",
      "https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "ec79288164e657a6770558c7e361bf039abbc3c1",
        "sponsorName": "Biocryst Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 09 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "REGN10933+REGN10987,REGN-COV2",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "COVID19SiteInterest@regeneron.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "There is conflicting information. I found a trial that used these drugs for MERS suggesting it is reporpused-not approved but here it says they are starting a first in human trial: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/ -- The combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "REGN10933+REGN10987,REGN-COV2",
    "primaryCompletionDate": "Sun, 11 Apr 2021 00:00:00 GMT",
    "productId": 44,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04452318",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/",
      "https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1",
      "https://www.google.com/search?q=regeneron&rlz=1C5CHFA_enGB854GB854&oq=regeneron&aqs=chrome..69i57j0l3j69i60l4.1356j0j7&sourceid=chrome&ie=UTF-8",
      "https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1; https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/",
      "Implied P1 from first in human here: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/"
    ],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 11 Apr 2021 00:00:00 GMT",
    "studyStartDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Sylvant",
    "chemicalName": "siltuximab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Clinical trial NCT04322188 started but phase UNKNOWN",
    "numSites": "1",
    "otherPartners": "Ergomed,Papa Giovanni XXIII Hospital",
    "phase": "",
    "preferredName": "siltuximab",
    "primaryCompletionDate": "Tue, 19 May 2020 00:00:00 GMT",
    "productId": 60,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Bergamo",
        "country": "ITA",
        "lat": 45.686107,
        "lng": 9.638066,
        "locationId": "57fbf653730a1f3297118a2c1d52437351eee7bb",
        "name": "Piazza OMS, 1, 24127 Bergamo BG, Italy",
        "state": "Lombardia"
      }
    ],
    "sources": [
      "https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/",
      "https://www.clinicaltrials.gov/ct2/show/record/NCT04322188"
    ],
    "sponsors": [
      {
        "sponsorId": "887084fb166ace787dba446286c132705fbea1b3",
        "sponsorName": "EUSA Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 19 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "SNG001",
    "chemicalName": "Interferon beta",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "inhaled forumation of beta-1a interferon",
    "numSites": "",
    "otherPartners": "Public funding through shares",
    "phase": "",
    "preferredName": "SNG001",
    "primaryCompletionDate": "",
    "productId": 45,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.synairgen.com/covid-19/",
      "https://www.morningstar.co.uk/uk/news/AN_1585205934091906300/synairgen-raises-cash-to-go-towards-covid-19-drug-trial.aspx",
      "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB",
      "https://www.clinicaltrialsarena.com/news/cansino-synairgen-covid-19-trials/"
    ],
    "sponsors": [
      {
        "sponsorId": "844645398c47a20691e7b88009bf4a28ca9e0a56",
        "sponsorName": "Synairgen Research"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "AmnioBoost",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Lattice Biologics",
    "phase": "1",
    "preferredName": "AmnioBoost",
    "primaryCompletionDate": "",
    "productId": 46,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Seattle",
        "country": "USA",
        "lat": 47.6062095,
        "lng": -122.3320708,
        "locationId": "875020b3e5677795da0e156d120aaf26c0d6ae83",
        "name": "Seattle, WA, USA",
        "state": "WA"
      }
    ],
    "sources": [
      "https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/",
      "https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients"
    ],
    "sponsors": [
      {
        "sponsorId": "3269ba5b3b1fa17511555e6336cff3ddd90b84b2",
        "sponsorName": "Lattice Biologics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 17 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Enanta Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "direct acting antiviral,Starting phase II study for RSV patients",
    "numSites": "",
    "otherPartners": "Enanta Pharmaceuticals",
    "phase": "",
    "preferredName": "Enanta_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 47,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx",
      "https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx; https://www.pharmaceutical-technology.com/news/enanta-pharmaceuticals-covid-19-drugs/"
    ],
    "sponsors": [
      {
        "sponsorId": "7bf6d2f389a2e6a86e1d696dcc1c2052ef9a9eae",
        "sponsorName": "Enanta Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "COVID-HIG",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "Manufactured using plasma donations from people who have recovered from COVID19 with antibodies,human hyperimmune product,NIAID has agreed to include COVID-HIG product candidate in one of its clinical studies of treatment of COVID-19 upon availability of clinicla material.",
    "numSites": "",
    "otherPartners": "US Government,BARDA,ASPR",
    "phase": "",
    "preferredName": "VAAST",
    "primaryCompletionDate": "",
    "productId": 48,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/",
      "https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]="
    ],
    "sponsors": [
      {
        "sponsorId": "cd5be69c518689ef12547e8559a4ff1c7ebed1d1",
        "sponsorName": "Emergent BioSolutions"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "LEAPS COVID-19",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 03 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "immunotherapy",
    "numSites": "",
    "otherPartners": "CEL-SCI,University of Georgia\u2019s (UGA\u2019s) Center for Vaccines",
    "phase": "1",
    "preferredName": "LEAPS COVID-19",
    "primaryCompletionDate": "",
    "productId": 49,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7146a8671f847f80a0c4c99c0466916089840d58",
        "sponsorName": "CELSCI"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "TAK-888",
    "chemicalName": "Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "a plasma-derived therapy",
    "numSites": "",
    "otherPartners": "Takeda Pharmaceutical Company",
    "phase": "1",
    "preferredName": "Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)",
    "primaryCompletionDate": "",
    "productId": 50,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ab95e09c1c41756dc8b947ebd1fa0e087a23da6c",
        "sponsorName": "Takeda Pharmaceutical Company"
      }
    ],
    "status": "On Hold",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Azithromycin,Hydroxychloroquine",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "Pfizer",
    "phase": "",
    "preferredName": "Azithromycin-Hydroxychloroquine Combination",
    "primaryCompletionDate": "",
    "productId": 51,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "FRA",
        "lat": 46.227638,
        "lng": 2.213749,
        "locationId": "872f9fb8b7d0711cd17658a24ed7a23c9c348ce4",
        "name": "France",
        "state": null
      }
    ],
    "sources": [
      "https://pfe-pfizercom-prod.s3.amazonaws.com/news/ZithroComboStatement.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "531d5b28f1f18f219741627c0f2a1e09d355e46a",
        "sponsorName": "Pfizer"
      },
      {
        "sponsorId": "fd203d1438cfd911102049306e6081fba3f89b87",
        "sponsorName": "Intermountain Healthcare"
      },
      {
        "sponsorId": "e8c2d02eac49d122b3733cdbc1e0009caae5b4c7",
        "sponsorName": "University of Utah Health"
      },
      {
        "sponsorId": "f504a9b418cd0c0f06bc0337180c16761e95b8b1",
        "sponsorName": "Fondation Mediterranee Infection"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OT-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Appears to still be in vitro testing",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OT-101",
    "primaryCompletionDate": "",
    "productId": 52,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3",
      "http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate",
      "http://investor.mateon.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "839146f1d67c1b00a841adde72a3555186ed2ee2",
        "sponsorName": "Mateon Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Southwest Research Institute Screening Platform",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 19 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "Developed Rhodium a novel-structure based virtual screening tool that can help screen millions of drug compounds and speed up preliminary efficacy and safety evaluations",
    "numSites": "",
    "otherPartners": "Texas Biomedical Research Institute",
    "phase": "",
    "preferredName": "Southwest_Research_Institute_Screening_Platform",
    "primaryCompletionDate": "",
    "productId": 53,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.swri.org/swri-covid-19-response-resources",
      "Assumed given large number of compounds investigated: https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research",
      "https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research",
      "https://www.swri.org/sites/default/files/rhodium-covid19-infographic.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "24d9d6c7cef2fb07a9bf63de1e32e0d49e73466f",
        "sponsorName": "Southwest Research Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "NanoViricides Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "NanoViricides_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 54,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["http://www.nanoviricides.com/"],
    "sponsors": [
      {
        "sponsorId": "ce9215688edb9650cbc3b3d92876af43dd53d52b",
        "sponsorName": "NanoViricides"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VIR-7831",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "2 different modifications of one single clone of antibody originally developed against SARS-CoV-1,shown to act as both vaccine and therapeutic",
    "numSites": "",
    "otherPartners": "Wuxi Biologics,Biogen",
    "phase": "",
    "preferredName": "modified anti-SARS-CoV-2 antibodies",
    "primaryCompletionDate": "",
    "productId": 55,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/",
      "https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer; https://www.biospace.com/article/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus/",
      "https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer",
      "https://www.vir.bio/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "6c32fa743ed510db10e7c97fd975d2a2a5700a4a",
        "sponsorName": "Vir Biotechnology Inc"
      },
      {
        "sponsorId": "b0667c7bd3f77f09b501f5439a15d5af327ec17f",
        "sponsorName": "GSK"
      },
      {
        "sponsorId": "7b6f419a075a9d4cfc1742367fdc3d11cc35f994",
        "sponsorName": "Biogen Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VIR-2703,ALN-COV",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "350 candidates undergoing in vitro test",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "siRNA against  SARS-CoV-1/2",
    "primaryCompletionDate": "",
    "productId": 56,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://investors.alnylam.com/press-release?id=24656",
      "https://www.vir.bio/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "2a0f6fec0d49bd2ca117ccbc0cfd8c816f776165",
        "sponsorName": "Alnylam"
      },
      {
        "sponsorId": "ec6e5f3e381b52ffa801d3826f90ffc80615c431",
        "sponsorName": "Vir Biotechnology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "siRNA against  SARS-CoV-2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "150 candidates under in vitro test",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "siRNA against  SARS-CoV-2",
    "primaryCompletionDate": "",
    "productId": 57,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/",
      "https://sirnaomics.com/contact-us/",
      "https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib"
    ],
    "sponsors": [
      {
        "sponsorId": "d4d4713f1054b2bc9d367a86155cb363519d5ad5",
        "sponsorName": "Sirnaomics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "LY3819253,LY-CoV555",
    "chemicalName": "UPDATE1",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies,500 antibody sequences isolated 03/12/2020",
    "numSites": "",
    "otherPartners": "Vaccine Research Centre - NIAID",
    "phase": "",
    "preferredName": "UPDATE1",
    "primaryCompletionDate": "",
    "productId": 58,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/"
    ],
    "sponsors": [
      {
        "sponsorId": "c3e548eb19a8c76ea5f8eeabdbc8086a91e469af",
        "sponsorName": "AbCellera Biologics"
      },
      {
        "sponsorId": "3415f73b4bae4701d6612a2aa318423dc3c571b2",
        "sponsorName": "Eli Lilly and Company"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "BDB-001",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Anti-C5a Antibody,Phase 2 trial number 2020L0003",
    "numSites": "",
    "otherPartners": "Staidson (Beijing) Biopharmaceuticals Co. Ltd,InflaRx",
    "phase": "2",
    "preferredName": "BDB-001",
    "primaryCompletionDate": "",
    "productId": 59,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/",
      "https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf",
      "https://www.bioworld.com/articles/433447-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads",
      "https://www.staidson.com/article/147.html",
      "https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1"
    ],
    "sponsors": [
      {
        "sponsorId": "0086ba154cc66744d6566f5674dc67a137770778",
        "sponsorName": "Beijing Defengrei Biotechnology  Staidson"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "47D11",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies created in lab that target COVID-19 infected cells as well as similar proteins of molecules that cause SARS",
    "numSites": "",
    "otherPartners": "Mount Sinai,Utrecht University,Eurasmus MC",
    "phase": "",
    "preferredName": "47D11",
    "primaryCompletionDate": "",
    "productId": 61,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html",
      "https://www.nature.com/articles/s41467-020-16256-y#change-history",
      "https://www.bloomberg.com/news/articles/2020-05-04/scientists-create-antibody-that-defeats-coronavirus-in-lab"
    ],
    "sponsors": [
      {
        "sponsorId": "4e2f58ce0e723737336ad8f95d829829f4eca5cd",
        "sponsorName": "Harbour Biomed"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PolyTope mAb Therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies candidates created using AI - computations - and statistics that will target multiple epitopes. 1200 ideal candidates will be chosen and validated in vitro.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PolyTope mAb Therapy",
    "primaryCompletionDate": "",
    "productId": 62,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html",
      "https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic",
      "https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html ; https://www.genengnews.com/covid-19-candidates/immunoprecise-antibodies-ipa-and-evqlv/",
      "https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/",
      "https://www.immunoprecise.com/immunoprecise-announces-the-launch-of-polytope-mab-therapy-tm-to-tackle-coronavirus-pandemic/"
    ],
    "sponsors": [
      {
        "sponsorId": "7670240cc18d7cdc6c4cdc1e43d130218caa45c4",
        "sponsorName": "ImmunoPrecise Antibodies Ltd"
      },
      {
        "sponsorId": "6eab2ef2c61e3007604b07fb544709610e671afa",
        "sponsorName": "EVQLV"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "IFX-1",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "korinna.pilz@inflarx.de\t",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "IFX-1",
    "primaryCompletionDate": "Sat, 31 Oct 2020 00:00:00 GMT",
    "productId": 63,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04333420",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Amsterdam",
        "country": "NLD",
        "lat": 52.35581819999999,
        "lng": 4.955726299999999,
        "locationId": "36cf6c0b65ff86ef13d2e0baa04d7c0ef6fff47b",
        "name": "1012 WX Amsterdam, Netherlands",
        "state": "NH"
      },
      {
        "city": "Maastricht",
        "country": "NLD",
        "lat": 50.8471422,
        "lng": 5.686401699999999,
        "locationId": "db999e211f79bf6f0fca8a11bed000f2ec5ec93d",
        "name": "Minderbroedersberg 4-6, 6211 LK Maastricht, Netherlands",
        "state": "LI"
      }
    ],
    "sources": [
      "https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html",
      "https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/",
      "https://www.nature.com/articles/d41587-020-00005-z",
      "https://www.inflarx.de/Home/Research---Development/Pipeline.html",
      "https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html",
      "https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/",
      "https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5"
    ],
    "sponsors": [
      {
        "sponsorId": "8b37254ccb340a35bc492a85125002e78f979b1e",
        "sponsorName": "InflaRx"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 31 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Aplidin",
    "chemicalName": "Plitidepsin",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Anti-melanoma agent,Currenlt approved in Australia for the treatment of multiple myeloma and demonstrated antiviral activity in vitro,Protcol for Phase 2 clinical trial for COVID-19 treatment was submitted on 04/02/2020 and is being evaluated.",
    "numSites": "",
    "otherPartners": "CSIC",
    "phase": "2",
    "preferredName": "Plitidepsin",
    "primaryCompletionDate": "",
    "productId": 64,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Spanish Fork",
        "country": "USA",
        "lat": 40.1335888,
        "lng": -111.6381703,
        "locationId": "7e97b056d296d630175bedc02f30b6ca64a1839a",
        "name": "E Market Pl Dr, Spanish Fork, UT 84660, USA",
        "state": "UT"
      }
    ],
    "sources": [
      "https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards",
      "https://www.drugbank.ca/drugs/DB04977",
      "https://www.researchgate.net/publication/26280244_The_mechanism_of_action_of_plitidepsin",
      "https://www.pharmamar.com/wp-content/uploads/2018/12/PR_Approval-APLIDIN-Australia.pdf",
      "https://www.oncozine.com/plitidepsin-a-novel-anti-cancer-agent-possibly-active-against-covid18/",
      "http://pharmamar.com/?lang=en",
      "https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505631/ ; http://pharmamar.com/wp-content/uploads/2020/04/PR_clinical_trial_plitidepsin_covid19_DEF.pdf",
      "https://www.thepharmaletter.com/article/pharmamar-says-its-drug-aplidin-could-treat-covid-19",
      "https://www.contractpharma.com/contents/view_breaking-news/2020-03-13/pharmamar-reports-positive-results-for-aplidin-against-coronavirus/"
    ],
    "sponsors": [
      {
        "sponsorId": "ec5f02cd738afe63b04534d0cc394af54573dc39",
        "sponsorName": "Pharmamar"
      },
      {
        "sponsorId": "880c99550c8a42deeaff83ad0902af0b020c8848",
        "sponsorName": "Centro Nacional Biotecnologia"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-immunosupressive",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Ganovo",
    "chemicalName": "Danoprevir,Ritonavir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Sat, 25 Jan 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Danoprevir has been approved in China for treatment of Hepititis C,Ritonavir is found in a combination FDA-approved product for treamtent of Hepititis C virus,A Phase 4 clinical trial was completed by no results have been posted,2nd Phase 4 clinical trial is currently underway.",
    "numSites": "1",
    "otherPartners": "Shaoxing Government",
    "phase": "4",
    "preferredName": "Ganovo,Ritonavir",
    "primaryCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "productId": 65,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04345276",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "71fb608dc17d1eaf10cc991028a010732590838d",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/",
      "https://pubmed.ncbi.nlm.nih.gov/30117020/ ; https://clinicaltrials.gov/ct2/show/NCT04291729?term=Ganovo&draw=1&rank=1 ; https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2",
      "https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "3799735fca71d687b33e157b0589e09999052c4f",
        "sponsorName": "Ascletis Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 18 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Protease Inhibitor",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "LUNAR-COV19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 08 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 27 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "mRNA vaccine. They color code where in the pipeline their drugs are. Someone who can tell shades of blue apart better than me should double check their current status. On 05/08/2020 preclinical data was reported to have strong support for human vaccine clinical trials to begin this summer.",
    "numSites": "",
    "otherPartners": "Duke-National University of Singapore",
    "phase": "",
    "preferredName": "LUNAR-COV19",
    "primaryCompletionDate": "",
    "productId": 66,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://arcturusrx.com/pipeline/#lunarcovid19",
      "https://www.globenewswire.com/news-release/2020/03/27/2007544/0/en/Arcturus-COVID-19-Vaccine-to-Benefit-from-Duke-NUS-Genetic-Correlation-System.html",
      "https://arcturusrx.com/pipeline/#lunarcovid19 ;  https://www.genengnews.com/covid-19-candidates/arcturus-therapeutics-and-duke-nus/",
      "https://arcturusrx.com/pipeline/#lunarcovid19 ; https://www.genengnews.com/covid-19-candidates/arcturus-therapeutics-and-duke-nus/ ; https://www.globenewswire.com/news-release/2020/05/08/2030402/0/en/Arcturus-Reports-Additional-Supportive-Preclinical-Data-for-its-COVID-19-Vaccine-Candidate-LUNAR-COV19.html",
      "https://www.globenewswire.com/news-release/2020/05/08/2030402/0/en/Arcturus-Reports-Additional-Supportive-Preclinical-Data-for-its-COVID-19-Vaccine-Candidate-LUNAR-COV19.html"
    ],
    "sponsors": [
      {
        "sponsorId": "20dfe597bbef86e0b9719260a7c300a5b0df15ae",
        "sponsorName": "Arcturus"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Avigan,favilavir,T-705",
    "chemicalName": "Favipiravir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Japan has stockpile of 2 million,Interim clinical test reports no clear efficiency so Japan has given up fasttracking approval. Clinical studies will still continue to show efficacy.",
    "numSites": "11",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Favipiravir",
    "primaryCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "productId": 67,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CHN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "fc031aa317078fca15980f229a50755d121cb4ce",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Beijing",
        "country": "CHN",
        "lat": 39.90419989999999,
        "lng": 116.4073963,
        "locationId": "4bed0d8e630e451ca7f1f0f81f925b1f9c6c0194",
        "name": "Beijing, China",
        "state": "Beijing"
      },
      {
        "city": null,
        "country": "CHN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "a8e3792c4f9f1ad8167c967d34f1c309e6377b9b",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "ca31c0141e42d7e92d07a3fa76f4c567bc224bbb",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CHN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "8d20a51a5707e385b5dc44146e3c00ce29986ece",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "71314ce9c1ec6216a9371500cba8f838b4f571f0",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "e6b736310add4a0d09a7abe4a125f78335283812",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "fe1aeda3b87a6f35f9bfa1d449579eb0785d51b6",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "90520b647f0cec9dcfea5821730c40c9bd488ae8",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "4c9e016b9c05309cccab0807ca7d795b9e63a87a",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "14966298e0e199c59ab938b0a23cefef9f4215ca",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [
      "https://www.fujifilm.com/jp/en/news/hq/3211",
      "https://www.fujifilm.com/jp/en/news/hq/3211 ; https://english.kyodonews.net/news/2020/05/10107f9396b1-breaking-news-japan-gives-up-on-approving-avigan-in-may-minister.html",
      "https://clinicaltrials.gov/ct2/show/NCT04359615?term=Avigan&phase=3&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04310228"
    ],
    "sponsors": [
      {
        "sponsorId": "d3f2295022832956ff09046194ed9b4ab9077636",
        "sponsorName": "Fujifilm"
      },
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 08 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "STI-6991",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "STI6991",
    "primaryCompletionDate": "",
    "productId": 94,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine",
      "https://www.sciencedirect.com/science/article/pii/S2590098620300130?via%3Dihub",
      "https://sorrentotherapeutics.com/contact-us/"
    ],
    "sponsors": [
      {
        "sponsorId": "d4f038c1fd0e4c52d93147fc334849bc67394496",
        "sponsorName": "Sorrento Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "DNA plasmid Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Taufik.Momin@zyduscadila.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 05 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 03 Jul 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Jul 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Uses a measles vector. They also are working on a DNA vaccine.",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1/2",
    "preferredName": "DNA_plasmid_Vaccine",
    "primaryCompletionDate": "",
    "productId": 68,
    "registryLink": "http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Changodar",
        "country": "IND",
        "lat": 22.9127385,
        "lng": 72.4314974,
        "locationId": "143b9f4318acf6df7609e14255dca4fce69f50f4",
        "name": "Changodar, Gujarat 382213, India",
        "state": "GJ"
      }
    ],
    "sources": [
      "https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf",
      "https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05",
      "https://zyduscadila.com/public/pdf/pressrelease/Zydus_vaccine_for_COVID-19_ZyCoV-D)_successfully_completes_preclinical_development_and_receives_permission_to_initiate_human_clinical_trials.pdf",
      "https://www.hindustantimes.com/india-news/zydus-cadilla-begins-human-dosing-in-trials/story-WI0sdKieiVMbnWdoAhJ8ZK.html"
    ],
    "sponsors": [
      {
        "sponsorId": "9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7",
        "sponsorName": "Zydus Cadila"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "CoronaVac",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Ricardo.palacios@butantan.gov.br",
        "name": null,
        "notes": "",
        "phone": "55 11 37232121",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 20 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Jul 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Dynaxax is contributing an adjuvant to boost immune responses in vaccinated patients and Sinovac is contributing an inactivated coronavirus vaccine candidate. Based on a SARS platform. Very little direct information. \"many months\" before its current stage of research is complete. Promise of efficacy has been shown in primates.",
    "numSites": "12",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "CoronaVac",
    "primaryCompletionDate": "Wed, 01 Sep 2021 00:00:00 GMT",
    "productId": 69,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04456595",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "BRA",
        "lat": -15.7631573,
        "lng": -47.8706311,
        "locationId": "6f72dab1a7260e4c80eba7d6b1f3a74ae12fe9a9",
        "name": "Brasilia, Federal District, 70910-900, Brazil",
        "state": "DF"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -19.870682,
        "lng": -43.9677359,
        "locationId": "1af4fdf327875076494ae1388dd974d35cc4a3f0",
        "name": "Av. Pres. Ant\u00f4nio Carlos, 6627 - Pampulha, Belo Horizonte - MG, 31270-901, Brazil",
        "state": "MG"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -25.4241606,
        "lng": -49.26194779999999,
        "locationId": "dece7e3f415986e54de202629721e1e326075919",
        "name": "R. Gen. Carneiro, 181 - Alto da Gl\u00f3ria, Curitiba - PR, 80060-900, Brazil",
        "state": "PR"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -30.0552693,
        "lng": -51.1733967,
        "locationId": "2ce9016f14175336b9a512ef4bc69bd7ae07696f",
        "name": "Av. Ipiranga, 6690 - Jardim Bot\u00e2nico, Porto Alegre - RS, 90610-000, Brazil",
        "state": "RS"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -22.8269585,
        "lng": -47.064116,
        "locationId": "7856f21231541ddbde4e5ced0fb0f8252bd6453e",
        "name": "R. Vital Brasil, 251 - Cidade Universit\u00e1ria, Campinas - SP, 13083-888, Brazil",
        "state": "SP"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -21.1624332,
        "lng": -47.8528816,
        "locationId": "4a050580036334a7e9988ea7eaa343b712031994",
        "name": "Campus Universit\u00e1rio - Rua Bernardino de Campos, 1000 - Centro, Ribeir\u00e3o Preto - SP, 65470-000, Brazil",
        "state": "SP"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -23.5558033,
        "lng": -46.6675382,
        "locationId": "73987899e769e0df3f97b8c98e7cceb8afbc090f",
        "name": "Av. Dr. Arnaldo, 165 - Pacaembu, S\u00e3o Paulo - SP, 01246-900, Brazil",
        "state": "SP"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -23.5571357,
        "lng": -46.6698263,
        "locationId": "97f1e6aa05dd4c3bb91be9c4682b5908cfff7276",
        "name": "Rua - Av. Dr. En\u00e9as Carvalho de Aguiar, 255 - Cerqueira C\u00e9sar, S\u00e3o Paulo - SP, 05403-000, Brazil",
        "state": "SP"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -23.558394,
        "lng": -46.659163,
        "locationId": "9372c037b95875ab6e7e574482623931a4e84a59",
        "name": "Av. Paulista, 2028 - Bela Vista, S\u00e3o Paulo - SP, 01310-200, Brazil",
        "state": "SP"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -23.6093792,
        "lng": -46.5735025,
        "locationId": "fce9e7555daad6aa53703a649af9ce4e7ad9660d",
        "name": "R. Santo Antonio, 50 - Centro, S\u00e3o Caetano do Sul - SP, 09521-160, Brazil",
        "state": "SP"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -20.8275796,
        "lng": -49.3962249,
        "locationId": "a37173a19e61af6bdb1e3354c9a925581b9d6de9",
        "name": "Av. Brg. Faria Lima, 5416 - Vila Sao Pedro, S\u00e3o Jos\u00e9 do Rio Preto - SP, 15090-000, Brazil",
        "state": "SP"
      },
      {
        "city": null,
        "country": "BRA",
        "lat": -22.8793797,
        "lng": -43.2435363,
        "locationId": "781cc17a4924220228cace5c0dbbd700e5b2d116",
        "name": "Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ, 21040-360, Brazil",
        "state": "RJ"
      }
    ],
    "sources": [
      "http://www.sinovac.com/?optionid=748",
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1",
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1 ; https://www.fool.com/investing/2020/05/29/dynavax-stock-soars-264-today-on-covid-19-vaccine.aspx"
    ],
    "sponsors": [
      {
        "sponsorId": "8cc7224f8b0bf621aabeff6011656a8d75f8d1ef",
        "sponsorName": "Sinovac Biotech Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 01 Oct 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "",
        "name": null,
        "notes": "No contact information found",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 12 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 25 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Jul 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Currently entered in Phase 2 Clinical Trial and will take about a year to complete a Phase 3 trial.",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Inactivated_Vaccine",
    "primaryCompletionDate": "",
    "productId": 70,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Abu Dhabi",
        "country": "ARE",
        "lat": 24.4690012,
        "lng": 54.33757689999999,
        "locationId": "9777ca1e8d54fcd22325b577b99b7feec73fbee2",
        "name": "Executive Building, Das Tower, 9th Floor, Sultan Bin Zayad Street 32nd Street - Khalidiyah St - Al BateenW12 - Abu Dhabi - United Arab Emirates",
        "state": "Abu Dhabi"
      },
      {
        "city": "Al Ain",
        "country": "ARE",
        "lat": 24.2211084,
        "lng": 55.7139272,
        "locationId": "1e8fcffc5d01d8af1bf52d0fa5e5b85993adfb24",
        "name": "Villa No. 38, Near Marriage Fund - Sheik Khalifa Bin Zayed St,Al Muwaiji, Al Ain - Al Muwaij'iOud Bin Sag-Han - Abu Dhabi - United Arab Emirates",
        "state": "Abu Dhabi"
      }
    ],
    "sources": [
      "http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm",
      "https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T",
      "https://www.firstpost.com/health/first-phase-3-human-trials-of-sinopharms-covid-19-vaccine-with-inactivated-virus-begins-in-abu-dhabi-8618421.html"
    ],
    "sponsors": [
      {
        "sponsorId": "3bd129a36a22b99edf40b395c2fad7b78193bda9",
        "sponsorName": "Sinopharm"
      },
      {
        "sponsorId": "ad6a16130480e1a77d5ffb88a5752fdae6685597",
        "sponsorName": "Wuhan Institute of Biological Products"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 15 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Codagenix Live-Attenuated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 28 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 13 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Live-Attenuated vaccine. Country might need to be switched to India later. Targeting September for human trials and 2022 for release.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Codagenix_LiveAttenuated_Vaccine",
    "primaryCompletionDate": "",
    "productId": 71,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html",
      "https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401",
      "https://www.hindustantimes.com/cities/serum-institute-confident-of-manufacturing-covid-vaccine-s-100-million-doses-if-trials-establish-efficacy/story-MrVAw982iSC2IdxAqWt9II.html"
    ],
    "sponsors": [
      {
        "sponsorId": "4f658739e6abe56363d5f2d9559538ae578e3aad",
        "sponsorName": "Codagenix"
      },
      {
        "sponsorId": "adee3b214297c2f83d459d75e4e295cde4fd187c",
        "sponsorName": "Serum Institute of India"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MVA-S encoded",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "The MVA vaccine for MERS acts as a basis for developing a vaccine for COVID-19. The first-human trial for MVA was completed 04/22/2020 and demonstrated safety and triggered the development of antibodies and T cell immunity.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MVAS_encoded",
    "primaryCompletionDate": "",
    "productId": 72,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.sciencedaily.com/releases/2020/04/200422132600.htm"
    ],
    "sponsors": [
      {
        "sponsorId": "42dc4894fcc96aa20e701b0f9bbb2fb79c1f0279",
        "sponsorName": "DZIF  German Center for Infection Research"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Greffex Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 11 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "They lack funding to start animal trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Greffex_Vaccine",
    "primaryCompletionDate": "",
    "productId": 73,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/",
      "https://markets.businessinsider.com/news/stocks/greffex-inc-completes-covid-19-vaccine-and-prepares-for-testing-1028986183"
    ],
    "sponsors": [
      {
        "sponsorId": "6c01129b833a3f153fc0408879e5a2bb4bf21b9b",
        "sponsorName": "Greffex"
      }
    ],
    "status": "On Hold",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AdaptVac Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 09 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Consortium of Danish companies and universities. One of the universities will likely be the sponsor when they go to clinical trials.",
    "numSites": "",
    "otherPartners": "PREVENT-nCOV Consortium,Bavarian Nordic,AGC Biologics",
    "phase": "",
    "preferredName": "AdaptVac_Vaccine",
    "primaryCompletionDate": "",
    "productId": 74,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf",
      "https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_8a2ffeae006e4e64981c2275ce894c89.pdf; https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_643c666ae7d84b0fb2189e635332a363.pdf",
      "https://www.adaptvac.com/",
      "https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_8a2ffeae006e4e64981c2275ce894c89.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "b3dd9ec1147ddf57383d3eda6cd2d861e37911df",
        "sponsorName": "AdaptVac"
      },
      {
        "sponsorId": "af0e9043938d3ffd18d4aa4f263c303abe7a87c1",
        "sponsorName": "PREVENTnCoV consortium"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "Being utilized in various COVID-19 therapeutic developments",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 75,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project",
      "c3102671",
      "https://news.cision.com/expres2ion-biotechnologies"
    ],
    "sponsors": [
      {
        "sponsorId": "433f99ff8c5ca5efa43e610e5d05b69e4f37d5ef",
        "sponsorName": "ExpreS2ion Biotechnologies ApS"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "USAMRIID Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "USAMRIID_Vaccine",
    "primaryCompletionDate": "",
    "productId": 76,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "455288f646569f2165f9af95d690d300bbd182a8",
        "sponsorName": "WRAIR"
      },
      {
        "sponsorId": "301d4da21e654a4dac3ab28cf3feba940a10bc5f",
        "sponsorName": "USAMRIID"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VaxHit",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 13 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "Utilized single peptide technology",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VaxHit",
    "primaryCompletionDate": "",
    "productId": 77,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf",
      "https://vaxil-bio.com/",
      "https://vaxil-bio.com/vaxil-provides-update-on-preclinical-experiment/",
      "https://www.bioworld.com/COVID19products",
      "https://vaxil-bio.com/vaxil-announces-the-identification-of-a-potential-corona-virus-vaccine-and-provides-an-update-in-the-previously-announced-debt-financing/",
      "https://www.globenewswire.com/news-release/2020/03/27/2007667/0/en/VAXIL-COMMENCES-PRECLINICAL-COVID-19-VACCINE-TRIAL-AND-FILES-AN-ADDITIONAL-COVID-19-PATENT.html"
    ],
    "sponsors": [
      {
        "sponsorId": "6326cfa8bba7bb5f22c4c0c558835079ac7fc122",
        "sponsorName": "Vaxil Bio Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "FlowVax COVID 19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Approach - Biodegradable microsphere peptide vaccine targeting SARS-CoV-2 nucleocapsid,T-cell vaccine,Expected to be used for pre- and post-exposure prophylaxis,Currently being tested on nonhuman primates",
    "numSites": "",
    "otherPartners": "University of Texas Medical Branch at Galveston",
    "phase": "",
    "preferredName": "FlowVax_COVID_19",
    "primaryCompletionDate": "",
    "productId": 78,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.flowpharma.com/",
      "https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine"
    ],
    "sponsors": [
      {
        "sponsorId": "306b4a5ca7bafa2c8cb1637d2068fec4dcf4c872",
        "sponsorName": "Flow Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "EPV-CoV19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Peptide-based epitope driven vaccine candidate,Expected to stimulate protective T-cell response,Expected to protect against severe disease rather than protect against infection,Specifically targeted at healthcare workers,Availability of no-cost licenses for the vaccine recipe for developing world countries who have GMP facilities for production of the vaccine,Phase 1 trial expected to begin in 3 months",
    "numSites": "",
    "otherPartners": "Generex Biotechnology,GAIA Vaccine Foundation,Entos Pharmaceuticals",
    "phase": "",
    "preferredName": "EPVCoV19",
    "primaryCompletionDate": "",
    "productId": 79,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://epivax.com/home/vaccine-services/covid-19",
      "https://www.generex.com/covid-19; https://epivax.com/home/vaccine-services/covid-19",
      "https://epivax.com/pipeline/epv-cov19"
    ],
    "sponsors": [
      {
        "sponsorId": "bd27e9eeb1bca08ea29864fa4bd2121d5abb6345",
        "sponsorName": "EpiVax Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "EpiVax Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "This seems to be separate from the partnership between Epivax and Generex,Also seems to be in pre-discovery phase as no specific mechanism has been identified",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "EpiVax_Vaccine",
    "primaryCompletionDate": "",
    "productId": 80,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology",
      "https://epivax.com/home/vaccine-services/covid-19",
      "https://news.uga.edu/uga-researchers-developing-coronavirus-vaccine/"
    ],
    "sponsors": [
      {
        "sponsorId": "2b2068ecd13962f5098c0b0cd04aaf01f7c38c14",
        "sponsorName": "EpiVax"
      },
      {
        "sponsorId": "e4bf2c53813e4971a809acf75b015ef7d10cbebc",
        "sponsorName": "University of Georgia"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "COVID 19 Vaccine",
    "chemicalName": "gp96-mediated vaccine",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Mechanism of action - gp96 + Viral Antigens",
    "numSites": "",
    "otherPartners": "University of Miami",
    "phase": "",
    "preferredName": "gp96mediated_vaccine",
    "primaryCompletionDate": "",
    "productId": 81,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b",
      "https://www.heatbio.com/product-pipeline/covid-19-vaccine",
      "https://physician-news.umiamihealth.org/miller-school-and-heat-biologics-to-collaborate-on-covid-19-vaccine/"
    ],
    "sponsors": [
      {
        "sponsorId": "69a6b23cf97fddaef2d35262b69a690f029417f4",
        "sponsorName": "Heat Biologics Inc"
      },
      {
        "sponsorId": "0fc2d17219cc99046bce21a2c41bc8215617c73d",
        "sponsorName": "University of Miami"
      },
      {
        "sponsorId": "9166254a6d2692220fda9b8f507259e0813000b3",
        "sponsorName": "Zolovax Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "T-cell therapies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "T-cell therapy,Baylor college of medicine is also pushing for testing of a vaccine developed against SARS-Cov-1 in 2016 - not much information about this",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Tcell_therapies",
    "primaryCompletionDate": "",
    "productId": 82,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "41801411fe7d66b24eae2e0411ee409f9ad29507",
        "sponsorName": "Baylor College of Medicine"
      },
      {
        "sponsorId": "e6c4cbd24fa49f8c604388e030a0790d277ad9a6",
        "sponsorName": "AlloVir"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IBIO-200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Virus-like particle,Developed using FastPharming technology,Patent filed in March 2020",
    "numSites": "",
    "otherPartners": "Texas A&M University System Laboratories",
    "phase": "",
    "preferredName": "IBIO200",
    "primaryCompletionDate": "",
    "productId": 83,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.ibioinc.com/pipeline",
      "https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates",
      "https://www.ibioinc.com/news/ibio-announces-advancement-of-covid-19-vaccine-program",
      "https://www.ibioinc.com/therapeutics-and-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "505b07d6981f93ee187513e197589f4c16f04b35",
        "sponsorName": "iBio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OncoGen Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Romania"],
    "countryCodes": ["ROU"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OncoGen_Vaccine",
    "primaryCompletionDate": "",
    "productId": 84,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf",
      "https://oncogen.ro/recognition-by-who/"
    ],
    "sponsors": [
      {
        "sponsorId": "102fe9bb3724bbad454162ce2f31318baff6facb",
        "sponsorName": "OncoGen"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Measles Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Molecule type - DNA based vaccine,Based on the use of measles vaccine as a vector",
    "numSites": "",
    "otherPartners": "Themis Bioscience GmbH,University of Pittsburg - Center for Vaccine Research,CEPI - MSD",
    "phase": "",
    "preferredName": "Measles_Vector_Vaccine",
    "primaryCompletionDate": "",
    "productId": 85,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut",
      "https://www.pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects",
      "https://www.pasteur.fr/en/press-area/press-documents/cepi-collaborates-institut-pasteur-consortium-develop-covid-19-vaccine",
      "http://pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects#p1 https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut"
    ],
    "sponsors": [
      {
        "sponsorId": "4504468bad51eef6a2ac6172fa89a91614df3c56",
        "sponsorName": "Merck"
      },
      {
        "sponsorId": "613e550610f0a7b4bbfd4fa0ab61e13afc1f9b01",
        "sponsorName": "Themis"
      },
      {
        "sponsorId": "a2a15d79e1f0b774dbc631aeed3b73af7f225cfe",
        "sponsorName": "Institute Pasteur"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "RNACure 2019-nCoV Vaccine Candidate VLP",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "RNACure Biopharma",
    "phase": "",
    "preferredName": "RNACure_2019nCoV_Vaccine_Candidate_VLP",
    "primaryCompletionDate": "",
    "productId": 86,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1",
      "https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm",
      "http://rnacure.com/pipeline"
    ],
    "sponsors": [
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      },
      {
        "sponsorId": "aa6799f660cd49b264d3e155560878bb15e8b804",
        "sponsorName": "Shanghai JiatTong University"
      },
      {
        "sponsorId": "f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0",
        "sponsorName": "RNACure Biopharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Stermina 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Stermina Therapeutics",
    "phase": "",
    "preferredName": "Stermina_2019nCoV_Vaccine_Candidate",
    "primaryCompletionDate": "",
    "productId": 87,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1",
      "https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/"
    ],
    "sponsors": [
      {
        "sponsorId": "20e19a20e9874c07beba2c307650020c6a63535b",
        "sponsorName": "China CDC"
      },
      {
        "sponsorId": "0a82122244646304c943aa942a96ad3ace268562",
        "sponsorName": "Tongji University"
      },
      {
        "sponsorId": "30508a3774a3fd8aeb4cf75885e2ee9011d8514f",
        "sponsorName": "Stermina"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OpenCorona 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Sweden"],
    "countryCodes": ["SWE"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Horizon 2020",
    "phase": "",
    "preferredName": "OpenCorona_2019nCoV_Vaccine_Candidate",
    "primaryCompletionDate": "",
    "productId": 88,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine"
    ],
    "sponsors": [
      {
        "sponsorId": "a26c2ef25366b153b9c8bb0d553426bbab80d427",
        "sponsorName": "Karolinska Institute"
      },
      {
        "sponsorId": "4b38f0c3421f6f67e79a27c6fd64a3930c0c2627",
        "sponsorName": "CobraBiologics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ReiThera 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "expected to enter clinical trials summer 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ReiThera_2019nCoV_Vaccine_Candidate",
    "primaryCompletionDate": "",
    "productId": 89,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://born2invest.com/articles/italian-biotech-companies-entered-the-race-to-find-a-vaccine-against-covid-19/",
      "https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/"
    ],
    "sponsors": [
      {
        "sponsorId": "6887e6de5a46033245e0bcb4f49450dcbadd7441",
        "sponsorName": "ReiThera"
      },
      {
        "sponsorId": "47a629349220fd43fa70123dac8ceb26e2dffba6",
        "sponsorName": "Leukocare"
      },
      {
        "sponsorId": "83f1710949070fb1e8f686c8dc72ac16dd164641",
        "sponsorName": "and Univercell"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "COVIGEN,BioNet 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Gene therapies",
    "notes": "phase 1/2 trial is planned for Q3 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "COVIGEN_BioNet_2019nCoV_Vaccine_Candidate",
    "primaryCompletionDate": "",
    "productId": 90,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "http://www.bionet-asia.com/media/news-events/",
      "https://www.nationthailand.com/news/30383030"
    ],
    "sponsors": [
      {
        "sponsorId": "6a4be0a2fbeb04dd3db2a97fc2f68a2388bb723b",
        "sponsorName": "BioNet Asia"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Ivomec",
    "chemicalName": "Ivermectin",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "chm@jhmi.edu",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Ivermectin",
    "primaryCompletionDate": "",
    "productId": 91,
    "registryLink": " https://clinicaltrials.gov/ct2/show/NCT04374279  ",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Baltimore",
        "country": "USA",
        "lat": 39.2967385,
        "lng": -76.59273619999999,
        "locationId": "beb4638a730897780762a89152902e0e1bb1b895",
        "name": "1800 Orleans St, Baltimore, MD 21287, USA",
        "state": "MD"
      }
    ],
    "sources": [
      "https://www.thejakartapost.com/news/2020/04/06/covid-19-antiparasitic-drug-can-kill-coronavirus-within-two-days-study-finds.html",
      "https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists",
      "https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=2",
      "https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=3",
      "https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=4",
      "https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=5",
      "https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=6",
      "https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=7"
    ],
    "sponsors": [
      {
        "sponsorId": "e8af2a52a069a3c9d2e7076dbd1450dcac577b76",
        "sponsorName": "Doherty Institute"
      },
      {
        "sponsorId": "5f1bf89bc842335651ec9768cc0377edaff0185e",
        "sponsorName": "Monash University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "NIH",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 92,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.newswise.com/articles/tulane-university-awarded-10-3-million-to-test-therapeutics-vaccines-for-novel-coronavirus"
    ],
    "sponsors": [
      {
        "sponsorId": "b4a99af9eec1a8f807ede0e67dd5e8d77867b245",
        "sponsorName": "Tulane University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaxcelerate vaccine,Hoth Voltron 2019-nCoV Vaccine Candidate,HaloVax",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "",
    "otherPartners": "Hoth,Voltron,MGH",
    "phase": "",
    "preferredName": "Vaxcelerate_vaccine_Hoth_Voltron_2019nCoV_Vaccine_Candidate_HaloVax",
    "primaryCompletionDate": "",
    "productId": 93,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://finance.yahoo.com/news/hoth-surges-collaboration-voltron-covid-134601408.html",
      "https://www.globenewswire.com/news-release/2020/03/24/2005714/0/en/Emerging-Markets-Report-Hoth-Therapeutics-is-Working-on-a-Potential-Coronavirus-Vaccine-COVID-19.html",
      "https://www.sec.gov/Archives/edgar/data/1711786/000121390020007153/ea119888ex99-1_hoththerap.htm"
    ],
    "sponsors": [
      {
        "sponsorId": "a0e1dd25259a873fb5bbf352459b984c718be493",
        "sponsorName": "Hoth Therapeutics"
      },
      {
        "sponsorId": "465edc414eb3f341233a89dca1b03de024926e45",
        "sponsorName": "Voltron Therapeutics"
      },
      {
        "sponsorId": "d515d87719a8a1e6a5874fe40dfaa22d5f577854",
        "sponsorName": "Vaccine and Immunotherapy Center"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA vaccines",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Sanofi Pasteur",
    "phase": "",
    "preferredName": "mRNA_vaccines",
    "primaryCompletionDate": "",
    "productId": 96,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00",
      "https://translate.bio/pipeline/"
    ],
    "sponsors": [
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      },
      {
        "sponsorId": "1ddb247542fcbc349fe829611d29e6ded2b999e7",
        "sponsorName": "Translate Bio"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "nebulized Ampion",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "In Phase 3 Trials for Osteoarthritis of the Knee",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nebulized_Ampion",
    "primaryCompletionDate": "",
    "productId": 97,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/",
      "https://www.drugbank.ca/drugs/DB14940",
      "https://ampiopharma.com/pipeline/",
      "https://ampiopharma.com/wp-content/uploads/2020/04/01-Apr-2020-Ampion-SARS-COV-2-and-ARDS-Flyer_v4.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "02881a510323f0cd43a11e035e7be1138b026116",
        "sponsorName": "Ampio Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Piclidenoson",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Zivit@canfite.co.il",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "In Phase 3 Trials for Rhumetoid Arthritis",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Piclidenoson",
    "primaryCompletionDate": "",
    "productId": 98,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04333472",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7261135,
        "lng": -73.99561469999999,
        "locationId": "cd7f5a372e5afa518afeb79e4c4e2c0679429c07",
        "name": "636 Broadway #218, New York, NY 10012, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "http://www.canfite.com/?KPageId=19",
      "https://ir.canfite.com/press-releases/detail/894/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university",
      "http://www.canfite.com/?KPageId=18",
      "https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel",
      "https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "2ea7e102c17c41b12f5ea330cafbdf8e967c6742",
        "sponsorName": "CanFite BioPharma Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 06 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "IFX-1",
    "chemicalName": "BDB-1",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "korinna.pilz@inflarx.de",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "BDB1",
    "primaryCompletionDate": "",
    "productId": 99,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04333420",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Amsterdam",
        "country": "NLD",
        "lat": 52.35581819999999,
        "lng": 4.955726299999999,
        "locationId": "31bdf7d46ac1141c00096cbe2ba46235f2e39062",
        "name": "1012 WX Amsterdam, Netherlands",
        "state": "NH"
      },
      {
        "city": "Maastricht",
        "country": "NLD",
        "lat": 50.8471422,
        "lng": 5.686401699999999,
        "locationId": "6bdeb2255b5f74c5411cccb89939a346950ce3cf",
        "name": "Minderbroedersberg 4-6, 6211 LK Maastricht, Netherlands",
        "state": "LI"
      }
    ],
    "sources": [
      "https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html",
      "https://www.inflarx.de/Home/Research---Development/Pipeline.html",
      "https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5",
      "https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "ecc0feedb452374f3f35ae9224fd597c82fca6a1",
        "sponsorName": "InflaRx NV"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 31 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Ryoncil",
    "chemicalName": "remestemcel-L",
    "conditionOrDisease": "ARDS",
    "contact": [
      {
        "email": "mary.marks@mountsinai.org",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "15",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "remestemcelL",
    "primaryCompletionDate": "",
    "productId": 100,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04371393",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Los Angeles",
        "country": "USA",
        "lat": 34.0223519,
        "lng": -118.285117,
        "locationId": "7a68730a1dcc791302216f7b6df1bc697fe03c2d",
        "name": "Los Angeles, CA 90007, USA",
        "state": "CA"
      },
      {
        "city": "Atlanta",
        "country": "USA",
        "lat": 33.7971368,
        "lng": -84.32224,
        "locationId": "536cae7d3673a67b9d9888e82806a6f154ac3ef0",
        "name": "201 Dowman Dr, Atlanta, GA 30322, USA",
        "state": "GA"
      },
      {
        "city": "Fort Wayne",
        "country": "USA",
        "lat": 41.0389032,
        "lng": -85.249408,
        "locationId": "8901bc26fb0b66af116732b7f4c522d15c1a48c9",
        "name": "7950 W Jefferson Blvd, Fort Wayne, IN 46804, USA",
        "state": "IN"
      },
      {
        "city": "New Orleans",
        "country": "USA",
        "lat": 29.9631002,
        "lng": -90.1436859,
        "locationId": "71cb1aba32f422796f0c8c07e41eee650d780d36",
        "name": "1315 Jefferson Hwy, New Orleans, LA 70121, USA",
        "state": "LA"
      },
      {
        "city": "Baltimore",
        "country": "USA",
        "lat": 39.2892017,
        "lng": -76.6257057,
        "locationId": "93f55711a3d5259dca07354a86a51dd94ea8dab6",
        "name": "620 W Lexington St, Baltimore, MD 21201, USA",
        "state": "MD"
      },
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3361091,
        "lng": -71.1074884,
        "locationId": "b23b063af13f7bf7098d83d1c6c9a2553a5cb6c5",
        "name": "75 Francis St, Boston, MA 02115, USA",
        "state": "MA"
      },
      {
        "city": "Ann Arbor",
        "country": "USA",
        "lat": 42.2780436,
        "lng": -83.7382241,
        "locationId": "2c21d3350b83efe1f000b1c6863717dd2285b6e2",
        "name": "500 S State St, Ann Arbor, MI 48109, USA",
        "state": "MI"
      },
      {
        "city": "Lebanon",
        "country": "USA",
        "lat": 43.6754932,
        "lng": -72.2729588,
        "locationId": "f36d0847e074837a00639a8869c19fa291546e91",
        "name": "1 Medical Center Dr, Lebanon, NH 03766, USA",
        "state": "NH"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7702407,
        "lng": -73.9906883,
        "locationId": "dd6e3d4d4106d32e81094d0b3e4f871930514fca",
        "name": "555 W 57th St, New York, NY 10019, USA",
        "state": "NY"
      },
      {
        "city": "Asheville",
        "country": "USA",
        "lat": 35.576583,
        "lng": -82.54922200000001,
        "locationId": "0b5176ea712d2004ab7a2fd4fe6ce63f34878b47",
        "name": "509 Biltmore Ave, Asheville, NC 28801, USA",
        "state": "NC"
      },
      {
        "city": "Durham",
        "country": "USA",
        "lat": 36.0075052,
        "lng": -78.938442,
        "locationId": "fab4f5d719be21f5cd72495eafc407c22aa4983d",
        "name": "2301 Erwin Rd, Durham, NC 27710, USA",
        "state": "NC"
      },
      {
        "city": "Cleveland",
        "country": "USA",
        "lat": 41.502527,
        "lng": -81.620983,
        "locationId": "057fd7644c3a492024ef7b959bae193a03845157",
        "name": "9500 Euclid Ave, Cleveland, OH 44195, USA",
        "state": "OH"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9522188,
        "lng": -75.1932137,
        "locationId": "9b0e9ac55396a9ffc6017b7380dfa5ebd2b5eac6",
        "name": "Philadelphia, PA 19104, USA",
        "state": "PA"
      },
      {
        "city": "Plano",
        "country": "USA",
        "lat": 33.0136238,
        "lng": -96.7910986,
        "locationId": "0b2f9dca029f65f2e72c93c927474e27598464d4",
        "name": "4700 Alliance Blvd, Plano, TX 75093, USA",
        "state": "TX"
      },
      {
        "city": "Charlottesville",
        "country": "USA",
        "lat": 38.0335529,
        "lng": -78.5079772,
        "locationId": "ca1de73a46ab9cd9067efeb02c7455b16c78cadd",
        "name": "Charlottesville, VA, USA",
        "state": "VA"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14",
      "http://investorsmedia.mesoblast.com/static-files/336699fe-c5ab-41f2-801e-404c3739275c",
      "http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc",
      "http://investorsmedia.mesoblast.com/static-files/f9eb8ecd-9c72-4207-8a51-0187607948b6",
      "https://clinicaltrials.gov/ct2/show/study/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "d4959407d4633b3c9180469947d99a947263aeb9",
        "sponsorName": "Mesoblast Limited"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Actemra",
    "chemicalName": "tocilizumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "",
        "name": null,
        "notes": "",
        "phone": "888-662-6728",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 03 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "69",
    "otherPartners": "Biomedical Advanced Research and Development Authority,U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response",
    "phase": "3",
    "preferredName": "tocilizumab",
    "primaryCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "productId": 101,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04320615",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "La Jolla",
        "country": "USA",
        "lat": 32.8800604,
        "lng": -117.2340135,
        "locationId": "2416d61bee763afa0a8bbe9cbffae12f1936f236",
        "name": "9500 Gilman Dr, La Jolla, CA 92093, USA",
        "state": "CA"
      },
      {
        "city": "La Mesa",
        "country": "USA",
        "lat": 32.7804422,
        "lng": -117.0094774,
        "locationId": "0d2888d4d809377ef0a5b9fc9ca27fae04905d27",
        "name": "5565 Grossmont Center Dr building 2 suite, La Mesa, CA 91942, USA",
        "state": "CA"
      },
      {
        "city": "Los Angeles",
        "country": "USA",
        "lat": 34.06428289999999,
        "lng": -118.4423562,
        "locationId": "572fc1891c7ee8852f9ec2d562e8ae962126cf1f",
        "name": "10833 Le Conte Ave, Los Angeles, CA 90095, USA",
        "state": "CA"
      },
      {
        "city": "Stanford",
        "country": "USA",
        "lat": 37.4274745,
        "lng": -122.169719,
        "locationId": "3b19aad8359bd9449d3419a33ddef0ff6e57b1fa",
        "name": "450 Serra Mall, Stanford, CA 94305, USA",
        "state": "CA"
      },
      {
        "city": "Denver",
        "country": "USA",
        "lat": 39.7279895,
        "lng": -104.9913193,
        "locationId": "d7204a4845aef1341ec3bbd0917fc97d91387a83",
        "name": "777 Bannock St, Denver, CO 80204, USA",
        "state": "CO"
      },
      {
        "city": "Miami",
        "country": "USA",
        "lat": 25.7904064,
        "lng": -80.21199279999999,
        "locationId": "fb43b6e092a588a96f93eefca550c747b6bae8ba",
        "name": "1600 NW 10th Ave #1140, Miami, FL 33136, USA",
        "state": "FL"
      },
      {
        "city": "Chicago",
        "country": "USA",
        "lat": 41.8747917,
        "lng": -87.6674637,
        "locationId": "bc2e855f7e60bf812c01ce5a8bbdf8adb26d60aa",
        "name": "1620 W Harrison St, Chicago, IL 60612, USA",
        "state": "IL"
      },
      {
        "city": "Baton Rouge",
        "country": "USA",
        "lat": 30.442823,
        "lng": -90.99998509999999,
        "locationId": "f9e68737bcec0d7144b9a5d2550a607cd6ab6d2c",
        "name": "17000 Medical Center Dr, Baton Rouge, LA 70816, USA",
        "state": "LA"
      },
      {
        "city": "Springfield",
        "country": "USA",
        "lat": 42.1216158,
        "lng": -72.6037013,
        "locationId": "dfeadb52eed270984a60e54f8a5f60770f0b5b2e",
        "name": "759 Chestnut St, Springfield, MA 01199, USA",
        "state": "MA"
      },
      {
        "city": "Rochester",
        "country": "USA",
        "lat": 44.0226255,
        "lng": -92.46688329999999,
        "locationId": "0fda3b86f6de6a21de6c2a0f5363eb368bf40953",
        "name": "200 1st St SW, Rochester, MN 55905, USA",
        "state": "MN"
      },
      {
        "city": "Hackensack",
        "country": "USA",
        "lat": 40.8840343,
        "lng": -74.05648819999999,
        "locationId": "245979b5bbbdd16c3f4833be4c912347fcbe7be2",
        "name": "30 Prospect Ave, Hackensack, NJ 07601, USA",
        "state": "NJ"
      },
      {
        "city": "New Brunswick",
        "country": "USA",
        "lat": 40.4945833,
        "lng": -74.4491668,
        "locationId": "f060ee853251a035ab3c96d818cb419f3e858817",
        "name": "125 Paterson St # 5100, New Brunswick, NJ 08901, USA",
        "state": "NJ"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 40.8674032,
        "lng": -73.9064045,
        "locationId": "cc879a5b17180e93053bbbe2bf9a51d9c36d4d2f",
        "name": "130 W Kingsbridge Rd, The Bronx, NY 10468, USA",
        "state": "NY"
      },
      {
        "city": "Cleveland",
        "country": "USA",
        "lat": 41.4620067,
        "lng": -81.69753519999999,
        "locationId": "de9ace28ed1016294eeccc1d3c57e0d350451ee6",
        "name": "2500 Metrohealth Dr, Cleveland, OH 44109, USA",
        "state": "OH"
      },
      {
        "city": "Cleveland",
        "country": "USA",
        "lat": 41.4613462,
        "lng": -81.6974151,
        "locationId": "765f01bab1a29dcdad3e8cb04fdc61ecbfbaad74",
        "name": "2500 Metrohealth Dr, Cleveland, OH 44109, USA",
        "state": "OH"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9478658,
        "lng": -75.1560106,
        "locationId": "995054edcce4642ce87a253e5004134b6b89e27a",
        "name": "901 Walnut St, Philadelphia, PA 19107, USA",
        "state": "PA"
      },
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.7077057,
        "lng": -95.40062239999999,
        "locationId": "d3e199fd2ac33d7a127f1cc776bc7b197e8f46c3",
        "name": "6720 Bertner Ave, Houston, TX 77030, USA",
        "state": "TX"
      },
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.7110567,
        "lng": -95.3945559,
        "locationId": "172f00436da4d891323f4857dc9a321268d8ea70",
        "name": "1504 Ben Taub Loop, Houston, TX 77030, USA",
        "state": "TX"
      },
      {
        "city": "St. George",
        "country": "USA",
        "lat": 37.0982795,
        "lng": -113.5559579,
        "locationId": "109ac1852929370dcfa2038699834192a9cc8152",
        "name": "577 River Rd, St. George, UT 84790, USA",
        "state": "UT"
      },
      {
        "city": "Salt Lake City",
        "country": "USA",
        "lat": 40.7607793,
        "lng": -111.8910474,
        "locationId": "f49c376943e153ffbbf56415b6b97d2c7415b3ad",
        "name": "Salt Lake City, UT, USA",
        "state": "UT"
      },
      {
        "city": "Kirkland",
        "country": "USA",
        "lat": 47.715878,
        "lng": -122.1786164,
        "locationId": "036d65c53ff61936b681c1234146b6921a81bfca",
        "name": "12303 Northeast 130th Lane, Suite Coral 120, Kirkland, WA 98034, USA",
        "state": "WA"
      },
      {
        "city": "Seattle",
        "country": "USA",
        "lat": 47.6073059,
        "lng": -122.3102867,
        "locationId": "93c2cd3e582456d2cd2127f33e4caa1523d2e1e1",
        "name": "500 17th Ave, Seattle, WA 98122, USA",
        "state": "WA"
      },
      {
        "city": "Hamilton",
        "country": "CAN",
        "lat": 43.2624646,
        "lng": -79.85409159999999,
        "locationId": "fba5fe2d9199ca015aa1b66db5dcfb747dcc38b8",
        "name": "237 Barton St E, Hamilton, ON L8L 2X2, Canada",
        "state": "ON"
      },
      {
        "city": "Hamilton",
        "country": "CAN",
        "lat": 43.2218746,
        "lng": -79.7743193,
        "locationId": "55a95bfb997fefdaaaae08dfed0c70e86e6fe3b3",
        "name": "2757 King St E, Hamilton, ON L8G 5E4, Canada",
        "state": "ON"
      },
      {
        "city": "Toronto",
        "country": "CAN",
        "lat": 43.6598777,
        "lng": -79.38761810000001,
        "locationId": "4619823c8e7362f02262888eb21263794f535213",
        "name": "101 College St, Toronto, ON M5G 1L7, Canada",
        "state": "ON"
      },
      {
        "city": "Toronto",
        "country": "CAN",
        "lat": 43.6534793,
        "lng": -79.4052302,
        "locationId": "e39091b4816ddf9f2ca36c4bfb5518fe0150bf56",
        "name": "399 Bathurst St, Toronto, ON M5T 2S8, Canada",
        "state": "ON"
      },
      {
        "city": "Montr\u00e9al",
        "country": "CAN",
        "lat": 45.513589,
        "lng": -73.5761859,
        "locationId": "db408242f15c9a082c1774f405df1a10a736db7a",
        "name": "110 Avenue des Pins, Montr\u00e9al, QC H2W 1R7, Canada",
        "state": "QC"
      },
      {
        "city": "K\u00f8benhavn",
        "country": "CNK",
        "lat": 55.6960841,
        "lng": 12.5667877,
        "locationId": "2a9d9235eac02be765053076f607e2483af3512b",
        "name": "Blegdamsvej 9, 2100 K\u00f8benhavn, Denmark",
        "state": null
      },
      {
        "city": "Hvidovre",
        "country": "CNK",
        "lat": 55.648779,
        "lng": 12.470292,
        "locationId": "1ea1862019fc39f44880c315c50c15091f25488b",
        "name": "Ketteg\u00e5rd Alle 30, 2650 Hvidovre, Denmark",
        "state": null
      },
      {
        "city": "Odense",
        "country": "CNK",
        "lat": 55.3850091,
        "lng": 10.3675736,
        "locationId": "2fb0c49311697c799913d1f84dfc9ddb9f01d0f6",
        "name": "J. B. Winsl\u00f8ws Vej 4, 5000 Odense, Denmark",
        "state": null
      },
      {
        "city": "Roskilde",
        "country": "CNK",
        "lat": 55.6361646,
        "lng": 12.0903485,
        "locationId": "3e7e56e6ccede6f09ad057a7ee8b03115d47573a",
        "name": "Sygehusvej 10, 4000 Roskilde, Denmark",
        "state": null
      },
      {
        "city": "La Roche-sur-Yon",
        "country": "FRA",
        "lat": 46.6677714,
        "lng": -1.4118805,
        "locationId": "a8d45b3789b7946f04ca2cdfedf51ee4899bece6",
        "name": "Centre Hospitalier D\u00e9partemental Vend\u00e9e, Boulevard St\u00e9phane Moreau, 85000 La Roche-sur-Yon, France",
        "state": "Pays de la Loire"
      },
      {
        "city": "Limoges",
        "country": "FRA",
        "lat": 45.812311,
        "lng": 1.2357132,
        "locationId": "8e5ab32329d70141e93b33e5dc44b84f17ef2468",
        "name": "2 Avenue Martin Luther King, 87000 Limoges, France",
        "state": "Nouvelle-Aquitaine"
      },
      {
        "city": "Lyon",
        "country": "FRA",
        "lat": 45.7818414,
        "lng": 4.8308236,
        "locationId": "71d293c395f38140c46df757609ef39721fea7aa",
        "name": "103 Grande Rue de la Croix-Rousse, 69004 Lyon, France",
        "state": "Auvergne-Rh\u00f4ne-Alpes"
      },
      {
        "city": "Nantes",
        "country": "FRA",
        "lat": 47.218371,
        "lng": -1.553621,
        "locationId": "d2d78c994766339a6603ed6988c1be8dae4fedfe",
        "name": "44000 Nantes, France",
        "state": "Pays de la Loire"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.8370792,
        "lng": 2.3650429,
        "locationId": "1e75ffb4bbf73fd2d0cf2f06cc4420932db8c13c",
        "name": "47-83 Boulevard de l'H\u00f4pital, 75013 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.8368937,
        "lng": 2.3402667,
        "locationId": "1ee896db0af15495ead8c000e3b1648eca988489",
        "name": "27 Rue du Faubourg Saint-Jacques, 75014 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Tours",
        "country": "FRA",
        "lat": 47.3872732,
        "lng": 0.6696852999999999,
        "locationId": "f05eca221bc5372b2b0263da880d88c2dfbd57c3",
        "name": "2 Boulevard Tonnell\u00e9, 37000 Tours, France",
        "state": "Centre-Val de Loire"
      },
      {
        "city": "D\u00fcsseldorf",
        "country": "DEU",
        "lat": 51.1987065,
        "lng": 6.788855099999999,
        "locationId": "18a05286f9e0962873f2838a33506b04245d16ce",
        "name": "Universit\u00e4tsklinikum D\u00fcsseldorf, Moorenstra\u00dfe 5, 40225 D\u00fcsseldorf, Germany",
        "state": "NRW"
      },
      {
        "city": "Hannover",
        "country": "DEU",
        "lat": 52.3835661,
        "lng": 9.804956899999999,
        "locationId": "a8477cab3853222e04b65617504c0545e2bd324b",
        "name": "Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany",
        "state": "NDS"
      },
      {
        "city": "KI",
        "country": "DEU",
        "lat": 54.3298132,
        "lng": 10.1406978,
        "locationId": "0633545d9b2a4281ac3a063c85a5cee890116376",
        "name": "Arnold-Heller-Stra\u00dfe 3/Haus K3, 24105 Kiel, Germany",
        "state": "SH"
      },
      {
        "city": "K\u00f6ln",
        "country": "DEU",
        "lat": 50.9234823,
        "lng": 6.917063499999999,
        "locationId": "ede35a2113f86994e9eb173d8eed4b02f6937059",
        "name": "Kerpener Str. 62, 50937 K\u00f6ln, Germany",
        "state": "NRW"
      },
      {
        "city": "M\u00fcnchen",
        "country": "DEU",
        "lat": 48.110982,
        "lng": 11.4721475,
        "locationId": "53c16b98d8c31355b7911a2fc43000a2f41931cf",
        "name": "Marchioninistra\u00dfe 15, 81377 M\u00fcnchen, Germany",
        "state": "BY"
      },
      {
        "city": "Napoli",
        "country": "ITA",
        "lat": 40.8677625,
        "lng": 14.2207009,
        "locationId": "cafb46693a1763cf3ab777dd461f1552584a02e1",
        "name": "Zona Ospedaliera, 80131 Napoli NA, Italy",
        "state": "Campania"
      },
      {
        "city": "Roma",
        "country": "ITA",
        "lat": 41.866501,
        "lng": 12.4564793,
        "locationId": "bf0dea8eeb5580b65fa20bf8652de39f33c89f69",
        "name": "Via Portuense, 292, 00149 Roma RM, Italy",
        "state": "Lazio"
      },
      {
        "city": "Bergamo",
        "country": "ITA",
        "lat": 45.686107,
        "lng": 9.638066,
        "locationId": "1d4683f3cd867828fecdc26269d4c9fec8de7f76",
        "name": "Piazza OMS, 1, 24127 Bergamo BG, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Bergamo",
        "country": "ITA",
        "lat": 45.686107,
        "lng": 9.638066,
        "locationId": "50f07f80f75d759985799a9df97c9c83357f4844",
        "name": "Piazza OMS, 1, 24127 Bergamo BG, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Milano",
        "country": "ITA",
        "lat": 45.4847912,
        "lng": 9.2190716,
        "locationId": "95fd55908eb3e04927455f1f9b652c4e952ac674",
        "name": "Via Giovanni Ricordi, 1, 20131 Milano MI, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Monza",
        "country": "ITA",
        "lat": 45.6018705,
        "lng": 9.2597899,
        "locationId": "32e5542b7b76b93054098c9732a8ecdd29d603f8",
        "name": "Via G. B. Pergolesi, 33, 20900 Monza MB, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Pavia",
        "country": "ITA",
        "lat": 45.1962179,
        "lng": 9.1488319,
        "locationId": "c42549eaabc147ba3f3a75533b3ce04e066d2bd8",
        "name": "Viale Camillo Golgi, 19, 27100 Pavia PV, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Pavia",
        "country": "ITA",
        "lat": 45.1847248,
        "lng": 9.1582069,
        "locationId": "c9b09dc2eebb846c467137d892c2cddee8f11d7a",
        "name": "27100 Pavia, Province of Pavia, Italy",
        "state": "Lombardy"
      },
      {
        "city": "Breda",
        "country": "NLD",
        "lat": 51.57417,
        "lng": 4.7628566,
        "locationId": "596d9f061382a7fd6afad4b2e39e68f6aaf1ffd6",
        "name": "Langendijk 75, 4819 EV Breda, Netherlands",
        "state": "NB"
      },
      {
        "city": "Nieuwegein",
        "country": "NLD",
        "lat": 52.0252656,
        "lng": 5.081456,
        "locationId": "04bf1b6cc61f22108363d9122bff3321717ac615",
        "name": "Koekoekslaan 1, 3435 CM Nieuwegein, Netherlands",
        "state": "UT"
      },
      {
        "city": "Rotterdam",
        "country": "NLD",
        "lat": 51.9112533,
        "lng": 4.470303700000001,
        "locationId": "deb1687a76cd69b0774648eab53b9617db4fe7cb",
        "name": "Dijkzigt, 3015 CN Rotterdam, Netherlands",
        "state": "ZH"
      },
      {
        "city": "Utrecht",
        "country": "NLD",
        "lat": 52.0865646,
        "lng": 5.179913099999999,
        "locationId": "e3226a8c4a3110bcf6ec8dc1c6acbfcd9a8b35b8",
        "name": "Heidelberglaan 100, 3584 CX Utrecht, Netherlands",
        "state": "UT"
      },
      {
        "city": "L'Hospitalet de Llobregat",
        "country": "ESP",
        "lat": 41.3448959,
        "lng": 2.1042573,
        "locationId": "c06cf186a2c6fd116124ba2404e7a335eae4967d",
        "name": "Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain",
        "state": "CT"
      },
      {
        "city": "L'Hospitalet de Llobregat",
        "country": "ESP",
        "lat": 41.3661865,
        "lng": 2.1164942,
        "locationId": "003815dd0dfb4a01d84644f8dba1b25efdab9f95",
        "name": "L'Hospitalet de Llobregat, Barcelona, Spain",
        "state": "CT"
      },
      {
        "city": "Barcelona",
        "country": "ESP",
        "lat": 41.4283018,
        "lng": 2.142488,
        "locationId": "70e4b5a3568e64ae64b5683a6b41a5fc23cbee4b",
        "name": "Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain",
        "state": "CT"
      },
      {
        "city": "Barcelona",
        "country": "ESP",
        "lat": 41.3894436,
        "lng": 2.1523119,
        "locationId": "1d3342d7752a12907b1f9f980fa519231806ed93",
        "name": "C. de Villarroel, 170, 08036 Barcelona, Spain",
        "state": "CT"
      },
      {
        "city": "Madrid",
        "country": "ESP",
        "lat": 40.4811633,
        "lng": -3.6873977,
        "locationId": "b0c458eee6e914441456be843d45423b5ea79e13",
        "name": "Paseo de la Castellana, 261, 28046 Madrid, Spain",
        "state": "Comunidad de Madrid"
      },
      {
        "city": "Madrid",
        "country": "ESP",
        "lat": 40.48760430000001,
        "lng": -3.6951156,
        "locationId": "a1a0ab8ecc027ccfc1f24081ea90004884608033",
        "name": "M-607, km. 9, 100, 28034 Madrid, Spain",
        "state": "Comunidad de Madrid"
      },
      {
        "city": "Madrid",
        "country": "ESP",
        "lat": 40.4185038,
        "lng": -3.6724986,
        "locationId": "50f3e9fcd7ed361e0d9dfc25a86ca169543f0ad9",
        "name": "Calle del Dr. Esquerdo, 46, 28003 Madrid, Spain",
        "state": "Comunidad de Madrid"
      },
      {
        "city": "Madrid",
        "country": "ESP",
        "lat": 40.4902031,
        "lng": -3.6667259,
        "locationId": "9b33c69d594978173b47027c42c4c76965913364",
        "name": "Calle de O\u00f1a, 10, 28050 Madrid, Spain",
        "state": "Comunidad de Madrid"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 55.883619,
        "lng": -4.321016,
        "locationId": "2aa8494af208755a409d83d36496cfadc5d42a66",
        "name": "1055 Great Western Rd, Glasgow G12 0XH, UK",
        "state": "Scotland"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 53.80254309999999,
        "lng": -1.5528919,
        "locationId": "303a40e03718b26cfd888e35408727338b2d1fbe",
        "name": "Great George St, Leeds LS1 3EX, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.5250834,
        "lng": -0.1363551,
        "locationId": "94746a6fa0870d32cdc36bd235f72cfeb0f9bffa",
        "name": "235 Euston Rd, Bloomsbury, London NW1 2BU, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.55314749999999,
        "lng": -0.1659994,
        "locationId": "7004023e95f41d305cade6ba23b31c18dddebe05",
        "name": "Pond St, Hampstead, London NW3 2QG, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.4266437,
        "lng": -0.1756245,
        "locationId": "6d26e09a9b69d8232cab4f75922fe3b675a1ae16",
        "name": "St George's Hospital, Blackshaw Rd, Tooting, London SW17 0QT, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.49879970000001,
        "lng": -0.1748772,
        "locationId": "1efbf6ac57aa47ce516d40a04b731f8392700a92",
        "name": "South Kensington, London SW7 2BU, UK",
        "state": "England"
      },
      {
        "city": "Crumpsall",
        "country": "GBR",
        "lat": 53.5184925,
        "lng": -2.2301193,
        "locationId": "02d8abc51c59aa61a87a906eb6549c31fe4331e3",
        "name": "Delaunays Rd, Crumpsall, Manchester M8 5RB, UK",
        "state": "England"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 53.48340959999999,
        "lng": -2.2641302,
        "locationId": "00b1bcc13ab3ba39ade2d2e43e070eed7c6fae23",
        "name": "Salford M5, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t",
      "https://www.drugbank.ca/drugs/DB06273",
      "https://www.drugbank.ca/drugs/DB06274",
      "https://www.drugbank.ca/drugs/DB06275",
      "https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "5a5027c645a5720c448e627baafac159a26508b8",
        "sponsorName": "Genetech"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 03 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Diammonium glycyrrhizinate",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Unclear if any clincial trials are occuring",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Diammonium_glycyrrhizinate",
    "primaryCompletionDate": "",
    "productId": 102,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate",
      "https://pubchem.ncbi.nlm.nih.gov/compound/Diammonium-glycyrrhizinate"
    ],
    "sponsors": [
      {
        "sponsorId": "828d3ce717e4188e36142a37dde46c7150e54532",
        "sponsorName": "Sino Biopharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Dantonic",
    "chemicalName": "T89",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "T89 is an industrialized botanical drug formula developed from traditional Chinese Medicine. It is a mixture of multiple plant extracts and other excipients. It is to be tested for increasing blood O2 saturation in the ongoing clinical trial registered in US. The trial was approved but not yet recruiting.",
    "numSites": "Not specified",
    "otherPartners": "Tasly Pharmaceuticals",
    "phase": "",
    "preferredName": "T89",
    "primaryCompletionDate": "Mon, 15 Jun 2020 00:00:00 GMT",
    "productId": 103,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04285190",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "b7ba1629417aaa0bcc9fba336509da223ffe73a3",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04285190",
      "https://www.taslyus.com/pipeline/t89/",
      "https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "0dda51f9c95a47c39d878234d93d16d7902c83f1",
        "sponsorName": "Tasly Pharmaceuticals"
      },
      {
        "sponsorId": "3a0d49eb534018ed04f1ba984529ab2611135695",
        "sponsorName": "Arbor Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 15 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 26 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Monoclonal Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Monoclonal_Antibodies",
    "primaryCompletionDate": "",
    "productId": 104,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html"
    ],
    "sponsors": [
      {
        "sponsorId": "156a9d5b5c0452de6985da63b61ee8521a939741",
        "sponsorName": "AstraZeneca PLC"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Monoclonal Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "they have 300 candidates now will narrow down to fewer candidates",
    "numSites": "",
    "otherPartners": "Celltrion",
    "phase": "",
    "preferredName": "Monoclonal_Antibodies",
    "primaryCompletionDate": "",
    "productId": 105,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/",
      "https://www.centerforbiosimilars.com/news/celltrion-amgen-join-race-to-develop-antisarscov2-antibodies"
    ],
    "sponsors": [
      {
        "sponsorId": "625c2965f7108c1ad1edf37eef366aad6b28fbd8",
        "sponsorName": "Celltrion"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Monoclonal Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "IIBR will use the manufacturing platform of Dyadic to produce their monoclonal antibody candidate",
    "numSites": "",
    "otherPartners": "IIBR,Dyadic",
    "phase": "",
    "preferredName": "Monoclonal_Antibodies",
    "primaryCompletionDate": "",
    "productId": 106,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://apnews.com/4e3931bb97391362be6cd5da36e8ef28"],
    "sponsors": [
      {
        "sponsorId": "bc5f1b8a05634976386ebb4a0eb43f430166cf2f",
        "sponsorName": "Israel Institute for Biological Research IIBR"
      },
      {
        "sponsorId": "4aa813a58d95ae6daf00386144326869f4a7e3ee",
        "sponsorName": "Dyadic International Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "KPL-301",
    "chemicalName": "mavrilimumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "The drug had up to phase-2 trial for other indications. Successfully used in Covid-19 pts in Italy (did not find the exact trial description).",
    "numSites": "1",
    "otherPartners": "Kiniksa Pharmaceuticals,Virginia Commonwealth University",
    "phase": "2",
    "preferredName": "mavrilimumab",
    "primaryCompletionDate": "",
    "productId": 107,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Richmond",
        "country": "USA",
        "lat": 37.5407246,
        "lng": -77.4360481,
        "locationId": "21c619833e0d240c60ded2b0ca3c8ce43d83cb59",
        "name": "Richmond, VA, USA",
        "state": "VA"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2",
      "https://www.kiniksa.com/our-pipeline/mavrilimumab/",
      "https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2",
      "https://clinicaltrials.gov/ct2/results?term=Mavrilimumab; https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab"
    ],
    "sponsors": [
      {
        "sponsorId": "f0b7d34b0d2bf183e3127d2f2ae6859f2e0c2303",
        "sponsorName": "Kiniksa Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Plasma-derived hyperimmune globulin therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      {
        "email": "",
        "name": null,
        "notes": "",
        "phone": "",
        "website": "https://www.donatingplasma.org/donation/find-a-donor-center"
      }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Takeda started development as TAK-888. Several groups working on immunoglobulin strategies are now working together. They need plasma donors.",
    "numSites": "",
    "otherPartners": "Biotest,Bio Products Laboratory,Octa Pharma,LFB,CSL Behrig",
    "phase": "",
    "preferredName": "Plasmaderived_hyperimmune_globulin_therapy",
    "primaryCompletionDate": "",
    "productId": 108,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/",
      "https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/",
      "https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19",
      "https://www.donatingplasma.org/donation/find-a-donor-center"
    ],
    "sponsors": [
      {
        "sponsorId": "43916cc52a3993e63c8a49430c524b6ee70b288e",
        "sponsorName": "CoVIg19 Plasma Alliance"
      },
      {
        "sponsorId": "33b00f7cf4a1544653db151375b5993b9a65892b",
        "sponsorName": "Biotest"
      },
      {
        "sponsorId": "117e9d7e0ecaab7bb098d842d06eeb5b61264077",
        "sponsorName": "BPL"
      },
      {
        "sponsorId": "55f0aa800f25c9093f14e24ae7f37b8f48615a59",
        "sponsorName": "CSL Behring"
      },
      {
        "sponsorId": "1a10f3633823419c6252ef6740cd1775636313a8",
        "sponsorName": "LFB"
      },
      {
        "sponsorId": "0a79402e1456155833c273467179eed61b8a15b2",
        "sponsorName": "Octapharma"
      },
      {
        "sponsorId": "31759effba9dd9037b4a5b2a4e1bf87cb0e4042b",
        "sponsorName": "Takeda"
      },
      {
        "sponsorId": "33f0ad8645fb9f5cb965a79f41b7d258aeb45002",
        "sponsorName": "ADMA Biologics"
      },
      {
        "sponsorId": "8602f1675de8eabf55cab947fb769a020c61501b",
        "sponsorName": "BioPharma Plasma"
      },
      {
        "sponsorId": "fb88543fd60aa16c3c184e6208739bc678ea7909",
        "sponsorName": "GC Pharma"
      },
      {
        "sponsorId": "fdcec5fc0acc497097b5595f555306625de122b3",
        "sponsorName": "Sanquin"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Tamiflu",
    "chemicalName": "oseltamivir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Thailand"],
    "countryCodes": ["THA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Rajavithi Hospital",
    "phase": "3",
    "preferredName": "oseltamivir",
    "primaryCompletionDate": "Sat, 31 Oct 2020 00:00:00 GMT",
    "productId": 127,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04303299",
      "https://www.drugbank.ca/drugs/DB00198"
    ],
    "sponsors": [
      {
        "sponsorId": "6929a0f7701affd68fc35e0bb16ed03f8cfbfee6",
        "sponsorName": "Rajavithi Hospital"
      },
      {
        "sponsorId": "ef7f40a7a4970541f7271499b9755b383671309d",
        "sponsorName": "Roche AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 30 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 26 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma",
    "numSites": "",
    "otherPartners": "Cerus Corporation,California Department of Public Health,University of California,Irvine\u2019s Vaccine Development Research Laboratory,Vitalant Research Institute,California National Primate Research Center,Enable Biosciences",
    "phase": "Discovery",
    "preferredName": "Plasma_Immunoglobulins",
    "primaryCompletionDate": "",
    "productId": 109,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19"
    ],
    "sponsors": [
      {
        "sponsorId": "fe619f6a989eee7d5e22b0c5a964b30deeb615db",
        "sponsorName": "CERS actually spelt Cerus Corporation"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 25 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma",
    "numSites": "",
    "otherPartners": "Grifols,BARDA,FDA",
    "phase": "Discovery",
    "preferredName": "Plasma_Immunoglobulins",
    "primaryCompletionDate": "",
    "productId": 110,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "893c4bdb7386d6aa83dda414cb161d199a4e191f",
        "sponsorName": "Grifols"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "On Market",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma Program. Ongoing. No dates given.",
    "numSites": "6",
    "otherPartners": "Mayo Clinic",
    "phase": "On Market",
    "preferredName": "Plasma_Immunoglobulins",
    "primaryCompletionDate": "",
    "productId": 111,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.79002089999999,
        "lng": -73.9526456,
        "locationId": "cb5198b829999f502f099db32be296f99678beb3",
        "name": "1468 Madison Ave, New York, NY 10029, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7695024,
        "lng": -73.9864118,
        "locationId": "104c3684d6d0625ceca3081233c63d914f853183",
        "name": "1000 10th Ave, New York, NY 10019, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.8052591,
        "lng": -73.96117029999999,
        "locationId": "7c344265b605550d298da2b33bc830c80a093ae4",
        "name": "1111 Amsterdam Ave, New York, NY 10025, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7331965,
        "lng": -73.9820857,
        "locationId": "da1bfffd9e8979a711ec210ab0111e98fad5dcf7",
        "name": "281 1st Avenue, New York, NY 10003, USA",
        "state": "NY"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 40.7680385,
        "lng": -73.9248154,
        "locationId": "4567819011b11eee66c32fad2d16246f97548dac",
        "name": "25-10 30th Ave, Queens, NY 11102, USA",
        "state": "NY"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 40.6187604,
        "lng": -73.94282380000001,
        "locationId": "59c7d024eef22e1917948609b4c5fc36061e7199",
        "name": "3201 Kings Hwy, Brooklyn, NY 11234, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://www.mountsinai.org/about/covid19/convalescent-plasma-program"
    ],
    "sponsors": [
      {
        "sponsorId": "67cc1b58cfec53c29d2af191d961276e32239c1b",
        "sponsorName": "Mount Sinai Health System"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma Program. Ongoing. No dates given.",
    "numSites": "3",
    "otherPartners": "China National Biotec Group",
    "phase": "2",
    "preferredName": "Plasma_Immunoglobulins",
    "primaryCompletionDate": "",
    "productId": 112,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "2fb4f1ce3d7fd1b031864a135709bf1a0d22d10a",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.375552,
        "lng": 114.320726,
        "locationId": "7fcb3ac168bc2fe0c09371275434ea6de23232e3",
        "name": "Jiangxia District, Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.3500539,
        "lng": 114.328985,
        "locationId": "6499915cf5ee22167bea5e4884945e7e3f1dc560",
        "name": "116 Jiangxia Ave, Jiangxia Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [
      "http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm",
      "https://www.pnas.org/content/early/2020/04/02/2004168117"
    ],
    "sponsors": [
      {
        "sponsorId": "de649c1e3ec322020be03d52590a6461de6d1a6a",
        "sponsorName": "China National Biotec"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Aviptadil",
    "chemicalName": "",
    "conditionOrDisease": "ARDS",
    "contact": [
      {
        "email": "rbesthof@neurorxpharma.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Vasoactive Intestinal Polypeptide which inhibits inflammatory cytokines causing ARDS",
    "numSites": "4",
    "otherPartners": "NeuroRx",
    "phase": "3",
    "preferredName": "Aviptadil",
    "primaryCompletionDate": "",
    "productId": 113,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04311697",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Miami",
        "country": "USA",
        "lat": 25.7897,
        "lng": -80.211478,
        "locationId": "64a88bfb98c895b8b0c843c2e3172fc9e9a7c100",
        "name": "1550 NW 10th Ave #118, Miami, FL 33136, USA",
        "state": "FL"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7422466,
        "lng": -73.9743033,
        "locationId": "e34a3617e4fbb6f94b05e95258d85757c19f1bee",
        "name": "560 1st Avenue, New York, NY 10016, USA",
        "state": "NY"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9495623,
        "lng": -75.1580318,
        "locationId": "eff31c7e3299d1e565868bd7dd184f68232278d9",
        "name": "111 S 11th St, Philadelphia, PA 19107, USA",
        "state": "PA"
      },
      {
        "city": "Haifa",
        "country": "ISR",
        "lat": 32.8329785,
        "lng": 34.9857062,
        "locationId": "f588b56eea347dbee03e359e28891e6b1ae39260",
        "name": "HaAliya HaShniya St 8, Haifa, 3109601, Israel",
        "state": "Haifa District"
      }
    ],
    "sources": [
      "https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/",
      "https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "b5a0fa2b0ae4008c8789c58eee3a5db3b93fdc0e",
        "sponsorName": "NeuroRx"
      },
      {
        "sponsorId": "a30d64bea24fb02aa2230fa1359a99643a0fc3a3",
        "sponsorName": "Relief Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 01 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "STI-4398,COVIDTRAP",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells - which is expected to effectively interrupt the viral life cycle",
    "numSites": "",
    "otherPartners": "Sorrento Theraputics",
    "phase": "",
    "preferredName": "STI4398_COVIDTRAP",
    "primaryCompletionDate": "",
    "productId": 114,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential",
      "https://sorrentotherapeutics.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "dd736e19d9cf47b8b0d9049c8729f5f8c706b691",
        "sponsorName": "Sorrento Therapeutics inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "INOpulse",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Inhaled Nitric Oxide at Phase 2 for  for COPD - ILD - Sarcoidosis",
    "numSites": "",
    "otherPartners": "Bellerophon Therapeutics",
    "phase": "2",
    "preferredName": "INOpulse",
    "primaryCompletionDate": "",
    "productId": 115,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug",
      "http://www.bellerophon.com/",
      "http://www.bellerophon.com/pipeline/",
      "http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-receives-approval-commence-phase-2-trial-ph-copd",
      "http://www.bellerophon.com/ ; http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug"
    ],
    "sponsors": [
      {
        "sponsorId": "e5750b2be1ef356fc53942e9fba92281f2fa8b6f",
        "sponsorName": "Bellerophon Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CytoSorb",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "On Market",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 10 Apr 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Miller School of Medicine University of Miami Medical Center - Florida - United States,Robert I Grossman School of Medicine NYU Langone Medical Center New York United States,Thomas Jefferson University Hospital Philadelphia Pennsylvania United States,Rambam Health Care Campus Haifa Israel",
    "numSites": "",
    "otherPartners": "CytoSorb",
    "phase": "",
    "preferredName": "CytoSorb",
    "primaryCompletionDate": "",
    "productId": 116,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://next.cytosorb-therapy.com/en/the-adsorber/",
      "https://cytosorbents.com/cytosorb-used-to-treat-more-than-70-critically-ill-covid-19-patients-and-specifically-added-to-coronavirus-treatment-guidelines-in-italy-and-panama/",
      "https://www.fda.gov/media/136867/download"
    ],
    "sponsors": [
      {
        "sponsorId": "d550d39fbfcc114bb9424feb7ee3922ee7889355",
        "sponsorName": "CytoSorbents Corporation"
      }
    ],
    "status": "On Market",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "SNX-5542",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "SNX5542",
    "primaryCompletionDate": "",
    "productId": 117,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "282eaef03c22bad7cc8a8fd8da311711425b1a20",
        "sponsorName": "Esanex"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Mytesi",
    "chemicalName": "crofelemer",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "antidiarrheal for those on anti-retroviral therapy - used in HIV patients - permission sought from FDA for use in COVID patients",
    "numSites": "",
    "otherPartners": "Jaguar Health",
    "phase": "",
    "preferredName": "crofelemer",
    "primaryCompletionDate": "",
    "productId": 118,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support",
      "https://www.marketscreener.com/JAGUAR-HEALTH-INC-59550999/news/JAGUAR-HEALTH-INC-Other-Events-form-8-K-30397142/",
      "https://www.reuters.com/article/brief-jaguar-health-says-declined-to-iss/brief-jaguar-health-says-declined-to-issue-an-eua-for-crofelemer-at-this-time-idINFWN2BY04H"
    ],
    "sponsors": [
      {
        "sponsorId": "c7563c3b7fe4829bad22fa8782140bff9d34561f",
        "sponsorName": "Jaguar Health"
      }
    ],
    "status": "Failed",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Leibniz Instutute Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find therapeutic use,only antibody test for covid?",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Leibniz_Instutute_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 119,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.wbur.org/commonhealth/2020/04/10/covid-19-coronavirus-antibody-testing"
    ],
    "sponsors": [
      {
        "sponsorId": "8e15d495d6fb7018df95d75779b82dcd926be20f",
        "sponsorName": "Leibniz Institute"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Allergan Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find any therapeutic drug/vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Allergan_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 120,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "81ce487fc0d3a5b4c58a218b8adceb96a044468f",
        "sponsorName": "Allergan"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CD24Fc",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "first-in-class recombinant fusion protein (biologic)",
    "numSites": "1",
    "otherPartners": "OncoImmune",
    "phase": "3",
    "preferredName": "CD24Fc",
    "primaryCompletionDate": "Thu, 20 May 2021 00:00:00 GMT",
    "productId": 121,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Baltimore",
        "country": "USA",
        "lat": 39.2892017,
        "lng": -76.6257057,
        "locationId": "12ba34775c2be25e16bb0a6dcf86bdd55ff5e752",
        "name": "620 W Lexington St, Baltimore, MD 21201, USA",
        "state": "MD"
      }
    ],
    "sources": [
      "https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/",
      "http://www.oncoimmune.com/product-development/",
      "https://www.clinicaltrials.gov/ct2/show/NCT04317040"
    ],
    "sponsors": [
      {
        "sponsorId": "01bbc68194bde084f23cb9df2a7ae7d59d15b54f",
        "sponsorName": "OncoImmune"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 20 May 2022 00:00:00 GMT",
    "studyStartDate": "Wed, 08 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "PUL-042 Inhalation Solution",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "2 Clinical Trials: one for short term immunisation,also one for reducing severity (link below for latter)",
    "numSites": "",
    "otherPartners": "Pulmotect",
    "phase": "2",
    "preferredName": "PUL042_Inhalation_Solution",
    "primaryCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "productId": 122,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.71072,
        "lng": -95.3995173,
        "locationId": "6239c6000ec6369bc67b4f51d893db5a613c7e48",
        "name": "6565 Fannin St, Houston, TX 77030, USA",
        "state": "TX"
      }
    ],
    "sources": [
      "https://pulmotect.com/covid19-update/",
      "https://www.clinicaltrials.gov/ct2/show/NCT04312997",
      "https://clinicaltrials.gov/ct2/show/NCT04313023"
    ],
    "sponsors": [
      {
        "sponsorId": "1eab813cb618e383ce0ca0e7f81c6684b50fdddc",
        "sponsorName": "Pulmotect"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DDRI Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find therapeutic drug/vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DDRI_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 123,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4df36b5a59c84e2083f2bc2c1d75bda25e29f290",
        "sponsorName": "Digestive Disease Research Institute"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "INSERM Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Clinical Trials - stage unknown - to test 4 therapes: Remdesevir,Hydroxychloroquine,Lopinavir and Rotinavir,plus IFN-beta",
    "numSites": "",
    "otherPartners": "National Insitute for Health and Medical Research",
    "phase": "",
    "preferredName": "INSERM_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 124,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial",
      "https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#"
    ],
    "sponsors": [
      {
        "sponsorId": "0e1ea407af0902261db76719a57a5c127ea53bfe",
        "sponsorName": "INSERM"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Nitric Oxide",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "4 Current/upcoming trials - to assess use of Nitric Oxide for treating COVID patients - and also potentially preventing the disease",
    "numSites": "2",
    "otherPartners": "Massachusetts General Hospital",
    "phase": "2",
    "preferredName": "Nitric_Oxide",
    "primaryCompletionDate": "Mon, 01 Mar 2021 00:00:00 GMT",
    "productId": 125,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3626109,
        "lng": -71.067566,
        "locationId": "043f0a606a92383a9a69a543af794ce552bcb209",
        "name": "55 Fruit St, Boston, MA 02114, USA",
        "state": "MA"
      },
      {
        "city": "Xi'an",
        "country": "CHN",
        "lat": 34.2706897,
        "lng": 108.9880179,
        "locationId": "e8335e264abbd20ee86071e6f73840927efd4b31",
        "name": "Kangfu Road Shangquan, Xincheng District, Xi'an, Xi'an, Shaanxi, China",
        "state": "Shaanxi"
      }
    ],
    "sources": [
      "https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests",
      "https://clinicaltrials.gov/ct2/show/NCT04290871"
    ],
    "sponsors": [
      {
        "sponsorId": "8a365c9b40d6477fb64fadbb35d6bac33dafb436",
        "sponsorName": "Massachusetts General Hospital"
      },
      {
        "sponsorId": "df85596f7d7dbeb2a2e8c43c35f6f8fa02b44690",
        "sponsorName": "Mallincrodt plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 01 Mar 2022 00:00:00 GMT",
    "studyStartDate": "Mon, 23 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "RoActerma",
    "chemicalName": "Tocilizumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Phase 3 approved",
    "numSites": "",
    "otherPartners": "Roche and BARDA",
    "phase": "2",
    "preferredName": "Tocilizumab",
    "primaryCompletionDate": "",
    "productId": 126,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2ca60c923f9bd40c651529c4a7b5a6972829d31d",
        "sponsorName": "National Cancer Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Hydroxychloroquine,Lopinavir,Ritonavir,Interferon-\u03b2 1a",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Hydroxychloroquine_Lopinavir_Ritonavir_Interferon\u03b2_1a_",
    "primaryCompletionDate": "",
    "productId": 128,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.smartpatients.com/trials/NCT04343768"],
    "sponsors": [
      {
        "sponsorId": "eb058ec8d1b15050f17777e54392b41479ffda20",
        "sponsorName": "Shahid Beheshti Univeristy of Medical Sciences"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "sofosbuvir,ledipasvir",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Iran", "Islamic Republic of"],
    "countryCodes": ["IRN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sofosbuvir_ledipasvir",
    "primaryCompletionDate": "",
    "productId": 129,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3d91d8a2763ff7a2305e9571ce331344f8db21d8",
        "sponsorName": "Tehran University of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Beijing Chaoyang Hospital Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Beijing_Chaoyang_Hospital_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 130,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2edadb0a368326e19a38c17e17aa31d37ca94581",
        "sponsorName": "Beijing Chaoyang Hospital"
      },
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Beijing You'an Hospital Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Beijing_Youan_Hospital_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 131,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "321cfa99e2d96ffd805132b7d743b6bce706e380",
        "sponsorName": "Beijing Youan Hospital"
      },
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Carrimycin",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "11",
    "otherPartners": "Beijing YouAn Hospital",
    "phase": "4",
    "preferredName": "Carrimycin",
    "primaryCompletionDate": "Sun, 28 Feb 2021 00:00:00 GMT",
    "productId": 132,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/record/NCT04286503"],
    "sponsors": [
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      },
      {
        "sponsorId": "47b3533192dd0db49fc64ee3adb03d999199d9d4",
        "sponsorName": "Shenyang Tonglian Group Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 28 Feb 2021 00:00:00 GMT",
    "studyStartDate": "Thu, 27 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CMAB806",
    "chemicalName": "Interleukin-6 monoclonal antibody",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "Study goes to May 31st",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Interleukin6_monoclonal_antibody",
    "primaryCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "productId": 133,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=49883",
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "9f637a84ab94dfcde5aa3c7d77599bf545764fa3",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": ["http://www.chictr.org.cn/showprojen.aspx?proj=49883"],
    "sponsors": [
      {
        "sponsorId": "6c1d2cca1e1c545b115cedcb4a88a86dfc5cc4c0",
        "sponsorName": "JinYu BioTechnology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "studyStartDate": "Thu, 20 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CAStem",
    "chemicalName": "Mesenchymal Stem Cells",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Mesenchymal_Stem_Cells",
    "primaryCompletionDate": "Wed, 15 Jul 2020 00:00:00 GMT",
    "productId": 134,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04288102",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.522832,
        "lng": 114.330432,
        "locationId": "5a2820cc7ff5f545228848fbffe85e986f5a06e8",
        "name": "53 Dingziqiao Rd, Hong Shan Jie Dao Kou Shang Quan, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "4c25d333ecf2030a67d23c8c7888d801e8a9eadd",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04288102",
      "http://www.xinhuanet.com/english/2020-03/05/c_138846353.htm"
    ],
    "sponsors": [
      {
        "sponsorId": "e13a47c3805a5ea782acbdd30bf4d9672426da11",
        "sponsorName": "Beijing 302 Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 31 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Thu, 05 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "NKG2D-ACE2 CAR-NK Cells",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "gwzxliumin@foxmail.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 21 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 21 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Phase I/II Trial",
    "numSites": "1",
    "otherPartners": "Chongqing Sidemu Biotechnology",
    "phase": "2",
    "preferredName": "NKG2DACE2_CARNK_Cells",
    "primaryCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "productId": 135,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04324996",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 29.550499,
        "lng": 106.470884,
        "locationId": "bab9844e59154fffbe086615a9effb410b3a76d6",
        "name": "62 Shixiao Rd, Shapingba Qu, Chongqing Shi, China",
        "state": "Chongqing Shi"
      }
    ],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04324996"],
    "sponsors": [
      {
        "sponsorId": "45c8692c794fd50c930fb0b97c607465d7d554b9",
        "sponsorName": "Chongqing Public Health Medical Center"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 21 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Long-acting interferon alpha-2a,ribavirin",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "5",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Longacting_interferon_alpha2a_ribavirin",
    "primaryCompletionDate": "Wed, 26 Aug 2020 00:00:00 GMT",
    "productId": 136,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=51141",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Foshan Shi",
        "country": "CHN",
        "lat": 22.8500072,
        "lng": 113.2578008,
        "locationId": "28b8f71d15929cb865a6b80f80c4cb142e9e22a1",
        "name": "Yungui 7th St, Shunde Qu, Foshan Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Zhongshan Shi",
        "country": "CHN",
        "lat": 22.594904,
        "lng": 113.234473,
        "locationId": "58361bf622390a2ad665ab2cc109bff639055f9c",
        "name": "China, Guangdong Sheng, Zhongshan Shi, Lefeng Middle Rd, \u83ca\u82b1\u5927\u9053\u4e2d68\u53f7",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Dongguan",
        "country": "CHN",
        "lat": 23.020673,
        "lng": 113.751799,
        "locationId": "46c58b9988e07da25e6cb99cc66f463abcad7d2c",
        "name": "Dongguan, Guangdong Province, China",
        "state": "Guangdong Province"
      },
      {
        "city": "Jiangmen Shi",
        "country": "CHN",
        "lat": 22.605688,
        "lng": 113.115602,
        "locationId": "677f8bdd0237ec849b9256c57eafc2a12f5499dd",
        "name": "China, Guangdong Sheng, Jiangmen Shi, Pengjiang Qu, \u5317\u8857\u6d77\u65c1\u885723\u53f7",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Foshan Shi",
        "country": "CHN",
        "lat": 22.960003,
        "lng": 112.978451,
        "locationId": "fc4073ddb749195070ca817d65be3eb86a22952c",
        "name": "China, Guangdong Sheng, Foshan Shi, Nanhai Qu, Qiaojin Hwy, \u6a35\u91d1\u8def",
        "state": "Guangdong Sheng"
      }
    ],
    "sources": ["http://www.chictr.org.cn/showprojen.aspx?proj=51141"],
    "sponsors": [
      {
        "sponsorId": "0aa5baf3a5bfcd9bd34bc49ddd68b3369a8bd29f",
        "sponsorName": "Foshan First Peoples Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 26 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 26 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Triazavirin",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Originally developed in Russia for Influenza.",
    "numSites": "4",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Triazavirin",
    "primaryCompletionDate": "Thu, 28 May 2020 00:00:00 GMT",
    "productId": 137,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=49723",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Haerbin Shi",
        "country": "CHN",
        "lat": 45.768768,
        "lng": 126.655785,
        "locationId": "a526fc8551eac62dd1978f47f1d68f8f4e3b2a04",
        "name": "The First Affiliated Hospital of Harbin Medical University, Nangang Qu, Haerbin Shi, China",
        "state": null
      },
      {
        "city": "Haerbin Shi",
        "country": "CHN",
        "lat": 45.696577,
        "lng": 126.616301,
        "locationId": "9867713d54db91be287408a7b31154a3d0b4831d",
        "name": "246 Xuefu Rd, Nangang Qu, Haerbin Shi, Heilongjiang Sheng, China, 150086",
        "state": "Heilongjiang Sheng"
      },
      {
        "city": "Haerbin Shi",
        "country": "CHN",
        "lat": 45.762255,
        "lng": 126.63621,
        "locationId": "a0331dc9b3d4f054ffdb8ce464b1562d2843afd2",
        "name": "37 Yiyuan St, Nangang Qu, Haerbin Shi, Heilongjiang Sheng, China",
        "state": "Heilongjiang Sheng"
      },
      {
        "city": "Haerbin Shi",
        "country": "CHN",
        "lat": 45.7289211,
        "lng": 126.6869291,
        "locationId": "cf606ad78cf7cff74e71153f0d63301567191c54",
        "name": "405 Gongbin Rd, Xiangfang Qu, Haerbin Shi, Heilongjiang Sheng, China, 150036",
        "state": "Heilongjiang Sheng"
      }
    ],
    "sources": [
      "http://www.chictr.org.cn/showprojen.aspx?proj=49723",
      "https://www.drugbank.ca/drugs/DB15622"
    ],
    "sponsors": [
      {
        "sponsorId": "74eb28bb89c6d76ecbdcbb4b00449a43dd0efd98",
        "sponsorName": "Health commission of Heilongjiang province"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 28 May 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 15 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "azvudine",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "http://www.chictr.org.cn/showprojen.aspx?proj=50507",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "azvudine",
    "primaryCompletionDate": "",
    "productId": 138,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.digitaltrends.com/health-fitness/coronavirus-covid-19-vaccines-treatments-list/",
      "https://en.wikipedia.org/wiki/Azvudine",
      "http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml",
      "http://www.chictr.org.cn/showprojen.aspx?proj=49532"
    ],
    "sponsors": [
      {
        "sponsorId": "590809afc11f993a1d02526632882469be2ae713",
        "sponsorName": "Henan Provincial Peoples Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Esbriet",
    "chemicalName": "Pirfenidone",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 3",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Pirfenidone",
    "primaryCompletionDate": "",
    "productId": 139,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://en.wikipedia.org/wiki/Pirfenidone",
      "https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "abf659ef96c4f7cef8ec83e1e16ec37d171098bb",
        "sponsorName": "Huilan Zhang"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Chloroquine",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Chloroquine",
    "primaryCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "productId": 140,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "d29f3d054481f01f1a9e383cad1196d5c7c48419",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [
      "https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935",
      "https://en.wikipedia.org/wiki/Chloroquine#Medical_uses"
    ],
    "sponsors": [
      {
        "sponsorId": "617b848747bc14a2a9fc203852ab5529565cab2a",
        "sponsorName": "Hwa Mei Hospital"
      },
      {
        "sponsorId": "ac1ac20ca0b9ec951428fe364c421040f1f4829b",
        "sponsorName": "University of Chinese Academy of Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Tue, 04 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antimalarial drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "XueBiJing",
    "chemicalName": "XueBiJing",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 18 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Traditional Chinese Medicine,5-herb combination",
    "numSites": "1",
    "otherPartners": "N/A",
    "phase": "1",
    "preferredName": "XueBiJing",
    "primaryCompletionDate": "",
    "productId": 141,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=50306",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Jingzhou Shi",
        "country": "CHN",
        "lat": 30.30907899999999,
        "lng": 112.259189,
        "locationId": "13896da6f8779654ff8a2a718a3efa53e2c987bc",
        "name": "8 Hangkong Rd, Shashi Qu, Jingzhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [
      "http://www.chictr.org.cn/showprojen.aspx?proj=50306",
      "https://reader.elsevier.com/reader/sd/pii/S0254627211600113?token=59E71863CD81881AD517D44BB2CFB5E0524ACEE75F7729C3AEEE19F30F987FC7F744F2B5CEC187F763578C32AA680098",
      "https://clinicaltrials.gov/ct2/show/study/NCT03475732",
      "https://clinicaltrials.gov/ct2/show/NCT03475732"
    ],
    "sponsors": [
      {
        "sponsorId": "de88121edbf4cca2b6df882b71a3a79995714b11",
        "sponsorName": "Jingzhou First Peoples Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 18 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Methylprednisolone",
    "conditionOrDisease": "Acute Respiratory Failure",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Jan 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Zhongda Hospital,Renmin Hospital of Wuhan University",
    "phase": "2",
    "preferredName": "Methylprednisolone",
    "primaryCompletionDate": "Sat, 25 Apr 2020 00:00:00 GMT",
    "productId": 142,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04244591",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 39.9127464,
        "lng": 116.4142481,
        "locationId": "6aa53d3850e2e0a9719c8d356deef50b23f1d028",
        "name": "Dongdan, Beijing, Dongcheng, Beijing, China",
        "state": "Beijing"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts",
      "https://www.drugbank.ca/drugs/DB00959"
    ],
    "sponsors": [
      {
        "sponsorId": "10172e384c8eaa0f469f305f6d2b50b0eabb14f5",
        "sponsorName": "Peking Union Medical College Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sun, 26 Jan 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Favipiravir,Tocilizumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "john131212@sina.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 08 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Favipiravir - Small molecule,Tocilizumab - protein based,Anti-viral and monoclonal antibody combination",
    "numSites": "9",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "Favipiravir_Tocilizumab",
    "primaryCompletionDate": "Fri, 01 May 2020 00:00:00 GMT",
    "productId": 143,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04310228",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CHN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "bd1bf1209e61386425c91708cffa32580b80c2a1",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": null,
        "country": "CHN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "9a788084e8015f613bb84db590872598053b19c2",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "5282e5d3cff616396b7cec9b40e844db6bd3c9ba",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CHN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "8f289387dd9f0f2d4725ca5cb01fdd13db8f8d6f",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "b633efe6890d2470f9931fee9a89e54461057820",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "e449ca6c885593ed8cac0983d81bae28767b5852",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "6dfe3bc5cf9552f0779503767e22d7ba3d1dadc4",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "d28b30c8ac87f73273243b5ae9750fe6a78a399d",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "78aacc53de48679a429d7c409d54cbd00a3c65a0",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "797f9bfbb13c5d6fe0f6ea9d5a7f46b61d32aca2",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts",
      "https://www.drugbank.ca/drugs/DB12466; https://www.drugbank.ca/drugs/DB06273",
      "https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs"
    ],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 01 May 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 08 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Azvudine",
    "chemicalName": "RO-0622",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 0",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "RO0622",
    "primaryCompletionDate": "Thu, 16 Apr 2020 00:00:00 GMT",
    "productId": 144,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=49532",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Xinyang",
        "country": "CHN",
        "lat": 32.014808,
        "lng": 114.906546,
        "locationId": "74fc24845edfd607622451f4fca87295f5563693",
        "name": "Guangshan County, Xinyang, China",
        "state": null
      }
    ],
    "sources": [
      "https://en.wikipedia.org/wiki/Azvudine",
      "http://www.chictr.org.cn/showprojen.aspx?proj=49532",
      "https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine#section=Structures",
      "https://www.ncbi.nlm.nih.gov/pubmed/25144636"
    ],
    "sponsors": [
      {
        "sponsorId": "9b38a8623a43ac6813f56ef17b83f2ca2a213237",
        "sponsorName": "Peoples Hospital of Guangshan County"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sun, 16 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Noscovid",
    "chemicalName": "Noscapine",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Iran", "Islamic Republic of"],
    "countryCodes": ["IRN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 17 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "N/A",
    "phase": "2",
    "preferredName": "Noscapine",
    "primaryCompletionDate": "",
    "productId": 145,
    "registryLink": "https://en.irct.ir/trial/46576",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Qazvin",
        "country": "IRN",
        "lat": 36.3245163,
        "lng": 49.9972276,
        "locationId": "d9cdc22c3405dc6e2acefcdf6874b7429b4bdfeb",
        "name": "Qazvin, \u060c\u060c \u0627\u0633\u062a\u0627\u0646 \u0642\u0632\u0648\u06cc\u0646 \u0642\u0632\u0648\u064a\u0646 \u060c \u0634\u0647\u0631\u06a9 \u0645\u06cc\u0646\u0648\u062f\u0631\u060c\u06a9\u0648\u06cc \u0627\u0644\u0647\u06cc\u0647 \u060c \u0628\u0644\u0648\u0627\u0631 22 \u0628\u0647\u0645\u0646\u060c Tavon Square, 34719 76161, Iran",
        "state": null
      }
    ],
    "sources": [
      "http://ethics.research.ac.ir/ProposalViewEn.php?id=125991",
      "https://www.irct.ir/trial/46576",
      "https://www.drugbank.ca/drugs/DB06174",
      "https://pubchem.ncbi.nlm.nih.gov/compound/Noscapine",
      "http://en.qums.ac.ir/Portal/home/?124884/Velayat-Hospital"
    ],
    "sponsors": [
      {
        "sponsorId": "2c3dce78e2656e4bdf014ec95f1f244efcb85b05",
        "sponsorName": "Qazvin University of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Fri, 17 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Avastin",
    "chemicalName": "Bevacizumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "jiaojiaopang@126.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Renmin Hospital of Wuhan University,Ialy Moriggia Pelascini Gravedona Hospital S.p.A,Wuhan University,Jiangbei Union Hospital of Huazhong University of Science and Technology,Shandong Provincial Chest Hospital",
    "phase": "",
    "preferredName": "Bevacizumab",
    "primaryCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "productId": 146,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04305106",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Jinan Shi",
        "country": "CHN",
        "lat": 36.655439,
        "lng": 117.018034,
        "locationId": "53fb33027e3a3f8ddca4bf942b3b28077e3f7ad2",
        "name": "107 Wenhua W Rd, Lixia Qu, Jinan Shi, Shandong Sheng, China",
        "state": "Shandong Sheng"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04305106",
      "https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/bevacizumab",
      "https://www.drugbank.ca/drugs/DB00112",
      "https://www.drugs.com/history/avastin.html"
    ],
    "sponsors": [
      {
        "sponsorId": "5097a8114e431ac8ebcbd82cdf94884e315a5cba",
        "sponsorName": "Qilu Hospital of Shandong University"
      },
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      },
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 31 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Tue, 17 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Leflunomide",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Leflunomide",
    "primaryCompletionDate": "",
    "productId": 147,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "14a2146233138c07a64e0baef6cc949f64c7af25",
        "sponsorName": "Renmin Hospital of Wuhan University"
      },
      {
        "sponsorId": "b28e8b218d5a198cef37e9f446f38a9e8846175b",
        "sponsorName": "University of Chicago"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ST-266",
    "chemicalName": "cell-free platform biologic containing hundreds of anti-inflammatory proteins",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Noveome Biotherapeutics Inc.,US government",
    "phase": "",
    "preferredName": "cellfree_platform_biologic_containing_hundreds_of_antiinflammatory_proteins",
    "primaryCompletionDate": "",
    "productId": 268,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "8c4038c7c0eddd116fc3688efef61be78abbacb4",
        "sponsorName": "Noveome Biotherapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Bisolvon",
    "chemicalName": "Bromhexine Hydrochloride",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "WanBangDe Pharmaceutical Group Co. Ltd.",
    "phase": "",
    "preferredName": "Bromhexine_Hydrochloride",
    "primaryCompletionDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "productId": 148,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04273763",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wenzhou Shi",
        "country": "CHN",
        "lat": 28.006211,
        "lng": 120.67225,
        "locationId": "ba58f93636254aceddc1844536a4d20181e65c94",
        "name": "109 Xueyuan W Rd, Lucheng Qu, Wenzhou Shi, Zhejiang Sheng, China",
        "state": "Zhejiang Sheng"
      }
    ],
    "sources": [
      "https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=",
      "https://www.drugbank.ca/drugs/DB09019",
      "https://www.drugsbanks.com/bisolvon/",
      "https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "87b385be246abb1a4c3e0d7f6bbe23e811156173",
        "sponsorName": "Second Affiliated Hospital of Wenzhou Medical University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 16 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Avigan",
    "chemicalName": "Interferon beta,Favipiravir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Iran", "Islamic Republic of"],
    "countryCodes": ["IRN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 27 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Used to treat Influenza",
    "numSites": "1",
    "otherPartners": "ChemRar,RDIF",
    "phase": "3",
    "preferredName": "Interferon_beta_Favipiravir",
    "primaryCompletionDate": "",
    "productId": 149,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "JPN",
        "lat": 36.204824,
        "lng": 138.252924,
        "locationId": "cdc120d5a143b22f7894dcb016b058ce13e41244",
        "name": "Japan",
        "state": null
      }
    ],
    "sources": [
      "https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug",
      "https://www.drugbank.ca/drugs/DB12466",
      "https://www.ncbi.nlm.nih.gov/pubmed/25333492",
      "https://www.thepharmaletter.com/article/russia-s-rdif-backs-chemrar-for-the-production-of-favipiravir-against-covid-19",
      "https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/"
    ],
    "sponsors": [
      {
        "sponsorId": "b58861dc99cd85f531c98907e3577fe93964d0f3",
        "sponsorName": "Shahid Beheshti University of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Prezcobix",
    "chemicalName": "Darunavir,cibicistat",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "",
        "name": null,
        "notes": "",
        "phone": "008602137990333 ext 3222",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Treat pneumonia",
    "numSites": "1",
    "otherPartners": "Johnson and Johnson",
    "phase": "3",
    "preferredName": "Darunavir_cibicistat",
    "primaryCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "productId": 150,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Shanghai",
        "country": "CHN",
        "lat": 31.230416,
        "lng": 121.473701,
        "locationId": "c5595ef49e94af6ce7e9fbf0b5f11cb04c9866c2",
        "name": "Shanghai, China",
        "state": "Shanghai"
      }
    ],
    "sources": [
      "https://aidsinfo.nih.gov/drugs/397/darunavir/0/patient",
      "https://www.drugbank.ca/drugs/DB01264",
      "https://www.europeanpharmaceuticalreview.com/news/111977/johnson-johnson-launch-response-to-coronavirus/",
      "https://www.natureindex.com/institution-outputs/china/shanghai-public-health-clinical-center-fudan-university/52cf526a140ba04763000006",
      "https://clinicaltrials.gov/ct2/show/NCT04252274"
    ],
    "sponsors": [
      {
        "sponsorId": "78190ce5e186ac701c260b91aa1008a6c4b862de",
        "sponsorName": "Shanghai Public Health Clinical Center"
      },
      {
        "sponsorId": "0ff0405e4544cd120687a915ea369ae1dac78dca",
        "sponsorName": "Johnsons  Johnson"
      },
      {
        "sponsorId": "667987d4de01dd23efc5563684db4e2117b5d910",
        "sponsorName": "Janssen"
      },
      {
        "sponsorId": "8cd26a383793b281ef40085df75c92792db1b43d",
        "sponsorName": "Gilead"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 30 Jan 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral - protease inhibitor",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "PD1,thymosin,Camrelizumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Cancer therapy",
    "numSites": "",
    "otherPartners": "NIHR",
    "phase": "2",
    "preferredName": "PD1_thymosin_Camrelizumab",
    "primaryCompletionDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "productId": 151,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.cebm.net/covid-19/registered-trials-and-analysis/",
      "https://www.frontiersin.org/articles/10.3389/fimmu.2019.02298/full",
      "https://www.frontiersin.org/articles/10.3389/fonc.2019.00873/full",
      "https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0779-5",
      "https://www.seu.edu.cn/english/",
      "https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0636-7",
      "https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "9ba50a6c509f14bcba0e2116a0a021e05e985ae6",
        "sponsorName": "Southeast University  China"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Meplazumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Treat pneumonia",
    "numSites": "1",
    "otherPartners": "National Science and Technology Major Project",
    "phase": "2",
    "preferredName": "Meplazumab",
    "primaryCompletionDate": "Mon, 10 Feb 2020 00:00:00 GMT",
    "productId": 152,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Huizhou",
        "country": "CHN",
        "lat": 22.94223,
        "lng": 114.29824,
        "locationId": "085940f7254da9cbf8c4b8b88b6338c03727feed",
        "name": "Tangdu, Huiyang District, Huizhou, Guangdong Province, China",
        "state": "Guangdong Province"
      }
    ],
    "sources": [
      "https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf",
      "https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1"
    ],
    "sponsors": [
      {
        "sponsorId": "90580332dd2c5e7458dc3f0dc0ba01024427917e",
        "sponsorName": "TangDu Hospital"
      },
      {
        "sponsorId": "2453464d7d85243db737220519ad6c684bfec004",
        "sponsorName": "Jingsu Pacific Meinuoke Biopharmaceutical Co"
      },
      {
        "sponsorId": "fd9f01621385a9d2c18ef56159f02c2acd10e0e0",
        "sponsorName": "Fourth Military Medical University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 03 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Gilenya",
    "chemicalName": "Fingolimod",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "wanjinchen75@fjmu.edu.cn",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 22 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Treats MS",
    "numSites": "1",
    "otherPartners": "NIHR",
    "phase": "2",
    "preferredName": "Fingolimod",
    "primaryCompletionDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "productId": 153,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Fuzhou",
        "country": "CHN",
        "lat": 26.074478,
        "lng": 119.296482,
        "locationId": "258689f775f258284a74b78e3e9d4f13a57fc47d",
        "name": "Fuzhou, Fujian, China",
        "state": "Fujian"
      }
    ],
    "sources": [
      "https://www.drugbank.ca/drugs/DB08868",
      "https://www.ncbi.nlm.nih.gov/pubmed/17785617",
      "http://www.io.nihr.ac.uk/wp-content/uploads/migrated_new/11115-Fingolimod-oral.pdf",
      "https://en.fjmu.edu.cn/",
      "https://clinicaltrials.gov/ct2/show/NCT04280588"
    ],
    "sponsors": [
      {
        "sponsorId": "beea472f9414420dd2ba494bd1b0dbf60d0df7a7",
        "sponsorName": "The First Affiliated Hospital of Fujian Medical University"
      },
      {
        "sponsorId": "a47ed0af8e79c0d5e04834a88fa5c0fa3a019663",
        "sponsorName": "Novartis AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 22 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Avigan",
    "chemicalName": "ASCO9F,ritonavir,favipiravir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "HIV protease inhibitor",
    "numSites": "1",
    "otherPartners": "Self funding,National Natural Science Foundation of China",
    "phase": "2",
    "preferredName": "ASCO9F_ritonavir_favipiravir",
    "primaryCompletionDate": "",
    "productId": 154,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "9d08b1f131f6c1f9e11b22cf804bb6c881d6be67",
        "name": "China",
        "state": null
      }
    ],
    "sources": [
      "https://www.ncbi.nlm.nih.gov/pubmed/32147628",
      "https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/",
      "https://www.drugbank.ca/drugs/DB00503",
      "http://www.chictr.org.cn/sourceofspendsprojen.aspx",
      "https://english.tjh.com.cn/",
      "https://www.sciencedaily.com/releases/2020/04/200406120130.htm"
    ],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 06 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs- HIV protease inhibitor",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Nitric Oxide (g)",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "2",
    "otherPartners": "Private",
    "phase": "2",
    "preferredName": "Nitric_Oxide_g",
    "primaryCompletionDate": "Mon, 01 Mar 2021 00:00:00 GMT",
    "productId": 155,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "755c8681b59d717c5d92a9e072f184e1d2313474",
        "name": "China",
        "state": null
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04290858",
      "https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news",
      "https://aospine.aofoundation.org/education/fellowship/spine-centers-asia-pacific/xijing-hospital",
      "https://www.streetwisereports.com/article/2020/03/26/inhaled-nitric-oxide-being-tested-as-covid-19-treatment.html"
    ],
    "sponsors": [
      {
        "sponsorId": "c8523547da03b9b3e757de3bc960672aa18072e3",
        "sponsorName": "Xijing Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 01 Feb 2022 00:00:00 GMT",
    "studyStartDate": "Sun, 01 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Vitamin C,Sodium Ascorbate",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "pengzy5@hotmail.com",
        "name": null,
        "notes": "",
        "phone": "8618672396028",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Prevent cytokine induced damage to lungs",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Vitamin_C_Sodium_Ascorbate",
    "primaryCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "productId": 156,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "4af588f3f8861bec210ad3924dfddc4130e8ad3f",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": null,
        "country": "CHN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "76f0c9f1b072f3a9ccde8f465476c829cbcacc11",
        "name": "China",
        "state": null
      }
    ],
    "sources": [
      "https://www.drugbank.ca/drugs/DB14482",
      "https://www.medicinenet.com/script/main/art.asp?articlekey=228745",
      "https://lpi.oregonstate.edu/mic/vitamins/vitamin-C",
      "https://www.researchgate.net/scientific-contributions/2136361683_Zhiyong_Peng",
      "https://clinicaltrials.gov/ct2/show/NCT04264533"
    ],
    "sponsors": [
      {
        "sponsorId": "4aa837dcf498f3cc77b727f1990dd1d645311b0b",
        "sponsorName": "ZhiYong Peng"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 14 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antioxidant",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CYNK-001",
    "chemicalName": "antibody",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "CYNK-001-COVID-19@idri.org",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 29 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "2",
    "otherPartners": "Sorrento Therapeutics Inc.",
    "phase": "2",
    "preferredName": "antibody",
    "primaryCompletionDate": "Mon, 30 Nov 2020 00:00:00 GMT",
    "productId": 157,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04365101",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Hackensack",
        "country": "USA",
        "lat": 40.8840343,
        "lng": -74.05648819999999,
        "locationId": "686d216acd83ce60bc3e4d068f52c8d77d076725",
        "name": "30 Prospect Ave, Hackensack, NJ 07601, USA",
        "state": "NJ"
      },
      {
        "city": "Tacoma",
        "country": "USA",
        "lat": 47.29469539999999,
        "lng": -122.3812852,
        "locationId": "8f2776975b6e2aa8f86efd80d99f7ecce8240492",
        "name": "4215 49th Ave NE, Tacoma, WA 98422, USA",
        "state": "WA"
      }
    ],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04365101"],
    "sponsors": [
      {
        "sponsorId": "4f61c20da897e770e987eca3fb88439618947bee",
        "sponsorName": "Celularity Incorporated"
      },
      {
        "sponsorId": "d4f038c1fd0e4c52d93147fc334849bc67394496",
        "sponsorName": "Sorrento Therapeutics"
      },
      {
        "sponsorId": "766438974fbc280cb2aed1baca9444d8e3a9f66c",
        "sponsorName": "IDRI"
      },
      {
        "sponsorId": "edbbafc744cc960bef0e37292940fec196315898",
        "sponsorName": "Lung Biotechnology PBC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 30 Nov 2021 00:00:00 GMT",
    "studyStartDate": "Sat, 13 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ACE-MAB\u2122",
    "chemicalName": "STI-4920 (CMAB020)",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "bispecific ACE-MAB fusion protein",
    "numSites": "",
    "otherPartners": "Sorrento Therapeutics Inc.,Mabpharm Limited",
    "phase": "",
    "preferredName": "STI4920_CMAB020",
    "primaryCompletionDate": "",
    "productId": 158,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      },
      {
        "sponsorId": "c9c165926c1b9b7b8832e8afef24f2834d6e595c",
        "sponsorName": "Mabpharm Limited"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Gene MAb\u2122",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "uses Gene MAb\u2122 platform for ab delivery",
    "numSites": "",
    "otherPartners": "Sorrento Therapeutics Inc.",
    "phase": "",
    "preferredName": "antibody",
    "primaryCompletionDate": "",
    "productId": 159,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus"
    ],
    "sponsors": [
      {
        "sponsorId": "99401ebed0fa84553f3dab49ec5651d6e16ebb72",
        "sponsorName": "SmartPharm Therapeutics Inc"
      },
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Anti-Corona Immunoglobulin (IgG)",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 11 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "plasma of recovered people w ab is used in patients",
    "numSites": "",
    "otherPartners": "Kamada",
    "phase": "",
    "preferredName": "antibody",
    "primaryCompletionDate": "",
    "productId": 160,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "5929da2b33c19978e9dd493734a7e92160428081",
        "sponsorName": "Kamada Ltd"
      },
      {
        "sponsorId": "3e412b7cf7607d2c373441c8651e88306e8012b0",
        "sponsorName": "Kedrion Biopharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Centivax",
    "phase": "",
    "preferredName": "antibody",
    "primaryCompletionDate": "",
    "productId": 161,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.distributedbio.com/covid19"],
    "sponsors": [
      {
        "sponsorId": "06e3c85a544975e5dfcec88f45b51e3fdf635c59",
        "sponsorName": "Centivax"
      },
      {
        "sponsorId": "bcb8d1f52e45cce0b2413d1c2485755444633dbb",
        "sponsorName": "Swiftscale Biologics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Human mAb 47D11",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Erasmus MC",
    "phase": "",
    "preferredName": "antibody",
    "primaryCompletionDate": "",
    "productId": 162,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.nature.com/articles/s41467-020-16256-y"],
    "sponsors": [
      {
        "sponsorId": "fe367a0d5ee946a16335321f006255c41d4c8e7b",
        "sponsorName": "Erasmus MC"
      },
      {
        "sponsorId": "b80905e2bb739693e1253446c2e0849e97ab16dd",
        "sponsorName": "Utrecht University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "darunavir,cobicistat,CYP3A inhibitor",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "luhongzhou@fudan.edu.cn",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 30 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Janssen Pharmaceutical Companies,Shanghai Public Health Clinical Center",
    "phase": "3",
    "preferredName": "darunavir_cobicistat_CYP3A_inhibitor",
    "primaryCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "productId": 163,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04252274",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 30.791749,
        "lng": 121.341627,
        "locationId": "1526a406b7e22553a47f70147973ee5c27fdb3d3",
        "name": "2901 Caolang Hwy, Jinshan Qu, Shanghai Shi, China",
        "state": "Shanghai Shi"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "78190ce5e186ac701c260b91aa1008a6c4b862de",
        "sponsorName": "Shanghai Public Health Clinical Center"
      },
      {
        "sponsorId": "7745b01b52b6f1cf88a706afd1b056e344c46e24",
        "sponsorName": "Zhongnan Hospital of Wuhan University"
      },
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 20 Jan 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Arbidol",
    "chemicalName": "Umifenovir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Membrane fusion inhibitor",
    "numSites": "1",
    "otherPartners": "China\u2019s Ruijin Hospital",
    "phase": "4",
    "preferredName": "Umifenovir",
    "primaryCompletionDate": "Wed, 22 Apr 2020 00:00:00 GMT",
    "productId": 164,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04350684",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Tehran",
        "country": "IRN",
        "lat": 35.6891975,
        "lng": 51.3889736,
        "locationId": "519d8a9f68d476e59bd4e57592c759cbc523e1e3",
        "name": "Tehran, Tehran Province, Iran",
        "state": "Tehran Province"
      }
    ],
    "sources": [
      "https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata",
      "https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "deef1b7181395ef02ad3b7cd894fb64716ba0215",
        "sponsorName": "Pharmstandard"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 23 Apr 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Xofluza",
    "chemicalName": "baloxavir marboxil",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "qiuyq@zju.edu.cn",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "polymerase acidic endonuclease inhibitor",
    "numSites": "1",
    "otherPartners": "The First Hospital Affiliated to Zhejiang University's Medical School,Roche",
    "phase": "1",
    "preferredName": "baloxavir_marboxil",
    "primaryCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "productId": 165,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=49013",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Hangzhou",
        "country": "CHN",
        "lat": 30.2558917,
        "lng": 120.1780985,
        "locationId": "1aa21d4ce88e8e3f60efb97c72b49c453211c14c",
        "name": "Shangcheng District, Hangzhou, Zhejiang, China",
        "state": "Zhejiang"
      }
    ],
    "sources": ["http://www.chictr.org.cn/showprojen.aspx?proj=49013"],
    "sponsors": [
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      },
      {
        "sponsorId": "50a9bfad2cbb96596fb34d34cdfbd349c1a4fbbc",
        "sponsorName": "The First Hospital Affiliated to Zhejiang Universitys Medical School"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 02 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PLX cell product",
    "chemicalName": "placenta-based cells",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 08 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 08 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "placenta-based cell therapy",
    "numSites": "",
    "otherPartners": "Pluristem Therapeutics,BIH Center for Regenerative Therapy,Berlin Center for Advanced Therapies",
    "phase": "",
    "preferredName": "placentabased_cells",
    "primaryCompletionDate": "",
    "productId": 166,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf",
      "https://www.pluristem.com/wp-content/uploads/2020/05/FDA-Clearance-COVID-19-FINAL.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "2b9a512817547dd6eca9ae64392478de4df5ea55",
        "sponsorName": "Pluristem Therapeutics"
      },
      {
        "sponsorId": "14df6ecd68ad3a991782c40f386042236234019a",
        "sponsorName": "BIH Center for Regenerative Therapy"
      },
      {
        "sponsorId": "3c023d5d2630d83ff1f51fee219f0e0dec252a08",
        "sponsorName": "Berlin Center for Advanced Therapies"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Thalidomide",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "An approved drug with noted immunosuppressive and anti-angiogenic activity,used for a number of immunological and inflammatory disorders,clinical trials aim to see if these properties of thalidomide can be used to prevent or treat COVID-19 induced lung injury instead of functioning as a direct antiviral,note that there is a second study with the same sponsors and utilizing thalidomide as well - but that includes the use of low does hormones as well and only enrolls 40 participants,discovery start - NDA approval - and on the market are completed with respect to thalidomide itself without taking into account its prospective use in treating COVID-19",
    "numSites": "",
    "otherPartners": "Second Affliated Hospital of Wenzhou Medical University,Wenzou Central Hospital",
    "phase": "2",
    "preferredName": "Thalidomide",
    "primaryCompletionDate": "Sat, 30 May 2020 00:00:00 GMT",
    "productId": 167,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04273529,https://clinicaltrials.gov/ct2/show/NCT04273581",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1",
      "https://www.drugbank.ca/drugs/DB01041 https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2",
      "https://www.drugbank.ca/drugs/DB01041",
      "https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1",
      "https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_ThalidomideTOC.cfm",
      "https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2",
      "https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts",
      "https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "c34399f07cbf1f511eb20748b32ec47045ae18f5",
        "sponsorName": "Celgene Corp"
      },
      {
        "sponsorId": "4337c2a735b1c82b0b730abbf6b584dd7f97e512",
        "sponsorName": "The First Affiliated Hospital of Wenzhou Medical University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Thu, 20 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "ARB,Cozaar",
    "chemicalName": "Losartan",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Covid19trial@umn.edu",
        "name": null,
        "notes": "",
        "phone": "612-624-4373",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Approved drug used to treat hypertension by functioning as an angiotensin II receptor blocker,study intends to track COVID-19 patients' risk status in the ICU using the Sequential Organ Failure Assessment (SOFA) respiratory score following treatment with losartan or a placebo",
    "numSites": "3",
    "otherPartners": "Bill and Melinda Gates Foundation",
    "phase": "2",
    "preferredName": "Losartan",
    "primaryCompletionDate": "Thu, 01 Apr 2021 00:00:00 GMT",
    "productId": 168,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04311177,https://clinicaltrials.gov/ct2/show/NCT04312009",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Minneapolis",
        "country": "USA",
        "lat": 44.9722477,
        "lng": -93.2615378,
        "locationId": "d4545fdc03dba05331a96fac50dda323db64e727",
        "name": "730 S 8th St, Minneapolis, MN 55415, USA",
        "state": "MN"
      },
      {
        "city": "Minneapolis",
        "country": "USA",
        "lat": 44.96751159999999,
        "lng": -93.23755399999999,
        "locationId": "11856552f60f7005006b0137983e70b8d85f6ec6",
        "name": "2450 Riverside Ave, Minneapolis, MN 55454, USA",
        "state": "MN"
      },
      {
        "city": "Minneapolis",
        "country": "USA",
        "lat": 44.97399,
        "lng": -93.2277285,
        "locationId": "f538e3c99ce563964659a3b7717a4aeac127d5b9",
        "name": "Minneapolis, MN 55455, USA",
        "state": "MN"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts",
      "https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1",
      "https://www.drugbank.ca/drugs/DB00678 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts",
      "https://www.drugbank.ca/drugs/DB00678",
      "https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "d49e1350f4c21eef623eb4e22b9709b13ac08f82",
        "sponsorName": "University of Minnesota"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 01 Apr 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 13 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "sildenafil citrate",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 09 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Approved drug used to treat pulmonary arterial hypertension,angina,and erectile dysfunction,study evaluates rate of disease remission,rate of entering the critical stage,and time of entering the critical stage after treatment with sildenafil citrate",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "sildenafil_citrate",
    "primaryCompletionDate": "Sun, 01 Mar 2020 00:00:00 GMT",
    "productId": 169,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04304313",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "f9f1896801ea6c9efb70e9af769d618dffdb59de",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1",
      "https://www.drugbank.ca/drugs/DB00203 https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts",
      "https://www.drugbank.ca/drugs/DB00203",
      "https://www.drugbank.ca/drugs/DB00203#reference-A175732",
      "https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 09 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 09 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "a lipic acid",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "a_lipic_acid",
    "primaryCompletionDate": "",
    "productId": 170,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d8a6fb8782589eff1784a987131a3510fd1991ff",
        "sponsorName": "Zhongshan Hospital"
      },
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Chloroquine phosphate",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Chloroquine_phosphate",
    "primaryCompletionDate": "",
    "productId": 171,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2d7ffefe148247749f6402c5edc286a5095cc88a",
        "sponsorName": "Jingzhou Central Hospital"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Ebastine,Lopinavir,Interferon a",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ebastine_Lopinavir_Interferon_a",
    "primaryCompletionDate": "",
    "productId": 172,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a61efee7bdf9baf309997f1ccf652ee02887c52",
        "sponsorName": "Wuhan Red Cross Hospital"
      },
      {
        "sponsorId": "1be6e3f3520226675b831cc738fab10a9812c4fd",
        "sponsorName": "Minanyang Central Hospital"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Danoprevir,Ritonavir,Interferon",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Danoprevir is an oral hepatitis C virus protease inhibitor approved in China in June 2018,used in a phase 4 trial that began 02/17/2020 to observe its effects on the rate of composite adverse outcomes and time to recovery among other measures",
    "numSites": "1",
    "otherPartners": "Ascletis Pharmaceutials Co. Ltd.",
    "phase": "4",
    "preferredName": "Danoprevir_Ritonavir_Interferon",
    "primaryCompletionDate": "Thu, 19 Mar 2020 00:00:00 GMT",
    "productId": 173,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04291729",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Nanchang",
        "country": "CHN",
        "lat": 28.682892,
        "lng": 115.858197,
        "locationId": "b8b47d27552c094acf70e61d56242b1c7f9d1495",
        "name": "Nanchang, Jiangxi, China",
        "state": "Jiangxi"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "bdb545b6c04a880d9d0382f48b816fee837c1330",
        "sponsorName": "The Ninth Hospital of Nanchang"
      },
      {
        "sponsorId": "e1bafffd3c4ccdf8eaf5841a8838a032654edc76",
        "sponsorName": "Ascletis Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 19 Mar 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 17 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Mesenchymal Stem Cells",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "447822853@qq.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "MSCs have been shown to exert antiinflammatory and immunoregulatory functions - promote regeneration of damaged tissues - and inhibit tissue fibrosis,trial aims to explore MSC's potential to treat COVID-19 patients",
    "numSites": "1",
    "otherPartners": "Puren Hospital Affliated to Wuhan University of Science and Technology,Shanghai University,Qingdao Co-orient Watson Biotechnology group co. LTD,Basic Medical Sciences - Chinese Academy of Medical Sciences",
    "phase": "1",
    "preferredName": "Mesenchymal_Stem_Cells",
    "primaryCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "productId": 174,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04339660",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "cdf9df5161f68358c17ac50916fa722b26775331",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "bf5e7b2bebc0928fcae433d07b46f1bb4fc5c3ba",
        "sponsorName": "Chinese Academy of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 01 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Peginterferon Lambda-1a",
    "chemicalName": "Peginterferon Lambda-1a",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "usingh@stanford.edu",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Peginterferon_Lambda1a",
    "primaryCompletionDate": "Mon, 31 May 2021 00:00:00 GMT",
    "productId": 188,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04331899",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/study/NCT04331899",
      "https://clinicaltrials.gov/ct2/show/NCT04331896",
      "https://clinicaltrials.gov/ct2/show/NCT04331897",
      "https://clinicaltrials.gov/ct2/show/NCT04331898",
      "https://clinicaltrials.gov/ct2/show/NCT04331899"
    ],
    "sponsors": [
      {
        "sponsorId": "683d20f6c6f23f9c1e0851b35e3f725262584fe3",
        "sponsorName": "Stanford University"
      },
      {
        "sponsorId": "4b56e1109e3c62392ddb122d219ce7bd5514472d",
        "sponsorName": "Eiger Biopharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 31 May 2022 00:00:00 GMT",
    "studyStartDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Recombinant ACE2",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Study to investigate if there is efficacy signal that warrants a large Phase 2B trial or harm that suggests trial should not be done,study in question has a not applicable phase,status is withdrawn as of 03/17/2020 (which is why many cells were left blank)",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Recombinant_ACE2",
    "primaryCompletionDate": "",
    "productId": 175,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04287686",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Guangzhou",
        "country": "CHN",
        "lat": 23.12911,
        "lng": 113.264385,
        "locationId": "0d0892096343f22381bacafdafc89fecfb674717",
        "name": "Guangzhou, Guangdong Province, China",
        "state": "Guangdong Province"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04287686"
    ],
    "sponsors": [
      {
        "sponsorId": "ea78fbfadca996d3b3279e672883c8476ffd78cf",
        "sponsorName": "The First Affiliated Hospital of Guangzhou Medical University"
      }
    ],
    "status": "On Hold",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 27 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Washed micrbiota transplantation",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 05 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Molecule type - microbiota. The recent study on using washed microbiota transplantation (WMT) as rescue therapy in critically ill patients with AAD demonstrated the important clinical benefits and safety of WMT. Additionally the recent animal study provided direct evidence supporting that antibiotics could decrease gut microbiota and the lung stromal interferon signature and facilitate early influenza virus replication in lung epithelia. Importantly the above antibiotics caused negative effects can be reversed by fecal microbiota transplantation (FMT) which suggested that FMT might be able to induce a significant improvement in the respiratory virus infection.",
    "numSites": "1",
    "otherPartners": "The Second Hospital of Nanjing Medical University",
    "phase": "",
    "preferredName": "Washed_micrbiota_transplantation",
    "primaryCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "productId": 176,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04251767",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Nanjing Shi",
        "country": "CHN",
        "lat": 32.069231,
        "lng": 118.749728,
        "locationId": "c17a45ae4d2ad85ff19a718ff285309c318daa07",
        "name": "China, Jiangsu Sheng, Nanjing Shi, Gulou Qu, \u6a21\u8303\u897f\u8def",
        "state": "Jiangsu Sheng"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1",
      "https://www.smartpatients.com/trials/NCT04251767",
      "https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/"
    ],
    "sponsors": [
      {
        "sponsorId": "3452304684b286fca6c4db5bb90b92026a7d077b",
        "sponsorName": "The Second Hospital of Nanjing Medical University"
      }
    ],
    "status": "On Hold",
    "studyCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 05 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Persantine",
    "chemicalName": "Dipyridamole",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "zqling68@hotmail.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Type - vasodilator",
    "numSites": "6",
    "otherPartners": "Major regional immunity cultivation project - 91742109",
    "phase": "4",
    "preferredName": "Dipyridamole",
    "primaryCompletionDate": "Fri, 10 Apr 2020 00:00:00 GMT",
    "productId": 177,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=49864",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Guangzhou Shi",
        "country": "CHN",
        "lat": 23.096999,
        "lng": 113.23067,
        "locationId": "e27e75b83aa198aed4b95561fa434eab7739fb5b",
        "name": "47 Dongjiao N Rd, Fang Cun, Liwan Qu, Guangzhou Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.53535699999999,
        "lng": 114.299525,
        "locationId": "308edc509d089e9d2995f8b4ff279e82d4997fff",
        "name": "Wuchang District, Wuhan, China",
        "state": null
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.583826,
        "lng": 114.273585,
        "locationId": "8266fc23ec774b64cb8c48bf847b52df960b7b20",
        "name": "Jiefang Ave, Xi Bei Hu, Jianghan Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.88255699999999,
        "lng": 114.375743,
        "locationId": "f485f0797a8cea830b016d76da6e79069f687e96",
        "name": "Huangpi District, Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Xiaogan",
        "country": "CHN",
        "lat": 31.561164,
        "lng": 114.127022,
        "locationId": "b1770e6adf2b5bbd2a3bac8a95f3bf71512e9f82",
        "name": "Dawu County, Hubei, Xiaogan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wenzhou",
        "country": "CHN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "0ee5d1d2f148ee2d52e0c46848fe28ab3cdcce58",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [
      "http://www.chictr.org.cn/showprojen.aspx?proj=49864",
      "https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/",
      "https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "ea78fbfadca996d3b3279e672883c8476ffd78cf",
        "sponsorName": "The First Affiliated Hospital of Guangzhou Medical University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 10 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Bromhexine hydrochloride,Arbidol umifenovir,Favipiravir,Interferon a2b",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "On going recruitment",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Bromhexine_hydrochloride_Arbidol_umifenovir_Favipiravir_Interferon_a2b",
    "primaryCompletionDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "productId": 178,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04273763",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wenzhou Shi",
        "country": "CHN",
        "lat": 28.006211,
        "lng": 120.67225,
        "locationId": "1e77f351af5f1f572c7cb9bfcc289949fee71b40",
        "name": "109 Xueyuan W Rd, Lucheng Qu, Wenzhou Shi, Zhejiang Sheng, China",
        "state": "Zhejiang Sheng"
      }
    ],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04273763"],
    "sponsors": [
      {
        "sponsorId": "1a54d298d5b18d923897d81e7dd0a48df5240f94",
        "sponsorName": "The Second Affiliated Hospital of Wenzhou Medical University"
      },
      {
        "sponsorId": "9b98ab2f7f83afd2e87f907a0f64dbc3220477b6",
        "sponsorName": "WanBangDe Pharmaceutical Group"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 16 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Dihydroartemisinin,piperaquine,arbidol umifenovir,interferon a",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Cancelled by investigator",
    "numSites": "4",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "Dihydroartemisinin_piperaquine_arbidol_umifenovir_interferon_a",
    "primaryCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "productId": 179,
    "registryLink": "http://www.chictr.org.cn/showproj.aspx?proj=49915",
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Independence",
        "country": "USA",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "f0f891c8228de1f4067384b2ce1587f5d893b5e0",
        "name": "Independence, KS 67301, USA",
        "state": "KS"
      },
      {
        "city": null,
        "country": "CHN",
        "lat": 39.9127464,
        "lng": 116.4142481,
        "locationId": "4e6715cd4f3071b7d9470d56a448eba4a4d89fdc",
        "name": "Dongdan, Beijing, Dongcheng, Beijing, China",
        "state": "Beijing"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.599041,
        "lng": 114.301165,
        "locationId": "dc05553455648080171bc8da4c50ba04181b6bcc",
        "name": "China, Hubei Sheng, Wuhan Shi, Jiangan Qu, \u4e09\u9633\u8def",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "c37ee7db83f1ac9281d23626cfb1a2ed8f038fca",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [
      "http://www.chictr.org.cn/showprojen.aspx?proj=49915",
      "https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/"
    ],
    "sponsors": [
      {
        "sponsorId": "b2025696e611deea59bde95a78322849a7a75f10",
        "sponsorName": "The First Affiliated Hospital of Nanchang University"
      }
    ],
    "status": "Failed",
    "studyCompletionDate": "",
    "studyStartDate": "Sun, 23 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified,Anti-malarial",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Intravenous Immunoglobulin",
    "chemicalName": "Human Immunoglobulin (pH4)",
    "conditionOrDisease": "Pneumonia",
    "contact": [
      {
        "email": "litsh@263.net",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology",
    "phase": "2",
    "preferredName": "Human_Immunoglobulin_pH4",
    "primaryCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "productId": 180,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04261426",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 39.911431,
        "lng": 116.41481,
        "locationId": "8490f991fefa0765b34dad1354b8d45bb10e0371",
        "name": "9 Dongdan 3rd Alley, Dong Dan, Dongcheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts",
      "https://www.drugbank.ca/drugs/DB00028"
    ],
    "sponsors": [
      {
        "sponsorId": "10172e384c8eaa0f469f305f6d2b50b0eabb14f5",
        "sponsorName": "Peking Union Medical College Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 10 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "RoActemra",
    "chemicalName": "Tocilizumab",
    "conditionOrDisease": "Covid-19",
    "contact": [
      {
        "email": "john131212@sina.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "SKIPPED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 08 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Being used in above trial",
    "numSites": "9",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "Tocilizumab",
    "primaryCompletionDate": "Fri, 01 May 2020 00:00:00 GMT",
    "productId": 181,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04310228",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CHN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "d7b8119747c59e43fdd8d8dc499b6f627fa82b64",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": null,
        "country": "CHN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "45058abc8aac590b5bb10f364e0245ecd315e0a2",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "3ec857da6529e35632d8d5a948a7aeea2f528713",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CHN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "900e03265097feff6739b8555ed450bf6f57fdb3",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "cc9dce45c8953ed622d87f1fcaa8ffad0ecf661d",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "a91b15bf30ba4847c597d60ca8b03f3f495cb850",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "89f3b7c4e223200d57a4f61a748ff88ad503259a",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "1d7990d6f67e354b1d7a849fbd492ff6f9f53dbd",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "4810497e6076aead12ebc8e3cde79de5bf26deaf",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "19f670c2a64498b793ec74ca10600e1f42fcbf67",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1",
      "https://www.drugbank.ca/drugs/DB06273"
    ],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      },
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 01 May 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 08 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Anulohuaxian",
    "chemicalName": "Anulohuaxian",
    "conditionOrDisease": "Covid-19",
    "contact": [
      {
        "email": "john131212@sina.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Traditional Chinese Medicine",
    "numSites": "8",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "Anulohuaxian",
    "primaryCompletionDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "productId": 182,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04334265",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Fuyang Shi",
        "country": "CHN",
        "lat": 33.164296,
        "lng": 115.628262,
        "locationId": "f1f5483190cd4235742aa4825b35ccd396b4941e",
        "name": "Wenming Rd, Taihe Xian, Fuyang Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CHN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "a883026a21de191e792eaa27b2521ab0548ef798",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "54be44d6200d9c6f2d1e7b32ca0d3c06cac0e951",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "4ba7777c723e0fb91db624245dfbaf9635dc6cd9",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "c5bc2dc6b89bb88846fd3d85ff947c6760f0e273",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "5bb17ffc4f87aebbb220a51b3068fe759518780e",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "3826145f31a8296329467787192c0c9a3d685b6c",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "3a08bf18dac2eed494a40fff3e1d70be7899f730",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wenzhou",
        "country": "CHN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "14422b9b9208714f3ccd5e52c49ca519eba253dc",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3",
      "https://journals.lww.com/md-journal/fulltext/2019/05310/the_efficacy_of_chinese_patent_medicine_combined.18.aspx",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/"
    ],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 01 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Allogeneic human dental pulp stem cells",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "\tqingsongye@foxmail.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Beijing SH Bio-Tech Corporation - Beijing - China,Utooth Biological Technology Co. Ltd. - Hubei - China",
    "phase": "1",
    "preferredName": "Allogeneic_human_dental_pulp_stem_cells",
    "primaryCompletionDate": "",
    "productId": 183,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04336254",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.53535699999999,
        "lng": 114.299525,
        "locationId": "540c0fa26b4e7a9b68d2100fc630569a482a2706",
        "name": "Wuchang District, Wuhan, China",
        "state": null
      }
    ],
    "sources": [
      "https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429131/"
    ],
    "sponsors": [
      {
        "sponsorId": "14a2146233138c07a64e0baef6cc949f64c7af25",
        "sponsorName": "Renmin Hospital of Wuhan University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 31 Mar 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 06 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IBIO-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Being repurposed to treat idiopathic pulmonary fibrosis,Previously granted orphan drug designation for treatment of systemic sclerosis investigated to systemic scleroderma",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IBIO100",
    "primaryCompletionDate": "",
    "productId": 184,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.ibioinc.com/pipeline#IBIO100"],
    "sponsors": [
      {
        "sponsorId": "505b07d6981f93ee187513e197589f4c16f04b35",
        "sponsorName": "iBio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "chloroquine,azithromycin",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chloroquine_azithromycin",
    "primaryCompletionDate": "",
    "productId": 185,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b"
    ],
    "sponsors": [
      {
        "sponsorId": "9f993454bdb55447c232ff4e925773960b482c3a",
        "sponsorName": "Population Health Research"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Favipiravir,Baloxavir marboxil",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Favipiravir_Baloxavir_marboxil",
    "primaryCompletionDate": "",
    "productId": 186,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b"
    ],
    "sponsors": [
      {
        "sponsorId": "a81e304214bfeeb11d72efbec071b026a7bec070",
        "sponsorName": "First Hospital Affiliated"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Jakafi,Jakavi",
    "chemicalName": "Ruxolitinib",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "medinfo@incyte.com",
        "name": null,
        "notes": "",
        "phone": "18554633463",
        "website": ""
      }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Being evaluated for treatment of COVID 19 associated cytokine storm",
    "numSites": "",
    "otherPartners": "",
    "phase": "Expanded Access ",
    "preferredName": "Ruxolitinib",
    "primaryCompletionDate": "",
    "productId": 187,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04355793",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.janssen.com/lack-evidence-support-use-darunavir-based-treatments-sars-cov-2-0",
      "https://www.globenewswire.com/news-release/2020/04/02/2011153/0/en/Novartis-announces-plan-to-initiate-clinical-study-of-Jakavi-in-severe-COVID-19-patients-and-establish-international-compassionate-use-program.html",
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04355793?term=ruxolitinib&cond=covid+19&draw=1&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      },
      {
        "sponsorId": "28de4f9051af1771961895dd1ee280ee55497988",
        "sponsorName": "Incyte Corporation"
      },
      {
        "sponsorId": "a47ed0af8e79c0d5e04834a88fa5c0fa3a019663",
        "sponsorName": "Novartis AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Working on discovering monoclonal antibodies against SARS CoV-2,aims to begin clinical trials within 6 months",
    "numSites": "",
    "otherPartners": "Brii Biosciences",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "primaryCompletionDate": "",
    "productId": 214,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.briibio.com/news/45.html"
    ],
    "sponsors": [
      {
        "sponsorId": "a635c9162245b5b265427b6b347bf36ec00ab510",
        "sponsorName": "Brii Biosciences"
      },
      {
        "sponsorId": "597be3ec42623eb2b339b165717d84c7c3137601",
        "sponsorName": "Columbia University"
      },
      {
        "sponsorId": "bfce396095503d26f651c5dad224c79f44d87649",
        "sponsorName": "Tsinghua University"
      },
      {
        "sponsorId": "8bdecc942a48de24772aedb84f5bd52bc0737054",
        "sponsorName": "3rd Peoples Hospital of Shenzhen"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "LV-SMENP-DC,Synthetic Minigene Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "c@szgimi.org",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Vaccine to treat and prevent severe Covid-19 pneumonia,Innovative COVID19 minigenes engineered based on multiple viral genes using an efficient lentiviral vector system to express viral proteins and immune modulatory genes to modify dendritic cells and to activate T cells",
    "numSites": "3",
    "otherPartners": "Shenzhen Third People's Hospital,Shenzhen Second People's Hospital",
    "phase": "2",
    "preferredName": "LVSMENPDC_Synthetic_Minigene_Vaccine",
    "primaryCompletionDate": "Mon, 31 Jul 2023 00:00:00 GMT",
    "productId": 189,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04276896",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Shenzhen",
        "country": "CHN",
        "lat": 22.543096,
        "lng": 114.057865,
        "locationId": "23419ab51639568fb05cf523ca990bab02f9ce81",
        "name": "Shenzhen, Guangdong Province, China",
        "state": "Guangdong Province"
      },
      {
        "city": "Shenzhen",
        "country": "CHN",
        "lat": 22.5717957,
        "lng": 113.8992079,
        "locationId": "d76815eebb4bd83b99798b4de9d4c2300d623fe2",
        "name": "Bao'an District, Shenzhen, Guangdong Province, China",
        "state": "Guangdong Province"
      },
      {
        "city": "Shenzhen Shi",
        "country": "CHN",
        "lat": 22.556599,
        "lng": 114.086145,
        "locationId": "b6d16b4abec6439972be94aa26889ffafa7fe5df",
        "name": "3002 Sungang W Rd, Futian Qu, Shenzhen Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      }
    ],
    "sources": [
      "https://www.nature.com/articles/d41573-020-00073-5",
      "https://clinicaltrials.gov/ct2/show/NCT04276896",
      "https://clinicaltrials.gov/ct2/show/NCT04276897"
    ],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 24 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "aAPC Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "c@szgimi.org",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells",
    "numSites": "3",
    "otherPartners": "Shenzhen Third People's Hospital,Shenzhen Second People's Hospital",
    "phase": "1",
    "preferredName": "aAPC_Vaccine",
    "primaryCompletionDate": "Mon, 31 Jul 2023 00:00:00 GMT",
    "productId": 190,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04299724",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.nature.com/articles/d41573-020-00073-5",
      "https://clinicaltrials.gov/ct2/show/NCT04299724"
    ],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sat, 15 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Peptide-based therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "48Hour Discovery Inc.",
    "phase": "",
    "preferredName": "Peptidebased_therapeutic",
    "primaryCompletionDate": "",
    "productId": 191,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "970c9dcb0770cc2be64dd33cbfa88ac640f9e606",
        "sponsorName": "48Hour Discovery Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Pharmetrx therapeutics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "The compounds were identified using PharmetRx\u00ae Afecta's proprietary artificial intelligence platform and demonstrate bioactivity via two key therapeutic mechanisms of action-(1) immunomodulation similar to that of hydroxychloroquine or (2) inhibition of viral replication or attachment to host cells.",
    "numSites": "",
    "otherPartners": "Afecta Pharmaceuticals Inc.",
    "phase": "",
    "preferredName": "Pharmetrx_therapeutics",
    "primaryCompletionDate": "",
    "productId": 192,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "f3b4e5e84c266ea60771ec2883e82c2204ec2f04",
        "sponsorName": "Afecta Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 20 May 2021 00:00:00 GMT",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Active Agent",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 04 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Aicuris Anti-infective Cures GmbH",
    "phase": "",
    "preferredName": "Active_Agent",
    "primaryCompletionDate": "",
    "productId": 193,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "f2b34e7e5c8d41cfa0c7e4ca7543514b6c633fe9",
        "sponsorName": "Aicuris Antiinfective Cures GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antiviral component",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "The compounds seek to inhibit replication of multiple viruses,including Influenza virus,SARS-CoV,MERS-CoV,Ebolavirus and Marburg virus.",
    "numSites": "",
    "otherPartners": "Aikido Pharma Inc.,the University of Maryland -Baltimore",
    "phase": "",
    "preferredName": "Antiviral_component",
    "primaryCompletionDate": "",
    "productId": 194,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "39b3f1f3677b274c50b99d83330f4862d0b8f6a8",
        "sponsorName": "Aikido Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ADX-629,reproxalap",
    "chemicalName": "reproxalap(reactive aldehyde species (RASP) inhibitor)",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Aldeyra Therapeutics Inc.",
    "phase": "",
    "preferredName": "reproxalapreactive_aldehyde_species_RASP_inhibitor",
    "primaryCompletionDate": "",
    "productId": 195,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "5525922d920320b60e93d8e039b662d088125b7d",
        "sponsorName": "Aldeyra Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Soliris",
    "chemicalName": "Eculizumab",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "replaced by Ultomiris(ravulizumab-cwvz) for further tests.",
    "numSites": "",
    "otherPartners": "Alexion Pharmaceuticals Inc.",
    "phase": "",
    "preferredName": "Eculizumab",
    "primaryCompletionDate": "",
    "productId": 196,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "41794d8c7643f99fc7895546d19147d1b41daf20",
        "sponsorName": "Alexion Pharmaceuticals Inc"
      }
    ],
    "status": "On Hold",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DAS-181",
    "chemicalName": "recombinant sialidase",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Ansun Biopharma Inc.,Renmin Hospital of Wuhan University",
    "phase": "",
    "preferredName": "recombinant_sialidase",
    "primaryCompletionDate": "",
    "productId": 197,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "5e79a7dfd885e0baf118378ff6d6ac832c4a44f3",
        "sponsorName": "Ansun Biopharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "SARS-CoV-2 targeting recombinant methioninase",
    "chemicalName": "Methioninase",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Anticancer Inc.,AntiCancer Beijing",
    "phase": "",
    "preferredName": "Methioninase",
    "primaryCompletionDate": "",
    "productId": 198,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "84e8fc3396832ade5506a951a3b3ebbaebd87cde",
        "sponsorName": "Anticancer Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Solnatide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 28 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 04 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Solnatide IMP has been designed for activation of the pulmonary epithelial sodium channel (ENaC) and for the restoration of the injured endothelial-epithelial barrier of pulmonary alveoli.",
    "numSites": "",
    "otherPartners": "Apeptico Forschung und Entwicklung GmbH,The Austrian Research Promotion Agency",
    "phase": "",
    "preferredName": "Solnatide",
    "primaryCompletionDate": "",
    "productId": 199,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "f8b9528ccb10701b24f862db161ec27fbc4847fd",
        "sponsorName": "Apeptico Forschung und Entwicklung GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Cannabinoid-based therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "cannabinoids may act as anti-androgens",
    "numSites": "",
    "otherPartners": "Applied Biology Inc.,Applied Bonanics LLC",
    "phase": "",
    "preferredName": "Cannabinoidbased_therapy",
    "primaryCompletionDate": "",
    "productId": 200,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "30a0bfe60f04ff11e51d1901a52fbea2c76f2b5d",
        "sponsorName": "Applied Biology Inc"
      },
      {
        "sponsorId": "0112e7fffc5a7da4b036b0306729e2a12720f796",
        "sponsorName": "Applied Bonanics LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AT-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Aldose Reductase Inhibitor,New York Hospital Investigator Initiated Studies used under an emergency IND",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AT001",
    "primaryCompletionDate": "",
    "productId": 201,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated",
      "https://www.sec.gov/Archives/edgar/data/1697532/000104746919002659/a2238624zs-1a.htm"
    ],
    "sponsors": [
      {
        "sponsorId": "3304021f998972cba57fa873b78bbbcda69f3122",
        "sponsorName": "Applied Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Small molecules",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "3 molecules targeting two viral replication enzymes- 3CL-Protease and RNA dependent RNA Polymerase,Pre-Clinical studies will be taken over by the University of Hong Kong,Covar Pharmaceuticals is another collaborator",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Small_molecules",
    "primaryCompletionDate": "",
    "productId": 202,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3"
    ],
    "sponsors": [
      {
        "sponsorId": "552bb9ce9d50b56342d0722bdf6a2e671ba4796e",
        "sponsorName": "Aptorum Group Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ALT-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "eNAMPTOR is a platform of three products which includes ALT-100",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ALT100",
    "primaryCompletionDate": "",
    "productId": 203,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.aqualungtherapeutics.com/enamptor/",
      "https://www.aqualungtherapeutics.com/contact",
      "https://www.aqualungtherapeutics.com/pipeline/",
      "https://aqualungtherapeutics.reportablenews.com/pr/aqualung-therapeutics-advances-its-investigational-monoclonal-antibody-into-ind-enabling-studies-of-acute-respiratory-distress-syndrome-ards-and-ventilator-induced-lung-injury-vili",
      "https://www.technologynetworks.com/biopharma/blog/antibody-to-treat-lung-inflammation-may-offer-potential-in-covid-19-332369",
      "https://www.aqualungtherapeutics.com/key-activities-and-press/"
    ],
    "sponsors": [
      {
        "sponsorId": "4e3c43064be49069b8902b88fe3a123622091b1f",
        "sponsorName": "Aqualung Therapeutics Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "HB-adMSCs",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 24 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Clinical study mentioned is one of three,two more are in earlier stages",
    "numSites": "1",
    "otherPartners": "Medrio",
    "phase": "2",
    "preferredName": "HBadMSCs",
    "primaryCompletionDate": "",
    "productId": 240,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04349631",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Sugar Land",
        "country": "USA",
        "lat": 29.6018105,
        "lng": -95.625022,
        "locationId": "db18c382168669ee1dd264123de12164605b39e5",
        "name": "16700 Creekbend Dr, Sugar Land, TX 77478, USA",
        "state": "TX"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.hope.bio/clinical-trials",
      "https://www.pharmaceutical-business-review.com/news/hope-biosciences-covid-19-stem-cell/",
      "https://www.medindia.net/health-press-release/Medrio-Assisting-Hope-Biosciences-to-Combat-COVID-19-with-New-Stem-Cell-Clinical-Trial-461667-1.htm#",
      "https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071",
      "https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3"
    ],
    "sponsors": [
      {
        "sponsorId": "b6a4863d0716a8f9abb22fd5f19ab102949816cc",
        "sponsorName": "Hope Biosciences LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 07 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "ASC09F",
    "chemicalName": "TMC-310911,ritonavir",
    "conditionOrDisease": "COVID19",
    "contact": [
      {
        "email": "xxw69@126.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "HIV-1 Protease Inhibitor,Another clinical trial with oseltamivir retracted due to insufficient patients,ASC09-Ritonavir vs Lopinavir-Ritonavir trial sponsor is First Affiliated Hospital of Zhejiang University and Ascletis is collaborator",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "TMC310911_ritonavir",
    "primaryCompletionDate": "Sun, 31 May 2020 00:00:00 GMT",
    "productId": 204,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04261907",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://ascletis.com.cn/single/145.html",
      "https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503",
      "http://ascletis.com.cn/single2/139.html",
      "https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503; https://clinicaltrials.gov/ct2/show/record/NCT04261907",
      "http://www.chictr.org.cn/showprojen.aspx?proj=49075",
      "http://www.chictr.org.cn/showprojen.aspx?proj=49352",
      "https://clinicaltrials.gov/ct2/show/record/NCT04261907"
    ],
    "sponsors": [
      {
        "sponsorId": "9c77c2ee252590839e7e90f484ab0c46df479dbb",
        "sponsorName": "Ascletis Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 07 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Calquence",
    "chemicalName": "acalabrutinib",
    "conditionOrDisease": "COVID19",
    "contact": [
      {
        "email": "information.center@astrazeneca.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Acerta Pharma B.V. discovered acalabrutinib and is a collaborator on the clinical trial",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "acalabrutinib",
    "primaryCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "productId": 205,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04346199",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Barcelona",
        "country": "ESP",
        "lat": 41.3850639,
        "lng": 2.1734035,
        "locationId": "ce4af684a2220005fc3a2bc510cc02fced10e1bb",
        "name": "Barcelona, Spain",
        "state": "CT"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html",
      "https://www.drugbank.ca/drugs/DB11703",
      "https://www.astrazeneca.com/our-company/contact-us.html",
      "https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record",
      "https://www.acerta-pharma.com/about/",
      "https://www.astrazeneca.com/our-therapy-areas/oncology.html#OurOncologypipeline",
      "https://www.astrazeneca.com/our-therapy-areas/oncology.html#OurOncologymedicines",
      "https://clinicaltrials.gov/ct2/show/NCT04346199",
      "https://clinicaltrials.gov/ct2/show/study/NCT04346199"
    ],
    "sponsors": [
      {
        "sponsorId": "2c75b2d91db07786aabe9dcac98ed68f752804f1",
        "sponsorName": "AstraZeneca plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Fri, 24 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Virazole",
    "chemicalName": "ribavirin inhalation solution",
    "conditionOrDisease": "COVID19",
    "contact": [
      {
        "email": "Alexandre.Brkovic@bauschhealth.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Control # 238007 for Canadian Clinical Trial Website - works best with Internet Explorer,first posted on Clinicaltrials.gov 04/22/2020",
    "numSites": "",
    "otherPartners": "Hospira Inc.",
    "phase": "1",
    "preferredName": "ribavirin_inhalation_solution",
    "primaryCompletionDate": "Tue, 20 Apr 2021 00:00:00 GMT",
    "productId": 206,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04356677",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ir.bauschhealth.com/news-releases/2020/04-13-2020-120008693",
      "https://www.drugbank.ca/drugs/DB00811",
      "http://www.virazole.com/",
      "https://health-products.canada.ca/ctdb-bdec/search-recherche.do;jsessionid=6E35384F37BD4DFE705B0CEA1440F945",
      "https://clinicaltrials.gov/ct2/show/study/NCT04356677",
      "https://clinicaltrials.gov/ct2/show/record/NCT04356677"
    ],
    "sponsors": [
      {
        "sponsorId": "a88af720747218a96a8aad641b4265d2da310f54",
        "sponsorName": "Bausch Health Cos Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Niclocide",
    "chemicalName": "niclosamide",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Voluntarily withdrawn from market by Bayer in 1996,Another Brand name is Yomesan",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "niclosamide",
    "primaryCompletionDate": "",
    "productId": 207,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052",
      "https://www.drugbank.ca/drugs/DB06803",
      "https://www.kxan.com/news/coronavirus/can-an-existing-drug-be-re-purposed-to-treat-covid-19-patients-ut-researchers-working-to-find-out/",
      "https://www.drugbank.ca/drugs/DB06803; https://www.bayer.co.za/static/documents/MSDS/PIs/YOMESAN_EN_PI.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "67da3aa3718d35ed721af558ab42d840a58dfdbe",
        "sponsorName": "Bayer AG"
      },
      {
        "sponsorId": "541210ab7a6daa7079e19f753dbf3002c81ab5a8",
        "sponsorName": "Union Therapeutics AS"
      },
      {
        "sponsorId": "3f0f11935fb0a109bff465cc279e3b68c954fede",
        "sponsorName": "Ana Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Nanobody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ESTIMATED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Beroni Group submitted Emergency Use Authorization for COVID-19 Rapid Test Detection Kit to FDA in March",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nanobody",
    "primaryCompletionDate": "",
    "productId": 208,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/",
      "https://www.bioworld.com/COVID19products",
      "https://www.beronigroup.com/2020/03/06/beroni-group-collaborates-with-tianjin-university-to-develop-novel-solution-for-coronavirus-covid-19/",
      "https://www.beronigroup.com/2020/04/01/beroni-group-announces-submission-of-emergency-use-authorization-to-us-fda-for-its-covid-19-rapid-test-detection-kit/"
    ],
    "sponsors": [
      {
        "sponsorId": "b738e5214e4eac0d75fea1d6f1cfdd47e57c0e9b",
        "sponsorName": "Beroni Group"
      },
      {
        "sponsorId": "28bd9f926647c0b6e60a19fd1317a5fdb10635eb",
        "sponsorName": "Tianjin University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "rhu-pGSN",
    "chemicalName": "recombinant human plasma gelsolin",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Next step is to move into Phase 2b",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "recombinant_human_plasma_gelsolin",
    "primaryCompletionDate": "",
    "productId": 209,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/",
      "https://www.bioaegistherapeutics.com/overview-immunotherapy-treatment/",
      "http://www.globenewswire.com/news-release/2020/04/02/2010466/0/en/Small-NJ-Biotech-Firm-BioAegis-Therapeutics-Accelerating-Multiple-Clinical-Trial-Submissions-for-Severe-COVID-19-Pneumonia-Patients.html",
      "https://www.bioaegistherapeutics.com/news/may-17-2011-bioaegis-therapeutics-signs-exclusive-option-human-protein-clinical-development/",
      "https://www.bioaegistherapeutics.com/news/september-2018-bioaegis-therapeutics-enrolls-first-patients-in-phase-1b-2a-community-acquired-pneumonia-study-and-raises-4-mm-in-equity-round/",
      "https://clinicaltrials.gov/ct2/show/study/NCT03466073",
      "https://clinicaltrials.gov/ct2/show/record/NCT03466073"
    ],
    "sponsors": [
      {
        "sponsorId": "a6c2d1473eb80756c87eca409671a57e3947b727",
        "sponsorName": "Bioaegis Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Final product aim is a Nanobody-an antibody but contains only a single very small unit needed for recognition and disruption of the COVID-19 targets",
    "numSites": "",
    "otherPartners": "Wuxi-Jiangsu local government",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 210,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://bioduro.com/article/bioduro-announces-covid19-nanobody/"
    ],
    "sponsors": [
      {
        "sponsorId": "69fd255e06de9b1173c6fdf9c2a593c7a7784d3e",
        "sponsorName": "Bioduro LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Vazegepant,BHV-3500",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinicaltrials@biohavenpharma.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 25 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 25 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "CGRP receptor antagonist that is to be administered intranasally,currently in phase 2/3 trial to evaluate efficacy and potential for quick onset",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Vazegepant_BHV3500",
    "primaryCompletionDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "productId": 211,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04346615",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Washington",
        "country": "USA",
        "lat": 38.9075519,
        "lng": -77.07279849999999,
        "locationId": "321c3fbc17bb15f232fa40febe3b4256f233fdcf",
        "name": "37th and O Street, N.W., Washington, DC 20057, USA",
        "state": "DC"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9495623,
        "lng": -75.1580318,
        "locationId": "94ba89da4f9b6ac2ae34f55f7a2491c77ce5d68b",
        "name": "111 S 11th St, Philadelphia, PA 19107, USA",
        "state": "PA"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biohavenpharma.com/index.php/contact-us",
      "https://www.biohavenpharma.com/science-pipeline/cgrp/bhv-3500",
      "https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020",
      "https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "9416a898d6c70803634f7f9d56ed68eda301ff71",
        "sponsorName": "Biohaven Pharmaceutical Holding Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 25 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "anti-viroporin therapeutics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Biotron is currently testing whether their small molecules that target viroporins (virus-encoded proteins) will be effective against SARS CoV-2,the E protein of SARS CoV-2 was shown to be a viroporin and can potentially be a good target",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviroporin_therapeutics",
    "primaryCompletionDate": "",
    "productId": 212,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.ausbiotech.org/news/australian-biotech-at-the-forefront-of-global-health-responses"
    ],
    "sponsors": [
      {
        "sponsorId": "b9c81254affc60230c18ca7f16da8eb9fd4cc3e6",
        "sponsorName": "Biotron Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "BOLD-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Small molecule that downregulates GRP78 with the intention to treat cancer,completed phase 1 that involved 41 cancer patients with tolerable safety profile,currently under investigation for potential therapeutic effects among COVID-19 patients: downregulating GRP78 shows promise because SARS CoV-2 can bind to GRP78,note that there are no details on the phase 1 trial aside from the number of subjects",
    "numSites": "",
    "otherPartners": "University of Ottawa",
    "phase": "",
    "preferredName": "BOLD100",
    "primaryCompletionDate": "",
    "productId": 213,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.thepharmaletter.com/article/bold-therapeutics-partners-with-academia-to-study-bold-100-as-covid-19-therapy",
      "https://www.bold-therapeutics.com/COVID-19"
    ],
    "sponsors": [
      {
        "sponsorId": "d66e29eb51e46ebb67035da91e045d8c5ced9d8d",
        "sponsorName": "Bold Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CM-4620-IE",
    "chemicalName": "Auxora",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "sudarshan@calcimedica.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Originally developed to treat acute pancreatitis,currently undergoing phase 2 to observe efficacy in COVID-19 patients,functions by inhibiting CRAC channels to alleviate inflammation",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Auxora",
    "primaryCompletionDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "productId": 215,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04345614",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Detroit",
        "country": "USA",
        "lat": 42.3678016,
        "lng": -83.0854662,
        "locationId": "99fed941a64a72d017aecd70c7bd945387139c36",
        "name": "2799 W Grand Blvd, Detroit, MI 48202, USA",
        "state": "MI"
      },
      {
        "city": "St Louis Park",
        "country": "USA",
        "lat": 44.9300754,
        "lng": -93.3619384,
        "locationId": "22ac3e035f177bea07c3025d1f02d164402fbc21",
        "name": "6500 Excelsior Blvd, St Louis Park, MN 55426, USA",
        "state": "MN"
      },
      {
        "city": "St Paul",
        "country": "USA",
        "lat": 44.9561719,
        "lng": -93.0944148,
        "locationId": "5b5d93ba1303eaa8dd1fdcf794802e608e3bc63d",
        "name": "640 Jackson St, St Paul, MN 55101, USA",
        "state": "MN"
      }
    ],
    "sources": [
      "https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia",
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/",
      "https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "878b8442cb543076e452c2d646f57de1f361f6f6",
        "sponsorName": "Calcimedica Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 08 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CAP-1002",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Currently not approved for clinical investigation but FDA has granted expanded access protocol to treat up to 20 more COVID-19 patients after 6 compassionate care cases were treated successfully,plans to launch a randomized and placebo-controlled trial,drug is a cardiac cell therapy that modifies immune activity to promote cellular regeneration",
    "numSites": "",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "CAP1002",
    "primaryCompletionDate": "",
    "productId": 216,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://capricor.com/product-pipeline/cap-1002/",
      "http://capricor.com/contact/",
      "https://www.bioworld.com/articles/434747-capricors-covid-19-success-gets-fda-and-market-attention https://www.biospace.com/article/releases/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with-cap-1002u-s-fda-approves-company-s-expanded-access-protocol-to-treat-additional-patients/",
      "http://capricor.com/product-pipeline/",
      "https://www.biospace.com/article/releases/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with-cap-1002u-s-fda-approves-company-s-expanded-access-protocol-to-treat-additional-patients/",
      "https://clinicaltrials.gov/ct2/show/NCT04338347",
      "https://clinicaltrials.gov/ct2/show/record/NCT04338347"
    ],
    "sponsors": [
      {
        "sponsorId": "2488a9c05ed2f222808e0d9c70595368ed86a7a6",
        "sponsorName": "Capricor Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Carterra will use proprietary LSA platform to simultaneously screen and characterize antibodies to quickly determine ones that are effective against SARS CoV 2",
    "numSites": "",
    "otherPartners": "Coronavirus Immunotherapy Consortium (CoVIC)",
    "phase": "",
    "preferredName": "antibodies",
    "primaryCompletionDate": "",
    "productId": 217,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://carterra-bio.com/news/carterra-inc-selected-by-the-la-jolla-institute-of-immunology-to-provide-antibody-screening-and-characterization-for-the-coronavirus-immunotherapy-consortium-covic/"
    ],
    "sponsors": [
      {
        "sponsorId": "ef5993e2d91aec68e38a7180d305dc11099e9ba5",
        "sponsorName": "Carterra Inc"
      },
      {
        "sponsorId": "c4a8ae6729d9974f1941051e2956e64de583ec66",
        "sponsorName": "La Jolla Institute for Immunology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CK-0802",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 02 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Intends to collaborate with BARDA,the application for a phase-1 randomised double-blind trial has been approved by FDA,CK-0802 is an allogenic cell therapy that consists of TREG cells derived from umbilical cord blood units,hypothesized to improve ARDS by interrupting cytokine storm and resolving inflammation,pre-clinical studies showed favorable results,has been used in clinical trials for other inflammatory disorders",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CK0802",
    "primaryCompletionDate": "",
    "productId": 218,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html",
      "https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/",
      "https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/ ; https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html"
    ],
    "sponsors": [
      {
        "sponsorId": "92d27d31ee16c9150c4ce4a2d09f18d71707dba3",
        "sponsorName": "Cellenkos Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Mesenchymal stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Mesenchymal_stem_cells",
    "primaryCompletionDate": "",
    "productId": 219,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://celltexbank.com/celltex-has-submitted-emergency-expanded-access-clinical-study-for-subjects-with-coronavirus-2019-covid-19-using-multiple-dose-infusions-of-autologous-adipose-tissue-derived-mesenchymal-stem-cells/",
      "https://www.linkedin.com/company/celltex-therapeutics-corporation/"
    ],
    "sponsors": [
      {
        "sponsorId": "9e2adf519c2fb405939c957dd6389845849f22ca",
        "sponsorName": "CellTex Therapeutics Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "anti-LIGHT",
    "chemicalName": "",
    "conditionOrDisease": "ARDS,COVID-19 Pneumonia",
    "contact": [
      {
        "email": "jwilkins@cerecor.com",
        "name": null,
        "notes": "",
        "phone": "610-457-5095",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 26 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 28 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 26 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Fully human antibody targetting the cytokine storm in COVID-19 ARDS,antibody to LIGHT which has been shown to play key role in viral pneumonia,FDA has approved a randomised double blind placebo-controlled proof of concept clinical trial,also being developed for Pediatric-onset Crohn\u2019s Disease",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "antiLIGHT",
    "primaryCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "productId": 220,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04412057",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html",
      "https://www.cerecor.com/about/contact",
      "https://clinicaltrials.gov/ct2/show/record/NCT04412057",
      "https://ir.cerecor.com/press-releases/detail/90/cerecor-announces-exploration-of-the-role-of-an",
      "https://clinicaltrials.gov/ct2/show/study/NCT04412057"
    ],
    "sponsors": [
      {
        "sponsorId": "96d364e5af844fa0968bbd605a149ba3cfd69ca8",
        "sponsorName": "Cerecor Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 20 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 20 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Chromovert",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "NOT a treatment or a vaccine but tecnology. The tecnology is called Chromovert and is used to accelerate drug discovery against hard-to-express biological target.  It has been successfully used to identify a novel non-addictive pain blocker that is in clinical development and it has identified a number of compounds in its pipeline that may help address COVID-19-related disease",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Chromovert",
    "primaryCompletionDate": "",
    "productId": 221,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.prnewswire.com/news-releases/chromocell-makes-chromovert-technology-and-novel-compounds-available-to-support-covid-19-research-301036544.html",
      "https://www.bioworld.com/COVID19products",
      "https://www.linkedin.com/company/chromocell-corporation/"
    ],
    "sponsors": [
      {
        "sponsorId": "4f6dba72f4ca74bcc6cb4c053fcddbbd0605b4a8",
        "sponsorName": "Chromocell Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ENU-200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Oral drug intended for asymptomatic and mild to moderate cases,Ennaid in discussions with FDA and other agencies to bring ENU200 to market within 6-9 months through phase 3 in-home self-dosing clinical trial",
    "numSites": "",
    "otherPartners": "Catalent Inc.",
    "phase": "",
    "preferredName": "ENU200",
    "primaryCompletionDate": "",
    "productId": 231,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ennaidthera.com/science/",
      "https://ennaidthera.com/catalent-signs-development-agreement-with-ennaid-therapeutics-on-its-covid-19-lead-program/",
      "https://ennaidthera.com/science/ https://www.prnewswire.com/news-releases/ennaid-therapeutics-announces-development-of-enu200-a-new-antiviral-therapeutic-for-the-treatment-of-covid-19-301034232.html",
      "https://www.dallasweekly.com/articles/black-woman-scientist-files-patent-for-coronavirus-treatment/"
    ],
    "sponsors": [
      {
        "sponsorId": "5d1294f0cbab726f6c4136eaea842857641103a9",
        "sponsorName": "Ennaid Therapeutics LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "2-DG",
    "chemicalName": "WP1122",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "research was done by University of Frankfurt,2-DG inhibits glycolysis which prevents coronavirus replication in Caco-2 cells",
    "numSites": "",
    "otherPartners": "WPD Pharmaceuticals Inc.",
    "phase": "",
    "preferredName": "WP1122",
    "primaryCompletionDate": "",
    "productId": 222,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/",
      "https://www.bioworld.com/COVID19products",
      "https://www.bioworld.com/COVID19products; https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/",
      "https://www.drugbank.ca/drugs/DB08831",
      "https://cnspharma.com/",
      "https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/ ; https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/"
    ],
    "sponsors": [
      {
        "sponsorId": "b843740e853ec52aa48f7c4d941b036355d61f11",
        "sponsorName": "CNS Pharmaceuticals"
      },
      {
        "sponsorId": "c06ea1b1f971aa6a31cad5c82904f1d56d6c4a6f",
        "sponsorName": "WPD Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "protase inhibtors",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "the compouds are protase inhibitors with a novel mechanism of action",
    "numSites": "",
    "otherPartners": "Kansas State University Research Foundation",
    "phase": "",
    "preferredName": "protase_inhibtors",
    "primaryCompletionDate": "",
    "productId": 223,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with",
      "https://www.bioworld.com/COVID19products",
      "https://www.cocrystalpharma.com/development-pipeline/coronavirus/coronavirus-protease-inhibitor",
      "https://www.cocrystalpharma.com/about/overview",
      "https://www.cocrystalpharma.com/contact-us"
    ],
    "sponsors": [
      {
        "sponsorId": "85acfe2552787d1aab27f27a6db39a840956ca36",
        "sponsorName": "Cocrystal Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "NOT a treatment or vaccine the intervention is artifical intelligance. Cyclica used its proprietary deep learning engine MatchMakerTM to screen a collection of more than 6700 FDA-approved drugs and drug candidates.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Cyclica_Inc_Institute_of_Materia_Medica-224",
    "primaryCompletionDate": "",
    "productId": 224,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://cyclicarx.com/news/chinas-institute-of-materia-medica-partners-with-cyclica-on-innovative-drug-repurposing-for-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "96aa111d21b571477bd2e5134e5c70c2765f72d4",
        "sponsorName": "Cyclica Inc"
      },
      {
        "sponsorId": "90e13d0c6853ec68204942687ed0ccac12474d86",
        "sponsorName": "Institute of Materia Medica"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "NK immunotherapies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Bifunctional antibodies - NK activating antibodies combined with novel antibodies neutralising or blocking SARS CoV2",
    "numSites": "",
    "otherPartners": "Macromoltek",
    "phase": "",
    "preferredName": "NK_immunotherapies",
    "primaryCompletionDate": "",
    "productId": 225,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/5/",
      "https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html"
    ],
    "sponsors": [
      {
        "sponsorId": "96da9064b2e31d835251dbc8767057c31f3e37cf",
        "sponsorName": "Cytovia Inc"
      },
      {
        "sponsorId": "f9bfea84937e5d2a1fc4c5dd3aa3872a28df26f8",
        "sponsorName": "Macromoltek Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Trans Sodium Crocetinate",
    "chemicalName": "Transcrocetinate UPDATE1",
    "conditionOrDisease": "ARDS",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 01 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 26 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Believed to benefit patients that present with significantly impaired oxygen levels due to COVID-19",
    "numSites": "",
    "otherPartners": "University of Virginia Health,the Integrated Translational Research Institute of Virginia,Romanian National Institute of Infectious Diseases,ARENSIA Exploratory Medicine GmbH",
    "phase": "1",
    "preferredName": "Transcrocetinate_UPDATE1",
    "primaryCompletionDate": "",
    "productId": 226,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.drugbank.ca/drugs/DB05974",
      "https://www.bioworld.com/COVID19products",
      "https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Evaluating-TSC-Against-Acute-Respiratory-Distress-Syndrome-ARDS-in-COVID-19-Patients/default.aspx",
      "https://www.bioworld.com/COVID19products ; https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html",
      "https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Receives-Accelerated-FDA-Response-to-Proposed-TSC-COVID-19-Clinical-Trial-Program/default.aspx",
      "https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html"
    ],
    "sponsors": [
      {
        "sponsorId": "51372c96cd390e9e8158f561b56bea3bddd3f04d",
        "sponsorName": "Diffusion Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "LY3127804",
    "chemicalName": "UPDATE1",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Clinicaltrials.gov@lilly.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Selective against angiopoietin 2,which is elevated in ARDS patients",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "UPDATE1",
    "primaryCompletionDate": "Fri, 12 Jun 2020 00:00:00 GMT",
    "productId": 227,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04342897",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Evanston",
        "country": "USA",
        "lat": 42.0646732,
        "lng": -87.6899257,
        "locationId": "7d7a7a51ee06e197337adfb349d6d7787f7c0abe",
        "name": "1301 Central St, Evanston, IL 60201, USA",
        "state": "IL"
      },
      {
        "city": "Indianapolis",
        "country": "USA",
        "lat": 39.6490181,
        "lng": -86.0804521,
        "locationId": "90dae835c6bccd65629c3399282d445b94f06b49",
        "name": "8111 S Emerson Ave, Indianapolis, IN 46237, USA",
        "state": "IN"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/",
      "https://www.thestreet.com/latest-news/eli-lilly-studying-two-potential-treatments-for-covid-19",
      "http://www.pharmatimes.com/news/lilly_to_test_olumiant",
      "_ly3127804_against_covid-19_1338253",
      "https://clinicaltrials.gov/ct2/show/NCT04342897"
    ],
    "sponsors": [
      {
        "sponsorId": "c3304b2181ddd0c29d7e4e948394439adc182494",
        "sponsorName": "Eli Lilly and Co"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 16 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Olumiant",
    "chemicalName": "Baricitinib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Oral JAK1/JAK2 inhibitor previously approved for treatment of arthritis,Bioworld classifies the trial as a phase 2/3 hybrid but there exists no detailed entry for said trial",
    "numSites": "",
    "otherPartners": "National Institute of Allergy and Infectious Diseases",
    "phase": "",
    "preferredName": "Baricitinib",
    "primaryCompletionDate": "",
    "productId": 228,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/",
      "https://www.drugbank.ca/drugs/DB11817",
      "https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/ https://www.bioworld.com/COVID19products"
    ],
    "sponsors": [
      {
        "sponsorId": "c3304b2181ddd0c29d7e4e948394439adc182494",
        "sponsorName": "Eli Lilly and Co"
      },
      {
        "sponsorId": "d70d811c8de3a7e0ae950118837789ce8599f09b",
        "sponsorName": "Incyte Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "COVID-HIG,COVID-EIG",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "No indication that COVID-HIG or EIG (human and horse hyperimmune plasma - respectively) are entering pre-clinical or phase 1 trials any time soon,no projected dates either",
    "numSites": "",
    "otherPartners": "Biomedical Advanced Research and Development Authority,Emergent and the National Institute of Allergy and Infectious Diseases",
    "phase": "",
    "preferredName": "COVIDHIG_COVIDEIG",
    "primaryCompletionDate": "",
    "productId": 229,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=",
      "https://www.fool.com/investing/2020/03/25/fda-facilitating-use-of-plasma-from-recovered-pati.aspx",
      "https://www.fool.com/investing/2020/03/25/fda-facilitating-use-of-plasma-from-recovered-pati.aspx https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]="
    ],
    "sponsors": [
      {
        "sponsorId": "fb6f2b512443fdfe4d4b85aa2d74466d4ef9bcb4",
        "sponsorName": "Emergent Biosolutions Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Allocetra",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 07 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Undergoing multi-center investigator-initiated phase 2 trial as of May 7 but no entry on clinicaltrials,drug aims to balance immune response and prevent cytokine storm",
    "numSites": "",
    "otherPartners": "Israel Innovation Authority",
    "phase": "",
    "preferredName": "Allocetra",
    "primaryCompletionDate": "",
    "productId": 230,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.enlivex.com/investor-relations/#b2iLibScrollTo",
      "https://www.enlivex.com/allocetra/",
      "https://www.enlivex.com/investor-relations/#b2iLibScrollTo https://www.enlivex.com/allocetra/"
    ],
    "sponsors": [
      {
        "sponsorId": "35f03ea5c43e45df3a66c005c91958a6ddad2bc3",
        "sponsorName": "Enlivex Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Interferon-beta-1a,traumakine",
    "chemicalName": "FP-1201-lyo",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Finland"],
    "countryCodes": ["FIN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Tested with ritonavir and lopinavir in the WHO Solidarity Trial,the researchers who completed the first study is currently conducting two more",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "FP1201lyo",
    "primaryCompletionDate": "Sun, 19 Apr 2020 00:00:00 GMT",
    "productId": 232,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04343768",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Tehran",
        "country": "IRN",
        "lat": 35.68008950000001,
        "lng": 51.3881482,
        "locationId": "f5eb2565b7f3de1c468a4691a4b4565e071045c5",
        "name": "Tehran, \u0627\u0633\u062a\u0627\u0646 \u062a\u0647\u0631\u0627\u0646 \u062a\u0647\u0631\u0627\u0646 \u062e\u06cc\u0627\u0628\u0627\u0646 \u06a9\u0627\u0631\u06af\u0631 \u062c\u0646\u0648\u0628\u06cc\u060c Kamali St, 13336 31151, Iran",
        "state": null
      }
    ],
    "sources": [
      "https://www.faron.com/index.php/pipeline/traumakine-fp-1201-lyo",
      "https://www.bioworld.com/COVID19products",
      "https://www.faron.com/news-events/news-and-press-releases?rnsid=1387792&cid=2223",
      "https://www.sciencedirect.com/science/article/pii/S0166354220302059",
      "https://www.faron.com/contact",
      "https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-; https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3",
      "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30894-1/fulltext https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2",
      "https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments",
      "https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3",
      "https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2"
    ],
    "sponsors": [
      {
        "sponsorId": "a14a930a99f757de7464f323c64a61c4425eeab9",
        "sponsorName": "Faron Pharmaceuticals Oy"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 19 Apr 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 05 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "FW-1022",
    "chemicalName": "niclosamide",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "karine.faure@chru-lille.fr",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Oral drug targeting GI symptoms,expected to reach clinical trials in mid-2020 in the European Union and United States",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "niclosamide",
    "primaryCompletionDate": "Sat, 23 May 2020 00:00:00 GMT",
    "productId": 233,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04372082",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.firstwavebio.com/pipeline/",
      "https://www.bioworld.com/COVID19products",
      "https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/",
      "https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10"
    ],
    "sponsors": [
      {
        "sponsorId": "cbb02257499f9c2c7d7271d953b3560d56ea08ab",
        "sponsorName": "Firstwave Bio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 23 May 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 20 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "FIB Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Isolated and characterized antibody that can bind conserved epitope on spike protein and neutralize lab virus as of May 7,moving to enter preclinical testing",
    "numSites": "",
    "otherPartners": "Labs of Jason McLellan (University of Texas at Austin- US),Markus Hoffman and Stefan Pohlmann (German Primate Center - Leibniz Institute for Primate Research - Gottingen - Germany)",
    "phase": "",
    "preferredName": "FIB_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 234,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx",
      "https://www.sciencedaily.com/releases/2020/05/200506104425.htm"
    ],
    "sponsors": [
      {
        "sponsorId": "57edd5513cc69010f620c128c8a4cd203199a017",
        "sponsorName": "Flanders Institute for Biotechnology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "rCIG",
    "chemicalName": "gammaglobulin",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Polyclonal antibodies,will not enter clinical trials until early 2021",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "gammaglobulin",
    "primaryCompletionDate": "",
    "productId": 235,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502",
      "https://www.bioworld.com/COVID19products",
      "https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502 https://healthadvancesblog.com/2020/05/13/protective-antibody-therapy-preventing-future-covid-19-outbreaks/",
      "https://gigagen.com/#pipeline"
    ],
    "sponsors": [
      {
        "sponsorId": "88873a8fec57e2eafb81051d4b164951b8b32ded",
        "sponsorName": "Gigagen Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Truvada",
    "chemicalName": "emtricitabine,tenofovir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "jamo@mscbs.es; rpolor@mscbs.es",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Previously accepted HIV treatment that combines emtricitabine and tenofovir repurposed to treat COVID 19",
    "numSites": "62",
    "otherPartners": "Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital",
    "phase": "3",
    "preferredName": "emtricitabine_tenofovir",
    "primaryCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "productId": 236,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04334928",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "ESP",
        "lat": 40.46366700000001,
        "lng": -3.74922,
        "locationId": "ccd4f89600e7802ded77680ab52ad8e75c4e215d",
        "name": "Spain",
        "state": null
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.gilead.com/science-and-medicine/medicines",
      "https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071",
      "https://www.gilead.com/",
      "https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2",
      "https://www.pharmacytimes.com/ajax/prep-medications-may-be-potential-covid-19-treatments",
      "https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2"
    ],
    "sponsors": [
      {
        "sponsorId": "cbb34f9aed92e21ff89501b842a385faabf9c8c6",
        "sponsorName": "Gilead Sciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 31 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Trike therapeutic",
    "chemicalName": "GTB-3550 (OXS-3550)",
    "conditionOrDisease": "High-risk myelodysplastic syndromes,acute myelogenous leukemia,systemic mastocytosis,mast cell leukemia",
    "contact": [
      {
        "email": "mille011@umn.edu",
        "name": null,
        "notes": "",
        "phone": "612-625-7409",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 21 Jan 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently in clinical trial for acute myeloid lukemia,however it has not been cleared for clinical trials in COVID-19 patients - note that the clinical trial information in columns AD to AM is not representative of the COVID-19 pipeline",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "GTB3550_OXS3550",
    "primaryCompletionDate": "Thu, 01 Feb 2024 00:00:00 GMT",
    "productId": 237,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03214666",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Minneapolis",
        "country": "USA",
        "lat": 44.97399,
        "lng": -93.2277285,
        "locationId": "3eea33b81c5ca7d85cb1fb9962ed350a80fe3f3d",
        "name": "Minneapolis, MN 55455, USA",
        "state": "MN"
      }
    ],
    "sources": [
      "https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration",
      "https://www.bioworld.com/COVID19products",
      "https://www.gtbiopharma.com/news-media/press-releases/detail/185/gt-biopharma-announces-commencement-of-retreatment-of",
      "https://www.gtbiopharma.com/news-media/press-releases/detail/159/gt-biopharma-receives-fda-clearance-to-commence",
      "https://www.gtbiopharma.com/news-media/press-releases/detail/180/gt-biopharma-provides-update-concerning-triketm-drug",
      "https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "19311beed76e39b72841d55b12b1026f4994706e",
        "sponsorName": "GT Biopharma Inc"
      },
      {
        "sponsorId": "66f07a8584ac1fa31540d4786854faf6c4aa3957",
        "sponsorName": "Cytovance Biologics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 01 Aug 2025 00:00:00 GMT",
    "studyStartDate": "Wed, 01 Jan 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Harrington Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Aims to accelerate near-term therapies to treat COVID-19,developed a proven model to allow other scientists to accelerate their breakthrough discovers,overall I believe this entry should be deleted - very vague and little promise of anything,if anything this entry is more of a call to action for others to find therapies than a therapy in itself",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Harrington_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 238,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.uhhospitals.org/harrington-discovery-institute/multimedia/hdi-press-releases/hdi-at-uh-to-aid-in-global-fight-against-coronavirus-pandemic"
    ],
    "sponsors": [
      {
        "sponsorId": "bf94ba6ac350c9a5c8dc12ad79ceb170e893d9a7",
        "sponsorName": "Harrington Discovery Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "HLCM-051",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "t.oe@healios.jp",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 01 Jan 2019 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "stem cell therapy",
    "numSites": "2",
    "otherPartners": "Healios K.K.,Athersys Inc.",
    "phase": "2",
    "preferredName": "HLCM051",
    "primaryCompletionDate": "",
    "productId": 239,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03807804",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "\u5f18\u524d\u5e02",
        "country": "JPN",
        "lat": 40.5996478,
        "lng": 140.4659418,
        "locationId": "ca56bb90de09b09f8f9d6128d8af0eb319939162",
        "name": "Japan, \u3012036-8563 \u9752\u68ee\u770c\u5f18\u524d\u5e02\u5927\u5b57\u672c\u753a\uff15\uff13",
        "state": "\u9752\u68ee\u770c"
      },
      {
        "city": "Kumamoto",
        "country": "JPN",
        "lat": 32.7649934,
        "lng": 130.7008681,
        "locationId": "46b2cd52208e14a057e2c6e897915b55fab36c36",
        "name": "5-ch\u014dme-3-\uff13\u756a\uff11\u53f7 Chikami, Minami-ku, Kumamoto, 861-4193, Japan",
        "state": "Kumamoto"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.healios.co.jp/en/development/ssc/",
      "https://www.healios.co.jp/en/",
      "https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "7d37b38fc6903794e0d2745bf6a891faddf43237",
        "sponsorName": "Healios KK"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 31 May 2021 00:00:00 GMT",
    "studyStartDate": "Tue, 01 Jan 2019 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Nitricil therapeutic",
    "chemicalName": "nitric oxide",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Wainwright & Co. LLC",
    "phase": "",
    "preferredName": "nitric_oxide",
    "primaryCompletionDate": "",
    "productId": 267,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "ddee329111caa7d96be4e5aea7fa3ccfaccac422",
        "sponsorName": "Novan Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Lenzilumab",
    "chemicalName": "humanized monoclonal antibody (class IgG1 kappa)",
    "conditionOrDisease": "COVID 19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Catalent,Humanigen Inc.",
    "phase": "3",
    "preferredName": "humanized_monoclonal_antibody_class_IgG1_kappa",
    "primaryCompletionDate": "",
    "productId": 241,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04351152",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.humanigen.com/press/FDA-Approves-Initiation-of-Humanigen%E2%80%99s-Phase-III-Study-of-Lenzilumab-in-COVID-19-Patients",
      "https://clinicaltrials.gov/ct2/show/NCT04351152?term=lenzilumab&draw=2&rank=3"
    ],
    "sponsors": [
      {
        "sponsorId": "a81896aa5b137b226eae204c475800cdbc8c227f",
        "sponsorName": "Humanigen Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 20 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "endonuclease",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Considering the use of endonuclease inhibitors that have been proven useful in blocking the SARS virus",
    "numSites": "",
    "otherPartners": "Iktos SAS",
    "phase": "",
    "preferredName": "endonuclease",
    "primaryCompletionDate": "",
    "productId": 242,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.sri.com/iktos-and-sri-international-announce-collaboration-to-combine-artificial-intelligence-and-novel-automated-discovery-platform-for-accelerated-development-of-new-anti-viral-therapies/press-release/",
      "https://www.bioworld.com/COVID19products"
    ],
    "sponsors": [
      {
        "sponsorId": "9363c36807614b06638e420a1f2fa93b6641816b",
        "sponsorName": "SRI International"
      },
      {
        "sponsorId": "29880b129c04d0739018086a6448810f55c10ce5",
        "sponsorName": "Iktos"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Monoclonal Antibody",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "ImmuneCyte Life Sciences Inc.,Thermogenesis Holdings Inc.",
    "phase": "",
    "preferredName": "Monoclonal_Antibody",
    "primaryCompletionDate": "",
    "productId": 243,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://thermogenesis.com/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/"
    ],
    "sponsors": [
      {
        "sponsorId": "892eef6b8ee8f7b4199971bb0a2cbe4a6ac874c3",
        "sponsorName": "ImmuneCyte Life Sciences Inc"
      },
      {
        "sponsorId": "2d735c3d9d663fcc08e98c3576299ec02b7f8090",
        "sponsorName": "Thermogenesis Holdings Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Lodonal - CYTO 106,IRT-101",
    "chemicalName": "Low Dose Naltrexone",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Initially developed for use in HIV,Has shown efficacy in decreasing replication of H1N1 influenza",
    "numSites": "",
    "otherPartners": "Immune therapeutics Inc.",
    "phase": "2",
    "preferredName": "Low_Dose_Naltrexone",
    "primaryCompletionDate": "",
    "productId": 244,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "6ea4d83cf95f6a8d357720443be824816569a0f0",
        "sponsorName": "Cytocom Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Avdoralimab",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "nicolas.schleinitz@ap-hm.fr",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 27 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "In phase 1 development for treatment of solid tumors including hepatocellular carcinoma and non-small cell lung cancer",
    "numSites": "1",
    "otherPartners": "Assistance Publique Hopitaux De Marseille",
    "phase": "2",
    "preferredName": "Avdoralimab",
    "primaryCompletionDate": "Sat, 27 Jun 2020 00:00:00 GMT",
    "productId": 245,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04371367",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Marseille",
        "country": "FRA",
        "lat": 43.296482,
        "lng": 5.36978,
        "locationId": "dfb74044369807f4bc4cdf2a92b4ce741bdc1134",
        "name": "Marseille, France",
        "state": "Provence-Alpes-C\u00f4te d'Azur"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=1",
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/record/NCT04371367",
      "https://www.innate-pharma.com/en/news-events/press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia",
      "https://clinicaltrials.gov/ct2/show/study/NCT04371367",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=2",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=3",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=4",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=5",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=6",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=7",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=8",
      "https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=9"
    ],
    "sponsors": [
      {
        "sponsorId": "b337560632de8abae925da303babdc79ea05dadb",
        "sponsorName": "Innate Pharma SA"
      },
      {
        "sponsorId": "587b66a05b02fcac9b73edf0cbb79d9cd55ecd52",
        "sponsorName": "Marseille Immunopole"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 27 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 27 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IZN-101",
    "chemicalName": "Namilumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "At the Humanitas Research Hospital",
    "numSites": "",
    "otherPartners": "Humanitas Research Group",
    "phase": "2",
    "preferredName": "Namilumab",
    "primaryCompletionDate": "",
    "productId": 246,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Milan",
        "country": "ITA",
        "lat": 45.4642035,
        "lng": 9.189982,
        "locationId": "3493891c483187147e76782f8dd5330b5d49ac58",
        "name": "Milan, Metropolitan City of Milan, Italy",
        "state": "Lombardy"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/",
      "https://www.pharmaceutical-technology.com/news/izana-namilumab-covid-19-study/",
      "http://www.pharmatimes.com/news/izana_intiates_study_assessing_namilumab_for_covid-19_1337405"
    ],
    "sponsors": [
      {
        "sponsorId": "62b5112b8c89d1a47c69aa94e5bc89d7166f157b",
        "sponsorName": "Izana Bioscience Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Airuka",
    "chemicalName": "camrelizumab plus thymosin",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Originally intended for the treatment of Hodgkin Lymphoma and hepatocellular carcinoma",
    "numSites": "1",
    "otherPartners": "Southeast University",
    "phase": "2",
    "preferredName": "camrelizumab_plus_thymosin",
    "primaryCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "productId": 247,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04268537",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Lakeland",
        "country": "USA",
        "lat": 28.0301306,
        "lng": -81.9179961,
        "locationId": "901a3a7e4ef96a056162454df4c0eec576970030",
        "name": "1000 Longfellow Blvd, Lakeland, FL 33801, USA",
        "state": "FL"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04268537"
    ],
    "sponsors": [
      {
        "sponsorId": "44eafbed318ddb4f38d794fb4efd9f98455cbe54",
        "sponsorName": "Jingsu HengRui Medicine Co"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 31 Oct 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 10 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Tocilizumab biosimilar",
    "chemicalName": "monoclonal antibody",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Pengzy5@hotmail.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 25 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Originally intended for the treatment of Rheumatoid arthritis and systemic juvenile idiopathic arthritis",
    "numSites": "1",
    "otherPartners": "Central South Hospital of Wuhan University",
    "phase": "2",
    "preferredName": "monoclonal_antibody",
    "primaryCompletionDate": "",
    "productId": 248,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=49883",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Arkansas City",
        "country": "USA",
        "lat": 37.1329945,
        "lng": -97.0384445,
        "locationId": "80e150c0931bbe4b18888056b3b7e17789c44eee",
        "name": "6401 Patterson Pkwy, Arkansas City, KS 67005, USA",
        "state": "KS"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.5360485,
        "lng": 114.3643219,
        "locationId": "2669fa1804aa1b78da7d634a23a9520a24c11314",
        "name": "Wuchang District, Wuhan, Hubei, China, 430072",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196",
      "http://www.chictr.org.cn/showprojen.aspx?proj=49883",
      "http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030197",
      "http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030198",
      "http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030199",
      "http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030200",
      "http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030201",
      "http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030202"
    ],
    "sponsors": [
      {
        "sponsorId": "324d178c669e71e0405a90eac0b5a43232854ad4",
        "sponsorName": "Jinyu Biotechnology Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 25 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "Antibodies",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Antibody treatment for the neutralization of COVID-19 (The drug candidate is designed to prevent the binding of viruses to host cell surface receptor ACE2)",
    "numSites": "",
    "otherPartners": "Junshi Biosciences Ltd,Institute of Microbiology of the Chinese Academy of Sciences -Eli Lilly",
    "phase": "Pre-Clinical",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 249,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure"
    ],
    "sponsors": [
      {
        "sponsorId": "cf093c3c3034066cc4fc396f460d2433806ea0c3",
        "sponsorName": "Junshi Biosciences Ltd"
      },
      {
        "sponsorId": "e494e00fc769e5a7fbfae8fa40eb4e348fb6dd3b",
        "sponsorName": "Institute of Microbiology of the Chinese Academy of Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Xpovio",
    "chemicalName": "selinexor",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "jshah@karyopharm.com",
        "name": null,
        "notes": "",
        "phone": "(617) 658-0600",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "33",
    "otherPartners": "Karyopharm Therapeutics Inc ",
    "phase": "2",
    "preferredName": "selinexor",
    "primaryCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "productId": 250,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04349098",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "USA",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "43858457ee958bea8729bfbbddacfd93f32fe67d",
        "name": "United States",
        "state": null
      },
      {
        "city": null,
        "country": "AUT",
        "lat": 47.516231,
        "lng": 14.550072,
        "locationId": "c4f7887d925567d1061e12bd2ba889db677840c9",
        "name": "Austria",
        "state": null
      },
      {
        "city": null,
        "country": "FRA",
        "lat": 46.227638,
        "lng": 2.213749,
        "locationId": "1b29efc401e5935eac8c76d2870349548aff41dc",
        "name": "France",
        "state": null
      },
      {
        "city": null,
        "country": "ISR",
        "lat": 31.046051,
        "lng": 34.851612,
        "locationId": "7b0aa1ca51c08d751c5c81b8a4ae7776827062fe",
        "name": "Israel",
        "state": null
      },
      {
        "city": null,
        "country": "ESP",
        "lat": 40.46366700000001,
        "lng": -3.74922,
        "locationId": "9adcfba260e7e7e0140b95de1805059ebb7ca53a",
        "name": "Spain",
        "state": null
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "ede808078bc5e01e07fdf7f24591afebbb03f058",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=2",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=3",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=4",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=5",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=6",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=7",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=8",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=10",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=12",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=13",
      "https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=14",
      "https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation"
    ],
    "sponsors": [
      {
        "sponsorId": "e6cb84b316561809b01b60e49451ae9585f9599e",
        "sponsorName": "Karyopharma Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 17 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ARM/NK Therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "",
    "otherPartners": "Kleo Pharmaceuticals Inc.,Green Cross Labcell",
    "phase": "",
    "preferredName": "ARMNK_Therapy",
    "primaryCompletionDate": "",
    "productId": 251,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=605",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=606",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=607",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=608",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=609",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=610",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=611"
    ],
    "sponsors": [
      {
        "sponsorId": "65a4395646171957f48b542bb3f8a88cb60f8744",
        "sponsorName": "Kleo Pharmaceuticals Inc"
      },
      {
        "sponsorId": "5d01024199c1e46eb25ce5e44ac99c1bd0431f67",
        "sponsorName": "Green Cross Labcell"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Panaphix",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Komipharm International",
    "phase": "",
    "preferredName": "Panaphix",
    "primaryCompletionDate": "",
    "productId": 252,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html"
    ],
    "sponsors": [
      {
        "sponsorId": "80d5660a048cb4f5f9120ad0ee6693d572076feb",
        "sponsorName": "Komipharm International Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Giapreza",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "La Jolla Pharmaceutical Co.",
    "phase": "",
    "preferredName": "Giapreza",
    "primaryCompletionDate": "",
    "productId": 253,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.rxlist.com/giapreza-drug.htm",
      "https://www.giapreza.com/about-giapreza/"
    ],
    "sponsors": [
      {
        "sponsorId": "eaeb4d2f6090de798cc599bb33c63aece3ea3e59",
        "sponsorName": "La Jolla Pharmaceutical Co"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Lemellosome",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Novel treatment based on using lipid vesicles for nucleic acid delivery",
    "numSites": "",
    "otherPartners": "Lamellasome Biomedical",
    "phase": "Discovery",
    "preferredName": "Lemellosome",
    "primaryCompletionDate": "",
    "productId": 254,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html",
      "https://www.lamellar.com/",
      "https://www.lamellar.com/lamellasome-and-pulmonary-diseases/"
    ],
    "sponsors": [
      {
        "sponsorId": "a1a954d36a30fd0780c3b830f4faea0c8c2affb2",
        "sponsorName": "Lamellar Biomedical Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "LAU-7b",
    "chemicalName": "fenretinide",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Novel drug for CF,but Phase 2 will include 200 COVID-19 patients",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fenretinide",
    "primaryCompletionDate": "",
    "productId": 255,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.bioworld.com/COVID19products",
      "https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/laurent-pharmaceuticals-joins-battle-against-covid-19",
      "https://www.drugbank.ca/drugs/DB05076",
      "https://www.manchestertimes.com/news/business/laurent-pharmaceuticals-receives-health-canada-s-approval-to-initiate-covid-19-clinical-trial/article_a59fbdf1-509a-569f-a9c4-841fa17608ae.html"
    ],
    "sponsors": [
      {
        "sponsorId": "7fccb09ede9fdc5e7fac92574b058cb03352c217",
        "sponsorName": "Laurent Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "LB-1148",
    "chemicalName": "tranexamic acid",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tranexamic_acid",
    "primaryCompletionDate": "",
    "productId": 256,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://pipelinereview.com/index.php/2020040774270/Small-Molecules/Leading-BioSciences-Announces-Potential-for-Investigational-Drug-LB1148-to-Treat-Multiple-Organ-Dysfunction-Syndrome-in-COVID-19-Patients.html",
      "https://leadingbiosciences.com/lb1148/",
      "https://leadingbiosciences.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "939a860ac278db9d975ccb0616222eeeef87f0e8",
        "sponsorName": "Leading Biosciences Inc"
      },
      {
        "sponsorId": "910ae71fffb2962bd05519a67ecec935ef621b0d",
        "sponsorName": "University of Alabama"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Sanofi SA,Amneal Pharmaceuticals INc.,Rising Pharma Holdings Inc.,University of Minnesota,University of Oxford,IHU-M\u00e9diterran\u00e9e Infection,Sandoz Inc.,Bayer AG,University of Washington,Patient-Centerede Outcomes Research Institute,World Health Organization,New York State Department of Health,National Institute or Respiratory Diseases - Mexico,",
    "chemicalName": "chloroquine or hydroxychloroquine",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "On Market",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "On March 28th,FDA issued emergency use authorization of chloroquine phosphate and hydroxychloroquine sulfate",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chloroquine_or_hydroxychloroquine",
    "primaryCompletionDate": "",
    "productId": 257,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "86b83695165cca282e4f9c439eda39501ae4f0df",
        "sponsorName": "Lupus Therapeutics"
      }
    ],
    "status": "On Market",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antimalarial drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Thiolanox",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Inhaled gaseous Nitric Oxide",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Thiolanox",
    "primaryCompletionDate": "",
    "productId": 258,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03331445",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Vancouver",
        "country": "CAN",
        "lat": 49.2609056,
        "lng": -123.1259083,
        "locationId": "17384c44959bbdc65ec2180b6dddab6aa65a21aa",
        "name": "2775 Laurel St, Vancouver, BC V5Z 1M9, Canada",
        "state": "BC"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://pharmaphorum.com/news/mallinckrodt-novoteris-nitric-oxide-will-start-covid-19-trial/",
      "https://eyewire.news/articles/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "1bae5c9e81061a3096b953a0c281893f63528dcf",
        "sponsorName": "Mallinckrodt plc"
      },
      {
        "sponsorId": "6911212feb8516a3c67e4d56ab144214fba04e7c",
        "sponsorName": "Novoteris LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 31 Mar 2021 00:00:00 GMT",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Prototype powders",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Pulmonary Drug Delievery",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Prototype_powders",
    "primaryCompletionDate": "",
    "productId": 259,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.ondrugdelivery.com/mannkind-refocuses-pipeline-resources-in-response-to-covid-19-pandemic/"
    ],
    "sponsors": [
      {
        "sponsorId": "98d35ba7fbc9135eb8b0efad1c369b7efd428d50",
        "sponsorName": "Mannkind Corp"
      },
      {
        "sponsorId": "7879cb30e61a74d5398a4ad84131b67c7bdef5e5",
        "sponsorName": "Immix Biopharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Canadian Institutes for Health Research",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 260,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.medicago.com/en/covid-19-programs/",
      "https://www.medicago.com/en/"
    ],
    "sponsors": [
      {
        "sponsorId": "c3b31ebe3bec88be1939ba82b92fd751109ba63c",
        "sponsorName": "Medicago Inc"
      },
      {
        "sponsorId": "89ce3145e138aa498d0b8624253df8d652b51d01",
        "sponsorName": "Laval University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MN-166",
    "chemicalName": "ibudilast",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ibudilast",
    "primaryCompletionDate": "",
    "productId": 261,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.medicago.com/en/covid-19-programs/",
      "https://www.clinicaltrialsarena.com/news/yale-ibudilast-covid-19-trial/"
    ],
    "sponsors": [
      {
        "sponsorId": "93b330b91c5cf5de4858a317eb4e5d88f5c33274",
        "sponsorName": "Medicinova Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Ivermectin",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "sbudhiraja@maxhealthcare.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ivermectin",
    "primaryCompletionDate": "Sat, 25 Jul 2020 00:00:00 GMT",
    "productId": 262,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04373824",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "New Delhi",
        "country": "IND",
        "lat": 28.6139391,
        "lng": 77.2090212,
        "locationId": "33946140a73b6cc685329a2269d4a69224961640",
        "name": "New Delhi, Delhi, India",
        "state": "DL"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.ncbi.nlm.nih.gov/pubmed/28942281",
      "https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans"
    ],
    "sponsors": [
      {
        "sponsorId": "62af02d502c3b46af39cf1393ded764d02cf2dd3",
        "sponsorName": "Medincell SA"
      },
      {
        "sponsorId": "4504468bad51eef6a2ac6172fa89a91614df3c56",
        "sponsorName": "Merck"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 25 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 25 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "WP-1122",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "WP1122",
    "primaryCompletionDate": "",
    "productId": 263,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/moleculin-announces-active-compound-in-wp1122-reduces-coronavirus-replication-in-vitro-by-100-301037143.html",
      "https://www.moleculin.com/covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "bfc86f4330be66b8207ed43b7e662f038bf16e6e",
        "sponsorName": "Moleculin Biotech Inc"
      },
      {
        "sponsorId": "47b17e1c6508ca65a8f74513d8a91bf7fea67bd1",
        "sponsorName": "University of Texas Medical Branch"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Colchicine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "priscilla.hsue@ucsf.edu",
        "name": null,
        "notes": "",
        "phone": "6282068257",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Colchicine",
    "primaryCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "productId": 264,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04322682",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "SF",
        "country": "USA",
        "lat": 37.7749295,
        "lng": -122.4194155,
        "locationId": "0b0571960052800bf8585f88de1e5ab534da07de",
        "name": "San Francisco, CA, USA",
        "state": "CA"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7381644,
        "lng": -73.97821569999999,
        "locationId": "e394f82832f27188bac1055f4d36f41818125850",
        "name": "345 E 24th St, New York, NY 10010, USA",
        "state": "NY"
      },
      {
        "city": "Montr\u00e9al",
        "country": "CAN",
        "lat": 45.5734782,
        "lng": -73.5785783,
        "locationId": "8eac075a83c8d34e424ec7e9695e1200fde67bdf",
        "name": "5000 Rue B\u00e9langer, Montr\u00e9al, QC H1T 1C8, Canada",
        "state": "QC"
      },
      {
        "city": "Madrid",
        "country": "ESP",
        "lat": 40.4811633,
        "lng": -3.6873977,
        "locationId": "9ee25c97982e164fdb49dbeb4f30366e71605f55",
        "name": "Paseo de la Castellana, 261, 28046 Madrid, Spain",
        "state": "Comunidad de Madrid"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.icm-mhi.org/en/new-clinical-trial-treatment-covid-19-positive-patients-start-nyu-grossman-school-medicine",
      "https://www.drugbank.ca/drugs/DB01394"
    ],
    "sponsors": [
      {
        "sponsorId": "249179236abc76c285b00f0d0d7abc1e9abfdaa2",
        "sponsorName": "Montreal Heart Institute"
      },
      {
        "sponsorId": "21765278273510ad7dc80a80afe9b1cf27f3e6d5",
        "sponsorName": "NYU Grossman School of Medicine"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 23 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CD-16,N-803,mesenchymal stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "CD-16 off-the-shelf natural killer cells to enhance antibody killing of infected cells given alone or combined with Convalescent Plasma (CP) in combination with ImmunityBio\u2019s IL-15 superagonist N-803 and Avelumab",
    "numSites": "",
    "otherPartners": "Nantkwest Inc.,Immunitybio Inc.,National Institute of Allergy and Infectious Diseases.",
    "phase": "",
    "preferredName": "CD16_N803_mesenchymal_stem_cells",
    "primaryCompletionDate": "",
    "productId": 265,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "13fabd5b14178a13d0539b59d6a9be0b068e4309",
        "sponsorName": "Nantkwest Inc"
      },
      {
        "sponsorId": "8bfec75fcf441b5e6dfde4d8556e152456e80321",
        "sponsorName": "Immunitybio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Pritumumab",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 03 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "a natural human IgG1 kappa antibody that has been derived from a B cell isolated from regional draining lymph node of a cervical carcinoma patient",
    "numSites": "",
    "otherPartners": "Nascent Biotech Inc.",
    "phase": "",
    "preferredName": "Pritumumab",
    "primaryCompletionDate": "",
    "productId": 266,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "b3867b6cd9697e882535adad3e08532327c9d976",
        "sponsorName": "Nascent Biotech Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "RNAi therapeutic",
    "chemicalName": "small interfering RNAs",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "",
    "notes": "The siRNAs would operate within the RNAi pathway where it interferes with the expression of the genes with complementary nucleotide sequences by degrading mRNA after transcription resulting in no translation.",
    "numSites": "",
    "otherPartners": "OliX Pharmaceuticals Inc",
    "phase": "",
    "preferredName": "small_interfering_RNAs",
    "primaryCompletionDate": "",
    "productId": 269,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "96c730a852872cf66c35cb125b2d7d05d8530e76",
        "sponsorName": "Olix Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "KTH-222",
    "chemicalName": "inhibit the MAPK pathway by controlling initiation of the signaling cascade while synthetic drugs block only specific parts of the pathway",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "anticancer drug",
    "numSites": "",
    "otherPartners": "Kalos Therapeutics,Oncology Pharma Inc.",
    "phase": "",
    "preferredName": "inhibit_the_MAPK_pathway_by_controlling_initiation_of_the_signaling_cascade_while_synthetic_drugs_block_only_specific_parts_of_the_pathway",
    "primaryCompletionDate": "",
    "productId": 270,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "94591eec9484636deee6e0aa9cf402169c390282",
        "sponsorName": "Oncology Pharma Inc"
      },
      {
        "sponsorId": "eb7a2deb781669d168a882d3eb969a94f3b7b5d9",
        "sponsorName": "Kalos Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VNAR antibodies",
    "chemicalName": "Single domain variable new antigen receptor (VNAR) antibodies",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Lundbeck,Ossianix Inc.",
    "phase": "",
    "preferredName": "Single_domain_variable_new_antigen_receptor_VNAR_antibodies",
    "primaryCompletionDate": "",
    "productId": 271,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "e0168852b1423a84cb2e4cc6a63702915618d555",
        "sponsorName": "Ossianix Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Ostrich antibodies",
    "chemicalName": "ostrich IgY antibodies",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Ostrich Pharma USA",
    "phase": "1",
    "preferredName": "ostrich_IgY_antibodies",
    "primaryCompletionDate": "",
    "productId": 272,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Frisco",
        "country": "USA",
        "lat": 33.1021814,
        "lng": -96.84083869999999,
        "locationId": "99c8063102cc2dbe3c4211896d85ba4645693c4c",
        "name": "2840 Legacy Dr #100, Frisco, TX 75034, USA",
        "state": "TX"
      }
    ],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "81131cc14196ec0102f65dd04174c541d8ed0900",
        "sponsorName": "Ostrich Pharma USA Ostrigen"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sat, 04 Jan 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Leukine",
    "chemicalName": "Sargramostim",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Phase 4",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "University Hospital Ghent,Flanders Institute of Biotechnology",
    "phase": "4",
    "preferredName": "Sargramostim",
    "primaryCompletionDate": "",
    "productId": 273,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Gent",
        "country": "BEL",
        "lat": 51.0243757,
        "lng": 3.7261488,
        "locationId": "f04790bbc67f504cacdd10ebd88fd986d0ccbaba",
        "name": "Corneel Heymanslaan 10, 9000 Gent, Belgium",
        "state": "Vlaanderen"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.partnertx.com/11508-2/",
      "https://www.drugbank.ca/drugs/DB00020",
      "https://www.oncolink.org/cancer-treatment/oncolink-rx/sargramostim-leukine-r-gm-csf",
      "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE"
    ],
    "sponsors": [
      {
        "sponsorId": "8b5205e0d7efb338bddea3c077306518cd3232bc",
        "sponsorName": "Partner Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Microbiome therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Microbiome_therapeutic",
    "primaryCompletionDate": "",
    "productId": 274,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/persephone-biosciences-announces-ai-driven-microbiome-therapeutic-and-diagnostic-programs-for-covid-19-301033668.html",
      "https://www.nbcsandiego.com/news/local/microbiome-targeted-therapeutics-may-have-role-in-covid-19-fight/2306310/"
    ],
    "sponsors": [
      {
        "sponsorId": "8a2aaacc01bd11f71c410206ebedcdc6087bc015",
        "sponsorName": "Persephone Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Centhaquine",
    "chemicalName": "PMZ-2010",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PMZ2010",
    "primaryCompletionDate": "",
    "productId": 275,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.pharmazz.com/pmz-2010-h.php",
      "https://www.bioworld.com/COVID19products",
      "https://www.pharmiweb.com/press-release/2020-04-09/centhaquine-can-provide-hemodynamic-stability-improve-tissue-oxygenation-reduce-pulmonary-edema-a",
      "https://pubchem.ncbi.nlm.nih.gov/compound/Centhaquine#section=Related-Compounds-with-Annotation",
      "https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Pharmazz%2C+Inc.&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=",
      "https://clinicaltrials.gov/ct2/show/NCT04045327"
    ],
    "sponsors": [
      {
        "sponsorId": "ccbaab96d082b74ca31a6f4f904d47ead69db5d3",
        "sponsorName": "Pharmazz INc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Neumifil",
    "chemicalName": "Sp2CBMTD",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Carbohydrate bonding module (CBM40) blocks sialic acid receptors in respiratory tract and prevents virus from entering host cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "Pre-clinical",
    "preferredName": "Sp2CBMTD",
    "primaryCompletionDate": "",
    "productId": 276,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.pneumagen.com/uploads/images/publications/Antimicrob.%20Agents%20Chemother.-2015-Govorkova-1495-504.pdf",
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.co.uk/news-releases/pneumagen-leverages-its-novel-glycan-approach-to-target-coronavirus-covid-19-infections-840930671.html",
      "https://www.pneumagen.com/science.html",
      "https://www.pneumagen.com/pipeline/respiratory-tract-infection.html",
      "https://www.linkedin.com/company/pneumagen-limited/",
      "https://www.pneumagen.com/pipeline.html"
    ],
    "sponsors": [
      {
        "sponsorId": "983efe23794f5ea689b6644c79f8581943a74fe3",
        "sponsorName": "Pneumagen Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CoreCyte,Others",
    "chemicalName": "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs)",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Manufacturing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Umbilical Cord Mesenchymal Stem Cells isolated from Wharton's Jelly,Applied for FDA approval for immediate use for Covid-19 on 04/09/2020",
    "numSites": "",
    "otherPartners": "Wuhan Union Hospital- China,Wuhan Hamilton Bio-technology Co. Ltd  - China.,ZhiYong Peng,Tuohua Biological Technology Co. Ltd",
    "phase": "",
    "preferredName": "Umbilical_Cord_Mesenchymal_Stem_Cells_UCMSCs",
    "primaryCompletionDate": "",
    "productId": 277,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/",
      "https://www.bioworld.com/COVID19products; https://www.predictivebiotech.com/company/",
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04269525",
      "https://clinicaltrials.gov/ct2/show/NCT04273646",
      "https://www.predictivebiotech.com/wp-content/uploads/2019/05/CC_Product_Snapshot_v3_2019.pdf",
      "https://clinicaltrials.gov/ct2/show/NCT04269525 ; https://clinicaltrials.gov/ct2/show/NCT04273646",
      "https://www.predictivebiotech.com/company/",
      "https://www.predictivebiotech.com/products/"
    ],
    "sponsors": [
      {
        "sponsorId": "761c8b0485e032a24d29f63f18726bb53f50bdc1",
        "sponsorName": "Predictive Biotech"
      },
      {
        "sponsorId": "0a520daf69e8730cf20a260e53d5354fd23003aa",
        "sponsorName": "Predictive Technology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "PRTX-007",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Activates TLR7 to stimulate innate immune system",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PRTX007",
    "primaryCompletionDate": "",
    "productId": 278,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.primmunerx.com/press-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications/",
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html",
      "https://www.primmunerx.com/#contact"
    ],
    "sponsors": [
      {
        "sponsorId": "59184ad543e6f439787b2e2ac1527ea53b1e5ac1",
        "sponsorName": "Primmune Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "SARS-CoV-2 neutralizing antibody",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Singapore"],
    "countryCodes": ["SGP"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 25 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "No candidate yet. Still at discovery stage.",
    "numSites": "",
    "otherPartners": "Heidelberg University Hospital,T\u00fcbingen University Hospital,the German Cancer Research Center (DKFZ),the NMI Natural and Medical Sciences Institute,NUS Enterprise,10x Genomics,NovogeneAIT",
    "phase": "",
    "preferredName": "SARSCoV2_neutralizing_antibody",
    "primaryCompletionDate": "",
    "productId": 279,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html"
    ],
    "sponsors": [
      {
        "sponsorId": "245b051b6523c597e8560495815affabbbd6151f",
        "sponsorName": "Proteona Pte Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Yeliva",
    "chemicalName": "Opaganib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 08 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Phase 2 trial IND application made",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Opaganib",
    "primaryCompletionDate": "",
    "productId": 280,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.redhillbio.com/yeliva",
      "https://www.bioworld.com/COVID19products",
      "https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112",
      "https://pubchem.ncbi.nlm.nih.gov/compound/abc294640#section=Pharmacology-and-Biochemistry",
      "http://apogee-biotech.com/index.php/news/",
      "https://www.globenewswire.com/news-release/2020/05/08/2030275/0/en/RedHill-Biopharma-Receives-FDA-Approval-for-COVID-19-Clinical-Study-with-Opaganib-in-the-U-S.html"
    ],
    "sponsors": [
      {
        "sponsorId": "e8c8185248be3a1b2daf8211acc52922e6293844",
        "sponsorName": "Redhill Biopharma Ltd"
      },
      {
        "sponsorId": "f01ab327db3d24c889ea79c039140f87ed85ab74",
        "sponsorName": "Apogee Biotechnology Group Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vascepa",
    "chemicalName": "icosapent ethyl",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "icosapent_ethyl",
    "primaryCompletionDate": "",
    "productId": 571,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "9daa331fe5b9e8dfada9be8fac934d427b5f3955",
        "sponsorName": "Amarin Corp"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Upamostat",
    "chemicalName": "RHB-107",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Passed phase 1 and 2 clinical trials for other diseases currently being tested in-vitro for Covid-19",
    "numSites": "",
    "otherPartners": "NIAID",
    "phase": "Pre-clinical",
    "preferredName": "RHB107",
    "primaryCompletionDate": "",
    "productId": 281,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15260",
      "https://www.bioworld.com/COVID19products",
      "https://www.pharmaceutical-technology.com/news/redhill-biopharma-covid-19-drug-candidate/",
      "https://www.drugbank.ca/drugs/DB13052",
      "https://www.redhillbio.com/rhb-107",
      "https://www.redhillbio.com/contact",
      "https://www.thepharmaletter.com/article/wilex-wx-671-enters-clinic",
      "https://clinicaltrials.gov/ct2/show/NCT00615940?spons=Wilex&draw=2&rank=4"
    ],
    "sponsors": [
      {
        "sponsorId": "e8c8185248be3a1b2daf8211acc52922e6293844",
        "sponsorName": "Redhill Biopharma Ltd"
      },
      {
        "sponsorId": "4f42e3229651f0892787042619eb74da72a1a688",
        "sponsorName": "Link Health Group"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Apabetalone",
    "chemicalName": "2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1,4-dihydroquinazolin-4-one",
    "conditionOrDisease": "COVID19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 15 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Private,NIHR",
    "phase": "3",
    "preferredName": "242hydroxyethoxy35dimethylphenyl57dimethoxy14dihydroquinazolin4one",
    "primaryCompletionDate": "",
    "productId": 282,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.drugbank.ca/drugs/DB12000",
      "https://www.bioworld.com/COVID19products",
      "https://adisinsight.springer.com/drugs/800027698",
      "https://www.resverlogix.com/science-and-programs/apabetalone",
      "http://www.io.nihr.ac.uk/wp-content/uploads/2018/11/11198-Apabetalone-for-MACE-V1.0-OCT18-NON-CONF.pdf",
      "https://www.resverlogix.com/science-and-programs/clinical",
      "https://www.resverlogix.com/investors/news.html?article=660",
      "https://www.resverlogix.com/upload/button/3/b9c82f751024/2019-rvx-corp-pres-march-18.pdf",
      "https://www.globenewswire.com/news-release/2020/03/23/2004624/0/en/Resverlogix-Invites-Collaborations-for-use-of-Apabetalone-in-Trials-and-Studies-to-Combat-the-Spread-of-COVID-19-Based-on-New-Research.html",
      "https://www.marketwatch.com/press-release/resverlogix-clinical-candidate-apabetalone-featured-as-a-potential-covid-19-treatment-in-recent-publication-2020-03-24?siteid=bigcharts&dist=bigcharts&tesla=y"
    ],
    "sponsors": [
      {
        "sponsorId": "9e60afe62e3596c8891ede53bfdc0f1c2a71320a",
        "sponsorName": "Resverlogix Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Bucillamine",
    "chemicalName": "N-(mercapto-2-methylpropionyl)-l-cysteine",
    "conditionOrDisease": "COVID19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Antirheumatic",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Nmercapto2methylpropionyllcysteine",
    "primaryCompletionDate": "",
    "productId": 283,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.globenewswire.com/news-release/2020/03/20/2003915/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-as-a-Novel-Treatment-for-Infectious-Diseases-including-COVID-19.html",
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/drugs/DB12160",
      "https://www.mdpi.com/1424-8247/12/4/165",
      "https://www.reuters.com/companies/RVV.CD",
      "https://clinicaltrials.gov/ct2/show/NCT02942420",
      "https://novotech-cro.com/news/novotech-selected-new-covid-19-clinical-trial-asia-pacific"
    ],
    "sponsors": [
      {
        "sponsorId": "df3723439d2a920860a172a5dd962f7ec0f7cc36",
        "sponsorName": "Revive Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "EIDD-2801",
    "chemicalName": "",
    "conditionOrDisease": "COVD19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 07 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 10 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Oral antiviral",
    "numSites": "4",
    "otherPartners": "Wayne and Wendy Holman",
    "phase": "1",
    "preferredName": "EIDD2801",
    "primaryCompletionDate": "Tue, 16 Jun 2020 00:00:00 GMT",
    "productId": 284,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Daytona Beach",
        "country": "USA",
        "lat": 29.21299549999999,
        "lng": -81.0822079,
        "locationId": "20d4e9ff27005cfe6e6978c7ae74212e7cbc82bb",
        "name": "1900 Mason Ave #140, Daytona Beach, FL 32117, USA",
        "state": "FL"
      },
      {
        "city": "Dallas",
        "country": "USA",
        "lat": 32.8224209,
        "lng": -96.86509079999999,
        "locationId": "25318eea6894ee342c0fdf745aee37d6b60bb604",
        "name": "1341 W Mockingbird Ln #400, Dallas, TX 75247, USA",
        "state": "TX"
      },
      {
        "city": "Madison",
        "country": "USA",
        "lat": 43.1268654,
        "lng": -89.33176209999999,
        "locationId": "e78852cf53d3bae777fa6809725585521d2a7371",
        "name": "3402 Kinsman Blvd, Madison, WI 53704, USA",
        "state": "WI"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 53.804327,
        "lng": -1.5563236,
        "locationId": "8a69343d970037e155947e519282df33be387c6e",
        "name": "Springfield House, Hyde St, Woodhouse, Leeds LS2 9LH, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/drugs/DB15661",
      "https://www.ptcommunity.com/wire/ridgeback-biotherapeutics-announces-mhra-clearance-begin-human-testing-eidd-2801-uk-covid-19",
      "https://www.ridgebackbio.com/",
      "https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1",
      "https://www.drugtargetreview.com/news/59567/eidd-2801-shows-efficacy-against-covid-19-in-human-cells-and-mice/"
    ],
    "sponsors": [
      {
        "sponsorId": "d4086aa4aca201f3493eee784dbab92ad400778f",
        "sponsorName": "Ridgeback Biotherapeutics LP"
      },
      {
        "sponsorId": "4504468bad51eef6a2ac6172fa89a91614df3c56",
        "sponsorName": "Merck"
      },
      {
        "sponsorId": "490f2c2447baa96b61de933f67b94a46fd87a097",
        "sponsorName": "Drug Innovations at Emory LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 16 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 10 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Gimsilumab",
    "chemicalName": "MORAb-022",
    "conditionOrDisease": "COVID19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 19 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 12 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "14",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "MORAb022",
    "primaryCompletionDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "productId": 285,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.drugbank.ca/drugs/DB15280",
      "https://www.bioworld.com/COVID19products",
      "https://www.technologynetworks.com/drug-discovery/news/first-us-trial-participant-receives-gimsilumab-for-covid-19-and-acute-respiratory-distress-syndrome-333448",
      "https://www.empr.com/home/news/drugs-in-the-pipeline/pipeline-investigational-therapies-for-covid-19/",
      "https://www.clinicaltrialsarena.com/news/roivant-gimsilumab-covid-19-trial/",
      "https://roivant.com/",
      "https://pharmaphorum.com/news/roche-begins-phase-3-trial-of-actemra-in-covid-19-pneumonia/"
    ],
    "sponsors": [
      {
        "sponsorId": "c0cd5a7a71a7a2120e0b79f29aacd606755aff2a",
        "sponsorName": "Roivant Sciences Ltd"
      },
      {
        "sponsorId": "f062e8029186acd42f78d91ab787d4579d4c5484",
        "sponsorName": "Altasciences Co Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "studyStartDate": "Sun, 12 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "SAB-185",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "BARDA",
    "phase": "",
    "preferredName": "SAB185",
    "primaryCompletionDate": "",
    "productId": 286,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.medicalcountermeasures.gov/newsroom/2020/sab-185/",
      "https://www.cslbehring.com/newsroom/2020/sab-covid-19",
      "https://globalbiodefense.com/2020/04/01/jpeo-cbrnd-barda-partner-with-sab-biotherapeutics-to-develop-covid-19-therapeutic/",
      "https://sabbiotherapeutics.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "21fe6f5f8237968ddc20622797f630647c872671",
        "sponsorName": "Sab Biotherapeutics"
      },
      {
        "sponsorId": "586353dc7d3f7de1b8b0aaf247aaacaa7293cc9f",
        "sponsorName": "CSL Behring LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "S-Protein/ACE2 Targeted prohylactic polypeptide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Apeiron Biologics",
    "phase": "",
    "preferredName": "SProteinACE2_Targeted_prohylactic_polypeptide",
    "primaryCompletionDate": "",
    "productId": 287,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "AUT",
        "lat": 47.516231,
        "lng": 14.550072,
        "locationId": "1ca544cfae093dd3ac636678ab8566312b2ad48f",
        "name": "Austria",
        "state": null
      },
      {
        "city": null,
        "country": "DEU",
        "lat": 51.165691,
        "lng": 10.451526,
        "locationId": "28ba786d4004fcc4007696f6d2cc300a85294f53",
        "name": "Germany",
        "state": null
      },
      {
        "city": null,
        "country": "CNK",
        "lat": 56.26392,
        "lng": 9.501785,
        "locationId": "ed0e7132afc75ae8f5405b41fdeaa25a8e871c5f",
        "name": "Denmark",
        "state": null
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.drugtargetreview.com/news/59290/decoy-ace2-receptors-could-be-promising-covid-19-infection-preventing-drug/",
      "https://www.clinicaltrialsarena.com/news/apeiron-biologics-phaseii-covid-19/",
      "https://www.cslbehring.com/",
      "https://www.technologynetworks.com/drug-discovery/news/phase-2-clinical-trial-of-apn01-for-treatment-of-covid-19-inititated-332897"
    ],
    "sponsors": [
      {
        "sponsorId": "8812b6d8e3894f01681250e96efa2ff723ccf680",
        "sponsorName": "Sichuan Kelun Pharmaceutical Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Lipocurc",
    "chemicalName": "Liposomal curcumin",
    "conditionOrDisease": "COVID19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Cancer Treatment",
    "numSites": "",
    "otherPartners": "Paracelsus Medical University,Discretionary Research Fund",
    "phase": "2",
    "preferredName": "Liposomal_curcumin",
    "primaryCompletionDate": "",
    "productId": 288,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "USA",
        "lat": 41.2033216,
        "lng": -77.1945247,
        "locationId": "1446b77a40e1d19bec4f92fb9ecc427f9bd4df2a",
        "name": "Pennsylvania, USA",
        "state": "PA"
      }
    ],
    "sources": [
      "https://www.ncbi.nlm.nih.gov/pubmed/30430227",
      "https://www.bioworld.com/COVID19products",
      "https://www.researchgate.net/publication/258347314_Liposomal-formulated_curcumin_Lipocurc_targeting_HDAC_Histone_Deacetylase_prevents_apoptosis_and_improves_motor_deficits_in_Park_7_DJ-1-knockout_rat_model_of_Parkinson's_disease_implications_for_epige",
      "https://finance.yahoo.com/news/signpath-pharma-focus-coronavirus-disease-132000816.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAMtxCulSHQRqpcWfz5eXklfWPZIxsyEpH3LfUs0lYTGd5XWIzXUfKYIN7lg0efispLMaTlsqNlKlgK0RXT8AEMJCBu_TipsZnVZutbwo1plJidTAfNKK9RxEYjbWGuefhN3x9Q-kMoFP-tPUWbZeHi2005ieCWY6KunPZMA8h7Bx",
      "https://link.springer.com/article/10.1007/s00280-018-3654-0 ;  https://www.researchgate.net/publication/258347314_Liposomal-formulated_curcumin_Lipocurc_targeting_HDAC_Histone_Deacetylase_prevents_apoptosis_and_improves_motor_deficits_in_Park_7_DJ-1-knockout_rat_model_of_Parkinson's_disease_implications_for_epige",
      "http://signpathpharma.com/",
      "http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/",
      "https://www.businesswire.com/news/home/20200317005082/en/SignPath-Pharma-Focus-Coronavirus-Disease-COVID-19-Developing",
      "http://signpathpharma.com/pipeline/#details"
    ],
    "sponsors": [
      {
        "sponsorId": "3a23c78238689fa6d8b86e48413a0fbe0d9d35c1",
        "sponsorName": "Signpath Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antiviral",
    "chemicalName": "Interferon Alpha",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase1/2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "NIHR",
    "phase": "",
    "preferredName": "Interferon_Alpha",
    "primaryCompletionDate": "",
    "productId": 289,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/drugs/DB05258",
      "https://www.thenews.com.pk/print/648623-chinese-healthcare-group-invites-nih-for-covid-19-vaccine-test",
      "http://www.sinopharm.com/1156.html"
    ],
    "sponsors": [
      {
        "sponsorId": "74c3cd3bc3fa22bf3900e0d4e84bb19508cb9132",
        "sponsorName": "Sinopharm Group"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antiviral",
    "chemicalName": "Glycosides",
    "conditionOrDisease": "COVID19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Private",
    "phase": "",
    "preferredName": "Glycosides",
    "primaryCompletionDate": "",
    "productId": 290,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Val-de-Reuil",
        "country": "FRA",
        "lat": 49.258212,
        "lng": 1.187725,
        "locationId": "17cf1f9efbe9adeba5c4acbbac9fa8c31c90e0e4",
        "name": "Voie de l Innovation, PharmaParc 2, 27100 Val-de-Reuil, France",
        "state": "Normandie"
      }
    ],
    "sources": [
      "https://www.barrons.com/press-release/PR-CO-20200331-902751?tesla=y",
      "https://www.bioworld.com/COVID19products",
      "https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/",
      "https://www.sironabiochem.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "b943d0928f25a94239b30d1f795032375383033f",
        "sponsorName": "Sirona Biotechem Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OP-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OP101",
    "primaryCompletionDate": "",
    "productId": 572,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "3ce1e9abeb85d87e23025b0e1a8632687a2195b9",
        "sponsorName": "Orpheris"
      },
      {
        "sponsorId": "269c37157681ff90864988b2d4948a61632db3ba",
        "sponsorName": "Ashvattha Therapeutics"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Therapeutic",
    "chemicalName": "Compounds that block the activity of the SARS-CoV-2 MPro protease",
    "conditionOrDisease": "COVID19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Compounds_that_block_the_activity_of_the_SARSCoV2_MPro_protease",
    "primaryCompletionDate": "",
    "productId": 291,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://soseiheptares.com/news/599/129/Sosei-Heptares-to-apply-its-Structure-based-Drug-Design-Expertise-in-New-COVID-19-RD-Program.html",
      "https://www.bioworld.com/COVID19products",
      "https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/"
    ],
    "sponsors": [
      {
        "sponsorId": "a116938a80ab1812d2085339b93325c5e6a0805b",
        "sponsorName": "Sosei Group Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Lung airway cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Manufacturing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Neither a treatment nor a prophylactic,mainly used to propagate the SARS-CoV-2 which allowed scientists at China's CDC to isolate the virus and obtain the gene sequence,clinical milestones and studies will not be filled out for this reason,development was finished before 03/25/2020 (which is when article about this breakthrough was published)",
    "numSites": "",
    "otherPartners": "CDC - China",
    "phase": "",
    "preferredName": "Lung_airway_cells",
    "primaryCompletionDate": "",
    "productId": 292,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.stemcell.com/canadian-biotechnology-company-stemcell-technologies-provides-critical-support-to-sequence-the-covid-19-virus-accelerating-vaccine-development.html",
      "https://www.bioworld.com/COVID19products https://www.stemcell.com/canadian-biotechnology-company-stemcell-technologies-provides-critical-support-to-sequence-the-covid-19-virus-accelerating-vaccine-development.html"
    ],
    "sponsors": [
      {
        "sponsorId": "49edcacef773406a08e3a11e32fb4caf84388c84",
        "sponsorName": "Stemcell Technologies Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Epaspire",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Purified EPA in a capsule currently in a Phase 3 clinical trial in Europe for treatment of FAP,well established safety profile and observed suppression of inflammatory cytokines that may contribute to COVID-19 progression,this allowed the quick initiation of Phase 3 COVID-19 trials and led to the goal of using EPAspire to reduce the complications of COVID-19",
    "numSites": "Undisclosed",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Epaspire",
    "primaryCompletionDate": "Mon, 13 Jul 2020 00:00:00 GMT",
    "productId": 293,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04335032",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.kdpharmagroup.com/en/news/kd-pharma-group-sla-pharma-initiate-clinical-trial-covid-19",
      "https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "06ec5df840715222bbeb972210bfa28ff5aceb2c",
        "sponsorName": "The KD Pharma Group SA"
      },
      {
        "sponsorId": "b47bc7cc175c3bb7640659ad687ac2f480ba8fd6",
        "sponsorName": "SLA Pharma AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 31 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 13 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "TD-0903",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "medinfo@theravance.com",
        "name": null,
        "notes": "",
        "phone": "1-855-633-8479",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Lung-selective inhaled JAK inhibitor that has the potential to block cytokines and chemokines associated with ALI and ARDS,shown to have effective and broad inhibition of JAK-STAT signaling in rodent models,CTA was submitted in the UK on 04/09/2020 - approval pending and phase 1 will begin immediately after",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "TD0903",
    "primaryCompletionDate": "Sat, 20 Jun 2020 00:00:00 GMT",
    "productId": 294,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04350736",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Manchester",
        "country": "GBR",
        "lat": 53.4807593,
        "lng": -2.2426305,
        "locationId": "30bb3e94eb3a45cef6a5d52ef819123ca2e15399",
        "name": "Manchester, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/theravance-biopharma-responds-to-covid-19-pandemic-by-advancing-td-0903-to-treat-hospitalized-patients-with-acute-lung-injury-301038037.html",
      "https://clinicaltrials.gov/ct2/show/NCT04350736"
    ],
    "sponsors": [
      {
        "sponsorId": "262d9fad81968c24466a839589f81bece22471db",
        "sponsorName": "Theravance"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 20 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "ARMS-I",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Other",
    "notes": "ARMS-I is a microbe-impermeable barrier with anti-viral action designed to prevent upper respiratory infections,currently holds an IND as a potential flu prophylaxis,clinical trial (unspecified phase but characteristics inmply phase 2) to investigate whether ARMS-I will help protect against COVID-19 in frontline health workers,no entry in clinicaltrials.gov yet",
    "numSites": "",
    "otherPartners": "ARMS Pharmaceutical LLC,Cleveland Foundation,Case Western Reserve University",
    "phase": "2",
    "preferredName": "ARMSI",
    "primaryCompletionDate": "",
    "productId": 295,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Cleveland",
        "country": "USA",
        "lat": 41.5050672,
        "lng": -81.605476,
        "locationId": "c1f76cc9ca030bb5b368e14549ca79b9d5fb75ea",
        "name": "University Hospitals, 2101 Adelbert Rd, Cleveland, OH 44106, USA",
        "state": "OH"
      },
      {
        "city": "Youngstown",
        "country": "USA",
        "lat": 41.1093131,
        "lng": -80.6429419,
        "locationId": "f2092ac254bfd42cc1b68df6e6eafdee487bacb1",
        "name": "726 Wick Ave, Youngstown, OH 44505, USA",
        "state": "OH"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19 https://www.trialsitenews.com/university-hospitals-cleveland-launch-clinical-trial-assessing-arms-i-to-protect-clinicians-from-covid-19/",
      "https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19",
      "https://www.armspharmaceutical.com/arms-i-science https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19"
    ],
    "sponsors": [
      {
        "sponsorId": "081649a78e8f049d5576bf2c9694fd3841668997",
        "sponsorName": "Cleveland University Hospitals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Fri, 01 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Tradipitant",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Tradipitant is currently undergoing clinical trials for other conditions such as gastroparesis,tradipitant is an NK-1R antagonist that is being tested to see if it can treat inflammatory lung injury associated with COVID-19",
    "numSites": "1",
    "otherPartners": "University of Illinois at Chicago",
    "phase": "3",
    "preferredName": "Tradipitant",
    "primaryCompletionDate": "Sat, 01 Aug 2020 00:00:00 GMT",
    "productId": 296,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04326426",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7736341,
        "lng": -73.9608549,
        "locationId": "1c29019927abbecc43456dbedc0971385d8dce82",
        "name": "130 E 77th St, New York, NY 10075, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2 https://vandapharmaceuticalsinc.gcs-web.com/node/14066/pdf",
      "https://vandapharmaceuticalsinc.gcs-web.com/node/14066/pdf",
      "https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "d2734c3b72bd97da45e8be5b00151cb1c2fe5838",
        "sponsorName": "Vanda Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 13 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "$14 million contract from US Department of Defense for Ology Bioservices and Vanderbilt to collaborate on antibody discovery against COVID-19,Twist to build a synthetic antibody discovery library based on sequences from a recovered COVID-19 patient from Vandebilt",
    "numSites": "",
    "otherPartners": "Twist Bioscience Corp.,DARPA,NIAID,Ology Bioservices Inc.",
    "phase": "",
    "preferredName": "Monoclonal_antibodies",
    "primaryCompletionDate": "",
    "productId": 297,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://news.vanderbilt.edu/2020/05/14/the-front-lines-vanderbilt-physicians-researchers-join-worldwide-fight-against-covid-19/",
      "https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-partners-vanderbilt-university-medical-center",
      "https://www.pharmaceutical-technology.com/news/covid-19-allovir-ology-drugs/ https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-partners-vanderbilt-university-medical-center",
      "https://www.pharmaceutical-technology.com/news/covid-19-allovir-ology-drugs/"
    ],
    "sponsors": [
      {
        "sponsorId": "3505691a86b3a9dacf9bb0dd76bfd49b7cd40e83",
        "sponsorName": "Vanderbilt University"
      },
      {
        "sponsorId": "bb9ed07e215d6bebb274790c7ee0711a0da9f41e",
        "sponsorName": "AstraZeneca"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Genosyl DS",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "On Market",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Genosyl DS is a tankless nitric oxide delivery system that obtained FDA approval on 12/20/19,FDA recently granted expanded access emergency use on 03/26/20 for the Genosyl DS to be used in treating cardiopulmonary symptoms associated with COVID-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Genosyl_DS",
    "primaryCompletionDate": "",
    "productId": 298,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.vero-biotech.com/contact/",
      "https://www.biospace.com/article/releases/vero-biotech-receives-us-fda-approval-of-genosyl-for-the-delivery-of-inhaled-nitric-oxide/ https://www.biospace.com/article/releases/fda-grants-vero-biotech-expanded-access-emergency-use-for-the-treatment-of-patients-with-covid-19-with-the-genosyl-ds-the-first-and-only-fda-approved-tankless-system-for-the-delivery-of-inhaled-nitric-oxide/",
      "https://www.biospace.com/article/releases/vero-biotech-receives-us-fda-approval-of-genosyl-for-the-delivery-of-inhaled-nitric-oxide/"
    ],
    "sponsors": [
      {
        "sponsorId": "9ec0b02ebf735a301023bce110203311a36cbe28",
        "sponsorName": "Vero Biotech"
      }
    ],
    "status": "On Market",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Biological Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Biological_Vaccine",
    "primaryCompletionDate": "",
    "productId": 354,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf",
      "https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html"
    ],
    "sponsors": [
      {
        "sponsorId": "18d359f3a6a2fc44b7f04abc4ab8baad62117955",
        "sponsorName": "Biological E Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VIR-7832",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "VIR-7831 and VIR-7832 are leading antibody candidates that have demonstrated high affinity for the SARS-CoV-2 spike protein,companies aim to directly enter phase 2 clinical trial within the next three to five months,currently still in the development phase",
    "numSites": "",
    "otherPartners": "Wuxi Biologics,National Institute of Allergy and Infectious Diseases,Xencor Inc.,Glaxosmithkline plc,Samsung Biologics Co. Ltd.",
    "phase": "",
    "preferredName": "VIR7832",
    "primaryCompletionDate": "",
    "productId": 299,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.vir.bio/contact/",
      "https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/"
    ],
    "sponsors": [
      {
        "sponsorId": "6c32fa743ed510db10e7c97fd975d2a2a5700a4a",
        "sponsorName": "Vir Biotechnology Inc"
      },
      {
        "sponsorId": "7b6f419a075a9d4cfc1742367fdc3d11cc35f994",
        "sponsorName": "Biogen Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Elpida",
    "chemicalName": "elsafavirine",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Elpida is a non-nucleoside reverse transcriptase inhibitor that received market approval from the Russian Ministry of Health to treat HIV on 06/30/2017,initated Phase 2 clinical study to evaluate efficacy of Elpida in adults with COVID-19 on 04/08/2020 but currently has no entry on clinicaltrials.gov",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "elsafavirine",
    "primaryCompletionDate": "",
    "productId": 300,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "RUS",
        "lat": 61.52401,
        "lng": 105.318756,
        "locationId": "79301b352f5465af41855eed9ee1548dce97470d",
        "name": "Russia",
        "state": null
      },
      {
        "city": null,
        "country": null,
        "lat": 52.0055148,
        "lng": 37.95874939999999,
        "locationId": "624e8829dd49bf2f5036d78203dc5435112e520a",
        "name": "Eastern Europe",
        "state": null
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.viriom.com/contact",
      "https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19 https://www.viriom.com/news/2017/11/30/viriom-obtains-first-market-approval-of-elsulfavirine-elpida-for-treatment-of-hiv-1-infection-in-russia",
      "https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "3e65bda0e3a4586a7154c208c474b7fc79f60ab1",
        "sponsorName": "Viriom Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Fri, 01 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Viscient Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Viscient is using 3D bioprinting tech to create lung tissue to support research efforts on finding and testing COVID-19 therapies - clinical trial in a dish, as of 04/20/2020 - still working on a way to develop infected lung tissue",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Viscient_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 301,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.10news.com/news/coronavirus/biotechs-3d-models-could-lead-to-coronavirus-treatments",
      "https://www.scienceboard.net/index.aspx?sec=sup&sub=can&pag=dis&ItemID=610 https://www.kusi.com/san-diego-biotech-company-fighting-coronavirus-through-3d-bioprinting/"
    ],
    "sponsors": [
      {
        "sponsorId": "8d59671a4747cb2aa6f2acfa1c51b5de8644ae5b",
        "sponsorName": "Viscient Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CB1 antagonist",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CB1_antagonist",
    "primaryCompletionDate": "",
    "productId": 302,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "96dc8ffb76c357cda9bf1ea512a6b3faedc50ed5",
        "sponsorName": "Viripharm Biopharmaceuticals LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "KL4 surfactant",
    "chemicalName": "Sinapultide",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Sinapultide",
    "primaryCompletionDate": "",
    "productId": 303,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "b9d4687e32bd1665b98b110c465c991959943db7",
        "sponsorName": "Windtree Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Mesenchymal stem cells",
    "chemicalName": "UC-MSCs",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "UCMSCs",
    "primaryCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "productId": 304,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04273646",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.583826,
        "lng": 114.273585,
        "locationId": "c703add9030ae9bb4f8f5747ed3acd07be0a67ed",
        "name": "Jiefang Ave, Xi Bei Hu, Jianghan Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "14038d17d9fa18917792c69af98837142687f2af",
        "sponsorName": "Wuhan Hamilton Biotechnology Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 15 Feb 2022 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibody",
    "primaryCompletionDate": "",
    "productId": 305,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "aceff18e5b0594f0ed960779ae931d91cbc7fa9f",
        "sponsorName": "VIBUGent Center for Medical Biotechnology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Plasma treatment",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Plasma_treatment",
    "primaryCompletionDate": "",
    "productId": 306,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "d1a873903a92cac9d889e8f9ff8977b7f9e100ce",
        "sponsorName": "Xbiotech Inc"
      },
      {
        "sponsorId": "96240c6492e03d5753e52d4da6fa236a7e4dc6f2",
        "sponsorName": "Biobridge Global"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "XRx-101",
    "chemicalName": "Oxypurinol",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Oxypurinol",
    "primaryCompletionDate": "",
    "productId": 307,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "3942d9eba6d7c598d2d7548e1f99237e337f7f56",
        "sponsorName": "Xortx Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antiviral",
    "primaryCompletionDate": "",
    "productId": 308,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "40539840e055053cf646a7a6c2d6f01184a9f4a3",
        "sponsorName": "Xphyto Therapeutics Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Slovakia"],
    "countryCodes": ["SVK"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 309,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "0fc1c2eb025301d74761cfdaad2e702a05e14ea7",
        "sponsorName": "Axon Neuroscience SE"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Dendritic cell vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Dendritic_cell_vaccine",
    "primaryCompletionDate": "",
    "productId": 310,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "08a21a27c82e51464712adac2679fb2dc228d69b",
        "sponsorName": "Betta Pharmaceuticals Co Ltd"
      },
      {
        "sponsorId": "5971cf2c808d095d9d239606be69759cc12a3ff5",
        "sponsorName": "Beijing Dingcheng Taiyuan Biotechnology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 311,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "61c10d4a8a5dee7e9c508ca4cf94e5fb4aedf2a3",
        "sponsorName": "Chongqing Zhifei Biological Products Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Fusogenix DNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Direct introduction of a plasmid encoding the antigen(s) against which an immune response is sought and relies on the production of the target antigen in the patient\u2019s own cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "Fusogenix_DNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 312,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform",
      "https://www.pharmaceutical-business-review.com/news/entos-pharmaceuticals-fusogenix-covid-19/",
      "https://www.entospharma.com/about"
    ],
    "sponsors": [
      {
        "sponsorId": "792d66b4f6751aa1d3eabedb66b4e1a4b26c759b",
        "sponsorName": "Entos Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ERC\u2019s SARS-Cov-2 Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "Vaccine containing virions,viral proteins at different stages of viral replication,whole human cells and cellular fragments,composing all elements of viral replication",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "ERC\u2019s_SARSCov2_Vaccine",
    "primaryCompletionDate": "",
    "productId": 313,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/09/2014261/0/en/ERC-Launches-Development-Program-for-Novel-Cell-Based-Therapeutic-and-Prophylactic-SARS-CoV-2-Vaccine.html",
      "https://www.erc-immunotherapy.com/",
      "https://www.erc-immunotherapy.com/media/news/latest-situation-%E2%80%93-ceo-statement"
    ],
    "sponsors": [
      {
        "sponsorId": "2bae05a8f1ef431f06f3f32e8a5b62ac2088a4e7",
        "sponsorName": "Epitopoietic Research Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Coroflu",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "Modification of M2SR by adding part of the coding region for the coronavirus spike protein",
    "numSites": "",
    "otherPartners": "Flugen Inc,Bharat Biotech International Ltd - India,University of Wisconsin-Madison",
    "phase": "Discovery",
    "preferredName": "Coroflu",
    "primaryCompletionDate": "",
    "productId": 314,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/",
      "https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-in-tie-up-to-develop-a-covid-vaccine/articleshow/74977030.cms?from=mdr",
      "http://flugen.com/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/"
    ],
    "sponsors": [
      {
        "sponsorId": "d0615a827003e8423ac0ea3c03f9fbd824fc52b3",
        "sponsorName": "Flugen Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Ii-Key-SARS 2 peptide vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "China Technology Exchange,Beijing Zhonghua Investment Fund Management Co. LTD,Biology Institute of Shandong Academy of Sciences,Sinotek-Advocates International Industry Development (Shenzhen) Co. LTD",
    "phase": "Discovery",
    "preferredName": "IiKeySARS_2_peptide_vaccine",
    "primaryCompletionDate": "",
    "productId": 315,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html",
      "https://generex.com/covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "bd241b032c9ac50523b8215691176cc94b2966b6",
        "sponsorName": "Generex Biotechnology Group"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Z-VacciRNA",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "ZVacciRNA",
    "primaryCompletionDate": "",
    "productId": 316,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "de3c929194d9aac1196f6a1b8c9e5983cfa58911",
        "sponsorName": "Guanhao Biotech Co Ltd"
      },
      {
        "sponsorId": "f12c99eed6736f965feb517d2d827d893d1cd2b0",
        "sponsorName": "Zy Therapeutics Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 317,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "344b517c43ad6d6219c6a66b35a3d655b2918e54",
        "sponsorName": "Hualan Biological Engineering"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 318,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "07b42758a4b70d9b70f8e828e2488a0d0c69160d",
        "sponsorName": "ID Pharma Co Ltd"
      },
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Virus Suppressing Factor",
    "chemicalName": "HzVSFv13",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Korea", "Democratic People's Republic of"],
    "countryCodes": ["PRK"],
    "currentStage": "Phase 1",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 28 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 21 Feb 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "HzVSFv13",
    "primaryCompletionDate": "",
    "productId": 319,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://www.koreabiomed.com/news/articleView.html?idxno=7596",
      "https://www.prnewswire.com/news-releases/immunemeds-hzvsf-used-for-treatment-of-covid-19-pneumonia-patients-301031662.html",
      "http://www.immunemed.co.kr/eng/news/news.asp?look_url=%2Feng%2Fnews%2Fnews.asp&BPart=news&SPart=eng&sno=4328&mode=read&page_no=1&search_field=&search_text="
    ],
    "sponsors": [
      {
        "sponsorId": "1b6935230a67257c55ec98d018cd779af0ce72b1",
        "sponsorName": "Immunemed"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Nucleic Acid Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nucleic_Acid_Vaccine",
    "primaryCompletionDate": "",
    "productId": 320,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://epivax.com/featured/press-release-immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform",
      "https://www.hospimedica.com/covid-19/articles/294781719/immunomic-epivax-and-pharmajet-jointly-developing-covid-19-vaccine.html",
      "https://epivax.com/news/press-release-pharmajet-partners-with-immunomic-therapeutics-and-epivax-to-develop-and-deliver-covid-19-vaccine"
    ],
    "sponsors": [
      {
        "sponsorId": "32698ef58730c0db442e4711afe4d8872c1122fa",
        "sponsorName": "Immunomic Therapeutics Inc"
      },
      {
        "sponsorId": "668459853f4364a918946339a776e7b4d8542169",
        "sponsorName": "Epivax Inc"
      },
      {
        "sponsorId": "4a67621b1cdb93f9e5a800f34f028cee1e42d049",
        "sponsorName": "Pharmajet"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DPX-COVID-19",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Epitope based vaccine,Design of a Phase 1 clinical study in 48 healthy subjects completed,clinical sites identified in Nova Scotia and Quebec",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "DPXCOVID19",
    "primaryCompletionDate": "",
    "productId": 321,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/",
      "https://ir.imv-inc.com/press-releases/detail/635/imv-inc-launches-plans-to-advance-clinical-development-of",
      "https://ir.imv-inc.com/press-releases/detail/638/imv-inc-provides-updates-on-the-development-of"
    ],
    "sponsors": [
      {
        "sponsorId": "48214836aaae1d030dc63fd584ec75a89c69a299",
        "sponsorName": "IMV Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IPT-001",
    "chemicalName": "peptide vaccine",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptide_vaccine",
    "primaryCompletionDate": "",
    "productId": 322,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://bioinformant.com/covid-19-vaccine-intellistem/",
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=IPT-001&searcher=drugs",
      "https://www.intellistemtech.com/contact"
    ],
    "sponsors": [
      {
        "sponsorId": "e307a242cd4a80ef8961828e2bd56978153ba4c4",
        "sponsorName": "Intellistem Technologies Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Polypeptide vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Polypeptide_vaccine",
    "primaryCompletionDate": "",
    "productId": 323,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.marketwatch.com/press-release/nucleic-acid-vaccine-market-report-covers-top-countries-data-2020-regional-analysis-by-top-key-players-development-size-global-industry-share-forecast-to-2026-2020-04-23"
    ],
    "sponsors": [
      {
        "sponsorId": "e01b4e370f661002ed37476bd661968f309a64db",
        "sponsorName": "Liaoning Chengda Biotechnology"
      },
      {
        "sponsorId": "bfce396095503d26f651c5dad224c79f44d87649",
        "sponsorName": "Tsinghua University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "peptide mini-scaffold",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "High-affinity peptide scaffold that blocks interactions of SARS-CoV-2 to ACE2 receptor",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptide_miniscaffold",
    "primaryCompletionDate": "",
    "productId": 324,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.ligandal.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "4f3b270f3c1a96d8081041d6786e25d3ccc38629",
        "sponsorName": "Ligandal Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Medigen Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Taiwan", "Province of China"],
    "countryCodes": ["TWN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "National Institutes of Health",
    "phase": "",
    "preferredName": "Medigen_Vaccine",
    "primaryCompletionDate": "",
    "productId": 325,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.malaysiakini.com/news/511154",
      "http://www.medigen.com.tw/en/home/"
    ],
    "sponsors": [
      {
        "sponsorId": "c76c86ae23d07fd42bbc979f6877c5fb8af70eb6",
        "sponsorName": "Medigen Biotechnology Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Mologic Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "UK Government COVID-19 research funding package",
    "phase": "",
    "preferredName": "Mologic_Vaccine",
    "primaryCompletionDate": "",
    "productId": 326,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "dd2867855c9bba29ec1a2f9db4b0e7896eb33b42",
        "sponsorName": "Mologic Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "NantKwest vaccine",
    "chemicalName": "second-generation AD5 platform",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Clinical trials expected to start this quarter",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "secondgeneration_AD5_platform",
    "primaryCompletionDate": "",
    "productId": 327,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/",
      "https://www.bioworld.com/COVID19products",
      "https://nantkwest.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/",
      "https://nantkwest.com/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "13fabd5b14178a13d0539b59d6a9be0b068e4309",
        "sponsorName": "Nantkwest Inc"
      },
      {
        "sponsorId": "8bfec75fcf441b5e6dfde4d8556e152456e80321",
        "sponsorName": "Immunitybio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Soligenix Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "University if Hawai'i at Manoa",
    "phase": "",
    "preferredName": "Soligenix_Vaccine",
    "primaryCompletionDate": "",
    "productId": 328,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19",
      "Seems implied in this article: http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19",
      "seems implied in this article: http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19"
    ],
    "sponsors": [
      {
        "sponsorId": "7795392453455f76046eb84a28aa370b14026e0c",
        "sponsorName": "Soligenix Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "S Protein Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "S_Protein_Vaccine",
    "primaryCompletionDate": "",
    "productId": 329,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806",
      "this source says the initial stages of clinical trials but I am not positive this means pre-clinical trials: https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806"
    ],
    "sponsors": [
      {
        "sponsorId": "8badc8865679f144a1d2fbf604740245348ebc8e",
        "sponsorName": "US Army Medical Research and Development Command"
      },
      {
        "sponsorId": "5dfde89cd058e25942ead74f974aa75a0b3ed04c",
        "sponsorName": "Walter Reed Army Institute of Research"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "COVID-19 XWG-03",
    "chemicalName": "truncated S-protein",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Originally started being developed to treat HPV",
    "numSites": "",
    "otherPartners": "GlaxoSmithKline",
    "phase": "",
    "preferredName": "truncated_Sprotein",
    "primaryCompletionDate": "",
    "productId": 330,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1",
      "https://www.bioworld.com/COVID19products",
      "https://www.chinadaily.com.cn/a/201909/07/WS5d734d85a310cf3e3556a43c.html",
      "https://www.reuters.com/article/brief-gsk-says-to-collaborate-with-xiame-idUSFWN2BR07C"
    ],
    "sponsors": [
      {
        "sponsorId": "f3e18d1badc8e3e140a4e145313f20f56e471293",
        "sponsorName": "Xiamen Innovax Biotech Co Ltd"
      },
      {
        "sponsorId": "bf45296df9f69d118ce8ad2b5fd20dcd2bb45568",
        "sponsorName": "Xiamen University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ZIP-1642",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ZIP1642",
    "primaryCompletionDate": "",
    "productId": 331,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020"
    ],
    "sponsors": [
      {
        "sponsorId": "12f2c56c2a8c8e754b73a3d0736ac5246e1fc2ca",
        "sponsorName": "Ziphius Therapeutics NV"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "AG0301-COVID19",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "anges-cr@anges.co.jp",
        "name": null,
        "notes": "",
        "phone": "81-3-5730-2488",
        "website": ""
      }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Takara Bio Inc.",
    "phase": "Phase 1",
    "preferredName": "AG0301COVID19",
    "primaryCompletionDate": "Sat, 26 Sep 2020 00:00:00 GMT",
    "productId": 332,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04463472?term=NCT04463472&draw=2&rank=1",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Osaka",
        "country": "JPN",
        "lat": 34.6466497,
        "lng": 135.5088616,
        "locationId": "a64ed5d1b2b0ece619b8a5264aba010b4662187e",
        "name": "1-ch\u014dme-5-7 Asahimachi, Abeno-ku, Osaka, 545-8586, Japan",
        "state": "Osaka"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf",
      "https://ir.takara-bio.co.jp/en/news_all/news_Release/news_Release201889409321505118082820200306.html",
      "https://www.japantimes.co.jp/news/2020/06/30/national/science-health/japan-first-coronavirus-vaccine-clinical-test-starts/#.XxXF5yhKgdU",
      "https://www.reuters.com/article/us-health-coronavirus-japan-anges/pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals-idUSKBN21B019",
      "https://japantoday.com/category/national/update-1-pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals"
    ],
    "sponsors": [
      {
        "sponsorId": "17be17f24c77c426a72f3b040131c995834c2be1",
        "sponsorName": "AnGes"
      },
      {
        "sponsorId": "51adf29b45adb2321acc929eef1a1764661b4261",
        "sponsorName": "Osaka University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 31 Jul 2021 00:00:00 GMT",
    "studyStartDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Ilaris",
    "chemicalName": "canakinumab",
    "conditionOrDisease": "COVID-19 Pneumonia",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Not yet recruiting for observational study,Very limited information on Novartis website about using Ilaris for COVID,just listed as one of numerous drugs under investigation for people with COVID infection",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "canakinumab",
    "primaryCompletionDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "productId": 333,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04348448",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1",
      "https://www.drugbank.ca/drugs/DB06168",
      "https://www.novartis.com/news/novartis-corporate-fact-sheet/major-facilities",
      "https://www.novartis.com/coronavirus/response",
      "https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1; https://www.novartis.com/coronavirus/response"
    ],
    "sponsors": [
      {
        "sponsorId": "b08c1310d27c7a8b020bed114122bccabe38726f",
        "sponsorName": "Novartis"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Gamifant",
    "chemicalName": "emapalumab",
    "conditionOrDisease": "Hyperinflammation and respiratory distress in COVID-19 patients",
    "contact": [
      {
        "email": "sobi.immuno@sobi.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Sweden"],
    "countryCodes": ["SWE"],
    "currentStage": "Phase 2",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "emapalumab",
    "primaryCompletionDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "productId": 334,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04324021",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Brescia",
        "country": "ITA",
        "lat": 45.5564352,
        "lng": 10.2310468,
        "locationId": "c25806b79335a5723a07f1fba11631f6965e7208",
        "name": "Piazzale Spedali Civili, 1, 25123 Brescia BS, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Milano",
        "country": "ITA",
        "lat": 45.458872,
        "lng": 9.1950515,
        "locationId": "8b72949baa814a7d1426c70c527b049bd0ecce5f",
        "name": "Via Francesco Sforza, 35, 20122 Milano MI, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Parma",
        "country": "ITA",
        "lat": 44.8016341,
        "lng": 10.3083481,
        "locationId": "3d5d56820b44c874be3f7fadaca47b0a36ea6981",
        "name": "Viale Antonio Gramsci, 14, 43126 Parma PR, Italy",
        "state": "Emilia-Romagna"
      },
      {
        "city": "Roma",
        "country": "ITA",
        "lat": 41.866501,
        "lng": 12.4564793,
        "locationId": "1f07864dd71cac75265e41a76d1428d77463f264",
        "name": "Via Portuense, 292, 00149 Roma RM, Italy",
        "state": "Lazio"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.sobi.com/index.php/en/press-releases/sobi-initiate-clinical-study-evaluate-whether-anakinra-and-emapalumab-may-relieve",
      "https://www.sobi.com/en/products",
      "https://www.drugbank.ca/drugs/DB14724",
      "https://www.sobi.com/en/about",
      "https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3",
      "https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "4be4dbabdaa77091d49b0c6b38bd5a8ef5b04a9d",
        "sponsorName": "Swedish Orphan Biovitrum Sobi"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Thu, 02 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Crowdsourcing",
    "phase": "",
    "preferredName": "Antibody",
    "primaryCompletionDate": "",
    "productId": 335,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.distributedbio.com/covid19"
    ],
    "sponsors": [
      {
        "sponsorId": "9ceaf8fbcb1950d5b4df0acbe1671777bd9893a0",
        "sponsorName": "Distributed Bio"
      },
      {
        "sponsorId": "06e3c85a544975e5dfcec88f45b51e3fdf635c59",
        "sponsorName": "Centivax"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "UK Government,University of Kent,Hong Kong University,National Institute for Biological Standards and Control",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 336,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/",
      "https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment; https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/",
      "https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment"
    ],
    "sponsors": [
      {
        "sponsorId": "9b2652ee65b8f7ac2fbc009851b6ef7d2faac03a",
        "sponsorName": "Chelsea and Westminster Hospital"
      },
      {
        "sponsorId": "1a693dd5acf9f3ae07a65241da0b2f2102ed1377",
        "sponsorName": "Imperial College London"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibody Therapeutic Innovent Biologics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibody_Therapeutic_Innovent_Biologics",
    "primaryCompletionDate": "",
    "productId": 337,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field",
      "https://www.btimesonline.com/articles/129691/20200403/chinese-drug-maker-innovent-biologics-developing-antibody-treatment-for-covid-19.htm"
    ],
    "sponsors": [
      {
        "sponsorId": "d6b2121d955a97b23570b0c2284d3d758aca0355",
        "sponsorName": "Innovent Biologics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "recombinant chimeric monoclonal antibody",
    "chemicalName": "IC14",
    "conditionOrDisease": "COVID-19,ARDS",
    "contact": [
      {
        "email": "dagna.lorenzo@unisr.it",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Expanded access available",
    "numSites": "1",
    "otherPartners": "",
    "phase": "Expanded access",
    "preferredName": "IC14",
    "primaryCompletionDate": "",
    "productId": 338,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04346277",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Milano",
        "country": "ITA",
        "lat": 45.5069106,
        "lng": 9.267293800000001,
        "locationId": "cf6030f5437d2536c569c7ee445a90d97960d4d7",
        "name": "Via Olgettina, 58, 20132 Milano MI, Italy",
        "state": "Lombardia"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://clinicaltrials.gov/ct2/show/NCT04346277",
      "https://implicitbioscience.com/home/"
    ],
    "sponsors": [
      {
        "sponsorId": "9676cb2db18bbea317e9ea9e591807187950be72",
        "sponsorName": "Implicit Bioscience"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vicromax",
    "chemicalName": "merimepodib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Submitted IND to FDA for Phase 2 trial for COVID-19 patients,Three Phase 2 trials completed in other idications,completed animal testing and phase 1 trials for other indications",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "merimepodib",
    "primaryCompletionDate": "",
    "productId": 339,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/releases/mayo-clinic-preparing-to-commence-phase-ii-fda-clinical-trial-for-the-treatment-of-covid-19-with-vicromax-/",
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf; https://www.biosig.com/viralclear",
      "https://www.biosig.com/viralclear",
      "https://www.drugbank.ca/drugs/DB04862",
      "https://www.biosig.com/contact-biosig",
      "https://www.biosig.com/viralclear; https://www.biosig.com/news-media/press-releases/detail/194/biosig-to-host-conference-call-on-recent-developments-of",
      "https://www.biosig.com/news-media/press-releases/detail/194/biosig-to-host-conference-call-on-recent-developments-of"
    ],
    "sponsors": [
      {
        "sponsorId": "7f3751a18145834311154ab95bfefa71b80ad512",
        "sponsorName": "ViralClear Pharmaceuticals"
      },
      {
        "sponsorId": "0d1321a5cc1c5a48c7918152a67c04e65aaf4844",
        "sponsorName": "BioSig Technologies"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ISR-50",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Sweden"],
    "countryCodes": ["SWE"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Hope to have animal testing done in 2nd quarter and human testing complete in 4th quarter",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ISR50",
    "primaryCompletionDate": "",
    "productId": 340,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf; http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0",
      "http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0"
    ],
    "sponsors": [
      {
        "sponsorId": "987e067b08e440461ef8fc126e195d7d57d749c7",
        "sponsorName": "ISR Immune System Regulation"
      },
      {
        "sponsorId": "5dcd0fc710b300f98746062aff74be3806516be0",
        "sponsorName": "TCER AB"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "antiviral Fc conjugates",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Uses Antiviaral Fc Conjugates (AVCs)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviral_Fc_conjugates",
    "primaryCompletionDate": "",
    "productId": 341,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.cidara.com/cloudbreak/",
      "https://www.cidara.com/pipeline/"
    ],
    "sponsors": [
      {
        "sponsorId": "124c17c54d9555bc7787cea6f6043207f25479ba",
        "sponsorName": "Cidara Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antiviral combination",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "It is indicted that combinations of FDA-approved drugs will be teste but unknown as to which ones.",
    "numSites": "",
    "otherPartners": "European Union's Horizon 2020 program",
    "phase": "",
    "preferredName": "Antiviral_combination",
    "primaryCompletionDate": "",
    "productId": 342,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://cordis.europa.eu/project/id/101003627",
      "https://www.lumc.nl/over-het-lumc/nieuws/2020/Maart/lumc-doet-onderzoek-naar-coranavirus-remmers/?setlanguage=English&setcountry=en"
    ],
    "sponsors": [
      {
        "sponsorId": "3ca1363324c98b475983319168e4c05919716630",
        "sponsorName": "SCORE Consortium"
      },
      {
        "sponsorId": "8717ea76eb52afd496f981afcc95aa693b0fbbd9",
        "sponsorName": "Helmholtz Centre for Infection Research"
      },
      {
        "sponsorId": "da5d8fe85f181501e049f3e20e8e1e2e438b9267",
        "sponsorName": "Janssen Pharmaceutica NV"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Multistem",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "The Multistem cells express a range of therapeutically-relevant proteins that act like drugs,Planning to start Phase 2/3 Clinical Trial by 06/30/2020,Completed Phase 1/2 Clinical Trial on July 2019,Fast-Track Designation by the FDA",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Multistem",
    "primaryCompletionDate": "",
    "productId": 343,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/",
      "https://www.athersys.com/our-company/contact-us/default.aspx",
      "https://www.athersys.com/clinical-trials/clinical-pipeline/default.aspx",
      "https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/ ; https://www.businesswire.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trial",
      "https://www.businesswire.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trial",
      "https://clinicaltrials.gov/ct2/show/study/NCT02611609?term=MultiStem&draw=2&rank=4"
    ],
    "sponsors": [
      {
        "sponsorId": "6a3a12b6d931e87c4b8d0d2273853f647cf3c65f",
        "sponsorName": "Athersys"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Inhalded mRNA",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 04 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Manufacturing intended to initiate summer 2020,Expected clinical testing in 4th quarter of 2020 pending regulatory approval",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inhalded_mRNA",
    "primaryCompletionDate": "",
    "productId": 344,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "1d194ed49d10f544c68a1c9d4116020692ba8b5b",
        "sponsorName": "Neurimmune"
      },
      {
        "sponsorId": "c6ddaeaa6ff1e400a4d8f29afd9415df2398bd02",
        "sponsorName": "Ethris"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Novaferon",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently licensed in China for treatment of Hepatitis B,Started recruiting for Phase 4 Clinical Trial(Hu'nan) for COVID-19 patients,Also in testing in another Phase 4 Clinical Trail (Zhejiang) for COVID-19 patients",
    "numSites": "2",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "Novaferon",
    "primaryCompletionDate": "",
    "productId": 345,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=48809",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Changsha",
        "country": "CHN",
        "lat": 28.301619,
        "lng": 113.005226,
        "locationId": "21a656b22098c03ba6cb7944be260f173c7733bf",
        "name": "Kaifu District, Changsha, Changsha, Hunan, China",
        "state": "Hunan"
      },
      {
        "city": "Changsha",
        "country": "CHN",
        "lat": 28.1869777,
        "lng": 112.9939852,
        "locationId": "b0649cc8f51367b94e01adb0c423f37131157e1b",
        "name": "Yuanjialing Shangquan, Furong District, Changsha, Hunan, China",
        "state": "Hunan"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "http://www.chictr.org.cn/showprojen.aspx?proj=48809",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/",
      "http://en.people.cn/n3/2018/0529/c90000-9465205.html",
      "https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1 ; http://en.people.cn/n3/2018/0529/c90000-9465205.html",
      "http://www.chictr.org.cn/showprojen.aspx?proj=48809 ;  http://www.chictr.org.cn/showproj.aspx?proj=49065",
      "https://www.medrxiv.org/content/10.1101/2020.03.04.20031401v1.full.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "818e1de4129b2f52a53d8da808ff6c036588610d",
        "sponsorName": "The First Hospital of Changsha"
      },
      {
        "sponsorId": "815809b19bd18eae88cb00c73fd9f3bbc9764dd3",
        "sponsorName": "The Second Xiangya Hospital of Central South University"
      },
      {
        "sponsorId": "9e8c8e9d300f14660fbd928824d2e2e27fbba9ce",
        "sponsorName": "First Affiliated Hospital of Zhejiang University Medical School"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 29 Jan 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "BIO-11006",
    "chemicalName": "",
    "conditionOrDisease": "ARDS",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently tested in a pilot Phase 2a clinical trial",
    "numSites": "5",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "BIO11006",
    "primaryCompletionDate": "",
    "productId": 346,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03202394",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Chicago",
        "country": "USA",
        "lat": 41.8952146,
        "lng": -87.623156,
        "locationId": "0cf1975ce13b6df7732c71569e891dd53a9d5ec4",
        "name": "150 E Huron St #900, Chicago, IL 60611, USA",
        "state": "IL"
      },
      {
        "city": "Chapel Hill",
        "country": "USA",
        "lat": 35.906058,
        "lng": -79.052199,
        "locationId": "740748f458ab001d592f76d385d9053e5054a9cd",
        "name": "321 S Columbia St, Chapel Hill, NC 27516, USA",
        "state": "NC"
      },
      {
        "city": "Winston-Salem",
        "country": "USA",
        "lat": 36.1363891,
        "lng": -80.2754289,
        "locationId": "a2a98d40db8e1494b7767efba19fd88f6d3eb645",
        "name": "Wake Forest University, Winston-Salem, NC 27109, USA",
        "state": "NC"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9522188,
        "lng": -75.1932137,
        "locationId": "7f3fad0c636c0b7de0ae9f28df376c500c6b188d",
        "name": "Philadelphia, PA 19104, USA",
        "state": "PA"
      },
      {
        "city": "Nashville",
        "country": "USA",
        "lat": 36.1447034,
        "lng": -86.8026551,
        "locationId": "b6743fa818c419a8ba4902fee01eacf311ce757f",
        "name": "2201 West End Ave, Nashville, TN 37235, USA",
        "state": "TN"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "http://www.biomarck.com/pipeline/",
      "https://www.ptcommunity.com/wire/biomarck-announces-statistically-significant-results-phase-2-controlled-clinical-study-non",
      "https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3"
    ],
    "sponsors": [
      {
        "sponsorId": "ee0168c868efcb79c99cceb1ad9c4b367356e247",
        "sponsorName": "Biomarck Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Nafamostat",
    "chemicalName": "nafamostat mesylate",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently recruiting for Phase 2/3 clinical trial in Padova-Italy,Set to start a unknown phase clinical trial at National Center for Global Health and Medicine in April 2020,Requested EUA from FDA with planned Phase 1/2 clinical trial in United States at unknown start time",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "nafamostat_mesylate",
    "primaryCompletionDate": "",
    "productId": 347,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04352400",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.drugbank.ca/drugs/DB12598",
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.businesswire.com/news/home/20200415005156/en/Ensysce-California-Based-Biotech-Company-Mission-Solve",
      "https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1 ; https://www.businesswire.com/news/home/20200415005156/en/Ensysce-California-Based-Biotech-Company-Mission-Solve ; https://www.trialsitenews.com/university-of-tokyo-institute-of-medical-science-considers-nafamostat-for-clinical-trial-assessing-potential-to-treat-covid-19-clinical/",
      "https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "ab1e8ad3d379bcd134e4e3f47f828591f21bca7b",
        "sponsorName": "University of Tokyo"
      },
      {
        "sponsorId": "e5fd2e305fd3cf838a58fa49356e6a687de59229",
        "sponsorName": "Ensysce Biosciences"
      },
      {
        "sponsorId": "e22bdba3cbf2ef89fffeee543c2f866f142cd77f",
        "sponsorName": "National Center for Global Health Medicine"
      },
      {
        "sponsorId": "fee8ee418bcb93a56059c6670596e6c18214fd42",
        "sponsorName": "University Hospital Padova"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Activase",
    "chemicalName": "alteplase",
    "conditionOrDisease": "ARDS",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 22 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "FDA-approved for treating blood clots but currently in Phase 2 clinical trial for COVID-19 patients,Therapeutic Approach is human tissue plasminogen activator",
    "numSites": "3",
    "otherPartners": "National Institutes of Health,Department of Defense Peer Reviewed Medical Research Program",
    "phase": "2",
    "preferredName": "alteplase",
    "primaryCompletionDate": "",
    "productId": 348,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04357730",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Aurora",
        "country": "USA",
        "lat": 39.7439668,
        "lng": -104.8379531,
        "locationId": "9ad9b3f95500e8baf943d681e75412e5263de5e7",
        "name": "13001 East 17th Place Mail Stop F413 Room CG001, Aurora, CO 80045, USA",
        "state": "CO"
      },
      {
        "city": "Denver",
        "country": "USA",
        "lat": 39.7279895,
        "lng": -104.9913193,
        "locationId": "35d07f294070d8316466248065e7ccb6bae0d18e",
        "name": "777 Bannock St, Denver, CO 80204, USA",
        "state": "CO"
      },
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3396063,
        "lng": -71.10498199999999,
        "locationId": "206476e8831968c17f1ababdd85653eba9d8fd79",
        "name": "330 Brookline Ave, Boston, MA 02215, USA",
        "state": "MA"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "http://news.mit.edu/2020/covid-19-treat-respiratory-patients-plasminogen-0324",
      "https://www.drugbank.ca/drugs/DB00009",
      "https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6",
      "https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6 ; https://www.drugbank.ca/drugs/DB00009"
    ],
    "sponsors": [
      {
        "sponsorId": "b03aa77c14c56ff5b4f5d3426dfb679c28ea44f9",
        "sponsorName": "Beth Israel Deaconess"
      },
      {
        "sponsorId": "4c60ee4e3a2c0a8b5e660916048f460f70033ae3",
        "sponsorName": "University of Colorado Anschultz Medical Campus"
      },
      {
        "sponsorId": "aeb9a00ace7546f0b60499cf3dd4a85be50b4e0d",
        "sponsorName": "Denver Health"
      },
      {
        "sponsorId": "3ef65938333d443798d2043926bf988ac4c3c305",
        "sponsorName": "Genentech"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 22 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Kineret",
    "chemicalName": "anakinra",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently testing in Phase 4 clinical trial named REMAP-CAP that was updated to include a sub-platform  REMAP-COVID for COVID-19 patients,Also testing in numerous other Phase 2/3 clinical trials",
    "numSites": "89",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "anakinra",
    "primaryCompletionDate": "",
    "productId": 349,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT02735707",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "AUS",
        "lat": -25.274398,
        "lng": 133.775136,
        "locationId": "124caa5cd2ed6c4a30908a202161847676edfd94",
        "name": "Australia",
        "state": null
      },
      {
        "city": null,
        "country": "BEL",
        "lat": 50.503887,
        "lng": 4.469936,
        "locationId": "aa6af0ba3530ef6cd9db70b2af99d5fc9abe3b7a",
        "name": "Belgium",
        "state": null
      },
      {
        "city": null,
        "country": "CAN",
        "lat": 56.130366,
        "lng": -106.346771,
        "locationId": "e01c1417364f5ef8679cc8a4a24565692e5940e9",
        "name": "Canada",
        "state": null
      },
      {
        "city": null,
        "country": "HRV",
        "lat": 45.1,
        "lng": 15.2000001,
        "locationId": "9cdfdf0d5ce397c4773cdd69d07203b8ef25df0c",
        "name": "Croatia",
        "state": null
      },
      {
        "city": null,
        "country": "DEU",
        "lat": 51.165691,
        "lng": 10.451526,
        "locationId": "5ecbece0eb44a0258bc9b9701c76856b72d4eacd",
        "name": "Germany",
        "state": null
      },
      {
        "city": null,
        "country": "HUN",
        "lat": 47.162494,
        "lng": 19.5033041,
        "locationId": "9c1ac4212d468023b2e0598f9884b41c09bb015e",
        "name": "Hungary",
        "state": null
      },
      {
        "city": null,
        "country": null,
        "lat": 53.1423672,
        "lng": -7.692053599999999,
        "locationId": "75949503a12f490b06e0c82680213105d7f4f1cf",
        "name": "Ireland",
        "state": null
      },
      {
        "city": null,
        "country": "NLD",
        "lat": 52.132633,
        "lng": 5.291265999999999,
        "locationId": "f904465c12f715fb27e06a99b6ec3ebc961b1bc9",
        "name": "Netherlands",
        "state": null
      },
      {
        "city": null,
        "country": "NZL",
        "lat": -40.900557,
        "lng": 174.885971,
        "locationId": "ca9b2b13996de1e6716b2a9072a02913265f79f3",
        "name": "New Zealand",
        "state": null
      },
      {
        "city": null,
        "country": "PRT",
        "lat": 39.39987199999999,
        "lng": -8.224454,
        "locationId": "331b66f507573ba63d5f1ee1bfb75e11602eb72a",
        "name": "Portugal",
        "state": null
      },
      {
        "city": null,
        "country": "ROU",
        "lat": 45.943161,
        "lng": 24.96676,
        "locationId": "333b397ca6abcc6c695ebd8075aa8fd0037d4c66",
        "name": "Romania",
        "state": null
      },
      {
        "city": null,
        "country": "ESP",
        "lat": 40.46366700000001,
        "lng": -3.74922,
        "locationId": "c27f4c52d6eb8c296a743e2ecc0f113bb4a6b893",
        "name": "Spain",
        "state": null
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "e0dd54bf6a5feba7011bafdf2a12a036e732a947",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://clinicaltrials.gov/ct2/show/NCT02735707",
      "https://www.drugbank.ca/drugs/DB00026",
      "https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/interleukin-1-receptor-antagonist",
      "https://clinicaltrials.gov/ct2/show/NCT02735707 ; https://clinicaltrials.gov/ct2/show/NCT04330638 ; https://clinicaltrials.gov/ct2/show/NCT04324021 ; https://clinicaltrials.gov/ct2/show/NCT04341584 ; https://clinicaltrials.gov/ct2/show/NCT04339712 ; https://clinicaltrials.gov/ct2/show/NCT04357366",
      "https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6"
    ],
    "sponsors": [
      {
        "sponsorId": "584eb38a0c9689f77c37d2ae76a472d221834c3c",
        "sponsorName": "Swedish Orphan Biovitrum"
      },
      {
        "sponsorId": "a3251a4d28a25ad747e6996701cdcb53bf96499b",
        "sponsorName": "Fundacion Miguel Servet"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PP-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Drug has just completed a Phase 2 clinical trial for treatment of severe eye disesases,Article states that clinical trials for COVID-19 could begin shortly.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PP001",
    "primaryCompletionDate": "",
    "productId": 350,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.lisavienna.at/news/the-austrian-biotech-company-panoptes-pharma-gmbh-has-a-promising-candidate-against-covid-19/",
      "https://www.4sc.com/product-pipeline/out-licensed-products/pp-001/"
    ],
    "sponsors": [
      {
        "sponsorId": "d84536309abcf2b1a75abfa06c2300e2a5917cb8",
        "sponsorName": "Panoptes Pharma GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Xeljanz",
    "chemicalName": "tofacitinib",
    "conditionOrDisease": "Pneumonia",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "FDA approved to treat arthritis and colitis,Currently testing in Phase 2 clinical trial for COVID-19 related pneuomia",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "tofacitinib",
    "primaryCompletionDate": "",
    "productId": 351,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04332042",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Torrette",
        "country": "ITA",
        "lat": 43.6019431,
        "lng": 13.4547895,
        "locationId": "390e2c674f324a78bed954db63ee2c9641e876a5",
        "name": "Via Conca, 71, 60126 Torrette AN, Italy",
        "state": "Marche"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.pfizer.com/news/press-release/press-release-detail/pfizer_advances_battle_against_covid_19_on_multiple_fronts",
      "https://www.drugbank.ca/drugs/DB08895",
      "https://www.pfizer.com/contact",
      "https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1 ; https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "531d5b28f1f18f219741627c0f2a1e09d355e46a",
        "sponsorName": "Pfizer"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 02 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "BLD-2660",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Caplain (protease) inhibitor,used to be a drug to treat fibrosis",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "BLD2660",
    "primaryCompletionDate": "Thu, 20 Aug 2020 00:00:00 GMT",
    "productId": 352,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04334460",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://clinicaltrials.gov/ct2/show/record/NCT04334460",
      "https://adisinsight.springer.com/drugs/800052329",
      "https://www.blademed.com/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "89667736796d6828f9626bcd8b0fbb2b3f0c30ba",
        "sponsorName": "Blade Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 20 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PREVENT",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "this consortium includes many different groups that are making different drugs,one main group involved is AdaptVac (line 79)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PREVENT",
    "primaryCompletionDate": "",
    "productId": 353,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "af0e9043938d3ffd18d4aa4f263c303abe7a87c1",
        "sponsorName": "PREVENTnCoV consortium"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Vaxine Vaccine",
    "chemicalName": "COVAX19",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "nikolai.petrovsky@flinders.edu.au",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "COVAX19",
    "primaryCompletionDate": "Thu, 01 Jul 2021 00:00:00 GMT",
    "productId": 355,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04453852",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Port Noarlunga South",
        "country": "AUS",
        "lat": -35.161927,
        "lng": 138.558553,
        "locationId": "758bcbe02f3f566ac7485aebd925b8c6ab41dd74",
        "name": "Onkaparinga River National Park, Port Noarlunga South SA 5167, Australia",
        "state": "SA"
      }
    ],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.eurekalert.org/pub_releases/2020-04/fu-cio040220.php",
      "https://news.flinders.edu.au/blog/2020/04/03/flinders-targets-covid-19-vaccine/"
    ],
    "sponsors": [
      {
        "sponsorId": "b103c316060fe38a9bb6cb32740cba7009ff4993",
        "sponsorName": "Vaxine Pty Ltd"
      },
      {
        "sponsorId": "5b15122e16efd5040af4ad925335499c22697ac0",
        "sponsorName": "Flinders University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 01 Jul 2021 00:00:00 GMT",
    "studyStartDate": "Sat, 20 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "University of Cambridge Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "University_of_Cambridge_Vaccine",
    "primaryCompletionDate": "",
    "productId": 356,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "83c94185cc09e66de46b286461805b6666ee47e1",
        "sponsorName": "University of Cambridge"
      },
      {
        "sponsorId": "7d21b3cf2e2c033e713858c5883640d91677f72e",
        "sponsorName": "DIOSynVax"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "St. Petersburg Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "St_Petersburg_Vaccine",
    "primaryCompletionDate": "",
    "productId": 357,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://tass.com/society/1136863",
      "https://www.corona24.news/c/2020/04/12/st-petersburg-scientists-will-take-part-in-the-development-of-a-standard-against-covid-19-news-news.html",
      "https://interfax.com/newsroom/top-stories/68233/"
    ],
    "sponsors": [
      {
        "sponsorId": "1c450dbef9738d9b66fe108c2438eedf9206b820",
        "sponsorName": "St Petersburg Scientific Research Institute of Vaccines and Serums"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VBI Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "in collaboration with the National Research Council of Canada (NRC),advances on VBI's enveloped virus-like particle vaccines (eVLP vaccines)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VBI_Vaccine",
    "primaryCompletionDate": "",
    "productId": 358,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/"
    ],
    "sponsors": [
      {
        "sponsorId": "ccba56f09bfbe72461df11aa67398b87f33bc6a5",
        "sponsorName": "VBI Vaccines"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "BIOCAD Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "BIOCAD_Vaccine",
    "primaryCompletionDate": "",
    "productId": 359,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
      "https://biocadglobal.com/index.php?posts&post=45",
      "https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/"
    ],
    "sponsors": [
      {
        "sponsorId": "7a849d71160735d95f7cfb3ca259e2bb33ed4fb8",
        "sponsorName": "BIOCAD"
      },
      {
        "sponsorId": "05fc10448e3ccf081b100a8e2f7113e804fec492",
        "sponsorName": "IEM"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IAVI Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "intends to help lower the cost for producing vaccines for Covid-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IAVI_Vaccine",
    "primaryCompletionDate": "",
    "productId": 360,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "https://www.bataviabiosciences.com/news/iavi-vsv-vector-epidemic-preparedness-vaccines/",
      "https://www.iavi.org/contact-us",
      "https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1"
    ],
    "sponsors": [
      {
        "sponsorId": "4504468bad51eef6a2ac6172fa89a91614df3c56",
        "sponsorName": "Merck"
      },
      {
        "sponsorId": "44d1bb59e8c48cd0b43da165d6d9606f2583b5fe",
        "sponsorName": "IAVI"
      },
      {
        "sponsorId": "f2e8788350358421b65552cc2679a931104ad1ab",
        "sponsorName": "Batavia"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Saiba Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Has been able to induce high levels of antibodies within a week in animals",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Saiba_Vaccine",
    "primaryCompletionDate": "",
    "productId": 361,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "Virus-like particles; https://biorender.com/covid-vaccine-tracker",
      "https://www.saiba-biotech.com/Latest",
      "https://www.saiba-biotech.com/contact"
    ],
    "sponsors": [
      {
        "sponsorId": "a558e81d8b75a91096450dac109735d6cb004a49",
        "sponsorName": "Saiba GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Imophoron Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Vaccines require no refrigeration",
    "numSites": "",
    "otherPartners": "University of Bristol's Emergency Research Group",
    "phase": "",
    "preferredName": "Imophoron_Vaccine",
    "primaryCompletionDate": "",
    "productId": 362,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",
      "http://www.pharmatimes.com/news/imophoron_develops_covid-19_vaccine_candidates_1337851",
      "https://www.thepharmaletter.com/article/imophoron-to-begin-preclinical-tests-on-covid-19-vaccines",
      "VLP; ADDomerTM multiepitopedisplay; https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "47418e382f699611afcc07ba422a212ac3cd258e",
        "sponsorName": "Imophoron Ltd"
      },
      {
        "sponsorId": "2142575a70dd242d662f1604a63d59f331c865ae",
        "sponsorName": "University of Bristol"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PRTX-007",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Activates TLR7 to stimulate innate immune system",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PRTX007",
    "primaryCompletionDate": "",
    "productId": 363,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html",
      "https://www.primmunerx.com/#contact"
    ],
    "sponsors": [
      {
        "sponsorId": "59184ad543e6f439787b2e2ac1527ea53b1e5ac1",
        "sponsorName": "Primmune Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AB00-1",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Acts on ACE-2 to inhibit the entry of the virus into the cell and workds on NSP15 to prevent its replication,Intends to begin human clinical trials this year",
    "numSites": "",
    "otherPartners": "",
    "phase": "Pre-Clinical",
    "preferredName": "AB001",
    "primaryCompletionDate": "",
    "productId": 364,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.agastiyabiotech.com/covid19/",
      "https://www.agastiyabiotech.com/contact/",
      "https://www.agastiyabiotech.com/covid19/;https://www.manchestertimes.com/news/business/agastiya-biotech-proceeding-with-drug-candidate-for-covid-19/article_52279711-3ec6-5087-a02f-e43158a68929.html"
    ],
    "sponsors": [
      {
        "sponsorId": "939b55ffb6ce9f4b830c8776c83f2f2116fd16d3",
        "sponsorName": "Agastiya Biotech LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Ultomiris",
    "chemicalName": "ravulizumab-cwvz",
    "conditionOrDisease": "COVID 19 Severe Pneumonia,Acute Lung Injury,or Acute Respiratory Distress Syndrome",
    "contact": [
      {
        "email": "clinicaltrials@alexion.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "A terminal complement inhibitor of C5",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "ravulizumabcwvz",
    "primaryCompletionDate": "Fri, 20 Nov 2020 00:00:00 GMT",
    "productId": 365,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04369469",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/alexion-announces-plans-to-initiate-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19/",
      "https://www.drugbank.ca/drugs/DB11580",
      "https://alexion.com/our-medicines/medicines/ultomiris",
      "https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5",
      "https://alexion.com/our-company/about-us"
    ],
    "sponsors": [
      {
        "sponsorId": "41794d8c7643f99fc7895546d19147d1b41daf20",
        "sponsorName": "Alexion Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 20 Feb 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 20 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Metablok",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "The primary endpoint is to prevent acute respiratory distress syndrome in patients infected with COVID19,DPEP-1 inhibitor treating inflammation in the lungs liver and kidneys",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Metablok",
    "primaryCompletionDate": "",
    "productId": 366,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03772678",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/157-arch-biopartners-submits-application-to-health-canada-to-conduct-covid19-phase-ii-human-trial-for-metablok-to-prevent-lung-and-kidney-inflammation",
      "https://www.precisionvaccinations.com/vaccines/metablok-lsalt-peptide",
      "https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/152-arch-biopartners-safely-completes-expanded-dosing-of-metablok-in-phase-i-human-trial-and-begins-focus-on-phase-ii-trial",
      "https://www.biospace.com/article/releases/arch-biopartners-releases-new-video-showing-metablok-reducing-lung-inflammation-in-an-animal-model-/",
      "https://clinicaltrials.gov/ct2/show/NCT03772678?term=LSALT+peptide&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "6ae7877eca7b978170ddee9d611fbce51b4868f7",
        "sponsorName": "Arch Biopartners Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MEDI-3506",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Targeting Interluekin 33",
    "numSites": "",
    "otherPartners": "Medimmune,ACCORd",
    "phase": "",
    "preferredName": "MEDI3506",
    "primaryCompletionDate": "",
    "productId": 367,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html",
      "https://www.astrazeneca.com/media-centre/articles/2020/investigating-an-existing-medicine-as-a-potential-treatment-for-covid-19.html",
      "https://adisinsight.springer.com/drugs/800049222; https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html",
      "https://clinicaltrials.gov/ct2/show/NCT03096795"
    ],
    "sponsors": [
      {
        "sponsorId": "e4db405906dfdb58ac2ee1ccf9877fc1ad52116d",
        "sponsorName": "Aztrazeneca plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Farxiga",
    "chemicalName": "dapagliflozin",
    "conditionOrDisease": "COVID19",
    "contact": [
      {
        "email": "swindsor@saint-lukes.org",
        "name": null,
        "notes": "",
        "phone": "816-932-9858",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "A sodium glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2,currently recruiting,estimated completion date October 2020",
    "numSites": "1",
    "otherPartners": "Saint Luke's Health System,AstraZeneca,George Clinical Pty Ltd",
    "phase": "3",
    "preferredName": "dapagliflozin",
    "primaryCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "productId": 368,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04350593",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "KCMO",
        "country": "USA",
        "lat": 39.0476518,
        "lng": -94.59045540000001,
        "locationId": "0b0eb08b86b5b7cfb3c24998b5df24a65f07fc38",
        "name": "4401 Wornall Rd, Kansas City, MO 64111, USA",
        "state": "MO"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/drugs/DB06292",
      "https://clinicaltrials.gov/ct2/show/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/record/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/results?cond=&term=Dapagliflozin&cntry=&state=&city=&dist=",
      "https://clinicaltrials.gov/ct2/show/study/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "e4db405906dfdb58ac2ee1ccf9877fc1ad52116d",
        "sponsorName": "Aztrazeneca plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IgM Antibodies,IgA Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Idenitfying the sequeneces of antibodies made by B cells found in blood from acutely infected COVID-19 patients and engineering IgM and IgA antibodies (from the identified sequence) with greater binding power per antibody.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IgM_Antibodies_IgA_Antibodies",
    "primaryCompletionDate": "",
    "productId": 369,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://ir.beigene.com/static-files/e62cb49b-21dd-40d0-b305-60946431c587",
      "https://www.atreca.com/about/; https://www.beigene.com/about/our-story; https://igmbio.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "300c03c87517131e06a725327908570fd8798f8b",
        "sponsorName": "Atreca Inc"
      },
      {
        "sponsorId": "5a19a0834e482d0229a397f62492ab8dfcd271d9",
        "sponsorName": "Beigene Ltd"
      },
      {
        "sponsorId": "4852c490222a54deb2d41b655f588096c92cb6ad",
        "sponsorName": "IGM Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Audax Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Audax_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 370,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.northeastern.edu/cri/news/northeastern-professor-partners-with-audax-medical-inc-to-combat-covid-19/",
      "https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "06fe14bef7ae50a2f1a152d1eba019ce4b0b33bf",
        "sponsorName": "Audax Medical Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Bemcentinib",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Norway"],
    "countryCodes": ["NOR"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Department of Health and Social Care (DHSC),UK Research and Innovation (UKRI)",
    "phase": "2",
    "preferredName": "Bemcentinib",
    "primaryCompletionDate": "",
    "productId": 371,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/",
      "https://www.bioworld.com/articles/434740-bergenbios-bemcentinib-joins-fast-tracked-accord-program-targeting-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "e99b1e4fd130967b98ec911ffe343851949fc17b",
        "sponsorName": "Bergenbio ASA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "COVID-19 treatments",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "AI company that helps identify drugs (Project Prodigy AI)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "COVID19_treatments",
    "primaryCompletionDate": "",
    "productId": 372,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biovista.com/artificial-intelligence-firm-biovista-repositions-four-promising-therapeutics-against-covid-19/",
      "https://www.biovista.com/solutions/project-prodigy-vs-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "8ff2bf908543da634f6c955434fd59ba86816e6d",
        "sponsorName": "Biovista Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CLBS-119",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Repairs lung damage",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CLBS119",
    "primaryCompletionDate": "",
    "productId": 373,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/"
    ],
    "sponsors": [
      {
        "sponsorId": "28d929d86c67592db08f4897b313d80028476e9e",
        "sponsorName": "Caladrius Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Dociparstat sodium",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Dociparstat_sodium",
    "primaryCompletionDate": "",
    "productId": 374,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung",
      "https://www.globenewswire.com/news-release/2019/12/10/1958467/0/en/Chimerix-Presents-Updated-Results-from-Phase-2-Clinical-Trial-of-DSTAT-in-Refractory-Myelodysplastic-Syndrome-and-Acute-Myeloid-Leukemia-at-American-Society-of-Hematology-Annual-Me.html",
      "https://www.chimerix.com/contact-us/"
    ],
    "sponsors": [
      {
        "sponsorId": "b205baf63638325039ee5a5cb8163c92032c7373",
        "sponsorName": "Chimerix Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Itanapraced",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Itanapraced",
    "primaryCompletionDate": "",
    "productId": 375,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/cerespir-incorporated-identifies-possible-link-between-covid-19-induced-brain-inflammation-and-acute-respiratory-stress-syndrome-via-breakdown-of-the-blood-brain-barrier/",
      "https://drugs.ncats.io/drug/C35RF1MWQZ",
      "https://www.globenewswire.com/news-release/2020/04/16/2017370/0/en/CERESPIR-INCORPORATED-Identifies-Possible-Link-Between-COVID-19-Induced-Brain-Inflammation-and-Acute-Respiratory-Stress-Syndrome-Via-Breakdown-of-the-Blood-Brain-Barrier.html"
    ],
    "sponsors": [
      {
        "sponsorId": "b3fae6fd4eeae1f99462dfff0a75d2eab3c4253a",
        "sponsorName": "Cerespir Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Niagen",
    "chemicalName": "nicotinamide riboside",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nicotinamide_riboside",
    "primaryCompletionDate": "",
    "productId": 376,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical"
    ],
    "sponsors": [
      {
        "sponsorId": "e44b4742cbdb4c8802c4d11e460311b5195d0a43",
        "sponsorName": "Chromadex Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Pacritinib",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Pacritinib",
    "primaryCompletionDate": "",
    "productId": 377,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/",
      "http://lincs.hms.harvard.edu/db/sm/10381-101/",
      "https://www.ctibiopharma.com/pacritinib/",
      "https://www.ctibiopharma.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "9f40c9583b5968ab1adbdf1d8a099bc79d1c1c88",
        "sponsorName": "CTI Biopharma Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CYC-065",
    "chemicalName": "Fadraciclib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Edinburgh,LifeArc",
    "phase": "",
    "preferredName": "Fadraciclib",
    "primaryCompletionDate": "",
    "productId": 378,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html",
      "https://www.bioworld.com/articles/434562-cyclacel-pharming-repurpose-drugs-to-fight-severe-respiratory-symptoms-of-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae",
        "sponsorName": "Cyclacel Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CYC-202,R-roscovitine",
    "chemicalName": "Seliciclib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Edinburgh,LifeArc",
    "phase": "",
    "preferredName": "Seliciclib",
    "primaryCompletionDate": "",
    "productId": 379,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html",
      "https://www.bioworld.com/articles/434562-cyclacel-pharming-repurpose-drugs-to-fight-severe-respiratory-symptoms-of-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae",
        "sponsorName": "Cyclacel Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Ryanodex",
    "chemicalName": "dantrolene sodium",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Growth inhibitor by modulating free intracellular calcium levels in host cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "dantrolene_sodium",
    "primaryCompletionDate": "",
    "productId": 380,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.eagleus.com/eagle-pharmaceuticals-corporate-website-statement/",
      "https://www.bioworld.com/COVID19products",
      "https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx",
      "https://www.drugbank.ca/drugs/DB01219",
      "https://www.eagleus.com/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "6bd89fd19b2baf31fb93f1a63de6b53953ee9577",
        "sponsorName": "Eagle Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Nucleic Acid Therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nucleic_Acid_Therapy",
    "primaryCompletionDate": "",
    "productId": 445,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html"
    ],
    "sponsors": [
      {
        "sponsorId": "330a20d0af980a475ef093d65b4d4ea3e054756b",
        "sponsorName": "Aligos Therapeutics Inc"
      },
      {
        "sponsorId": "a23d124d39198914a13ff22112de76a68eaed76e",
        "sponsorName": "Luxna Biotech Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "EB05 and EB06",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "NI-0101 and NI-0801 programs at lightchain bioscience work as TLR4 and CXCL10 antagonists respectively - being licensed to Edesa Biotech Inc",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "EB05_and_EB06",
    "primaryCompletionDate": "",
    "productId": 381,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders",
      "https://www.bioworld.com/COVID19products",
      "https://www.lightchainbio.com/our-focus/pipeline.html",
      "https://www.edesabiotech.com/about/contact-us/",
      "https://www.edesabiotech.com/clinical-pipeline/"
    ],
    "sponsors": [
      {
        "sponsorId": "df7336e82b3ee964918b55e0124c5c863386b59e",
        "sponsorName": "Edesa Biotech Inc"
      },
      {
        "sponsorId": "9898e6e8a31d2229ba186cbe74951fc0875a5ae1",
        "sponsorName": "Light Chain Bioscience"
      },
      {
        "sponsorId": "18504c03801e154a688184f061e282ba41d0c0e4",
        "sponsorName": "Novimmune SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Zotatifin",
    "chemicalName": "eFT226",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Eukaryotic initiation factor 4A inhibitor which is used by the virus for replication",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "eFT226",
    "primaryCompletionDate": "",
    "productId": 382,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://effector.com/pipeline/#zotatifin",
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html",
      "https://effector.com/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "d2b4445d416dbf8501b919b961f16cb45cf218d9",
        "sponsorName": "Effector Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 383,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics"
    ],
    "sponsors": [
      {
        "sponsorId": "09467ddba3462cd3be13db3493e74a1cd13ee832",
        "sponsorName": "Fairjourney Biologics SA"
      },
      {
        "sponsorId": "e461e3fcff3dfbf264418228bb2872ec75a77d64",
        "sponsorName": "Iontas Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Part of the Northern Ireland Coronavirus Antibody Development Alliance (\u201cNICADA\u201d)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 384,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/",
      "https://www.bioworld.com/COVID19products",
      "https://www.fusionantibodies.com/contact-us/"
    ],
    "sponsors": [
      {
        "sponsorId": "4c15e115bbf73c231a08f5b902eca1c36dbc7fe1",
        "sponsorName": "Fusion Antibodies plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Company is using its proprietary humanized mice called Advanced peripheral blood Hematopoietic Chimera",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 385,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/",
      "https://hemogenyx.com/contact/",
      "https://www.thearmchairtrader.com/hemogenyx-stock-price/"
    ],
    "sponsors": [
      {
        "sponsorId": "3f5e70ee0770a61cea95a52724b629ed752e8d50",
        "sponsorName": "Hemogenyx Pharmaceuticals plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "IMU-838",
    "chemicalName": "vidofludimus calcium",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "andreas.muehler@imux.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Inhibitor of dihydroorotate dehydrogenase- an enzyme of pyrimidine de novo biosynthesis",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "vidofludimus_calcium",
    "primaryCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "productId": 386,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04379271",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.immunic-therapeutics.com/imu838/",
      "https://www.bioworld.com/COVID19products",
      "https://www.immunic-therapeutics.com/2020/04/21/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients/",
      "https://www.immunic-therapeutics.com/contact/",
      "https://clinicaltrials.gov/ct2/show/record/NCT04379271?term=imu-838&draw=2&rank=3",
      "https://clinicaltrials.gov/ct2/show/NCT04379271?term=imu-838&draw=2&rank=3"
    ],
    "sponsors": [
      {
        "sponsorId": "8ebeaa89bdf967acb860530de89f2bf521947797",
        "sponsorName": "Immunic Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 20 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Xpro-1595 ",
    "chemicalName": "dominant-negative TNF Inhibitor",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "trials@inmunebio.com",
        "name": null,
        "notes": "",
        "phone": "1 (858) 964-3720",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Supposed to treat respiratory symptoms without being immunosuppressive-TNF has been linked to cytokine storm in COVID-19 patients",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "dominantnegative_TNF_Inhibitor",
    "primaryCompletionDate": "Wed, 20 Jan 2021 00:00:00 GMT",
    "productId": 387,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04370236",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420",
      "https://www.inmunebio.com/index.php/en/science/xpro1595/overview",
      "https://www.inmunebio.com/index.php/en/contact-2/contact-us",
      "https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3",
      "https://clinicaltrials.gov/ct2/show/record/NCT04370236?term=inmune&draw=2&rank=3&view=record"
    ],
    "sponsors": [
      {
        "sponsorId": "dab857f942f999776776bf0b8f3c12093bcdf582",
        "sponsorName": "Inmune Bio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sat, 20 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Cannabidiol-loaded exosomes",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Aim is to use exosome as a targeted delivery sytem to release cannabidiol into the lungs for anti-inflammatory effects",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Cannabidiolloaded_exosomes",
    "primaryCompletionDate": "",
    "productId": 388,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.newsfilecorp.com/release/54575/InnoCan-Pharma-Collaborates-with-Tel-Aviv-University-to-Develop-a-New-Revolutionary-Approach-to-Treat-the-COVID19-Corona-Virus-with-ExosomesLoaded-CBD",
      "https://innocanpharma.com/cell-therapy/",
      "https://innocanpharma.com/our-story/",
      "https://www.euroweeklynews.com/2020/04/27/israeli-scientists-begin-trials-into-the-effectiveness-of-cannabis-in-treating-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "f5509fdc8d977098de524cfe1324119bca44d958",
        "sponsorName": "Innocan Pharma Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "INS-1007",
    "chemicalName": "Brensocatib",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "j.chalmers@dundee.ac.uk",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Multi-center Investigator Initiated Trial,Drug is a Dipeptidyl Peptidase 1 inhibitor which ultimately aims to reduce neutrophil-mediated damage via serine proteases in the lungs",
    "numSites": "10",
    "otherPartners": "Insmed Inc.",
    "phase": "3",
    "preferredName": "Brensocatib",
    "primaryCompletionDate": "",
    "productId": 389,
    "registryLink": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "GBR",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "966454c5b7bba840f94d8e82684930b1de70860c",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial",
      "https://www.drugbank.ca/drugs/DB15638",
      "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB",
      "https://insmed.com/science/pipeline/"
    ],
    "sponsors": [
      {
        "sponsorId": "3705775d63e9f24d20b5c6e4736f7f613881237f",
        "sponsorName": "University of Dundee"
      },
      {
        "sponsorId": "e97f167fe7a9cdf40d469f7fe1f8fc68fcce2030",
        "sponsorName": "Insmed Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Sonlicromanol",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently in Phase 2b clinical trial for mitochondrial diseases,Sponsor looking for partners to start trial in COVID-19 patients as of April 15th",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Sonlicromanol",
    "primaryCompletionDate": "",
    "productId": 390,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/15/2016163/0/en/Khondrion-highlights-potential-role-of-inflammatory-lipid-modulator-prostaglandin-E2-in-COVID-19-disease-and-proposes-potential-treatment-pathway-with-sonlicromanol.html",
      "https://mitochondrialdiseasenews.com/2020/01/31/khondrion-doses-first-patient-phase-2b-trial-testing-sonlicromanol-mitochondrial-diseases/",
      "https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "515553435142eb535852e295f3bd6c501327f36b",
        "sponsorName": "Khondrion BV"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VAP-1 Inhibitors",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently in Discovery Phase,Screening for novel VAP-1 inhibitor compounds for inflammatory conditions",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VAP1_Inhibitors",
    "primaryCompletionDate": "",
    "productId": 391,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases"
    ],
    "sponsors": [
      {
        "sponsorId": "e738bf6a692bdb6a103840a21c304833dc861452",
        "sponsorName": "Kubota Vision Inc"
      },
      {
        "sponsorId": "267bf8e98b940f881544a2ce9ccf3dca31f50926",
        "sponsorName": "Leo Pharma AS"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "XAV-19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Manufacturing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Agreetment signed for first clinical batch of drug as of April 15th",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "XAV19",
    "primaryCompletionDate": "",
    "productId": 392,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections"
    ],
    "sponsors": [
      {
        "sponsorId": "e051009634417c8e337feeb1e73c8c03b2ff106c",
        "sponsorName": "LFB SA"
      },
      {
        "sponsorId": "39f19090c785e55de80ad34b54bc88b1ea610d27",
        "sponsorName": "Kenothera SAS"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Flarin",
    "chemicalName": "lipid ibupfofen",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "lipid_ibupfofen",
    "primaryCompletionDate": "",
    "productId": 573,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "041e7ac45c1c3b265ad83dc490a67c30317c318e",
        "sponsorName": "Kings College London"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Carragelose Inhalation therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Inhalation solution based on iota-carrageenan polymers derived from red seaweed with physical mode of action,Currently approved OTC in EU/Asia & other markets (non-US),Recieved funding for Phase 1 clinical trial and then a proof-of-concept study on viral pneumonia patients",
    "numSites": "",
    "otherPartners": "Austrian Research Promotion Agency",
    "phase": "",
    "preferredName": "Carragelose_Inhalation_therapy",
    "primaryCompletionDate": "",
    "productId": 393,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/",
      "https://media.marinomed.com/22/ea/2a/carragelose-teaser-new-072019.pdf",
      "https://media.marinomed.com/22/ea/2a/carragelose-teaser-new-072019.pdf ; https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/"
    ],
    "sponsors": [
      {
        "sponsorId": "b76c240d33285d07cee07c91c6542ec704092b3e",
        "sponsorName": "Marinomed Biotech AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Engineered trispecific antiviral proteins therapeutic that targets epitopes of viral spikeprotein needed for infection,Currently undergoing expedited preclinical testing for lead candidate,Target of manufactured drug product in Q3 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antiviral",
    "primaryCompletionDate": "",
    "productId": 394,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/",
      "https://www.molecularpartners.com/contact-us/"
    ],
    "sponsors": [
      {
        "sponsorId": "156f730ad2e8e71aaec7362be122a0c821d51c14",
        "sponsorName": "Molecular Partners AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Veyonda",
    "chemicalName": "idronoxil",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Manufacturing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently has IND approval as anti-cancer agent,Currently trying to get FDA approval to pursue clinical study for COVID-19 patients.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "idronoxil",
    "primaryCompletionDate": "",
    "productId": 395,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/noxopharm-investigating-potential-covid-19-treatment/",
      "https://www.drugbank.ca/drugs/DB04915",
      "https://www.biospace.com/employer/545349/noxopharm/",
      "https://www.pharmashots.com/31369/noxopharm-anticipates-the-us-fdas-approval-for-evaluating-veyonda-in-a-clinical-study-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "98fbd4c7c935e48e7246ffa9696377e27973373d",
        "sponsorName": "Noxopharm Co"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Peptides",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Ireland"],
    "countryCodes": ["IRL"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Curently using AI platform screen for peptide candidates (Takes 4-5 months)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Peptides",
    "primaryCompletionDate": "",
    "productId": 396,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "de93cb0c4a3bc024e5f42b0cf2117729b320a781",
        "sponsorName": "Nuritas Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "2X-121",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently in Phase 2 clinical trial for ovarian cancer,Started pre-clinical testing at Northern Arizona University as of 04/24/2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "2X121",
    "primaryCompletionDate": "",
    "productId": 397,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://oncologyventure.com/pipeline/2x-121/",
      "https://oncologyventure.com/about-us/",
      "https://www.technologynetworks.com/drug-discovery/news/covid-19-testing-service-center-to-evaluate-promising-drugs-333864 ; https://oncologyventure.com/pipeline/2x-121/",
      "https://www.technologynetworks.com/drug-discovery/news/covid-19-testing-service-center-to-evaluate-promising-drugs-333864"
    ],
    "sponsors": [
      {
        "sponsorId": "7c3734e76aa183a3eb2e24a57c0009a112b44055",
        "sponsorName": "Oncology Ventures AS"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Foipan",
    "chemicalName": "Camostat mesylate",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "joseph.vinetz@yale.edu",
        "name": null,
        "notes": "",
        "phone": "(203) 737-9730",
        "website": ""
      }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently approved in Japan to treat pancreatic inflammation,Currently in Phase 2a clinical trial for COVID-19 patients,Anti-inflammatory properties and shown in vitro virus inhibitory ability",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Camostat_mesylate",
    "primaryCompletionDate": "",
    "productId": 398,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04353284",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.thailandmedical.news/news/coronavirus-drug-research-german-researchers-identify-japanese-drug",
      "-camostat-mesylate-that-could-be-repurposed-to-treat-covid-19",
      "https://clinicaltrials.gov/ct2/show/NCT04353284#contacts",
      "https://www.drugbank.ca/drugs/DB13729",
      "https://clinicaltrials.gov/ct2/show/NCT04353284",
      "https://www.ono.co.jp/eng/about/business_locations.html"
    ],
    "sponsors": [
      {
        "sponsorId": "4c42301126ac99d75b7be429df5e77830bc45d8b",
        "sponsorName": "Ono Pharmaceuticals Inc"
      },
      {
        "sponsorId": "3066c4c7f3115869a60b33c425a7528be9a6e3bf",
        "sponsorName": "Yale University"
      },
      {
        "sponsorId": "7024be22f1d029e9b85014aef3977d4a224b9e27",
        "sponsorName": "Liebniz Institute for Primate Research"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 20 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Vafidemstat",
    "chemicalName": "",
    "conditionOrDisease": "ARDS",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 27 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently in a Phase 2 clinical trial",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Vafidemstat",
    "primaryCompletionDate": "",
    "productId": 399,
    "registryLink": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001618-39",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES",
      "https://www.biospace.com/article/releases/oryzon-to-initiate-escape-a-phase-ii-clinical-trial-to-test-efficacy-of-vafidemstat-in-severely-ill-covid-19-patients/"
    ],
    "sponsors": [
      {
        "sponsorId": "54df2e1eb201b7a6fc15d098af3042d22ffa6dde",
        "sponsorName": "Oryzon Genomics SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 27 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Q Biomed Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Mannin Research,Cyclica",
    "phase": "",
    "preferredName": "Q_Biomed_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 400,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics"
    ],
    "sponsors": [
      {
        "sponsorId": "b275b8324ed9b360015738d5c52283b783d3e511",
        "sponsorName": "Q Biomed Inc"
      },
      {
        "sponsorId": "6369487c22ff53cc21139097558058341e98e631",
        "sponsorName": "Mannin Research"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Recursion Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "this is a dataset,not a therapy",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Recursion_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 401,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.recursionpharma.com/news/rxrx19"
    ],
    "sponsors": [
      {
        "sponsorId": "11fe98d508be31415b00d71b9e4504f2beb1ee7a",
        "sponsorName": "Recursion Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "RTB-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "candidate is an inhibitor of target of rapamycin complex 1 (TORC-1)",
    "numSites": "",
    "otherPartners": "Restorbio stockholders will receive net proceeds from the commercialization",
    "phase": "",
    "preferredName": "RTB101",
    "primaryCompletionDate": "",
    "productId": 402,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020",
      "https://www.restorbio.com/pipeline/",
      "https://www.restorbio.com/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "2afef1b9b3945cdfc232fc3cd9fc8ed8d184003f",
        "sponsorName": "Restorbio Inc"
      },
      {
        "sponsorId": "b284e0fd16c925a93e4f38c453f4c70e7636b223",
        "sponsorName": "Adicet Bio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "RT-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "RT-001 is a chemically stabilized fatty acid",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "RT001",
    "primaryCompletionDate": "",
    "productId": 403,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.retrotope.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "db62040470630e8a5c0d95e03ff88dcb0d440132",
        "sponsorName": "Retrotope Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "NT-300",
    "chemicalName": "Nitazoxanide",
    "conditionOrDisease": "",
    "contact": [
      {
        "email": "matthew.bardin@romark.com",
        "name": null,
        "notes": "",
        "phone": "813-282-8544",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Nitazoxanide",
    "primaryCompletionDate": "",
    "productId": 404,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04343248",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.romark.com/research-development/clinical-trials-covid/",
      "https://www.drugbank.ca/drugs/DB00507",
      "https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "1a4907ea590dbc75efbbb16b2e8f00a1c68f3cf6",
        "sponsorName": "Romark Laboratories LC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "olokizumab,RPH-104",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "in phase 2/3",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "olokizumab_RPH104",
    "primaryCompletionDate": "",
    "productId": 405,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html"
    ],
    "sponsors": [
      {
        "sponsorId": "101d14f6d9ef50bd326177b2fd9683e6cfe02662",
        "sponsorName": "RPharm JSC"
      },
      {
        "sponsorId": "1e8c65f7ae6e1857da235f503ee96eecdfc212b5",
        "sponsorName": "Cromos Pharma LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Cocktail",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "POL-6014",
    "chemicalName": "Ionodelestat",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Cold Spring Harbor Laboratory (CSHL)",
    "phase": "",
    "preferredName": "Ionodelestat",
    "primaryCompletionDate": "",
    "productId": 406,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf",
      "http://www.santhera.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "6e39bc194deb64616e841179d70de0e3e8f6e7ad",
        "sponsorName": "Santhera Pharmaceuticals Holding AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "almitrine",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "almitrine",
    "primaryCompletionDate": "",
    "productId": 574,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "38652628acf1b84b92cad2bea1a82015a920b0c3",
        "sponsorName": "University of Oxford"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antisense oligonucleotides",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "will be using Sarepta\u2019s RNA technology to identify the antisense oligonucleotides",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antisense_oligonucleotides",
    "primaryCompletionDate": "",
    "productId": 407,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "318a3819bc03871596e0a772e1caa9643afd627c",
        "sponsorName": "Sarepta Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Shionogi Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Hokkaido University Research Center for Zoonosis Control",
    "phase": "",
    "preferredName": "Shionogi_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 408,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262",
      "http://www.shionogi.co.jp/en/"
    ],
    "sponsors": [
      {
        "sponsorId": "49af49978e8b9f02c1384c21ddd1c7526817f753",
        "sponsorName": "Shionogi  Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Cynarine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "The company\u2019s artificial intelligence (AI)-based screening technology,SOMAIPRO,was used to discover the inhibitors of 3CL proteases",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Cynarine",
    "primaryCompletionDate": "",
    "productId": 409,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://sombiotech.com/category/news/",
      "https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/"
    ],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "prexasertib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.",
    "numSites": "",
    "otherPartners": "Ewha Woman's University",
    "phase": "",
    "preferredName": "prexasertib",
    "primaryCompletionDate": "",
    "productId": 410,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/drugs/DB12008",
      "https://www.medchemexpress.com/LY2606368.html",
      "https://sombiotech.com/new-therapies-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Xerava",
    "chemicalName": "eravacycline",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 02 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.",
    "numSites": "",
    "otherPartners": "Ewha Woman's University",
    "phase": "",
    "preferredName": "eravacycline",
    "primaryCompletionDate": "",
    "productId": 411,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/drugs/DB12329",
      "https://sombiotech.com/new-therapies-for-covid-19/",
      "https://chemrxiv.org/articles/Fast_Identification_of_Possible_Drug_Treatment_of_Coronavirus_Disease_-19_COVID-19_Through_Computational_Drug_Repurposing_Study/11875446",
      "https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/"
    ],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      },
      {
        "sponsorId": "83cfc31290e69df07985c4197a3d92ab4c6b2d1c",
        "sponsorName": "Tetraphase Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Llama-derived antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Sysvax Inc. is investigating several different COVID-19 vaccine approaches.",
    "numSites": "",
    "otherPartners": "Quacell Biotechnology Co. LTD",
    "phase": "",
    "preferredName": "Llamaderived_antibodies",
    "primaryCompletionDate": "",
    "productId": 412,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches"
    ],
    "sponsors": [
      {
        "sponsorId": "94b9fb08c2b9a96fe640774a647230d6d7a7b34c",
        "sponsorName": "Sysvax Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PPP-003",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Tetra BioPharma aims to have completed pre-clinical stuudies by fall of 2020 and begin human clinical trials in Montreal.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PPP003",
    "primaryCompletionDate": "",
    "productId": 413,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx",
      "https://stockdaymedia.com/tetra-bio-pharma-discusses-development-of-ppp003-drug-for-cytokine-reduction-with-the-stock-day-podcast-tbpmf-may-7-2020/",
      "https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Announces-Drug-Candidate-as-Potential-Therapy-for-Managing-Cytokine-Release-Syndrome/default.aspx"
    ],
    "sponsors": [
      {
        "sponsorId": "d64052c9fc506bd796cd3404142772d1197adf54",
        "sponsorName": "Tetra BioPharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Allorx stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Vitro Biopharma has submitted an IND application and is waiting on results before beginning Phase I human clinical trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Allorx_stem_cells",
    "primaryCompletionDate": "",
    "productId": 414,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/",
      "https://vitrobiopharma.com/vitro-biopharma-2019-ceo-shareholder-letter-record-revenues-leading-to-further-growth-into-2020/",
      "https://vitrobiopharma.com/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "2a124d615112a39893fb8a499cdb57c08486b0e4",
        "sponsorName": "Vitro Diagnostics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VBI-S",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "VBI-S aims to lower blood pressure and oxygenation from septic shock,which is a common cause of death in COVID patients",
    "numSites": "",
    "otherPartners": "Ascendia Pharmaceuticals",
    "phase": "",
    "preferredName": "VBIS",
    "primaryCompletionDate": "",
    "productId": 415,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html",
      "https://clinicaltrials.gov/ct2/show/NCT04257136",
      "https://clinicaltrials.gov/ct2/show/NCT04257136?lead=Vivacelle+Bio&draw=2&rank=1",
      "https://www.businesswire.com/news/home/20190708005192/en/Vivacelle-Bio-Announces-FDA-Clearance-Enroll-Patients",
      "https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1#contacts",
      "https://clinicaltrials.gov/ct2/show/record/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1&view=record"
    ],
    "sponsors": [
      {
        "sponsorId": "96b4ec30be2b8b138d6a097ca033241b0479fed5",
        "sponsorName": "Vivacelle Bio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vyripharm Biopharmaceuticals LLC therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "The drug will combine anti-viral and anti-CB1 antagonist analogues for nuclear medicine imaging applications",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vyripharm_Biopharmaceuticals_LLC_therapeutic",
    "primaryCompletionDate": "",
    "productId": 416,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/",
      "https://www.bioworld.com/COVID19products",
      "https://www.pharmaceuticaldaily.com/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "078da56adc71e2a029154078183324f8f351e10a",
        "sponsorName": "Vyripharm Biopharmaceuticals LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Mesencure",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 19 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "BONUS BioGroup",
    "phase": "",
    "preferredName": "Mesencure",
    "primaryCompletionDate": "",
    "productId": 417,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia",
      "https://www.bonusbiogroup.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "21fffcbea9a29011a432f5076a9bf80e04b86566",
        "sponsorName": "Wize Pharma Inc"
      },
      {
        "sponsorId": "33a0699dc37b7638ed3184d943514267306a6b62",
        "sponsorName": "Bonus Biogroup Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MAPS vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Pneumonia",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Astellas Pharma Inc.",
    "phase": "",
    "preferredName": "MAPS_vaccine",
    "primaryCompletionDate": "",
    "productId": 418,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://affinivax.com/maps-platform/",
      "https://affinivax.com/vaccine-pipeline/",
      "https://www.bioworld.com/articles/434616-affinivax-raises-120m-series-b-to-advance-maps-vaccines-and-immunotherapies",
      "https://labcentral.org/resident-companies/affinivax",
      "https://affinivax.com/about/",
      "https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772",
      "https://www.clinicaltrials.gov/ct2/show/record/NCT03803202?term=ASP3772",
      "https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "d4c4eaf123ba9a0ed44f528ea27f445b3ebffc82",
        "sponsorName": "Affinivax Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Chimigen vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Akshaya's Chimigen vaccine platform is being reappropriated for COVID-19 in combination with Cytovance's GMP insect cell microbial manufacturing platform",
    "numSites": "",
    "otherPartners": "Cytovance Biologics",
    "phase": "",
    "preferredName": "Chimigen_vaccine",
    "primaryCompletionDate": "",
    "productId": 419,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/04/23/2020621/0/en/Cytovance-Biologics-and-Akshaya-Bio-Announce-Collaboration-Agreement-of-Therapeutics-for-Treatment-of-Coronavirus-and-Hepatitis-B-Virus-Infections.html",
      "http://www.akshayabio.com/technology.html",
      "http://www.akshayabio.com/pdf/Akshaya_Overview.pdf",
      "https://www.cytovance.com/news-articles/cytovance-biologics-and-akshaya-bio-announce-collaboration-agreement-of-therapeutics-for-treatment-of-coronavirus-and-hepatitis-b-virus-infections"
    ],
    "sponsors": [
      {
        "sponsorId": "8f43d7087cc0c2a8d9687603029d4f8c7c3e6446",
        "sponsorName": "Akshaya Bio Inc"
      },
      {
        "sponsorId": "66f07a8584ac1fa31540d4786854faf6c4aa3957",
        "sponsorName": "Cytovance Biologics"
      },
      {
        "sponsorId": "979bfa8ba62f21bb1e1f2b82b0e6aeb823504607",
        "sponsorName": "Shenzhen Hepalink Pharmaceutical Group Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Brilacidin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "A defense Protein (HDP)/Defensin-Mimetic drug candidate previously being investigated for inflammatory bowel disease and oral mucositis and Acute Bacterial Skin and Skin Structure Infection,Has antiviral and immunomodulatory/anti-inflammatory and antimicrobial properties,Phase 2 trial completed for other indications",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Brilacidin",
    "primaryCompletionDate": "",
    "productId": 420,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf",
      "http://www.ipharminc.com/stages-of-development"
    ],
    "sponsors": [
      {
        "sponsorId": "1d734ed76d96923533eb179ad68641d15e10b3a1",
        "sponsorName": "Innovation Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PDS02023",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "Leveraging existing Versamune\u00ae platform",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PDS02023",
    "primaryCompletionDate": "",
    "productId": 421,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.pdsbiotech.com/pipeline/overview",
      "https://www.bioworld.com/COVID19products",
      "https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/377-iotechnologynitiatesovelaccineevelopmentrogr20200416"
    ],
    "sponsors": [
      {
        "sponsorId": "e3a55329a850b005a641bf3bda030265211c6969",
        "sponsorName": "PDS Biotechnology Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Adenoviral vector vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Vaccine candidate expected to target the spike protein of SARS-CoV-2,Vaccine technology is based on a novel ReiThera-proprietary simian adenoviral vector with strong immunological potency and low pre-existing immunity in humans",
    "numSites": "",
    "otherPartners": "Leukocare AG,Univercells SA",
    "phase": "",
    "preferredName": "Adenoviral_vector_vaccine",
    "primaryCompletionDate": "",
    "productId": 422,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/",
      "https://www.bioworld.com/COVID19products"
    ],
    "sponsors": [
      {
        "sponsorId": "9b79c8bf08e2131d6f17af795021cda7e20aa3f7",
        "sponsorName": "Reithera Srl"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Candidate to target the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain of the spike (S) protein to generate both T cell responses and virus neutralizing antibodies",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 423,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.scancell.co.uk/product-pipeline",
      "https://www.bioworld.com/COVID19products",
      "https://www.scancell.co.uk/Data/Sites/1/media/publications/news/covid-19-vaccine-programme.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "092bd155058a125cab87c808b5adaf8207b382dd",
        "sponsorName": "Scancell Holdings plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Pathogen-specific aAPC",
    "chemicalName": "",
    "conditionOrDisease": "COVID 19",
    "contact": [
      {
        "email": "c@szgimi.org",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells",
    "numSites": "3",
    "otherPartners": "Shenzhen Third People's Hospital,Shenzhen Second People's Hospital",
    "phase": "1",
    "preferredName": "Pathogenspecific_aAPC",
    "primaryCompletionDate": "Mon, 31 Jul 2023 00:00:00 GMT",
    "productId": 424,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04299724",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.nature.com/articles/d41573-020-00073-5",
      "https://clinicaltrials.gov/ct2/show/NCT04299724"
    ],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sat, 15 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OraPro-COVID-19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "It is a viral vectored adenovirus 5 containing the spike protein DNA from SARS-CoV-2,As of 04/30/2020 they announced successful completion of initial animal safety trials. Website says they'll soon be raising funds for clinical trials and manufacturing. Clinical trials are expected to start in June",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OraProCOVID19",
    "primaryCompletionDate": "",
    "productId": 425,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://invest.stabilitech.com/",
      "https://www.stabilitech.com/",
      "https://www.stabilitech.com/orapro-covid-19/; https://invest.stabilitech.com/; https://www.stabilitech.com/news/",
      "https://www.stabilitech.com/orapro-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "d3558ec7487260af8eeda161f466322bb598e734",
        "sponsorName": "Stabilitech Biopharma Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vivagel,SPL-7013",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Uses dendrimers--not sure how to classify the molecule type,Repurposing the active ingredient (SPL7013) but would come up with new products/formulations for COVID-19 application",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vivagel_SPL7013",
    "primaryCompletionDate": "",
    "productId": 426,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://starpharma.com/news/473",
      "https://starpharma.com/about_us"
    ],
    "sponsors": [
      {
        "sponsorId": "8d39bbb89598527ce93987da7ed5e69cefec828b",
        "sponsorName": "Starpharma Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VLP Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Company is developing recombinant protein vaccine (detailed in this row) as well as a nanobody therapeutic and working to increase the half-life of COVID treatments,CEO says he expects vaccine will be IND-ready in the end of 2020 or early 2021",
    "numSites": "",
    "otherPartners": "Quacell Biotechnology Co. Ltd.",
    "phase": "",
    "preferredName": "VLP_Vaccine",
    "primaryCompletionDate": "",
    "productId": 427,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches"
    ],
    "sponsors": [
      {
        "sponsorId": "94b9fb08c2b9a96fe640774a647230d6d7a7b34c",
        "sponsorName": "Sysvax Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Baculovirus Expression Vector System vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Japan Agency for Medical Research and Development (AMED)",
    "phase": "",
    "preferredName": "Baculovirus_Expression_Vector_System_vaccine",
    "primaryCompletionDate": "",
    "productId": 428,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/",
      "https://www.umnpharma.com/en/aboutus/"
    ],
    "sponsors": [
      {
        "sponsorId": "85a7bc9d8e40313776bed1f5693ea229f6014f09",
        "sponsorName": "UMN Pharma Inc"
      },
      {
        "sponsorId": "49af49978e8b9f02c1384c21ddd1c7526817f753",
        "sponsorName": "Shionogi  Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Ixiaro",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "I don't think they would be using Ixiaro --at least not as-is-- as a COVID vaccine -- change Product Name? Also why I left the New/Repurposed column blank",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ixiaro",
    "primaryCompletionDate": "",
    "productId": 429,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://valneva.com/press-release/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "059f2a3d5a1e49d84849751adc693a806e10964c",
        "sponsorName": "Valneva SE"
      },
      {
        "sponsorId": "8e7b2da49f08d6b67425d83fea0307211169ec91",
        "sponsorName": "Dynavax Technologies Corp"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Pepticrad vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Finland"],
    "countryCodes": ["FIN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "Other",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 22 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "It seems to be focused on tumor immunity rather virus immunity",
    "numSites": "",
    "otherPartners": "Valo Therapeutics",
    "phase": "",
    "preferredName": "Pepticrad_vaccine",
    "primaryCompletionDate": "",
    "productId": 430,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.valotx.com/what-pepticrad",
      "https://cordis.europa.eu/project/id/681219/reporting",
      "https://www.targovax.com/en/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology/ ; https://www.bioworld.com/COVID19products",
      "https://cordis.europa.eu/project/rcn/204117/reporting/en?rcn=4155",
      "https://www.prnewswire.com/news-releases/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology-301044964.html"
    ],
    "sponsors": [
      {
        "sponsorId": "647f2087ef04f50197602c4a93c8cd00e43f1216",
        "sponsorName": "Valo Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 446,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "acd14e0eb640e0edd21f95856232fcef09bac5ff",
        "sponsorName": "Amgen Inc"
      },
      {
        "sponsorId": "41e5fc673f8854b964c241d3e222a9d61b432222",
        "sponsorName": "Adaptive Biotechnologies Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaxipatch vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 01 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "The product is a combination of a new COVID-19 vaccine and new delivery system",
    "numSites": "",
    "otherPartners": "Verndari Inc.",
    "phase": "",
    "preferredName": "Vaxipatch_vaccine",
    "primaryCompletionDate": "",
    "productId": 431,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.verndariinc.com/news/4",
      "https://www.businesswire.com/news/home/20200429005243/en/Verndari-Begins-Preclinical-Testing-COVID-19-Vaccine-University",
      "https://www.ucdavis.edu/coronavirus/news/covid-19-vaccine-patch-delivery-technology-enters-preclinical-testing-uc-davis/",
      "https://www.verndariinc.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "d55c14eadb5f58261f7259e0d7eeaa8926742a23",
        "sponsorName": "Verndari Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Viravaxx Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Viravaxx - Medical University of Vienna",
    "phase": "",
    "preferredName": "Viravaxx_Vaccine",
    "primaryCompletionDate": "",
    "productId": 432,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.genomeweb.com/immunoassays/viravaxx-medical-university-vienna-partnering-covid-19-dx-vaccine-work#.XsAfSGhKg2w",
      "https://www.pharmiweb.com/press-release/2020-04-22/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform-for-immune-diagnosis-and-vaccination-for-covid-19",
      "https://www.lisavienna.at/news/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform/",
      "http://www.viravaxx.eu/company/covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "b49bbd5f20c2dcea7a6b4e32bbe73978f88a8fce",
        "sponsorName": "Viravaxx AG"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Masitinib",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "DL_MEDICALWRITERS@ab-science.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 04 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "AB Science SA",
    "phase": "2",
    "preferredName": "Masitinib",
    "primaryCompletionDate": "",
    "productId": 433,
    "registryLink": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.86537389999999,
        "lng": 2.3010134,
        "locationId": "7b1b16a7b475ee5d1d02c1e9ba2bea3a97d6c07e",
        "name": "3 Avenue George V, 75008 Paris, France",
        "state": "IDF"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7",
      "http://www.ab-science.com/pipeline/masitinib",
      "https://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001635-27-FR",
      "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR"
    ],
    "sponsors": [
      {
        "sponsorId": "789e5231b8f9ca65a7723cb16dd32889a34ed5bc",
        "sponsorName": "AB Science SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 04 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "MRx-4DP0004",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinicaltrials@4dpharmaplc.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 01 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "4D pharma plc",
    "phase": "2",
    "preferredName": "MRx4DP0004",
    "primaryCompletionDate": "Sat, 01 Aug 2020 00:00:00 GMT",
    "productId": 434,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04363372",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "GBR",
        "lat": 53.806631,
        "lng": -1.7966408,
        "locationId": "6b2c245b2632e87c19ef1009ba2d57315c082b20",
        "name": "Duckworth Ln, Bradford BD9 6RJ, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.4dpharmaplc.com/en/developing-science/pipeline",
      "https://clinicaltrials.gov/ct2/show/NCT04363372",
      "https://clinicaltrials.gov/ct2/show/NCT04363372#contacts",
      "https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372"
    ],
    "sponsors": [
      {
        "sponsorId": "cc2e5994616b4b7838fad454261c03059f72adda",
        "sponsorName": "4D Pharma plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 01 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ATYR-1923",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 21 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "aTyr Pharma Inc.",
    "phase": "",
    "preferredName": "ATYR1923",
    "primaryCompletionDate": "",
    "productId": 435,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-phase-2-study-atyr1923-covid-19-patients",
      "https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html",
      "https://pipelinereview.com/index.php/2020042274397/Antibodies/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html"
    ],
    "sponsors": [
      {
        "sponsorId": "9fe0e590c2f59e3993488b50e1454cf4b33f89cc",
        "sponsorName": "Atyr Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PH-94B",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "VistaGen Therapeutics",
    "phase": "",
    "preferredName": "PH94B",
    "primaryCompletionDate": "",
    "productId": 436,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include",
      "https://www.vistagen.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "ed125bf42550b194df6aae1e7e4306bf089a81c5",
        "sponsorName": "Vistagen Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Cymerus",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "Phase 1",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 08 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Cynata Therapeutics",
    "phase": "",
    "preferredName": "Cymerus",
    "primaryCompletionDate": "",
    "productId": 437,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/",
      "https://www.cynata.com/about-cymerus",
      "https://www.cynata.com/",
      "https://www.atsjournals.org/doi/abs/10.1164/rccm.201911-2143OC"
    ],
    "sponsors": [
      {
        "sponsorId": "e0209d6491b3ecdcf4e0f1ab73af91ca49a735f9",
        "sponsorName": "Cynata Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "7HP-349",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "7 Hills Pharma",
    "phase": "",
    "preferredName": "7HP349",
    "primaryCompletionDate": "",
    "productId": 438,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://drug-dev.com/7-hills-pharma-announces-covid-19-vaccine-program-targeting-at-risk-elderly/",
      "https://www.bio.org/events/bio-digital/sessions/677987",
      "http://www.7hillspharma.com/",
      "https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html/",
      "https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html"
    ],
    "sponsors": [
      {
        "sponsorId": "a3b71c8e66306bb94d3f940d89f1664a0561c909",
        "sponsorName": "7 Hills Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Plasma therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "CoVIg-19 Plasma Alliance",
    "phase": "",
    "preferredName": "Plasma_therapy",
    "primaryCompletionDate": "",
    "productId": 439,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/",
      "https://www.covig-19plasmaalliance.org/en-us#recruitment",
      "https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-interview-toni-hoover-covig-alliance"
    ],
    "sponsors": [
      {
        "sponsorId": "4fb6f98d06346dfb8480801ffdeb277e7bf9a142",
        "sponsorName": "Adma Biologics Inc"
      },
      {
        "sponsorId": "d57dd60076a98933462c35466d4808237238cb98",
        "sponsorName": "Biopharma Plasma LLC"
      },
      {
        "sponsorId": "fb88543fd60aa16c3c184e6208739bc678ea7909",
        "sponsorName": "GC Pharma"
      },
      {
        "sponsorId": "fdcec5fc0acc497097b5595f555306625de122b3",
        "sponsorName": "Sanquin"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Ampligen",
    "chemicalName": "rintatolimod",
    "conditionOrDisease": "SARS Coronavirus 2 Infection,Malignant Neoplasm",
    "contact": [
      {
        "email": "brahm.segal@roswellpark.org",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "rintatolimod",
    "primaryCompletionDate": "Sun, 06 Jun 2021 00:00:00 GMT",
    "productId": 440,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04379518",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Buffalo",
        "country": "USA",
        "lat": 42.8986822,
        "lng": -78.86464830000001,
        "locationId": "ed4c418c9277fdcbe7d1a594358313e88affbccf",
        "name": "665 Elm St, Buffalo, NY 14203, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://adisinsight.springer.com/drugs/800001203",
      "https://aidsinfo.nih.gov/drugs/530/rintatolimod/0/professional",
      "https://www.clinicaltrials.gov/ct2/show/NCT04379518?term=rintatolimod&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1",
      "https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "a5d57560d2358d025ed56eb6ac56526d88680140",
        "sponsorName": "Aim Immunotech Inc"
      },
      {
        "sponsorId": "2e24540b50be00a931dccd241b0636b9266f04e9",
        "sponsorName": "GP Pharma SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 30 Jun 2021 00:00:00 GMT",
    "studyStartDate": "Sat, 30 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "NK1R,MSC",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "NK1R_MSC",
    "primaryCompletionDate": "",
    "productId": 441,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "c9db829f16ef51a61f3cd081ad98c89a77816915",
        "sponsorName": "Biocardia Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CB-5064",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 05 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CB5064",
    "primaryCompletionDate": "",
    "productId": 442,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory",
      "https://www.biospace.com/article/releases/cohbar-to-target-covid-19-associated-acute-respiratory-distress-syndrome-ards-with-its-apelin-receptor-agonist-peptidespreclinical-testing-of-cb5064-analogs-initiated-in-ards/"
    ],
    "sponsors": [
      {
        "sponsorId": "afe0ce46a6b36052788fe265d4169a7e91f11c15",
        "sponsorName": "Cohbar Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DW-2008",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DW2008",
    "primaryCompletionDate": "",
    "productId": 443,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity"
    ],
    "sponsors": [
      {
        "sponsorId": "0ea71c946179e2be0e9be90836aebd96833546ef",
        "sponsorName": "Dongwha Pharmaceutical Co Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "EDP-1815",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "EDP1815",
    "primaryCompletionDate": "",
    "productId": 444,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://evelobio.com/portfolio/"
    ],
    "sponsors": [
      {
        "sponsorId": "f550d0dbaee63bc003995e8c7af74aca187e11a2",
        "sponsorName": "Evelo Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antiviral",
    "primaryCompletionDate": "",
    "productId": 447,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first",
      "https://ir.anixa.com/press-releases/detail/947/anixa-biosciences-and-ontochem-announce-collaboration-to"
    ],
    "sponsors": [
      {
        "sponsorId": "360810fb2f49838a5afb9da083af7b2c1effa9be",
        "sponsorName": "Anixa Bioscience Inc"
      },
      {
        "sponsorId": "a4ef2f5ab85094f28d88aa3073d73426d3009319",
        "sponsorName": "Ontochem GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Knockdown Coronavirus",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 06 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Knockdown_Coronavirus",
    "primaryCompletionDate": "",
    "productId": 448,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html",
      "https://www.bioworld.com/COVID19products"
    ],
    "sponsors": [
      {
        "sponsorId": "cd1a1a7e1700bd67f76dbb0979cfb550367890c2",
        "sponsorName": "Aum Lifetech Inc"
      },
      {
        "sponsorId": "2f3a07259231f646a8c98cf47cd635cd2837ff4e",
        "sponsorName": "Aum Biotech LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "bacTRL-Spike",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "mistin.wilkinson@bcchr.ubc.ca; jill.mutch@iwk.nshealth.ca",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "bacTRLSpike",
    "primaryCompletionDate": "Tue, 31 Aug 2021 00:00:00 GMT",
    "productId": 449,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04334980",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "San Diego",
        "country": "USA",
        "lat": 32.7555263,
        "lng": -117.1658249,
        "locationId": "41010c2bdcd53654b54ff977d63ef905e8ef11bf",
        "name": "220 Dickinson St suite a, San Diego, CA 92103, USA",
        "state": "CA"
      },
      {
        "city": "Vancouver",
        "country": "CAN",
        "lat": 49.2456824,
        "lng": -123.1257129,
        "locationId": "854207b5231251d92aa4c83670af91e63e06892b",
        "name": "938 W 28th Ave, Vancouver, BC V5Z 4H4, Canada",
        "state": "BC"
      },
      {
        "city": "Halifax",
        "country": "CAN",
        "lat": 44.6374778,
        "lng": -63.58356850000001,
        "locationId": "a4648c870ed00d7927bae60e080250400d4a103a",
        "name": "5980 University Ave #5850, Halifax, NS B3K 6R8, Canada",
        "state": "NS"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.symvivo.com/covid-19",
      "https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "e67cd6e6e2d90ce2d60b99c1798176c943a02d7e",
        "sponsorName": "Symvivo Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Recombinant vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Mexico"],
    "countryCodes": ["MEX"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Laboratorios Liomont",
    "phase": "",
    "preferredName": "Recombinant_vaccine",
    "primaryCompletionDate": "",
    "productId": 450,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue"
    ],
    "sponsors": [
      {
        "sponsorId": "ae65368e5dda7ac06191005363e4844d4740b0c1",
        "sponsorName": "Autonomous University of Mexico"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Queretero Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Mexico"],
    "countryCodes": ["MEX"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "National Council of Science and Technology",
    "phase": "",
    "preferredName": "Queretero_Vaccine",
    "primaryCompletionDate": "",
    "productId": 451,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine"
    ],
    "sponsors": [
      {
        "sponsorId": "0bbca0d5754c5267ed051d9e9e225d44a2afcb2d",
        "sponsorName": "Autonomous University of Queretero"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "CpG 1018",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "jszfc@vip.sina.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Dynavax,Sinovac Biotech Ltd.",
    "phase": "1",
    "preferredName": "CpG_1018",
    "primaryCompletionDate": "Thu, 13 Aug 2020 00:00:00 GMT",
    "productId": 452,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04352608",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Xuzhou",
        "country": "CHN",
        "lat": 33.912597,
        "lng": 117.941563,
        "locationId": "12a6e3f42d23f4606cbe55d066b8d2a91e354385",
        "name": "Suining, Xuzhou, Jiangsu, China",
        "state": "Jiangsu"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus",
      "https://www.dynavax.com/science/cpg-1018/",
      "https://www.dynavax.com/",
      "https://www.fiercebiotech.com/biotech/dynavax-sinovac-latest-to-ally-a-covid-19-vaccine",
      "https://www.fdanews.com/articles/196715-sinovac-begins-phase-1-trial-of-its-covid-19-vaccine-candidate",
      "https://clinicaltrials.gov/ct2/show/NCT04352608"
    ],
    "sponsors": [
      {
        "sponsorId": "8e7b2da49f08d6b67425d83fea0307211169ec91",
        "sponsorName": "Dynavax Technologies Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 16 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Daiichi Sankyo,University of Tokyo",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 453,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.daiichisankyo.com/about_us/responsibility/csr/support/index.html",
      "https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
      "https://www.daiichisankyo.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "0bd3e0565493c03d25691fe59c64e75df50c6269",
        "sponsorName": "Daiichi Sankyo"
      },
      {
        "sponsorId": "ab1e8ad3d379bcd134e4e3f47f828591f21bca7b",
        "sponsorName": "University of Tokyo"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Viral Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "German Center for Infection Research",
    "phase": "",
    "preferredName": "Viral_Vector_Vaccine",
    "primaryCompletionDate": "",
    "productId": 454,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines",
      "https://www.dzif.de/en/dzif-focuses-sars-cov-2-research"
    ],
    "sponsors": [
      {
        "sponsorId": "43c5ca205d979b4627d9786a10dbcc7a28efe620",
        "sponsorName": "German Center for Infection Research"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "TerraCoV2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Oragenics Inc.",
    "phase": "",
    "preferredName": "TerraCoV2",
    "primaryCompletionDate": "",
    "productId": 455,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated"
    ],
    "sponsors": [
      {
        "sponsorId": "525e613a8f2932fe3f0c17345916ceb457584531",
        "sponsorName": "Noachis Terra Inc"
      },
      {
        "sponsorId": "37d795f226c583b0923370765712cfb305ea7951",
        "sponsorName": "Oragenics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CORVax12",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "OncoSec",
    "phase": "",
    "preferredName": "CORVax12",
    "primaryCompletionDate": "",
    "productId": 456,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19",
      "https://idataresearch.com/oncosec-and-inovio-pursuing-phase-1-clinical-trials/"
    ],
    "sponsors": [
      {
        "sponsorId": "870027d79725ce8aba9d63e3e3e414b41ab3e6a9",
        "sponsorName": "Oncosec Medical Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Ose Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 05 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "OSE Immunotherapeutics",
    "phase": "",
    "preferredName": "Ose_Vaccine",
    "primaryCompletionDate": "",
    "productId": 457,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf",
      "https://ose-immuno.com/en/"
    ],
    "sponsors": [
      {
        "sponsorId": "b0c93e38a17b3b588585e151d3fc7aad0ba591b1",
        "sponsorName": "Ose Immunotherapeutics SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Lineage Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 05 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "California Institute for Regenerative Medicine",
    "phase": "",
    "preferredName": "Lineage_Vaccine",
    "primaryCompletionDate": "",
    "productId": 458,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell",
      "https://lineagecell.com/",
      "http://www.pharmaceuticaldaily.com/lineage-cell-therapeutics-to-apply-allogeneic-dendritic-cell-therapy-program-to-covid-19-vaccine-development-2/"
    ],
    "sponsors": [
      {
        "sponsorId": "af5704392ebc92bfa0587cb489a242a1ecec053a",
        "sponsorName": "Lineage Cell Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Zyus Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 07 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "ZYUS Life Sciences Inc.,VIDO-InterVac",
    "phase": "",
    "preferredName": "Zyus_Vaccine",
    "primaryCompletionDate": "",
    "productId": 459,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx",
      "https://www.vido.org/",
      "https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/zyus-collaborates-with-usasks-vido-intervac-to-develop-a-plant-based-vaccine-for-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "f0c03914ca02d3e8f2291af133d7cfda224953cd",
        "sponsorName": "Zyus Life Sciences Inc"
      },
      {
        "sponsorId": "7b2a555245dac6b0ae7cb9dd0f33a50d08853697",
        "sponsorName": "VIDOIntervac"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "COVID-19 Immunoglobulin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "COVID19_Immunoglobulin",
    "primaryCompletionDate": "",
    "productId": 460,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "086ded7bc6410c1971ea41cc7b102bd61b78be5d",
        "sponsorName": "CSL Behring Australia"
      },
      {
        "sponsorId": "c51b564ec05a307bbc3b22a4b89f9c032a847dca",
        "sponsorName": "CSL Limited"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Opdivo",
    "chemicalName": "nivolumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "gggjerry@gmail.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Hong Kong"],
    "countryCodes": ["HKG"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 22 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "nivolumab",
    "primaryCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "productId": 461,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04356508",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "HKG",
        "lat": 22.2829989,
        "lng": 114.1370848,
        "locationId": "b283b8aee4ddb086d15c02c26bb8316ba2ad501a",
        "name": "Pok Fu Lam, Hong Kong",
        "state": "Hong Kong Island"
      }
    ],
    "sources": [
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#",
      "https://clinicaltrials.gov/ct2/show/NCT04356508",
      "https://www.drugbank.ca/drugs/DB09035",
      "https://clinicaltrials.gov/ct2/show/NCT04356508#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "6b014b07406a291e8e325b2a212ac65562a16644",
        "sponsorName": "University of Hong Kong"
      },
      {
        "sponsorId": "45cb448ccda5ba5bd7b24c304ad43117f0f1545f",
        "sponsorName": "BMS"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 31 Aug 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 22 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "AiRuiKa",
    "chemicalName": "camrelizumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "camrelizumab",
    "primaryCompletionDate": "Thu, 30 Apr 2020 00:00:00 GMT",
    "productId": 462,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04268537",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.hrs.com.cn/hren/products_pipeline_oncology.html",
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#",
      "https://www.drugbank.ca/drugs/DB14776",
      "https://clinicaltrials.gov/ct2/show/NCT04268537"
    ],
    "sponsors": [
      {
        "sponsorId": "0c5c1dfd859ef4ba55b56530a5b4f12cf700ccc4",
        "sponsorName": "Wuhan Jinyintan Hospital"
      },
      {
        "sponsorId": "67daca15db7dda94d46b570fc990f1a5b1d276a7",
        "sponsorName": "Jiangsu HengRui Medicine Co"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 31 Oct 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 10 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "United Kindom  Government",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 463,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment",
      "https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "9b2652ee65b8f7ac2fbc009851b6ef7d2faac03a",
        "sponsorName": "Chelsea and Westminster Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IgY-110",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IgY110",
    "primaryCompletionDate": "",
    "productId": 566,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "4391ec9967da9a1a57bf2f12cfc8f17f209f34c2",
        "sponsorName": "IGY Life Sciences"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 464,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.businesswire.com/news/home/20200519005826/en/Prellis-Biologics-Generates-300-Human-Antibodies-Bind",
      "https://www.prellisbio.com/covid"
    ],
    "sponsors": [
      {
        "sponsorId": "090447dc6c4ec30f0734d643a191fd594b173d68",
        "sponsorName": "Prellis Biologics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 465,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.businesswire.com/news/home/20200406005284/en/Ligand-Corporate-Update-Announces-6th-Date-Quarter",
      "https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential"
    ],
    "sponsors": [
      {
        "sponsorId": "84ed689e0ab14d5e34784cc4f76cde94a060206f",
        "sponsorName": "Ligand Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Costa Rica"],
    "countryCodes": ["CRI"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 466,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#",
      "https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/"
    ],
    "sponsors": [
      {
        "sponsorId": "956cde5aa334fee5ea41b8ef8bfcd942e83008fc",
        "sponsorName": "Costa Rican Social Security Fund"
      },
      {
        "sponsorId": "b079ef3c1beae82abe8140f4ec81a68a9474e117",
        "sponsorName": "University of Cost Rica"
      },
      {
        "sponsorId": "23956132e25e7933f285e2c95f701acdc8fa75b3",
        "sponsorName": "Clodomiro Picado Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MEDI3506",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 28 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MEDI3506",
    "primaryCompletionDate": "",
    "productId": 467,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html",
      "https://adisinsight.springer.com/drugs/800049222"
    ],
    "sponsors": [
      {
        "sponsorId": "bb9ed07e215d6bebb274790c7ee0711a0da9f41e",
        "sponsorName": "AstraZeneca"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "BTK inhibitor",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "BTK_inhibitor",
    "primaryCompletionDate": "",
    "productId": 468,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html",
      "https://www.drugbank.ca/drugs/DB11703"
    ],
    "sponsors": [
      {
        "sponsorId": "bb9ed07e215d6bebb274790c7ee0711a0da9f41e",
        "sponsorName": "AstraZeneca"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Octagam",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "ctgov@clinicalresearchmgt.com",
        "name": null,
        "notes": "",
        "phone": "8663371868",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Octagam",
    "primaryCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "productId": 469,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04400058",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.businesswire.com/news/home/20200416005144/en/New-COVID-19-Clinical-Trial-Supported-Octapharma-USA",
      "https://www.drugbank.ca/drugs/DB00028",
      "https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "01f8847bee12adc194325c04b865f80d3f338fed",
        "sponsorName": "Octapharma USA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Immunoglobulin from Immunized Sheep",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Immunoglobulin_from_Immunized_Sheep",
    "primaryCompletionDate": "",
    "productId": 470,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710"
    ],
    "sponsors": [
      {
        "sponsorId": "f9a892adb6624b2c054ff75c09fe66c94b05ec8a",
        "sponsorName": "Public Health England"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 471,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.prnewswire.com/news-releases/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies-301045039.html",
      "https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/"
    ],
    "sponsors": [
      {
        "sponsorId": "3cf57c67576a69c157365187bca4fa4cae4548a6",
        "sponsorName": "Ablexis"
      },
      {
        "sponsorId": "6d78600d48c5ae40de6b7121b4357fa753958e26",
        "sponsorName": "AlivaMab Discovery Services"
      },
      {
        "sponsorId": "a3fae7815b10a27a8b4c46a4e980cc12bef7bc77",
        "sponsorName": "Berkeley Lights Collaborative"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "primaryCompletionDate": "",
    "productId": 472,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single"
    ],
    "sponsors": [
      {
        "sponsorId": "1753a313e0d479ef0ea4b9cb41d499dc5703aee5",
        "sponsorName": "Abcore"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Prezista",
    "chemicalName": "darunavir",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "luhongzhou@fudan.edu.cn",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "darunavir",
    "primaryCompletionDate": "Mon, 31 Aug 2020 00:00:00 GMT",
    "productId": 473,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04252274",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 30.791749,
        "lng": 121.341627,
        "locationId": "c78777c44bdd2ce748dd6682040a7946dcfb69f7",
        "name": "2901 Caolang Hwy, Jinshan Qu, Shanghai Shi, China",
        "state": "Shanghai Shi"
      }
    ],
    "sources": [
      "https://medcitynews.com/2020/04/jj-hiv-drug-already-in-covid-19-clinical-trials-flunks-in-vitro-study/",
      "https://www.drugbank.ca/drugs/DB01264",
      "https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      },
      {
        "sponsorId": "667987d4de01dd23efc5563684db4e2117b5d910",
        "sponsorName": "Janssen"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 30 Jan 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Levovir",
    "chemicalName": "clevudine",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "bk.E106@bukwang.co.kr",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "clevudine",
    "primaryCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "productId": 474,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04347915",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "KOR",
        "lat": 37.4922173,
        "lng": 126.8849478,
        "locationId": "2910435e4a2d5c99873ae00afd0fc64189b15ca6",
        "name": "148 Gurodong-ro, Guro-dong, Guro-gu, Seoul, South Korea",
        "state": "Seoul"
      }
    ],
    "sources": [
      "http://www.koreabiomed.com/news/articleView.html?idxno=8010",
      "https://en.yna.co.kr/view/AEN20200414006700320",
      "https://www.drugbank.ca/drugs/DB06683",
      "https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "9560701a2c38713238ec1009dbb4dcf6fdf36153",
        "sponsorName": "Bukwang Pharm"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 06 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "BTL-tml",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "BTLtml",
    "primaryCompletionDate": "",
    "productId": 475,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.beechtreelabs.com/",
      "https://www.clinicaltrialsarena.com/contractors/contract_research/ncra/pressreleases/press7-5/",
      "https://www.news10.com/news/local-news/president-ceo-of-beech-tree-labs-seeks-fda-approval-for-tml-covid-19-treatment/"
    ],
    "sponsors": [
      {
        "sponsorId": "726053ab8e4d96ab800e4589733fc5b6baaf03e3",
        "sponsorName": "Beech Tree Labs"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "emetine hydrochloride",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "emetine_hydrochloride",
    "primaryCompletionDate": "",
    "productId": 476,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/"
    ],
    "sponsors": [
      {
        "sponsorId": "5ad93754d0bd669c3270518802ff29ac3e9c49f5",
        "sponsorName": "Acer Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "AT-527",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "AteaClinicalTrials@ateapharma.com",
        "name": null,
        "notes": "",
        "phone": "888-481-1607",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 20 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "10",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "AT527",
    "primaryCompletionDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "productId": 477,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04396106",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Sacramento",
        "country": "USA",
        "lat": 38.5815719,
        "lng": -121.4943996,
        "locationId": "6a8fb560eeeb971ee46d176015f72421fe47d36c",
        "name": "Sacramento, CA, USA",
        "state": "CA"
      },
      {
        "city": "San Diego",
        "country": "USA",
        "lat": 32.715738,
        "lng": -117.1610838,
        "locationId": "e69afe49003da83f4e121221abc38c82957c0f69",
        "name": "San Diego, CA, USA",
        "state": "CA"
      },
      {
        "city": "Chicago",
        "country": "USA",
        "lat": 41.8781136,
        "lng": -87.6297982,
        "locationId": "1358747dae42e761f66bfb18bf4744d516420eda",
        "name": "Chicago, IL, USA",
        "state": "IL"
      },
      {
        "city": "Baltimore",
        "country": "USA",
        "lat": 39.2903848,
        "lng": -76.6121893,
        "locationId": "809a5344ec2307a957d2d12f156ff66d5c7e0941",
        "name": "Baltimore, MD, USA",
        "state": "MD"
      },
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3600825,
        "lng": -71.0588801,
        "locationId": "2f33f76d23ca7441043d850a3e0135dadb3500df",
        "name": "Boston, MA, USA",
        "state": "MA"
      },
      {
        "city": "St. Louis",
        "country": "USA",
        "lat": 38.6270025,
        "lng": -90.19940419999999,
        "locationId": "1999c959446cc6747f61ad1c0497501dc8566684",
        "name": "St. Louis, MO, USA",
        "state": "MO"
      },
      {
        "city": "Cincinnati",
        "country": "USA",
        "lat": 39.1031182,
        "lng": -84.5120196,
        "locationId": "c8097e1dd65a2c9077a4a2cbe03e29dfd6720b8b",
        "name": "Cincinnati, OH, USA",
        "state": "OH"
      },
      {
        "city": "Cleveland",
        "country": "USA",
        "lat": 41.49932,
        "lng": -81.6943605,
        "locationId": "39a244f096bacd3cdccc277281ff54dca2f24ffe",
        "name": "Cleveland, OH, USA",
        "state": "OH"
      },
      {
        "city": "Columbus",
        "country": "USA",
        "lat": 39.9611755,
        "lng": -82.99879419999999,
        "locationId": "e2a569ceb3776a508735c1f33dfdc27137f2cad1",
        "name": "Columbus, OH, USA",
        "state": "OH"
      },
      {
        "city": "Charleston",
        "country": "USA",
        "lat": 32.7764749,
        "lng": -79.93105120000001,
        "locationId": "93d7144903426fc046ed9a601af3d95880906c44",
        "name": "Charleston, SC, USA",
        "state": "SC"
      }
    ],
    "sources": [
      "https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html",
      "https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "1af131cb41f699e8e340d1a93623b584af0336e5",
        "sponsorName": "Atea Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 20 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 20 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Astrotem-V",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 1",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 17 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AstrotemV",
    "primaryCompletionDate": "",
    "productId": 478,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "http://www.theasian.asia/archives/107878",
      "http://en.kabar.kg/news/stem-cell-treatment-to-become-legal-in-south-korea/"
    ],
    "sponsors": [
      {
        "sponsorId": "684afe67ec273a6d3fa849859049d84db2437fbe",
        "sponsorName": "Naturecell"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Duke-NUS Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Singapore"],
    "countryCodes": ["SGP"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DukeNUS_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 479,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "341b155328dbb89ef8d5f50acdfff58dffee22a5",
        "sponsorName": "DukeNUS Medical School"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "Dexamethasone",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "recoverytrial@ndph.ox.ac.uk",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Dexamethasone",
    "primaryCompletionDate": "",
    "productId": 480,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04381936",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "GBR",
        "lat": 51.7516232,
        "lng": -1.2151574,
        "locationId": "f3aa08196e932ff4604e33e540c2b8111d4ee7e3",
        "name": "University of Oxford Richard Doll Building, Old Road Campus, Headington, Oxford OX3 7LF, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://www.recoverytrial.net/",
      "https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9",
      "https://www.drugbank.ca/drugs/DB01234"
    ],
    "sponsors": [
      {
        "sponsorId": "38652628acf1b84b92cad2bea1a82015a920b0c3",
        "sponsorName": "University of Oxford"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 19 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Alvesco",
    "chemicalName": "ciclesonide",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "ciclesonide",
    "primaryCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "productId": 481,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04377711",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html",
      "https://www.drugbank.ca/drugs/DB01410",
      "https://www.biospace.com/article/releases/covis-pharma-b-v-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19/",
      "https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2"
    ],
    "sponsors": [
      {
        "sponsorId": "531c7eed34b2778b17fc1ab00a5e3e9417e11f4e",
        "sponsorName": "Covis Pharma BV"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 26 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PegiHep",
    "chemicalName": "Pegylated Interferon alpha-2b",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Pegylated_Interferon_alpha2b",
    "primaryCompletionDate": "",
    "productId": 482,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7",
        "sponsorName": "Zydus Cadila"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Novaferon,Nova",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "gongguozhong@csu.edu.cn",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "Novaferon_Nova",
    "primaryCompletionDate": "",
    "productId": 483,
    "registryLink": "http://www.chictr.org.cn/showprojen.aspx?proj=48809",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Changsha",
        "country": "CHN",
        "lat": 28.301619,
        "lng": 113.005226,
        "locationId": "deda59102d1c147ee0b78c36f0d1c2a9902224aa",
        "name": "Kaifu District, Changsha, Changsha, Hunan, China",
        "state": "Hunan"
      },
      {
        "city": "Changsha Shi",
        "country": "CHN",
        "lat": 28.187002,
        "lng": 112.993998,
        "locationId": "7645159dfebc970bca857b952524df9b1da597f3",
        "name": "139 Renmin Middle Rd, Yuan Jia Ling Shang Quan, Furong Qu, Changsha Shi, Hunan Sheng, China",
        "state": "Hunan Sheng"
      }
    ],
    "sources": [
      "https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1",
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.f7ta2pb1z0as",
      "http://www.chictr.org.cn/showprojen.aspx?proj=48809"
    ],
    "sponsors": [
      {
        "sponsorId": "dfbc81449bec6db056d375ff6145db5fecbe6806",
        "sponsorName": "First Affiliated Hosptial of Zhejiang University Medical School"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 03 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Rebif",
    "chemicalName": "interferon beta-1a",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "florence.ader@chu-lyon.fr; helene.esperou@inserm.fr",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "34",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "interferon_beta1a",
    "primaryCompletionDate": "Mon, 20 Mar 2023 00:00:00 GMT",
    "productId": 484,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04315948",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Amiens",
        "country": "FRA",
        "lat": 49.8728114,
        "lng": 2.2558589,
        "locationId": "bf7037895fa37045cc1d246e9c213b9030c33569",
        "name": "1 Rue du Professeur Christian Cabrol, 80054 Amiens, France",
        "state": "Hauts-de-France"
      },
      {
        "city": "Ars-Laquenexy",
        "country": "FRA",
        "lat": 49.0830952,
        "lng": 6.242574299999999,
        "locationId": "4a4955975d8e978faf670ee3b0b9eb8edd42e4a9",
        "name": "1 All\u00e9e du Ch\u00e2teau, 57530 Ars-Laquenexy, France",
        "state": "Grand Est"
      },
      {
        "city": "Besan\u00e7on",
        "country": "FRA",
        "lat": 47.22530889999999,
        "lng": 5.962617799999999,
        "locationId": "7c8365444bbf988a110a47bc3b81f717899a42db",
        "name": "3 Boulevard Alexandre Fleming, 25000 Besan\u00e7on, France",
        "state": "Bourgogne-Franche-Comt\u00e9"
      },
      {
        "city": "Bordeaux",
        "country": "FRA",
        "lat": 44.829016,
        "lng": -0.6061928,
        "locationId": "7bd0132277a59b1bff8a20a8188ca44bc11a9089",
        "name": "Place Am\u00e9lie Raba L\u00e9on, 33000 Bordeaux, France",
        "state": "Nouvelle-Aquitaine"
      },
      {
        "city": "Cr\u00e9teil",
        "country": "FRA",
        "lat": 48.7980441,
        "lng": 2.4517989,
        "locationId": "3c206c57662f84b33f59bfcc4a063e27f4540dd8",
        "name": "51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010 Cr\u00e9teil, France",
        "state": "IDF"
      },
      {
        "city": "Dijon",
        "country": "FRA",
        "lat": 47.3213803,
        "lng": 5.069147099999999,
        "locationId": "60fc8ab568164272586c9166a8429170fbf7f532",
        "name": "2 Boulevard du Mar\u00e9chal de Lattre de Tassigny, 21000 Dijon, France",
        "state": "Bourgogne-Franche-Comt\u00e9"
      },
      {
        "city": "Le Kremlin-Bic\u00eatre",
        "country": "FRA",
        "lat": 48.8105963,
        "lng": 2.3522501,
        "locationId": "53666de6b34153f63aaa6ec835f4d70da50cd483",
        "name": "78 Rue du G\u00e9n\u00e9ral Leclerc, 94270 Le Kremlin-Bic\u00eatre, France",
        "state": "IDF"
      },
      {
        "city": "La Tronche",
        "country": "FRA",
        "lat": 45.202285,
        "lng": 5.741472,
        "locationId": "e1d5331a1a4e3cf18d59c43d96c2f4227f3d6f0d",
        "name": "Avenue Maquis du Gr\u00e9sivaudan, 38700 La Tronche, France",
        "state": "Auvergne-Rh\u00f4ne-Alpes"
      },
      {
        "city": "Lille",
        "country": "FRA",
        "lat": 50.6108999,
        "lng": 3.0347031,
        "locationId": "f31e0ad968a9f68465571a07dad44505de60c4b6",
        "name": "2 Avenue Oscar Lambret, 59000 Lille, France",
        "state": "Hauts-de-France"
      },
      {
        "city": "Lyon",
        "country": "FRA",
        "lat": 45.7608649,
        "lng": 4.8315594,
        "locationId": "c9df27b2f4166c117326abd61e3049ec3006ec74",
        "name": "3 Quai des C\u00e9lestins, 69002 Lyon, France",
        "state": "Auvergne-Rh\u00f4ne-Alpes"
      },
      {
        "city": "Montpellier",
        "country": "FRA",
        "lat": 43.6315886,
        "lng": 3.8504425,
        "locationId": "61d1c0f30dc2509c4ef78bdfa6544507457b48af",
        "name": "191 Av. du Doyen Gaston Giraud, 34295 Montpellier, France",
        "state": "Occitanie"
      },
      {
        "city": "Mulhouse",
        "country": "FRA",
        "lat": 47.7387331,
        "lng": 7.341206199999999,
        "locationId": "be6b24405468479590077b00d215fe6a2b8638c7",
        "name": "2A Rue du Jura, 68100 Mulhouse, France",
        "state": "Grand Est"
      },
      {
        "city": "Nancy",
        "country": "FRA",
        "lat": 48.6852009,
        "lng": 6.192022,
        "locationId": "74458bbca96a3c3c0498c4a8369d922583d6b71e",
        "name": "29 Avenue du Mar\u00e9chal de Lattre de Tassigny, 54035 Nancy, France",
        "state": "Grand Est"
      },
      {
        "city": "Nantes",
        "country": "FRA",
        "lat": 47.2120313,
        "lng": -1.5543918,
        "locationId": "ba8af3682ca3816fcbb816cdbd6340653462a409",
        "name": "1 Place Alexis-Ricordeau, 44093 Nantes, France",
        "state": "Pays de la Loire"
      },
      {
        "city": "Nice",
        "country": "FRA",
        "lat": 43.7243711,
        "lng": 7.2822826,
        "locationId": "907ee7c61765ebb2c4abcf3ceb44365cb4d411bd",
        "name": "30 Voie Romaine, 06000 Nice, France",
        "state": "Provence-Alpes-C\u00f4te d'Azur"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.8488116,
        "lng": 2.3827263,
        "locationId": "c20bedb6f4c9dc4d3f95b5e45d9a420471f89458",
        "name": "184 Rue du Faubourg Saint-Antoine, 75012 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.8370792,
        "lng": 2.3650429,
        "locationId": "15ab5141675ac102c620babc9f0898807a8197ef",
        "name": "47-83 Boulevard de l'H\u00f4pital, 75013 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.8368937,
        "lng": 2.3402667,
        "locationId": "2b6ca8358d6ab691bf1551d7b643c9dc2892fbcd",
        "name": "27 Rue du Faubourg Saint-Jacques, 75014 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.829771,
        "lng": 2.3103313,
        "locationId": "c9137ae2b24cb1739629919073c52d59b70ff80e",
        "name": "185 Rue Raymond Losserand, 75014 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.83857889999999,
        "lng": 2.2739604,
        "locationId": "56121321e0a8ea226ff778378499d4523d352bcd",
        "name": "20 Rue Leblanc, 75015 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.8986549,
        "lng": 2.3322212,
        "locationId": "883912eaed8fbf7c0774c6eb25e2a1d6ca86c5da",
        "name": "46 Rue Henri Huchard, 75018 Paris, France",
        "state": "IDF"
      },
      {
        "city": "Rennes",
        "country": "FRA",
        "lat": 48.1200595,
        "lng": -1.6950482,
        "locationId": "e875d174fc9af1122c90c7e69b7ea77d9b759c96",
        "name": "2 Rue Henri le Guilloux, 35000 Rennes, France",
        "state": "Bretagne"
      },
      {
        "city": "Saint-Denis",
        "country": "FRA",
        "lat": 48.9335315,
        "lng": 2.3711375,
        "locationId": "7780c3e45cbe2b5f3b818992235148a4cace840d",
        "name": "H\u00f4pital Delafontaine, 93200 Saint-Denis, France",
        "state": "IDF"
      },
      {
        "city": "Saint-Mand\u00e9",
        "country": "FRA",
        "lat": 48.843381,
        "lng": 2.4253137,
        "locationId": "e7c0b8a45763a66e636bdee26b8ce1a37929c1bc",
        "name": "69 Avenue de Paris, 94160 Saint-Mand\u00e9, France",
        "state": "IDF"
      },
      {
        "city": "Saint-Priest-en-Jarez",
        "country": "FRA",
        "lat": 45.4820275,
        "lng": 4.3629634,
        "locationId": "655c74b46a6764887658d48b11ec4b95824d16c1",
        "name": "Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez, France",
        "state": "Auvergne-Rh\u00f4ne-Alpes"
      },
      {
        "city": "Strasbourg",
        "country": "FRA",
        "lat": 48.5929237,
        "lng": 7.707166699999999,
        "locationId": "bfca7c9d2a3451bd820c6880370894eb6f481372",
        "name": "1 Avenue Moli\u00e8re, 67200 Strasbourg, France",
        "state": "Grand Est"
      },
      {
        "city": "Toulouse",
        "country": "FRA",
        "lat": 43.5995462,
        "lng": 1.4369245,
        "locationId": "f48dce58b557845b939417d2d00eff07590d3337",
        "name": "9, 9 Place Lange, 31300 Toulouse, France",
        "state": "Occitanie"
      },
      {
        "city": "Tourcoing",
        "country": "FRA",
        "lat": 50.724993,
        "lng": 3.16207,
        "locationId": "0d61a2937de3a99b64944b473de8b2ff1f51ca37",
        "name": "59200 Tourcoing, France",
        "state": "Hauts-de-France"
      },
      {
        "city": "Epagny Metz-Tessy",
        "country": "FRA",
        "lat": 45.9338394,
        "lng": 6.1175557,
        "locationId": "4478184b447145ac339bfba57ea871191e0dd388",
        "name": "1 Avenue de l'H\u00f4pital, 74370 Epagny Metz-Tessy, France",
        "state": "Auvergne-Rh\u00f4ne-Alpes"
      }
    ],
    "sources": [
      "https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html",
      "https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "23e976410b2cf3003eb62c734eb8e73702df9f66",
        "sponsorName": "Merck kGaA"
      },
      {
        "sponsorId": "501208e53cef559b699e97764991aad6e3fe9e17",
        "sponsorName": "French Institut National de la Sante et de la Recherche Medicale"
      },
      {
        "sponsorId": "0e1ea407af0902261db76719a57a5c127ea53bfe",
        "sponsorName": "INSERM"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 20 Mar 2023 00:00:00 GMT",
    "studyStartDate": "Sun, 22 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Micardis",
    "chemicalName": "telmisartan",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "shikuma@hawaii.edu; ogataara@hawaii.edu",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "telmisartan",
    "primaryCompletionDate": "Wed, 30 Jun 2021 00:00:00 GMT",
    "productId": 485,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04360551",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Honolulu",
        "country": "USA",
        "lat": 21.296939,
        "lng": -157.8171118,
        "locationId": "6550d85c47f194df3b9aa1a00ae8f8d51f9be7ba",
        "name": "2500 Campus Rd, Honolulu, HI 96822, USA",
        "state": "HI"
      }
    ],
    "sources": [
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36",
      "https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2",
      "https://www.drugbank.ca/drugs/DB00966"
    ],
    "sponsors": [
      {
        "sponsorId": "fddf7abcdfe84560834e2538e757cf92b17c723e",
        "sponsorName": "Boehringer Ingelheim"
      },
      {
        "sponsorId": "2754aaae83566135ed0f7567cbcbf97a4c92f738",
        "sponsorName": "University of Hawaii"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 30 Jun 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Heparin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "On Market",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Heparin",
    "primaryCompletionDate": "",
    "productId": 486,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103696/",
      "https://www.drugbank.ca/drugs/DB01109",
      "https://onlinelibrary.wiley.com/doi/10.1111/jth.14817"
    ],
    "sponsors": [
      {
        "sponsorId": "c271659ad5abc7b45c3da45b2f6d7536dd667619",
        "sponsorName": "Union Hospital"
      },
      {
        "sponsorId": "f857eb83d5547b637ff03a9a03a62ecae804b9ef",
        "sponsorName": "Tongji Medical College"
      },
      {
        "sponsorId": "206ac05e9d2f53359faa2f484ba97fb9947ad488",
        "sponsorName": "Huazhong University of Science and Technology"
      }
    ],
    "status": "On Market",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ST-001,nanoFenretinide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ST001_nanoFenretinide",
    "primaryCompletionDate": "",
    "productId": 487,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.scitechdevelopment.com/covid-19",
      "https://www.scitechdevelopment.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "300768e32f497d80e46fc738e6eb076afe1278b6",
        "sponsorName": "SciTech Development"
      },
      {
        "sponsorId": "f9ea624f8683db34fe27d8b66556e1c68a0bbff7",
        "sponsorName": "LLC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Ruconest",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ruconest",
    "primaryCompletionDate": "",
    "productId": 488,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf",
      "https://www.fdanews.com/articles/196751-pharming-reports-positive-results-from-compassionate-use-of-ruconest-in-covid-19-patients"
    ],
    "sponsors": [
      {
        "sponsorId": "201d1167355ba363a989f5f3c28beafd43c63d43",
        "sponsorName": "Pharming"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DIBI",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DIBI",
    "primaryCompletionDate": "",
    "productId": 489,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.chelationpartners.com/novel-covid-19-therapeutic"],
    "sponsors": [
      {
        "sponsorId": "6a6bd2de0eb5947c17ac3a602d9acff5ad7670aa",
        "sponsorName": "Chelation Partners"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "GP-1681",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "NIH\u2019s National Institute of Allergy and Infectious Diseases",
    "phase": "",
    "preferredName": "GP1681",
    "primaryCompletionDate": "",
    "productId": 490,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19",
      "https://www.businesswire.com/news/home/20200513005097/en/CytoAgents-Receives-NIH-Funding-Accelerate-Treatment-Cytokine",
      "https://www.cytoagents.com",
      "https://www.pharmaceutical-technology.com/news/cytoagents-nih-funding/"
    ],
    "sponsors": [
      {
        "sponsorId": "0be22b6b259f83f59ccbd5be89ac8e0889ac4303",
        "sponsorName": "Quotient Sciences"
      },
      {
        "sponsorId": "b70cb7686ccf395a7b83bebb5de6068269194a5a",
        "sponsorName": "CytoAgents Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "nebulized alkaline",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nebulized_alkaline",
    "primaryCompletionDate": "",
    "productId": 491,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.phbarrier.com/",
      "https://www.phbarrier.com/media/4143/ph-barrier-process-overview-brief-v19.pdf",
      "https://www.allrecipes.com/recipe/19247/soft-oatmeal-cookies/"
    ],
    "sponsors": [
      {
        "sponsorId": "96ddec31a0c1ab283619baa3878b527fb94d020f",
        "sponsorName": "pHbarrier"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Coronzot",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 22 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Coronzot",
    "primaryCompletionDate": "",
    "productId": 492,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.silkim.com/covid-19",
      "https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071"
    ],
    "sponsors": [
      {
        "sponsorId": "bd527ac2a1926e920092457295a6316ab04959d2",
        "sponsorName": "Silkim Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Lysteda,Cyklokapron",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "tness@uabmc.edu",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Lysteda_Cyklokapron",
    "primaryCompletionDate": "Thu, 15 Oct 2020 00:00:00 GMT",
    "productId": 493,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04338126",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Birmingham",
        "country": "USA",
        "lat": 33.5019893,
        "lng": -86.8064433,
        "locationId": "5f082975b346afc9f10f27d2cc093223ee6fc2f5",
        "name": "1720 University Blvd, Birmingham, AL 35294, USA",
        "state": "AL"
      }
    ],
    "sources": [
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.ifp099y9gyv",
      "https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1",
      "https://www.drugbank.ca/drugs/DB00302"
    ],
    "sponsors": [
      {
        "sponsorId": "554e9b0524bfdbca43acc75ad124f0ba00fa67b6",
        "sponsorName": "University of Alabama at Birmingham"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "senicapoc",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "senicapoc",
    "primaryCompletionDate": "",
    "productId": 494,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients",
      "https://www.drugbank.ca/drugs/DB06280"
    ],
    "sponsors": [
      {
        "sponsorId": "72e1254f1f77af47e0f6f7da408cde214f876377",
        "sponsorName": "Aarhus University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Luvox",
    "chemicalName": "fluvoxamine",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "stevens.a@wustl.edu; marissa@wustl.edu",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "fluvoxamine",
    "primaryCompletionDate": "Sat, 01 Aug 2020 00:00:00 GMT",
    "productId": 495,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04342663",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Belleville",
        "country": "USA",
        "lat": 38.5505222,
        "lng": -90.0221803,
        "locationId": "109924d0cfdf5fb5063fee51e37fb5c001f4e23a",
        "name": "4500 Memorial Dr, Belleville, IL 62226, USA",
        "state": "IL"
      },
      {
        "city": "St. Louis",
        "country": "USA",
        "lat": 38.6351441,
        "lng": -90.26292889999999,
        "locationId": "7f7997046e6bc08fa45778c7a546e53273e6bfaf",
        "name": "660 S Euclid Ave, St. Louis, MO 63110, USA",
        "state": "MO"
      }
    ],
    "sources": [
      "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#",
      "https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/",
      "https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1",
      "https://www.drugbank.ca/drugs/DB00176"
    ],
    "sponsors": [
      {
        "sponsorId": "088525c7f9eadc1d83414786054e0737521e7139",
        "sponsorName": "Washington University School of Medicine in St Louis"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 10 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Gleevac",
    "chemicalName": "imatinib",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "aemadi@umm.edu",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Ireland"],
    "countryCodes": ["IRL"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "imatinib",
    "primaryCompletionDate": "Wed, 01 Jun 2022 00:00:00 GMT",
    "productId": 496,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04394416",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million",
      "https://www.drugbank.ca/drugs/DB00619",
      "https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "d64dcdacea903a1d726c93fb9c27abff2ac03d67",
        "sponsorName": "Exvastat Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 01 Jun 2023 00:00:00 GMT",
    "studyStartDate": "Wed, 20 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "ABX464",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "paul.gineste@abivax.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "ABX464",
    "primaryCompletionDate": "",
    "productId": 497,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04393038",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Nice",
        "country": "FRA",
        "lat": 43.7243711,
        "lng": 7.2822826,
        "locationId": "41ee1beed2fb441d794a3d9d917618af34584b74",
        "name": "30 Voie Romaine, 06000 Nice, France",
        "state": "Provence-Alpes-C\u00f4te d'Azur"
      }
    ],
    "sources": [
      "https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted",
      "https://www.drugbank.ca/drugs/DB14828",
      "https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "c6da54a03f32dd41b8400b76dcd51eb01ec5cb77",
        "sponsorName": "Abivax"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 30 Apr 2021 00:00:00 GMT",
    "studyStartDate": "Fri, 01 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "sPIF",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sPIF",
    "primaryCompletionDate": "",
    "productId": 498,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": ["https://bioincept.com/", "https://bioincept.com"],
    "sponsors": [
      {
        "sponsorId": "a0388d32f7374fcd8165cab8a9c23eeb7f9c5b4a",
        "sponsorName": "BioIncept"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 499,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine"
    ],
    "sponsors": [
      {
        "sponsorId": "a07da6c1efe123b7fa3c2ce439820c1646f72988",
        "sponsorName": "University of Waterloo"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "GC376",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "GC376",
    "primaryCompletionDate": "",
    "productId": 567,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "87a69b194f663880aae077ec24d04b741ce55425",
        "sponsorName": "Anivive Lifesciences"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Small Mobile Stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Small_Mobile_Stem_cells",
    "primaryCompletionDate": "",
    "productId": 568,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "038bb1d2f34b750da43d8976c099f0e9c2384161",
        "sponsorName": "SMSbiotech"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 15 May 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 10 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1/2",
    "preferredName": "Inactivated_Vaccine",
    "primaryCompletionDate": "Sun, 01 Nov 2020 00:00:00 GMT",
    "productId": 500,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04470609",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Chengdu Shi",
        "country": "CHN",
        "lat": 30.585759,
        "lng": 104.14846,
        "locationId": "ca3e8dcf582c5166778734e4cc2f1b7406c4cd33",
        "name": "Chenglong Ave West Section, Jinjiang Qu, Chengdu Shi, Sichuan Sheng, China",
        "state": "Sichuan Sheng"
      }
    ],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true"
    ],
    "sponsors": [
      {
        "sponsorId": "bf5e7b2bebc0928fcae433d07b46f1bb4fc5c3ba",
        "sponsorName": "Chinese Academy of Medical Sciences"
      },
      {
        "sponsorId": "112dadb966996e2ab8f5db397f1a2361410582fc",
        "sponsorName": "Institute of Medical Biology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 01 Nov 2021 00:00:00 GMT",
    "studyStartDate": "Fri, 10 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Inactivated + CpG 1018 Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated__CpG_1018_Vaccine",
    "primaryCompletionDate": "",
    "productId": 501,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/",
      "https://clinicaltrials.gov/ct2/show/NCT04352608#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "93bef25f8dc322ecb56eae9b00dfed2b3169a709",
        "sponsorName": "Sinovac"
      },
      {
        "sponsorId": "8b4d210c885dc58c6711e526b8b4bd37c6acfd55",
        "sponsorName": "Dynavax"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated_Vaccine",
    "primaryCompletionDate": "",
    "productId": 502,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf",
      "https://pj.jiho.jp/article/241725"
    ],
    "sponsors": [
      {
        "sponsorId": "51adf29b45adb2321acc929eef1a1764661b4261",
        "sponsorName": "Osaka University"
      },
      {
        "sponsorId": "b82c2c21ac862400b11d6f29c7cae746450bbde7",
        "sponsorName": "BIKEN"
      },
      {
        "sponsorId": "780f15c43efde8ab3fb2054bfabbd4431f961fb1",
        "sponsorName": "NIBIOHN"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VLP-recombinant protein + Adjuvant Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VLPrecombinant_protein__Adjuvant_Vaccine",
    "primaryCompletionDate": "",
    "productId": 503,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "51adf29b45adb2321acc929eef1a1764661b4261",
        "sponsorName": "Osaka University"
      },
      {
        "sponsorId": "b82c2c21ac862400b11d6f29c7cae746450bbde7",
        "sponsorName": "BIKEN"
      },
      {
        "sponsorId": "17cbf856bb10416eb209f893f15592c5b0c5cf20",
        "sponsorName": "National Institutes of Biomedical Innovation"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Kazakhstan"],
    "countryCodes": ["KAZ"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 15 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated_Vaccine",
    "primaryCompletionDate": "",
    "productId": 504,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://astanatimes.com/2020/05/who-approves-kazakh-covid-19-vaccine-for-preclinical-trials/"
    ],
    "sponsors": [
      {
        "sponsorId": "491e7541c9106c54795c4fab54aeb1e6140c1faf",
        "sponsorName": "Research Institute for Biological Safety Problems"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Codon deoptimized live attenuated virus",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 23 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Codon_deoptimized_live_attenuated_virus",
    "primaryCompletionDate": "",
    "productId": 505,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/"
    ],
    "sponsors": [
      {
        "sponsorId": "b5cb9e1deb926ecff4779f7d91e9cb95f8813c17",
        "sponsorName": "Indian Immunologicals Ltd"
      },
      {
        "sponsorId": "4c0a544a8c18a6d3d126ac58097808c42561d093",
        "sponsorName": "Griffith University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Non-replicating viral vector MVA expressing structural proteins",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nonreplicating_viral_vector_MVA_expressing_structural_proteins",
    "primaryCompletionDate": "",
    "productId": 506,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "880c99550c8a42deeaff83ad0902af0b020c8848",
        "sponsorName": "Centro Nacional Biotecnologia"
      },
      {
        "sponsorId": "ff7e4fdfaae0a64a50db02f60295658c622d7b87",
        "sponsorName": "CNBCSIC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Non-replicating viral vector vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nonreplicating_viral_vector_vaccine",
    "primaryCompletionDate": "",
    "productId": 507,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "459eec13328a1d43f3fa5a6bd1f187b1c2e6ea3d",
        "sponsorName": "University of Manitoba"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "BBV152",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "kmohan@bharatbiotech.com  ",
        "name": null,
        "notes": "Go to clinical trial registry to site-specific emails",
        "phone": "",
        "website": "http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152"
      }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Jul 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "12",
    "otherPartners": "Thomas Jefferson University",
    "phase": "1/2",
    "preferredName": "BBV152",
    "primaryCompletionDate": "",
    "productId": 508,
    "registryLink": "http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Patna",
        "country": "IND",
        "lat": 25.562902,
        "lng": 85.04133379999999,
        "locationId": "5e9b6edb11204857e41157cab08c174122680d2d",
        "name": "Patna - Aurangabad Rd, Phulwari Sharif, Patna, Bihar 801507, India",
        "state": "BR"
      },
      {
        "city": "New Delhi",
        "country": "IND",
        "lat": 28.5671773,
        "lng": 77.2100451,
        "locationId": "eb3877fea7e410c3d77a2711748de364e6a50c6e",
        "name": "Sri Aurobindo Marg, Ansari Nagar, Ansari Nagar East, New Delhi, Delhi 110029, India",
        "state": "DL"
      },
      {
        "city": "Nagpur",
        "country": "IND",
        "lat": 21.131377,
        "lng": 79.10937679999999,
        "locationId": "deef5675c8aa292255c2a7f7caeb175379fe8448",
        "name": "20, Reshimbag, Umred Rd, Reshim Bagh, Nagpur, Maharashtra 440009, India",
        "state": "MH"
      },
      {
        "city": "Jajpur",
        "country": "IND",
        "lat": 20.8341019,
        "lng": 86.3326058,
        "locationId": "7b2eeb65b6d974175a8dc780c77d5042d191125a",
        "name": "Jajpur, Odisha, India",
        "state": "OD"
      },
      {
        "city": "Belgaum",
        "country": "IND",
        "lat": 15.871546,
        "lng": 74.5121013,
        "locationId": "305cee3679eff0028352e5e458427afa1428abb3",
        "name": "Ayodhya Nagar, Sadashiv Nagar, Belgaum, Karnataka 590019, India",
        "state": "KA"
      },
      {
        "city": "Visakhapatnam",
        "country": "IND",
        "lat": 17.7087374,
        "lng": 83.3060385,
        "locationId": "4bcde61e25a10b44ba436cfe53c544ccb1dcf750",
        "name": "KGH Down Rd, Opp KGH OP Gate, Maharani Peta, Visakhapatnam, Andhra Pradesh 531011, India",
        "state": "AP"
      },
      {
        "city": "Hyderabad",
        "country": "IND",
        "lat": 17.421937,
        "lng": 78.4520067,
        "locationId": "e049db3645d1f60f93acb89a0feb4ee29fc4f29b",
        "name": "Punjagutta Rd, Punjagutta Market, Punjagutta, Hyderabad, Telangana 500082, India",
        "state": "Telangana"
      },
      {
        "city": "Rohtak",
        "country": "IND",
        "lat": 28.8801261,
        "lng": 76.6055682,
        "locationId": "edb27bc8370ef9c951390f8d42b568f722bf9170",
        "name": "Medical Rd, Rohtak, Haryana 124001, India",
        "state": "HR"
      },
      {
        "city": "Kanpur",
        "country": "IND",
        "lat": 26.4812399,
        "lng": 80.3217327,
        "locationId": "524ff32bf7466f1cbe7f8105e4ff6540224b96fb",
        "name": "8/219, Khalasi Line, Arya Nagar, Kanpur, Uttar Pradesh 208002, India",
        "state": "UP"
      },
      {
        "city": "Gorakhpur",
        "country": "IND",
        "lat": 26.8047771,
        "lng": 83.39038110000001,
        "locationId": "954a91302531369957b975d9bed543375956c325",
        "name": "Rail Vihar, Medical College Road, Chargawa,, Gorakhpur, Uttar Pradesh 273001, India",
        "state": "UP"
      },
      {
        "city": "Oshalbag",
        "country": "IND",
        "lat": 15.6875535,
        "lng": 73.8307475,
        "locationId": "dc93dea4b16e443b7728783439bd80bd3861c70f",
        "name": "Mumbai - Goa Hwy, Dhargal, Oshalbag, Goa 403513, India",
        "state": "GA"
      },
      {
        "city": "Chengalpattu",
        "country": "IND",
        "lat": 12.8208657,
        "lng": 80.0481732,
        "locationId": "76c3bb0d69b40beeedae6aaa28f302d3bcf2e232",
        "name": "Chennai - Theni Highway, Potheri, SRM Nagar, Chengalpattu, Tamil Nadu 603211, India",
        "state": "TN"
      }
    ],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152"
    ],
    "sponsors": [
      {
        "sponsorId": "9d4dee599ac3bb32cc6f8f46985c93c9410e5262",
        "sponsorName": "Bharat Biotech"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 13 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Protein subunit S Protein + adjuvant",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 04 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "National Institute of Infectious Disease-Japan",
    "phase": "",
    "preferredName": "Protein_subunit_S_Protein__adjuvant",
    "primaryCompletionDate": "",
    "productId": 509,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://vpmthane.org/web2/assets/files/Dr.-SandeepKahandal-ArticleonCovid-19.pdf",
      "https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/4/",
      "https://covidvax.org/covid19-vaccine/NIIDJapan/S-protein-National-Institute-of-Infectious-Disease-Japan"
    ],
    "sponsors": [
      {
        "sponsorId": "e070ac198c1403ee83ff4b95b61c5b221dd1fe67",
        "sponsorName": "National Institute of Infectious Disease"
      },
      {
        "sponsorId": "fcf29f6cad3232704b33e962ef5194fad3b6817b",
        "sponsorName": "Japan"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PittCoVacc",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Pittsburgh School of Medicine",
    "phase": "",
    "preferredName": "PittCoVacc",
    "primaryCompletionDate": "",
    "productId": 510,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php",
      "https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/",
      "https://covidvax.org/covid19-vaccine/PittsburghUni/PittCoVacc-400-tiny-needles-array-skin-patch-University-of-Pittsburgh"
    ],
    "sponsors": [
      {
        "sponsorId": "0c65a74d63b7a88d66a6d28b2f99159bd2923517",
        "sponsorName": "University of Pittsburgh"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Peptide Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Rospotrebnadzor,FBRI SRC VB VECTOR",
    "phase": "",
    "preferredName": "Peptide_Vaccine",
    "primaryCompletionDate": "",
    "productId": 511,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1",
      "http://www.istc.int/en/institute/10150"
    ],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Rospotrebnadzor,FBRI SRC VB VECTOR",
    "phase": "",
    "preferredName": "Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 512,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1"
    ],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "LakePharma Inc.",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 513,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1",
      "https://lakepharma.com/integrated-solutions/covid-19-activities/overview",
      "https://covidvax.org/covid19-vaccine/LakePharma/Nanoparticle-vaccine-LakePharma"
    ],
    "sponsors": [
      {
        "sponsorId": "716eefa2065d7dc4e322e6d5e2d9319014688bc3",
        "sponsorName": "LakePharma"
      },
      {
        "sponsorId": "72a5f6c42a6c39ea891ecb24d22128fd281d0e18",
        "sponsorName": "Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 26 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Canadian Institutes of Health Research,Alberta Innovates",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 514,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1",
      "https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine"
    ],
    "sponsors": [
      {
        "sponsorId": "12c3dd5f9333a0c4d0ae98732f48bf25cad78edd",
        "sponsorName": "University of Alberta"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "AnyGo Technology",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 515,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1",
      "http://anygo.sell.everychina.com/aboutus.html",
      "https://covidvax.org/covid19-vaccine/AnyGoTech/S1---Fc-fusion-protein-AnyGo-Technology"
    ],
    "sponsors": [
      {
        "sponsorId": "077fdd2e748f24405b69a367b3773ec90b94b59d",
        "sponsorName": "AnyGo Technology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 08 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Yisheng Biopharma",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 516,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1",
      "https://covidvax.org/covid19-vaccine/YishengBiopharma/Recombinant-protein-Yisheng-Biopharma"
    ],
    "sponsors": [
      {
        "sponsorId": "ba53ce7d125486beb154102a37b226621b7f1fc7",
        "sponsorName": "Yisheng Biopharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 26 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Vabiotech,Bristol University",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 517,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1",
      "https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html",
      "https://vietnamnews.vn/society/716407/mice-administered-with-vietnamese-covid-19-vaccine-remain-healthy.html",
      "https://www.trialsitenews.com/vietnams-state-owned-vabiotech-pursues-a-vaccine-now-in-mice-testing-so-far-so-good/"
    ],
    "sponsors": [
      {
        "sponsorId": "d66666a3c071393a24620b24d358e69ba3509e16",
        "sponsorName": "Vabiotech"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "National Science Foundation",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 518,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine",
      "https://covidvax.org/covid19-vaccine/SanDiegoCaliUni/Plant-virus-nanotechnology-University-of-California-San-Diego"
    ],
    "sponsors": [
      {
        "sponsorId": "486a33cf556d4a11ca1a393e8f93ddeee90e3aa8",
        "sponsorName": "University of California"
      },
      {
        "sponsorId": "acb342916471ac6bed5f3a6a13ca8e3ecdc48429",
        "sponsorName": "San Diego"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OMV-based Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 06 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Quadram Institute",
    "phase": "",
    "preferredName": "OMVbased_Vaccine",
    "primaryCompletionDate": "",
    "productId": 519,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "442afaf6e99f2d9c98f45ff216cd938e8a81ddf1",
        "sponsorName": "Quadram Institute Biosciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "OMV-based Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 28 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "BiOMViS Srl,University of Trento",
    "phase": "",
    "preferredName": "OMVbased_Vaccine",
    "primaryCompletionDate": "",
    "productId": 520,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/"
    ],
    "sponsors": [
      {
        "sponsorId": "6d27be324405fd25505d58549d5f688eb822d1a3",
        "sponsorName": "BiOMVis SR"
      },
      {
        "sponsorId": "593791b280e8c3c839e73ca9110644e71cb76369",
        "sponsorName": "University of Trento"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Applied Biotechnology Institute Inc.",
    "phase": "",
    "preferredName": "Subunit_Vaccine",
    "primaryCompletionDate": "",
    "productId": 521,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "b7d9d4824d0196b796657e8d6d9728d256d6104b",
        "sponsorName": "Applied Biotechnology Institute Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Adjucanted recombinant protein",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 22 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 12 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Anhui Zhifei Longcom Biopharmaceutical,Institute of Microbiology Chinese Academy of Sciences",
    "phase": "2",
    "preferredName": "Adjucanted_recombinant_protein",
    "primaryCompletionDate": "Wed, 15 Sep 2021 00:00:00 GMT",
    "productId": 522,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04466085",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "CHN",
        "lat": 29.5598412,
        "lng": 106.5745894,
        "locationId": "fd87fe4d74b7df3808dbd8165e92725870054514",
        "name": "Yuzhong District, Chongqing, China",
        "state": "Chongqing"
      }
    ],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines",
      "https://clinicaltrials.gov/ct2/show/NCT04466085",
      "https://clinicaltrials.gov/ct2/show/NCT04445194"
    ],
    "sponsors": [
      {
        "sponsorId": "7b065d405ef1284ec1cbfd5ce6fb3719c2d87f0e",
        "sponsorName": "Anhui Zhifei Longcom Biopharmaceutical"
      },
      {
        "sponsorId": "63cba1aff0183a31e1f1c916b451513c8733fdf4",
        "sponsorName": "Institute of Microbiology"
      },
      {
        "sponsorId": "bc4227127320dc16e7fb7686767c7506d2a670a6",
        "sponsorName": "Chinese Academy of Sciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Sun, 12 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "RBD-based",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 13 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Tel Aviv University,Neovii",
    "phase": "",
    "preferredName": "RBDbased",
    "primaryCompletionDate": "",
    "productId": 523,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html"
    ],
    "sponsors": [
      {
        "sponsorId": "4dc81db10d5b875528cfc231d9c3e0179fdff8a1",
        "sponsorName": "Neovii"
      },
      {
        "sponsorId": "c70d6300461b60aa0d62ede7a42516869f6aeada",
        "sponsorName": "Tel Aviv University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Replicating Viral Vector,YF17D Vector",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 26 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "KU Leuven,UZ Leuven",
    "phase": "",
    "preferredName": "Replicating_Viral_Vector_YF17D_Vector",
    "primaryCompletionDate": "",
    "productId": 524,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.leuvenmindgate.be/news/support-our-leuven-researchers-in-finding-a-cure-against-corona"
    ],
    "sponsors": [
      {
        "sponsorId": "32ce15bbd44eb2c4a104acc7af8fe4766751c699",
        "sponsorName": "KU Leuven"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Measles Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 17 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Zydus Cadila",
    "phase": "",
    "preferredName": "Measles_Vector_Vaccine",
    "primaryCompletionDate": "",
    "productId": 525,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research"
    ],
    "sponsors": [
      {
        "sponsorId": "9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7",
        "sponsorName": "Zydus Cadila"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Measles Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "FBRI SRC VB VECTOR,Rospotrebnadzor",
    "phase": "",
    "preferredName": "Measles_Vector_Vaccine",
    "primaryCompletionDate": "",
    "productId": 526,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Recombinant Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "FBRI SRC VB VECTOR,Rospotrebnadzor",
    "phase": "",
    "preferredName": "Recombinant_Vaccine",
    "primaryCompletionDate": "",
    "productId": 527,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VSV Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "FBRI SRC VB VECTOR,Rospotrebnadzor",
    "phase": "",
    "preferredName": "VSV_Vector_Vaccine",
    "primaryCompletionDate": "",
    "productId": 528,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "FBRI SRC VB VECTOR,Rospotrebnadzor",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 529,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VSV-S Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "",
    "otherPartners": "Canadian Institutes of Health Research",
    "phase": "",
    "preferredName": "VSVS_Vaccine",
    "primaryCompletionDate": "",
    "productId": 530,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://covidvax.org/covid19-vaccine/WesternOntarioUni/VSV---S-University-of-Western-Ontario"
    ],
    "sponsors": [
      {
        "sponsorId": "64b8159213f0e0f1b682d64dcd70edf9ca69799b",
        "sponsorName": "University of Western Ontario"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Newcastle Disease Virus Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 14 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "WBVR,Intravacc,Utrecht",
    "phase": "",
    "preferredName": "Newcastle_Disease_Virus_Vector_Vaccine",
    "primaryCompletionDate": "",
    "productId": 531,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/show-bvr/Development-of-an-intranasal-vaccine-against-COVID-19.htm",
      "https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/About-us.htm",
      "https://www.hollandbio.nl/nieuws/intravacc-to-develop-emergency-and-conventional-covid-19-vaccines/"
    ],
    "sponsors": [
      {
        "sponsorId": "2fac1a221a15fc083eae5305d2594c769015b137",
        "sponsorName": "Intravacc"
      },
      {
        "sponsorId": "ce48076f605d7364d1dba7c47a51996d843222db",
        "sponsorName": "Wageningen Bioveterinary Research"
      },
      {
        "sponsorId": "b80905e2bb739693e1253446c2e0849e97ab16dd",
        "sponsorName": "Utrecht University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Avian paramyxovirus vector vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "",
    "otherPartners": "Lancaster University",
    "phase": "",
    "preferredName": "Avian_paramyxovirus_vector_vaccine",
    "primaryCompletionDate": "",
    "productId": 532,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://dnd.com.pk/pakistani-scientist-dr-muhammad-munir-listed-as-potential-covid-19-vaccine-maker-by-who/189385"
    ],
    "sponsors": [
      {
        "sponsorId": "3f5ef18f6b48973f961a316e793e87f14b04ffff",
        "sponsorName": "Lancaster University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Diovan",
    "chemicalName": "valsartan",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "valsartan",
    "primaryCompletionDate": "",
    "productId": 569,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "432bfc8336b289f3977566e16cf048972aa74569",
        "sponsorName": "Radbound Univeristy"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "LNP-encapsulated mRNA cocktail encoding RBD",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 07 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Fudan University,Shanghai JiaoTong University,RNACure Biopharma",
    "phase": "",
    "preferredName": "LNPencapsulated_mRNA_cocktail_encoding_RBD",
    "primaryCompletionDate": "",
    "productId": 533,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm",
      "https://covidvax.org/covid19-vaccine/FudanUniRBD/LNP-encapsulated-mRNA-cocktail-encoding-RBD-Fudan-University-Shangai-JiaoTong-University-RNACure-Bio"
    ],
    "sponsors": [
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      },
      {
        "sponsorId": "aa6799f660cd49b264d3e155560878bb15e8b804",
        "sponsorName": "Shanghai JiatTong University"
      },
      {
        "sponsorId": "f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0",
        "sponsorName": "RNACure Biopharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Replicating Defective SARS-CoV-2 derived RNAs Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 01 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Centro Nacional Biotecnolog\u00eda",
    "phase": "",
    "preferredName": "Replicating_Defective_SARSCoV2_derived_RNAs_Vaccine",
    "primaryCompletionDate": "",
    "productId": 534,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://covidvax.org/covid19-vaccine/CNB-RNA/RNA-defective-SARS-CoV-2-derived-RNAs-Centro-Nacional-Biotecnologia-CNB-CSIC-"
    ],
    "sponsors": [
      {
        "sponsorId": "c1eb0322cb877870cc4fe7c42c87c0a02c5d0674",
        "sponsorName": "Centro Nacional biotecnologia"
      },
      {
        "sponsorId": "ff7e4fdfaae0a64a50db02f60295658c622d7b87",
        "sponsorName": "CNBCSIC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "RNAimmune Inc",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 535,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "96c9c4abf003991d12896ec5fc930b3875d2aa18",
        "sponsorName": "RNAImmune Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Inovio Pharmaceuticals",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 536,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.houstonmethodist.org/research/covid19/geneone/",
      "https://www.chron.com/neighborhood/woodlands/health/article/Behind-the-scenes-Houston-doctor-preps-for-new-15192520.php"
    ],
    "sponsors": [
      {
        "sponsorId": "a16b70b82bdd9b5e61c50e750862a8851ee80507",
        "sponsorName": "GeneOne Life Science"
      },
      {
        "sponsorId": "0276ff1989d288ace3c36f410d4c8c1aa98a6910",
        "sponsorName": "Houston Methodist"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 12 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Greenlight Biosciences",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 537,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/greenlight-raises-17m-for-mrna-vaccine-capacity-hike-citing-covid-19-target/"
    ],
    "sponsors": [
      {
        "sponsorId": "9bc71603d5f1ceefbc96ff17289d5ada42219959",
        "sponsorName": "Greenligh Biosciences"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VLP Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "OSIVAX",
    "phase": "",
    "preferredName": "VLP_Vaccine",
    "primaryCompletionDate": "",
    "productId": 538,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "dbc7ace17cd35ff8f85b54d21988dfa7824dcf8a",
        "sponsorName": "OSIVAX"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VLP Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 27 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "ARTES Biotechnology",
    "phase": "",
    "preferredName": "VLP_Vaccine",
    "primaryCompletionDate": "",
    "productId": 539,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://pharma-industry-review.com/artes-joins-fight-against-covid-19-vlp-vaccine-platforms",
      "https://www.contractpharma.com/content-microsite/covid-19/2020-04-27/artes-biotech-to-develop-vlp-sars-cov-2-vax-candidates"
    ],
    "sponsors": [
      {
        "sponsorId": "07a812ba1b31cfbef19b397a145bcc9d34fc20a1",
        "sponsorName": "ARTES Biotechnology"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VLP,Whole Virus Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Brazil"],
    "countryCodes": ["BRA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Sao Paulo",
    "phase": "",
    "preferredName": "VLP_Whole_Virus_Vaccine",
    "primaryCompletionDate": "",
    "productId": 540,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376"
    ],
    "sponsors": [
      {
        "sponsorId": "65766da43898183e2da98c6704a2abbfa7aa4632",
        "sponsorName": "Univeristy of Sao Paulo"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 01 Sep 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "SK Biosciences,SK Group",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 541,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11",
      "http://www.koreabiomed.com/news/articleView.html?idxno=7798",
      "https://covidvax.org/covid19-vaccine/SK/SK-vaccine-SK-Bioscience"
    ],
    "sponsors": [
      {
        "sponsorId": "478b6fcffcd9bf799b6789693a95c51d1d06af57",
        "sponsorName": "SK Biosciences"
      },
      {
        "sponsorId": "b1e925b723690d4fd21dcf9ec6c1f26f2eb70ca5",
        "sponsorName": "SK Group"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Precision Vaccines Program,Boston Children's Hospital",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 542,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/",
      "https://discoveries.childrenshospital.org/coronavirus-vaccine/"
    ],
    "sponsors": [
      {
        "sponsorId": "1fed0b53fb22b1b1719e57613378cadb6bf64f66",
        "sponsorName": "Precision Vaccines Program"
      },
      {
        "sponsorId": "30710cd9a14eb8e8b8fa545333e304e084ebcfc4",
        "sponsorName": "Boston Childrens Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "guzmano@rjrt.com",
        "name": null,
        "notes": "",
        "phone": "336-741-5043",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04473690"
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Jul 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "2",
    "otherPartners": "Kentucky BioProcessing",
    "phase": "1/2",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 543,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04473690",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Wilmington",
        "country": "USA",
        "lat": 34.2085533,
        "lng": -77.92795559999999,
        "locationId": "42e4d2f729742bd0aa283ee127d4aa5b1924c0bf",
        "name": "1907 Tradd Ct, Wilmington, NC 28401, USA",
        "state": "NC"
      },
      {
        "city": "San Antonio",
        "country": "USA",
        "lat": 29.5139583,
        "lng": -98.47002189999999,
        "locationId": "9d3ade58a6bd5cc662ea9efb45c3ab5faaa7f268",
        "name": "8307 Gault Ln, San Antonio, TX 78209, USA",
        "state": "TX"
      }
    ],
    "sources": [
      "https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL",
      "https://clinicaltrials.gov/ct2/show/NCT04473690",
      "https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/"
    ],
    "sponsors": [
      {
        "sponsorId": "c166c578447a7c9ab34935edb79ae58af5c26833",
        "sponsorName": "Kentucky BioProcessing"
      },
      {
        "sponsorId": "04f6cb5885013bae64d2b1cecf249bb94735046b",
        "sponsorName": "BAT"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 13 Nov 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Canadian Institutes of Health Research",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 544,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.ulaval.ca/en/about-us/media-centre/press-releases/press-releases-2020/21-million-better-understand-and-combat-covid-19"
    ],
    "sponsors": [
      {
        "sponsorId": "68fc3905a9dd7aa4f14be93f6f536bd303d16bab",
        "sponsorName": "University of Laval"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Chile"],
    "countryCodes": ["CHL"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Scientists will use respiratory syncytial virus (RSV) and human metapneumovirus (MPVh) vaccine developments and apply them to COVID-19 research.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 545,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635448/"
    ],
    "sponsors": [
      {
        "sponsorId": "aaa32a3979ac5c274f389b02e07a20f54af034c7",
        "sponsorName": "Universidad Catolica Instituto Milenio de Inmunologia e Inmunoterapia"
      },
      {
        "sponsorId": "3ecea3e5816f686ca7b07b073600326888093983",
        "sponsorName": "Consorcio Technologica en Biomedicina Clinico Molecular"
      },
      {
        "sponsorId": "cfa06ba512db41f4402457107b0efb25017d088e",
        "sponsorName": "IMMII"
      },
      {
        "sponsorId": "cbfa70574d8abd0d988aca0261d66abecf7cdebb",
        "sponsorName": "BMRC"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Scientists are developing a T-cell-inducing vaccine that produces a strong T cell immune response to help target and kill infected cells. It works by using peptides to stimulate T-cells.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "primaryCompletionDate": "",
    "productId": 546,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/",
      "http://emergexvaccines.com/wp-content/uploads/2020/04/31-March-2020-White-Paper-Scientific-Rationale-for-the-Use-of-T-Cell-Priming-to-Reduce-R0-to-Limit-Spread-of-COVID-19-During-Active-Pandemic-FINAL.pdf",
      "https://asia.nikkei.com/Business/Startups/Coronavirus-vaccine-set-for-testing-says-startup-backed-by-Singapore-VC"
    ],
    "sponsors": [
      {
        "sponsorId": "edc8416948cc1ae11508ef4ae0b416a22c12ad4e",
        "sponsorName": "Emergex Vaccines Holding Limited"
      },
      {
        "sponsorId": "592426722c1b68f6ce3b0cb2833cd378cea35d20",
        "sponsorName": "George Mason Universitys National Center for Biodefense and Infectious Diseases"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AVI-205",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AVI205",
    "primaryCompletionDate": "",
    "productId": 547,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/",
      "http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/",
      "http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "a25563e72a99e3dab077dcbd5a35f0b05e1a851b",
        "sponsorName": "AbVision Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Recombinant LVS Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Scientists are attempting to develop a single vector platform vaccine that would protect against many emerging pathogens as well as \"Tier 1 Select Agents.\"",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Recombinant_LVS_Vaccine",
    "primaryCompletionDate": "",
    "productId": 548,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "http://ucla.technologypublisher.com/techcase/20-0322",
      "https://www.uclahealth.org/infectious-diseases/Workfiles/infectious-diseases/Marcus-Horwitz-profile-page2.pdf",
      "http://ucla.technologypublisher.com/techcase/18-1241"
    ],
    "sponsors": [
      {
        "sponsorId": "68a801de11b20a5784e2f9993135e416ea6d5ccc",
        "sponsorName": "University of California Los Angeles"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Pepcid",
    "chemicalName": "famotidine",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "famotidine",
    "primaryCompletionDate": "",
    "productId": 570,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "a4e79c4da197e20df061d83c37e4e3717861e721",
        "sponsorName": "Feinstein Institutes for Medical Research"
      },
      {
        "sponsorId": "239c019da219eac0cd5b03db2e1ae81decc90034",
        "sponsorName": "Northwell Health"
      },
      {
        "sponsorId": "fc16463de92affc9e97a314e701dcd0678083433",
        "sponsorName": "Alchem"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "An intranasal delivery system is being explored with this vaccine.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "primaryCompletionDate": "",
    "productId": 549,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine"
    ],
    "sponsors": [
      {
        "sponsorId": "b41a4d43ef7f7aa0b03c1fa4cb9acc260b974c38",
        "sponsorName": "eTheRNA"
      },
      {
        "sponsorId": "f67f36df3e690591d2422dcdf7a98d9c579d2302",
        "sponsorName": "Epivax"
      },
      {
        "sponsorId": "1705936639243ce00a503a24d65f03b3840a89c2",
        "sponsorName": "Nexelis"
      },
      {
        "sponsorId": "d018b4e85291ddac56b886398d68650a668bc8ba",
        "sponsorName": "Reprocell and the Center for the Evaluation of Vaccination of the University of Antwerp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Attenuated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Brazil"],
    "countryCodes": ["BRA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "LabWare",
    "phase": "",
    "preferredName": "Attenuated_Vaccine",
    "primaryCompletionDate": "",
    "productId": 550,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines",
      "https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine",
      "https://www.labware.com/en/p/About-Us/COVID19/Instituto-Butantan",
      "http://www.butantan.gov.br/"
    ],
    "sponsors": [
      {
        "sponsorId": "a428a9d798bc8d58f26fe00c022c9f48b3f79576",
        "sponsorName": "Fundacao Oswaldo Cruz"
      },
      {
        "sponsorId": "e23ad6b02eceefb9094a74410045931a10079a06",
        "sponsorName": "Instituto Butantan"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Organicell Flow",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinicaltrials@organicell.com",
        "name": null,
        "notes": "",
        "phone": "1-888-963-7881",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 11 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 12 May 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "Organicell_Flow",
    "primaryCompletionDate": "Wed, 30 Sep 2020 00:00:00 GMT",
    "productId": 551,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04384445",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Naples",
        "country": "USA",
        "lat": 26.2701046,
        "lng": -81.7885501,
        "locationId": "507200aa19d00c15be751f096e213fa019355331",
        "name": "1285 Creekside Blvd, Naples, FL 34109, USA",
        "state": "FL"
      },
      {
        "city": "Athens",
        "country": "USA",
        "lat": 33.9663705,
        "lng": -83.4115674,
        "locationId": "3063b24463340c041ffe36253aac0555303f1d77",
        "name": "775 Sunset Dr, Athens, GA 30606, USA",
        "state": "GA"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1",
      "https://organicell.com/organicell-flow/",
      "https://organicell.com/clinical-trials/",
      "https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "fd115f17ad17409455bb40c8d7b56ec40407be62",
        "sponsorName": "Organicell Regenerative Medicine"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 12 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "KB-109",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 14 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Scientists are studying outpatients in 2 non-IND clinical studies",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "KB109",
    "primaryCompletionDate": "",
    "productId": 552,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.38452909999999,
        "lng": -71.06756740000002,
        "locationId": "c27c9825a6dca0b710d3d7c01a20e9862cab143c",
        "name": "465 Medford St #500, Charlestown, MA 02129, USA",
        "state": "MA"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/05/14/2033339/0/en/Kaleido-Biosciences-Initiates-Controlled-Clinical-Study-of-Microbiome-Metabolic-Therapy-KB109-in-Outpatients-with-Mild-to-Moderate-COVID-19.html",
      "https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/",
      "https://kaleido.com/our-pipeline/"
    ],
    "sponsors": [
      {
        "sponsorId": "b7a8a2d712ee76890113aebcca4616bf1019b420",
        "sponsorName": "Kaleido Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 14 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Estradiol patch",
    "chemicalName": "",
    "conditionOrDisease": "COIVD-19",
    "contact": [
      {
        "email": "PatchStudy@stonybrookmedicine.edu",
        "name": null,
        "notes": "",
        "phone": "631-371-3309",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 24 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Scientists theorize that estrogen may effect angiotensin-converting enzyme 2 (ACE2) proteins which have receptors on cells that are used by COVID-19 as entry-points to the cell. Estrogen has also been shown to improve immune response,espeically in viral infections.",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Estradiol_patch",
    "primaryCompletionDate": "Sun, 15 Nov 2020 00:00:00 GMT",
    "productId": 553,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04359329",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Stony Brook",
        "country": "USA",
        "lat": 40.9088246,
        "lng": -73.1147874,
        "locationId": "98a206a8d04ce9c8713115a17f1afcd9d28af970",
        "name": "101 Nicolls Rd, Stony Brook, NY 11794, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04359329",
      "https://www.drugbank.ca/drugs/DB00783",
      "https://www.nytimes.com/2020/04/27/health/coronavirus-estrogen-men.html",
      "https://www.healio.com/news/endocrinology/20200501/study-investigates-estrogen-patch-use-to-lessen-covid19-complications",
      "https://clinicaltrials.gov/ct2/show/record/NCT04359329",
      "https://clinicaltrials.gov/ct2/show/study/NCT04359329"
    ],
    "sponsors": [
      {
        "sponsorId": "a7721518ad3f33d0aa3b8af76ef0c1880324607a",
        "sponsorName": "Stony Brook University Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 15 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 24 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Anticovir",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Drug will be dispensed via Metered Dose Inhaler (MDI).",
    "numSites": "",
    "otherPartners": "Altum Pharmaceuticals Inc.",
    "phase": "",
    "preferredName": "Anticovir",
    "primaryCompletionDate": "",
    "productId": 554,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/betterlife-pharma-enters-into-a-licensing-agreement/",
      "https://www.altumpharma.com/pipeline/ap-003/",
      "https://www.thepharmaletter.com/article/betterlife-pharma-inks-licensing-deal-for-anticovir"
    ],
    "sponsors": [
      {
        "sponsorId": "80e96db9c9f78a58f5b44d2793c88c981132970f",
        "sponsorName": "Betterlife Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Apograft-treated stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Apografttreated_stem_cells",
    "primaryCompletionDate": "",
    "productId": 555,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/cellect-biotechnologys-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmonary-diseases-301060683.html",
      "https://www.cellect.co/solutions",
      "https://www.cellect.co/"
    ],
    "sponsors": [
      {
        "sponsorId": "3677197cebff0cf7947d2809124f96acf1cf3201",
        "sponsorName": "Cellect Biotechnology Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Mesenchymal Stem Cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 27 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Citius Pharmaceuticals Inc.",
    "phase": "",
    "preferredName": "Mesenchymal_Stem_Cells",
    "primaryCompletionDate": "",
    "productId": 556,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license",
      "https://ir.citiuspharma.com/press-releases/detail/98/citius-announces-data-on-novecite-mesenchymal-stem-cells",
      "https://ir.citiuspharma.com/press-releases/detail/96/citius-announces-pre-ind-submission-to-fda-under-the"
    ],
    "sponsors": [
      {
        "sponsorId": "ea3716c6b0205d251944d5e3a61cc9f1ba3744d4",
        "sponsorName": "Citius Pharmaceuticals Inc"
      },
      {
        "sponsorId": "c48abd193caba28112832045ebaea95c6c5a0faf",
        "sponsorName": "Novellus Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "CAL-02",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CAL02",
    "primaryCompletionDate": "",
    "productId": 557,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.combioxin.com/pipeline/",
      "https://www.mdpi.com/2079-6382/9/2/94",
      "https://www.combioxin.com/news/",
      "http://www.lascco.com/documents/200504PR-Combioxin-PositivefeedbackfromFDAonPINDforCAL02inCOVID-19patients.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "01da66d9faf1279ac5cdf58ec85f96945d297558",
        "sponsorName": "Combioxin SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "e-Therapeutics Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Network-driven Drug Discovery works to determine host mechanisms that are critical for virus replication and spread",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "eTherapeutics_Therapeutic",
    "primaryCompletionDate": "",
    "productId": 558,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.etherapeutics.co.uk/media/1237/covid-19_ndd_overview.pdf",
      "https://www.etherapeutics.co.uk/what-we-do/covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "fa4ddbe589e7b8b772f35f4f16d787866b9f4ae9",
        "sponsorName": "eTherapeutics plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "KAND-567",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Sweden"],
    "countryCodes": ["SWE"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Kancera has applied to begin Phase II studies",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "KAND567",
    "primaryCompletionDate": "",
    "productId": 559,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://kancera.com/en/researchportfolio/",
      "http://kancera.com/en/press/press-releases/#"
    ],
    "sponsors": [
      {
        "sponsorId": "fe4146d58f781a4971c5ec8a946b4fe02036a3cb",
        "sponsorName": "Kancera AB"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Capton product",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Capton_product",
    "primaryCompletionDate": "",
    "productId": 560,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "5b62e5f42bf6b8790b1f5d3d525aa8d615ab1ac0",
        "sponsorName": "Mercaptor Discoveries Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "TR-C 19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "TRC_19",
    "primaryCompletionDate": "",
    "productId": 561,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.vsybiotechnology.com/a-new-drug-to-treat-covid-19-tr-c-19-at-human-testing-phase/",
      "https://www.vsybiotechnology.com/about-us/"
    ],
    "sponsors": [
      {
        "sponsorId": "daeec1530e0e8919a34fb5c99ed5ddc5cd2e8f43",
        "sponsorName": "Vsy Biotechnology GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibody",
    "primaryCompletionDate": "",
    "productId": 562,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx"
    ],
    "sponsors": [
      {
        "sponsorId": "0174fd8a066ed49f55c03cae0c00a6e53d1f1356",
        "sponsorName": "Xavier Saelens"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "On Market",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 563,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.proteogenix.science/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "dfe8fccd9d4a4ca4e46009e309f1281be6f25f78",
        "sponsorName": "Proteogenix SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 07 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 564,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "cc02b125f93be2b049360a4f49ab7a0c97bdfcf5",
        "sponsorName": "Yumab GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "TY027",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "TY027",
    "primaryCompletionDate": "",
    "productId": 565,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "336eecbaf567ac949aa38caead2ef8159f332f1d",
        "sponsorName": "Tychan"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "VP01",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "mimi.flensburg@vicorepharma.com",
        "name": null,
        "notes": "COVID-19 requiring hospitalization but not ventilation; only London location is recruiting",
        "phone": "45 2210 9950",
        "website": ""
      }
    ],
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Small molecule designed to target AT2R to reduce inflammation and treat pulmonary fibrosis,MHRA granted VP01 approval to commence phase 2 to investigate whether it reduced inflammation in COVID-19 patients",
    "numSites": "3",
    "otherPartners": "LifeArc,University College London",
    "phase": "2",
    "preferredName": "VP01",
    "primaryCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "productId": 575,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04452435",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Ahmedabad",
        "country": "IND",
        "lat": 23.0524508,
        "lng": 72.6028567,
        "locationId": "66f3f630ec8cc80d1a6d69c5aa079cbdf2ef8d74",
        "name": "Haripura, Asarwa, Ahmedabad, Gujarat 380016, India",
        "state": "GJ"
      },
      {
        "city": "Pune",
        "country": "IND",
        "lat": 18.5049439,
        "lng": 73.9270805,
        "locationId": "f3da8b448868ab7679e321ca5d8e5725d6180772",
        "name": "153, Road, Magarpatta, Hadapsar, Pune, Maharashtra 411013, India",
        "state": "MH"
      },
      {
        "city": null,
        "country": "GBR",
        "lat": 51.5250834,
        "lng": -0.1363551,
        "locationId": "cb84a5055177c91284cab442f20eebedab2c911b",
        "name": "235 Euston Rd, Bloomsbury, London NW1 2BU, UK",
        "state": "England"
      }
    ],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.lifearc.org/funding/covid-19-funding/attract/",
      "https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1",
      "https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "c2ea57bc39b23f4008b3b798267383fbd2c27571",
        "sponsorName": "Vicore Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 20 Sep 2021 00:00:00 GMT",
    "studyStartDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "AQCH",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 08 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Plant derived treatment initially intended for treating dengue but broad-spectrum anti-viral activity shows promise for COVID-19,no detailed entry on clinicaltrials",
    "numSites": "12",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "AQCH",
    "primaryCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "productId": 576,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "IND",
        "lat": 20.593684,
        "lng": 78.96288,
        "locationId": "1876f4958631af885091a790940cbe0f881c9738",
        "name": "India",
        "state": null
      }
    ],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/"
    ],
    "sponsors": [
      {
        "sponsorId": "ca23b6a4a7a874f5a61c26ea21f0112b4d78dbf0",
        "sponsorName": "Sun Pharmaceutical Industries Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 08 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CIGB-258",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "mcarmen.dominguez@cigb.edu.cu",
        "name": null,
        "notes": "TRIAL COMPLETED",
        "phone": "53 7271 6022",
        "website": ""
      }
    ],
    "countries": ["Cuba"],
    "countryCodes": ["CUB"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Immunoregulatory peptide,clinical trial did not have a traditional phase but description appears to indicate phase 2 and was completed in 05/30/2020 and published results on 6/30/2020 https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1",
    "numSites": "1",
    "otherPartners": "Ministry of Public Health - Cuba",
    "phase": "2",
    "preferredName": "CIGB258",
    "primaryCompletionDate": "Sat, 30 May 2020 00:00:00 GMT",
    "productId": 577,
    "registryLink": "https://apps.who.int/trialsearch/Trial2.aspx?TrialID=RPCEC00000313",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Havana",
        "country": "CUB",
        "lat": 23.0356075,
        "lng": -82.47696789999999,
        "locationId": "9d1f9824b98a10aca8a6d98dd895deee298cef0b",
        "name": "Havana, Cuba",
        "state": "Artemisa Province"
      }
    ],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://rpcec.sld.cu/en/trials/RPCEC00000313-En",
      "https://rpcec.sld.cu/en/trials/RPCEC00000313-En https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1"
    ],
    "sponsors": [
      {
        "sponsorId": "599b442f75a35f3a72fc558bc0202e8d0747618f",
        "sponsorName": "Genetic Engineering and Biotechnology Center"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Tue, 31 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "FSD-201",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "",
        "name": null,
        "notes": "TRIAL COMPLETED",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Drug is ultramicronized palmitoylethanolamide intended to reduce COVID-19 inflammation,currently is planning a phase 2a trial after receiving FDA approval,phase 1 results will be published soon",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "FSD201",
    "primaryCompletionDate": "Mon, 22 Jun 2020 00:00:00 GMT",
    "productId": 578,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Melbourne",
        "country": "AUS",
        "lat": -37.8456704,
        "lng": 144.9819197,
        "locationId": "df869b1b7a226892826dcfeb17cf7b01369bf112",
        "name": "55 Commercial Rd, Melbourne VIC 3004, Australia",
        "state": "VIC"
      }
    ],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://fsdpharma.com/about-us/",
      "https://www.businesswire.com/news/home/20200602005990/en/FSD-Pharma-Receives-U.S.-FDA-Approval-Design",
      "https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase"
    ],
    "sponsors": [
      {
        "sponsorId": "b2bbb974a00d8c7f0df2c6ef240c54f29e4dc8c3",
        "sponsorName": "FSD Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 22 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "PB-1046",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Clinicaltrials@phasebio.com",
        "name": null,
        "notes": "Male or Female aged 18-85; hospitalized for COVID-19; written or verbal consent; receiving O2 by face mask or nasal cannula and/or elevated markers of cardiac injury or dysfunction",
        "phone": "888 521 2805",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 27 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 26 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Vasoactive intestinal peptide recptor agonist that targets VPAC receptors to have anti-inflammatory effects among others,also in trials for Pulmonary Arterial Hypertension",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "PB1046",
    "primaryCompletionDate": "",
    "productId": 579,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04433546",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.businesswire.com/news/home/20200527005882/en/PhaseBio-Launches-Clinical-Trial-Evaluate-PB1046-Treatment",
      "https://clinicaltrials.gov/ct2/show/NCT04433546",
      "https://clinicaltrials.gov/ct2/show/NCT04433546#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "843438e9026597e688588c1e3b1ffd5e9a5e31a0",
        "sponsorName": "PhaseBio"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Fri, 26 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "PTC299",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "medinfo@ptcbio.com",
        "name": null,
        "notes": "Not yet recruiting; 18 or older with signed and dated informed consent; hospitalized for confirmed COVID19",
        "phone": "866 562 4620",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently in evaluation for AML besides COVID19,small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) that reduces SARS-CoV-2 viral replication and selectively modulates immune response",
    "numSites": "5",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "PTC299",
    "primaryCompletionDate": "Sat, 30 Jan 2021 00:00:00 GMT",
    "productId": 580,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04439071",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Augusta",
        "country": "USA",
        "lat": 33.4709094,
        "lng": -81.9898848,
        "locationId": "4339bf585b77be845704c8575db2e645c60da2b2",
        "name": "1120 15th St, Augusta, GA 30912, USA",
        "state": "GA"
      },
      {
        "city": "Baltimore",
        "country": "USA",
        "lat": 39.2967385,
        "lng": -76.59273619999999,
        "locationId": "10f5b4c03f8bd20a33b367ca4d1206ef0de0fcf8",
        "name": "1800 Orleans St, Baltimore, MD 21287, USA",
        "state": "MD"
      },
      {
        "city": "Barcelona",
        "country": "ESP",
        "lat": 41.38389069999999,
        "lng": 2.1941912,
        "locationId": "c3ba6471688d3d446c2254e6ca306eef272a7d94",
        "name": "Passeig Mar\u00edtim de la Barceloneta, 25, 29, 08003 Barcelona, Spain",
        "state": "CT"
      },
      {
        "city": "Madrid",
        "country": "ESP",
        "lat": 40.3864149,
        "lng": -3.6178463,
        "locationId": "6833ce9b07454d51f18c8cd1092c8da069753009",
        "name": "Av. Gran V\u00eda del Este, 80, 28031 Madrid, Spain",
        "state": "Comunidad de Madrid"
      },
      {
        "city": "Madrid",
        "country": "ESP",
        "lat": 40.3760381,
        "lng": -3.6990068,
        "locationId": "2b8473315e97e5d8cf31fff8a07a011192e79cde",
        "name": "Av. de C\u00f3rdoba, s/n, 28041 Madrid, Spain",
        "state": "Comunidad de Madrid"
      }
    ],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.ptcbio.com/about/contact-us/",
      "https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-the-initiation-of-a-phase-23-clinical-trial-to-evaluate-ptc299-for-the-treatment-of-covid-19-301078337.html",
      "https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4"
    ],
    "sponsors": [
      {
        "sponsorId": "85ebe6b2e2259437754addc4fb2e9365153c49ae",
        "sponsorName": "PTC Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Evista",
    "chemicalName": "raloxifene",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently on market for treatment of osteoporosis as raloxifene,currently in discussions with the EMA,drug intended to be used in clinical trials to observe efficacy against COVID-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "raloxifene",
    "primaryCompletionDate": "",
    "productId": 581,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.dompe.com/en/media/press-releases/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2"
    ],
    "sponsors": [
      {
        "sponsorId": "f56dc548d8bfe74984064c59095b7bfd19c6ae3f",
        "sponsorName": "Dompe farmaceutici"
      },
      {
        "sponsorId": "3290324bf4e652fd05bffce6079d5ebbe370538a",
        "sponsorName": "Exscalate4CoV"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "losmapimod",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 24 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 24 Jun 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Oral p38 MAPK inhibitor,phase 3 to begin soon - conducted on 400 patients and aims to have topline data by Q1 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "losmapimod",
    "primaryCompletionDate": "",
    "productId": 582,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.fulcrumtx.com/contact/",
      "https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3"
    ],
    "sponsors": [
      {
        "sponsorId": "754a6a32f07e76bc8bc858dd075c286dfea0349b",
        "sponsorName": "Fulcrum Therapeutics"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 20 Feb 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 24 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "AndroCoV",
    "chemicalName": "dutasteride",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "f.cadegiani@gmail.com",
        "name": null,
        "notes": "Not yet recruiting; male; 50 years or older; SARS Cov 2 positive but not hospitalized; informed consent",
        "phone": "5561996506111",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 26 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "AndroCoV is an experimental trial utilizing 3 drugs - dutasteride-ivermectin-azithromycine,dutasteride is FDA approved to treat enlarged prostate,no specific trial phase announced but description resembles phase 2",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "dutasteride",
    "primaryCompletionDate": "",
    "productId": 583,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04446429",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "BRA",
        "lat": -15.8226564,
        "lng": -47.92831349999999,
        "locationId": "d5bc5ea3e2c8d980f7894c302fca0cb5f7939074",
        "name": "SGAS 915, Lote 69/70, Centro Cl\u00ednico Advance, Sala 262 Brasilia/DF, CEP - Asa Sul, Bras\u00edlia - DF, 70390-150, Brazil",
        "state": "DF"
      }
    ],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.businesswire.com/news/home/20200624005871/en/Applied-Biology-Collaboration-Brown-University-Researchers-Corpometria",
      "https://clinicaltrials.gov/ct2/show/NCT04446429"
    ],
    "sponsors": [
      {
        "sponsorId": "30a0bfe60f04ff11e51d1901a52fbea2c76f2b5d",
        "sponsorName": "Applied Biology Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 31 Jan 2021 00:00:00 GMT",
    "studyStartDate": "Fri, 26 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Eritoran",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Eritoran",
    "primaryCompletionDate": "",
    "productId": 584,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "9014154541489159d60a164cdba2053774a7660f",
        "sponsorName": "Eisai"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "GX-19",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "yoonjeong.choi@genexine.com",
        "name": null,
        "notes": "",
        "phone": "82-31-628-3233",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 17 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "GX19",
    "primaryCompletionDate": "Wed, 17 Mar 2021 00:00:00 GMT",
    "productId": 585,
    "registryLink": "https://www.clinicaltrials.gov/ct2/show/NCT04445389",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "KOR",
        "lat": 37.5622702,
        "lng": 126.941068,
        "locationId": "8d11bf3463c2e4e8891a037077fa4cb1b786281f",
        "name": "50-1 Yonsei-ro, Sinchon-dong, Seodaemun-gu, Seoul, South Korea",
        "state": "Seoul"
      }
    ],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.clinicaltrials.gov/ct2/show/NCT04445389",
      "https://www.genengnews.com/covid-19-candidates/genexine-gx-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "5d9f7ffbf60a4d4017b42d8cdf7353cf0a4fe9e1",
        "sponsorName": "Genexine Consortium"
      },
      {
        "sponsorId": "92ea2b8d0437f2a5d21b14d54802dcf2c2104c66",
        "sponsorName": "GenNBio"
      },
      {
        "sponsorId": "ff047f0d6e9a5c4ac743aa16ce68aa6bcc915b64",
        "sponsorName": "International Vaccine Institute"
      },
      {
        "sponsorId": "53374e83cc0c8a0628e5295c9c2adac4bcf36d58",
        "sponsorName": "KAIST"
      },
      {
        "sponsorId": "9c5e4f465201422aa36c55b75e18717ad929bda9",
        "sponsorName": "POSTECH"
      },
      {
        "sponsorId": "c3990da1fa59778f19060e57f09b0c9d42a018e5",
        "sponsorName": "Binex"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 17 Jun 2022 00:00:00 GMT",
    "studyStartDate": "Wed, 17 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DNA with electroporation",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Thailand"],
    "countryCodes": ["THA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 26 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Human trials planned for October.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DNA_with_electroporation",
    "primaryCompletionDate": "",
    "productId": 586,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.chula.ac.th/en/clipping/31103/"
    ],
    "sponsors": [
      {
        "sponsorId": "e21faaa59cbe02fdff806f375f68495cc6e16e25",
        "sponsorName": "Chula Vaccine Research Center"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DNA plasmid vaccine S,S1,S2,RBD & N",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Egypt"],
    "countryCodes": ["EGY"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DNA_plasmid_vaccine_S_S1_S2_RBD__N",
    "primaryCompletionDate": "",
    "productId": 587,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "1212b57ee9ead30a43480c416ee4aea43b78bf38",
        "sponsorName": "National Research Centre"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MV-014-210",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MV014210",
    "primaryCompletionDate": "",
    "productId": 588,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv"
    ],
    "sponsors": [
      {
        "sponsorId": "e1f0e57b91f2b40d3988d49377f0952d32b1bef2",
        "sponsorName": "Meissa Vaccines"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MVA-S",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "GeoVax/BravoVax",
    "phase": "",
    "preferredName": "MVAS",
    "primaryCompletionDate": "",
    "productId": 589,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program"
    ],
    "sponsors": [
      {
        "sponsorId": "f46b68e943e93a62cdc8c93a4106f50eed6e636e",
        "sponsorName": "IDIBAPS Hospital Clinic"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AAVCOVID",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 14 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AAVCOVID",
    "primaryCompletionDate": "",
    "productId": 590,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna"
    ],
    "sponsors": [
      {
        "sponsorId": "724865bfbd0f66eb957dfad8bf5f581e6fa9602e",
        "sponsorName": "Grousbeck Gene Therapy"
      },
      {
        "sponsorId": "5793c63ebb6b37c9aa97b85cc7021dfdca0d829c",
        "sponsorName": "AveXis"
      },
      {
        "sponsorId": "913ccc1e99bd5cc53f8d0a15d443dc8f56dda47a",
        "sponsorName": "Viralgen"
      },
      {
        "sponsorId": "42794122ad2e94771c0a0338770ff57f42a60112",
        "sponsorName": "Aldevron"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Gam-COVID-Vac Lyo",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "",
        "name": null,
        "notes": "No contact details included",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 17 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 17 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1/2",
    "preferredName": "GamCOVIDVac_Lyo",
    "primaryCompletionDate": "Wed, 05 Aug 2020 00:00:00 GMT",
    "productId": 591,
    "registryLink": "https://clinicaltrials.gov/show/NCT04437875",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Moskva",
        "country": "RUS",
        "lat": 55.731551,
        "lng": 37.571717,
        "locationId": "0db5cc23ef5d25bb901cf125ec466ca6f7f47cd3",
        "name": "Bol'shaya Pirogovskaya Ulitsa, 19\u04411, Moskva, Russia, 119146",
        "state": null
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04437875",
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://clinicaltrials.gov/ct2/show/NCT04436471"
    ],
    "sponsors": [
      {
        "sponsorId": "8f805fbe6d3cf20118840cac06573229c25e36f4",
        "sponsorName": "Gamaleya Research Institute"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 15 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 17 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Influenza A H1N1 vector",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Egypt"],
    "countryCodes": ["EGY"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Influenza_A_H1N1_vector",
    "primaryCompletionDate": "",
    "productId": 592,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "1212b57ee9ead30a43480c416ee4aea43b78bf38",
        "sponsorName": "National Research Centre"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Structurally modified spherical particles of the tobacco mosaic virus (TMV)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Structurally_modified_spherical_particles_of_the_tobacco_mosaic_virus_TMV",
    "primaryCompletionDate": "",
    "productId": 593,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "172ecd90dfdb7af014ad7f2054b1fbef2c9c5302",
        "sponsorName": "Lomonosov Moscow State University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "RBD protein fused with Fc of IgG + Adjuvant",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Thailand"],
    "countryCodes": ["THA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "RBD_protein_fused_with_Fc_of_IgG__Adjuvant",
    "primaryCompletionDate": "",
    "productId": 594,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z",
      "https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"
    ],
    "sponsors": [
      {
        "sponsorId": "a16c5b03cf3aca5c2f20169b4caa909d5c2f07ad",
        "sponsorName": "Chulalongkorn University"
      },
      {
        "sponsorId": "3d073bdf33aac8137319358450ceb3f373467fed",
        "sponsorName": "GPO"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Targeted (Langerhans cell specific) protein subunit",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Targeted_Langerhans_cell_specific_protein_subunit",
    "primaryCompletionDate": "",
    "productId": 595,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "ca87c56cfc7bc3d6a4ca4eee62fa5d404dae1d8e",
        "sponsorName": "MaxPlanck Institute of Colloids and Interfaces"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Plant-based subunit (RBD-Fc + Adjuvant)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Plantbased_subunit_RBDFc__Adjuvant",
    "primaryCompletionDate": "",
    "productId": 596,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "5514dab962f84d4adc4e93787ec5d00d3be66545",
        "sponsorName": "Baiya Phytopharm"
      },
      {
        "sponsorId": "e21faaa59cbe02fdff806f375f68495cc6e16e25",
        "sponsorName": "Chula Vaccine Research Center"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Subunit",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Subunit",
    "primaryCompletionDate": "",
    "productId": 597,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "63bb1c3d46177bd2f5b93e35800302face1bfb45",
        "sponsorName": "Helix Biogen Consult"
      },
      {
        "sponsorId": "2e23b3149c032f51b36fccefbfba3b69bf7d08e8",
        "sponsorName": "Ogbomoso  Trinity Immonoefficient Laboratory"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VSV-S",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VSVS",
    "primaryCompletionDate": "",
    "productId": 598,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "7b216642104c590a170581ca3077e7e78905d4b1",
        "sponsorName": "Israel Institute for Biological Research"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA",
    "primaryCompletionDate": "",
    "productId": 599,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "f46b68e943e93a62cdc8c93a4106f50eed6e636e",
        "sponsorName": "IDIBAPS Hospital Clinic"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "mRNA in targeted LPNs (Langerhans cell specific)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA_in_targeted_LPNs_Langerhans_cell_specific",
    "primaryCompletionDate": "",
    "productId": 600,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "6a5c9de97b0c649b78e8f2e5bc3e4bf47383b2af",
        "sponsorName": "Max Planck Institute of Colloids and Interfaces"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Virus-like particles,lentivirus,and baculovirus vehicles",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Viruslike_particles_lentivirus_and_baculovirus_vehicles",
    "primaryCompletionDate": "",
    "productId": 601,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "cb0fbb316dd2dcb8ed548d5effd8fe9692992576",
        "sponsorName": "Navarrabiomed"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Covaxx-602",
    "primaryCompletionDate": "",
    "productId": 602,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"
    ],
    "sponsors": [
      {
        "sponsorId": "be8691003b7f44ea5a31017727a29311b9804c9e",
        "sponsorName": "Covaxx"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DMX-200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DMX200",
    "primaryCompletionDate": "",
    "productId": 603,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "9009c03f5ebbf1b6351bfcff0f15b20c3d063ea4",
        "sponsorName": "Dimerix Ltd"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Bivalirudin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Bivalirudin",
    "primaryCompletionDate": "",
    "productId": 604,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "c541605ff178d2aa4073412dd96a05c336a1d99e",
        "sponsorName": "Hamad Medical Corp"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Tacrolimus",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "xsolanich@bellvitgehospital.cat",
        "name": null,
        "notes": "",
        "phone": "0034 932607500 ext 8946",
        "website": ""
      }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Tacrolimus",
    "primaryCompletionDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "productId": 605,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04341038",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "L'Hospitalet de Llobregat",
        "country": "ESP",
        "lat": 41.3448959,
        "lng": 2.1042573,
        "locationId": "a564f639b4c4370e381952f64ed5a90e65255dbc",
        "name": "Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain",
        "state": "CT"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx",
      "https://clinicaltrials.gov/ct2/show/NCT04341038"
    ],
    "sponsors": [
      {
        "sponsorId": "6645ceaca15d1553ce17cc0dc6274a85ed816b86",
        "sponsorName": "Hospital Universitari de Bellvitge"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 01 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "BACTEK-R (MV130)",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "gangeles@gmail.com;mcasanovas@inmunotek.com",
        "name": null,
        "notes": "",
        "phone": "18299472222",
        "website": ""
      }
    ],
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStage": "Phase 3",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "BACTEKR_MV130",
    "primaryCompletionDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "productId": 606,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04363814",
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Stgo",
        "country": "DOM",
        "lat": 19.4361409,
        "lng": -70.6610997,
        "locationId": "6dc5cb60bfcedc7f7f5ae35126b125f814603d10",
        "name": "Autopista Duarte Km. 28, Santiago De Los Caballeros 51000, Dominican Republic",
        "state": "Santiago"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04363814",
      "https://www.inmunotek.com/en/022011-bactek-study/"
    ],
    "sponsors": [
      {
        "sponsorId": "a079e72ac22bb802b456578240fd4b30b55b76bd",
        "sponsorName": "Inmunotek SL"
      },
      {
        "sponsorId": "ba2f1de3e34ade67f95b6cbe61851e8b40a2b841",
        "sponsorName": "Bioclever 2005 SL"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 31 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 10 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Doxycycline",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "eve.maubec@aphp.fr; fabrice.bonnet@chu-bordeaux.fr; dompmartin-a@chu-caen.fr; lionel.piroth@chu-dijon.fr; mtleccia@chu-grenoble.fr; brigitte.dreno@atlanmed.fr; amir.khammari@chu-nantes.fr",
        "name": null,
        "notes": "Not yet recruiting",
        "phone": "1 48 95 70 90 ext 0033;  5 56 79 58 23 ext 0033; 2 31 27 25 10 ext 0033; 3 30 29 33 05 ext 0033; 476769320 ext 0033; 2 40 08 31 18 ext 0033",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "6",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Doxycycline",
    "primaryCompletionDate": "",
    "productId": 607,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04371952",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Bobigny",
        "country": "FRA",
        "lat": 48.91461940000001,
        "lng": 2.4239471,
        "locationId": "10da76907400a80c65985ee2bb9e4e1ba197220a",
        "name": "125 Rue de Stalingrad, 93000 Bobigny, France",
        "state": "IDF"
      },
      {
        "city": "Bordeaux",
        "country": "FRA",
        "lat": 44.829016,
        "lng": -0.6061928,
        "locationId": "c17650cdb68440798a41fd2815f013966dda974a",
        "name": "Place Am\u00e9lie Raba L\u00e9on, 33000 Bordeaux, France",
        "state": "Nouvelle-Aquitaine"
      },
      {
        "city": "Caen",
        "country": "FRA",
        "lat": 49.19005019999999,
        "lng": -0.3443813000000001,
        "locationId": "f7f9b14d2760cc5a767cc4d93d68232a02290639",
        "name": "Avenue Georges Clemenceau, 14033 Caen, France",
        "state": "Normandie"
      },
      {
        "city": "Dijon",
        "country": "FRA",
        "lat": 47.3209032,
        "lng": 5.0687494,
        "locationId": "391407ee20140c79e4798554ad0f19612268098e",
        "name": "1 Rue du Professeur Marion, 21000 Dijon, France",
        "state": "Bourgogne-Franche-Comt\u00e9"
      },
      {
        "city": "\u00c9chirolles",
        "country": "FRA",
        "lat": 45.148338,
        "lng": 5.732526399999999,
        "locationId": "1f3c6afef8d690ffb7fe3bf69ccbe5d3a5cf6407",
        "name": "38130 \u00c9chirolles, France",
        "state": "Auvergne-Rh\u00f4ne-Alpes"
      },
      {
        "city": "Nantes",
        "country": "FRA",
        "lat": 47.2120313,
        "lng": -1.5543918,
        "locationId": "4b30de8d2afcfbbb386656a5225def90e53adfd6",
        "name": "1 Place Alexis-Ricordeau, 44093 Nantes, France",
        "state": "Pays de la Loire"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04371952"
    ],
    "sponsors": [
      {
        "sponsorId": "e0899b75679b87aa721de05cfe789eaf7a84d54a",
        "sponsorName": "Nantes University Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Sarconeos (BIO-101)",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "sam.agus@biophytis.com",
        "name": null,
        "notes": "",
        "phone": "16176424891",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 02 Jul 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Potential treatment for respiratory failure associated with Covid-19.",
    "numSites": "1",
    "otherPartners": "Biophytis SA",
    "phase": "2",
    "preferredName": "Sarconeos_BIO101",
    "primaryCompletionDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "productId": 608,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Mechelen",
        "country": "BEL",
        "lat": 51.0514471,
        "lng": 4.475779699999999,
        "locationId": "e73dc1ccd70e8736cefa969ea548d7c70abb5916",
        "name": "Liersesteenweg 435, 2800 Mechelen, Belgium",
        "state": "Vlaanderen"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf",
      "https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1",
      "https://www.biospace.com/article/releases/biophytis-receives-fda-ind-clearance-for-cova-a-phase-2-3-clinical-trial-with-sarconeos-bio101-for-the-treatment-of-patients-with-covid-19-related-respiratory-failure/"
    ],
    "sponsors": [
      {
        "sponsorId": "b7349cea33d3083bc02d13c4b387b855d6b808c1",
        "sponsorName": "Biophytis SA"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "studyStartDate": "Tue, 16 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "sofosbuvir,daclatasvir,hydroxychloroquine",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "",
        "name": null,
        "notes": "Not yet recruiting",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "",
    "otherPartners": "Sovaldi - Gilead Sciences,Daklinza - Bristol-Myers Squibb,Plaquenil - Sanofi Pharmaceuticals",
    "phase": "2",
    "preferredName": "sofosbuvir_daclatasvir_hydroxychloroquine",
    "primaryCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "productId": 609,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04443725",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.healio.com/news/infectious-disease/20200709/hcv-drugs-sofosbuvir-daclatasvir-show-promise-as-potential-covid19-treatment",
      "https://www.medscape.com/viewarticle/933822",
      "https://clinicaltrials.gov/ct2/show/NCT04443725"
    ],
    "sponsors": [
      {
        "sponsorId": "a0e9f9902283ff153eeb6aeece1a1ac40ecb7c10",
        "sponsorName": "Cairo University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "",
    "chemicalName": "pamrevlumab",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 21 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Anti-connective growth factor monoclonal antibody",
    "numSites": "",
    "otherPartners": "Fibrogen Inc",
    "phase": "2",
    "preferredName": "pamrevlumab",
    "primaryCompletionDate": "",
    "productId": 610,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0"
    ],
    "sponsors": [
      {
        "sponsorId": "6f85ebbf6fab446350dc544d486ac541b13ce031",
        "sponsorName": "Fibrogen Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "NA-831",
    "chemicalName": "atazanavir,dexamethasone",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "BTran@neuroactiva.com; FKennedy@neuroactiva.com",
        "name": null,
        "notes": "",
        "phone": "14159413133; 14159413133",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 15 Aug 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Combination",
    "notes": "Anti-retroviral and anti-inflammatory combination therapy",
    "numSites": "31",
    "otherPartners": "NeuroActiva Inc.",
    "phase": "2",
    "preferredName": "atazanavir_dexamethasone",
    "primaryCompletionDate": "",
    "productId": 611,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04452565",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Los Angeles",
        "country": "USA",
        "lat": 34.070264,
        "lng": -118.4440562,
        "locationId": "3cbe1af9ddf4485902e6684f0874ea1ac2d7a020",
        "name": "Los Angeles, CA 90095, USA",
        "state": "CA"
      },
      {
        "city": "Orange",
        "country": "USA",
        "lat": 33.787596,
        "lng": -117.863124,
        "locationId": "b7d60892b9efb5bdb62965259cd2863ccbb9fe5f",
        "name": "1010 W Chapman Ave, Orange, CA 92868, USA",
        "state": "CA"
      },
      {
        "city": "Palo Alto",
        "country": "USA",
        "lat": 37.3813444,
        "lng": -122.1802812,
        "locationId": "847e31b19e214d13c2fefc826691ab98f93e1306",
        "name": "Palo Alto, CA 94304, USA",
        "state": "CA"
      },
      {
        "city": "Sacramento",
        "country": "USA",
        "lat": 38.5500434,
        "lng": -121.4599012,
        "locationId": "ab52e3fc114eda056953e3c19d71810887b28852",
        "name": "Sacramento, CA 95817, USA",
        "state": "CA"
      },
      {
        "city": "San Diego",
        "country": "USA",
        "lat": 32.715738,
        "lng": -117.1610838,
        "locationId": "f2eda56737c7e1c7a2047ec30f4094ac9be12845",
        "name": "San Diego, CA, USA",
        "state": "CA"
      },
      {
        "city": "SF",
        "country": "USA",
        "lat": 37.7485824,
        "lng": -122.4184108,
        "locationId": "bf32c19ed367bba58a0058edf14c3934bcb1fc5d",
        "name": "San Francisco, CA 94110, USA",
        "state": "CA"
      },
      {
        "city": "Sunnyvale",
        "country": "USA",
        "lat": 37.371859,
        "lng": -122.0212337,
        "locationId": "ce39cf538af6315ad3f8b29362a585f59b8bc1d2",
        "name": "Sunnyvale, CA 94086, USA",
        "state": "CA"
      },
      {
        "city": "Washington",
        "country": "USA",
        "lat": 38.9156487,
        "lng": -77.0737149,
        "locationId": "e060f4a1e848744bc6bfdb14aef2327682757151",
        "name": "Washington, DC 20007, USA",
        "state": "DC"
      },
      {
        "city": "Washington",
        "country": "USA",
        "lat": 38.9339046,
        "lng": -77.03053899999999,
        "locationId": "2dbae92a4e82c6132e4ad5079f211aa909d09034",
        "name": "Washington, DC 20010, USA",
        "state": "DC"
      },
      {
        "city": "LAUD BY SEA",
        "country": "USA",
        "lat": 26.1897731,
        "lng": -80.1037721,
        "locationId": "2528c490af06c2ff9eafeb26f8c741548dce46b3",
        "name": "LAUD BY SEA, FL 33308, USA",
        "state": "FL"
      },
      {
        "city": "Tampa",
        "country": "USA",
        "lat": 28.0634666,
        "lng": -82.4129729,
        "locationId": "d177b7fd06173cf9704d3ae766022b2bd1302d87",
        "name": "Tampa, FL 33620, USA",
        "state": "FL"
      },
      {
        "city": "Chicago",
        "country": "USA",
        "lat": 41.8816606,
        "lng": -87.6926257,
        "locationId": "aa42311473c331b4f37f6754159df3e4e6f95ead",
        "name": "Chicago, IL 60612, USA",
        "state": "IL"
      },
      {
        "city": "Naperville",
        "country": "USA",
        "lat": 41.7606321,
        "lng": -88.1437782,
        "locationId": "f69f27ecbd6d066f90ca5b0f854e599aa7e353af",
        "name": "Naperville, IL 60540, USA",
        "state": "IL"
      },
      {
        "city": "Baltimore",
        "country": "USA",
        "lat": 39.2962372,
        "lng": -76.5928888,
        "locationId": "5633f689b52aaf4c8ec093f360bb0205b1db1df7",
        "name": "Baltimore, MD 21287, USA",
        "state": "MD"
      },
      {
        "city": "Bethesda",
        "country": "USA",
        "lat": 39.0023604,
        "lng": -77.097455,
        "locationId": "8685ecab8502ca70e8bdaf56fac7d2cd76a1d949",
        "name": "Bethesda, MD 20892, USA",
        "state": "MD"
      },
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3652917,
        "lng": -71.0646337,
        "locationId": "a7f31336db794451879f743824317852c44abf21",
        "name": "Boston, MA 02114, USA",
        "state": "MA"
      },
      {
        "city": "Worcester",
        "country": "USA",
        "lat": 42.27174429999999,
        "lng": -71.7588217,
        "locationId": "c27e6068736b21cbfaed7fc1944199c7b1df3254",
        "name": "Worcester, MA 01655, USA",
        "state": "MA"
      },
      {
        "city": "Ann Arbor",
        "country": "USA",
        "lat": 42.3053253,
        "lng": -83.6694169,
        "locationId": "20efe7c2e7968093bb6ffb6f759d53eeec441ca9",
        "name": "Ann Arbor, MI 48109, USA",
        "state": "MI"
      },
      {
        "city": "Detroit",
        "country": "USA",
        "lat": 42.3664506,
        "lng": -83.0737195,
        "locationId": "c91632c0f8d486816cbd117ced0cd2e2f20a793b",
        "name": "Detroit, MI 48202, USA",
        "state": "MI"
      },
      {
        "city": "Newark",
        "country": "USA",
        "lat": 40.7350747,
        "lng": -74.17390569999999,
        "locationId": "eabd1e9abde7cb8b9bde6451c046085a06e7c3dd",
        "name": "Newark, NJ 07102, USA",
        "state": "NJ"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 40.8723987,
        "lng": -73.8713099,
        "locationId": "99e292b04e4e725d069a6cf7f352d570f9a840ff",
        "name": "The Bronx, NY 10467, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.74727,
        "lng": -73.9800645,
        "locationId": "8b2a6c4ac6bdc6068caab74c270b67a96ef7fcdc",
        "name": "New York, NY 10016, USA",
        "state": "NY"
      },
      {
        "city": "Rochester",
        "country": "USA",
        "lat": 43.12247660000001,
        "lng": -77.62425739999999,
        "locationId": "781b794bb777ead0e7dc5086aa783b37940e9c15",
        "name": "Rochester, NY 14642, USA",
        "state": "NY"
      },
      {
        "city": "Durham",
        "country": "USA",
        "lat": 36.0323222,
        "lng": -78.8269385,
        "locationId": "0d09338043b630f849ab7944d931569ea982edb8",
        "name": "Durham, NC 27704, USA",
        "state": "NC"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9570397,
        "lng": -75.205607,
        "locationId": "b84df347a24add04c2f8fad277d7313fdbabe9e8",
        "name": "4122 Market St, Philadelphia, PA 19124, USA",
        "state": "PA"
      },
      {
        "city": "San Antonio",
        "country": "USA",
        "lat": 29.4569597,
        "lng": -98.4458421,
        "locationId": "13b390ae83d8f695d445ebfd677ea99cca4bea60",
        "name": "Fort Sam Houston, San Antonio, TX, USA",
        "state": "TX"
      },
      {
        "city": "Galveston",
        "country": "USA",
        "lat": 29.3106102,
        "lng": -94.77724930000001,
        "locationId": "4bef11e8a1631377a2d16dbb58e27cc2c6242807",
        "name": "Galveston, TX 77555, USA",
        "state": "TX"
      },
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.7050857,
        "lng": -95.40180869999999,
        "locationId": "8ef0393f1feecbcd0c67ab79a6d6f7ea6d88f09d",
        "name": "Houston, TX 77030, USA",
        "state": "TX"
      },
      {
        "city": "Kirkland",
        "country": "USA",
        "lat": 47.71481259999999,
        "lng": -122.2031264,
        "locationId": "4225ff8f18dc3833879c3edb0ed3dc5b237c8e94",
        "name": "Kirkland, WA 98034, USA",
        "state": "WA"
      },
      {
        "city": "Seattle",
        "country": "USA",
        "lat": 47.6015566,
        "lng": -122.3323351,
        "locationId": "bb5aa859bd2cf23281f98bff529f9c16468b5ab0",
        "name": "Seattle, WA 98104, USA",
        "state": "WA"
      },
      {
        "city": "MADIGAN HOSP",
        "country": "USA",
        "lat": 47.11040999999999,
        "lng": -122.5512299,
        "locationId": "d975ac52e28a63979719d23ce41ce143ccc9dacd",
        "name": "MADIGAN HOSP, WA 98431, USA",
        "state": "WA"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04452565"
    ],
    "sponsors": [
      {
        "sponsorId": "322b1011c1d5b362545e86fc92bc54bfd5be2aa9",
        "sponsorName": "Neuroactiva Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 15 Feb 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 15 Aug 2020 00:00:00 GMT",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Epoprostenol (Ventoprost)",
    "chemicalName": "epoprostenol",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "judydoto@aerogenpharma.com",
        "name": null,
        "notes": "Not yet Recruiting",
        "phone": "4847165438",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation.",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "epoprostenol",
    "primaryCompletionDate": "",
    "productId": 612,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Columbus",
        "country": "USA",
        "lat": 40.0068363,
        "lng": -83.0306222,
        "locationId": "50f7ae688b66ada4c1cab4abbbead766dd490ef9",
        "name": "Columbus, OH 43210, USA",
        "state": "OH"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.acc.org/latest-in-cardiology/articles/2020/05/13/08/55/inpatient-use-of-inhaled-pulmonary-vasodilator-therapy-in-patients-infected-with-covid-19",
      "https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "bc9e5eca997a144be366f4d6e88ea283e30a3403",
        "sponsorName": "Aerogen Pharma Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 01 Feb 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 31 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "razuprotafib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Razuprotafib blocks vascular endothelial protein tyrosine phosphatase,or VE-PTP,that depresses production of Tie2 receptor proteins. Tie2 proteins are receptors on the surface of cells that bind to angiopoietins,which are protein growth factors needed to form blood vessels; Thus,razuprotafib activates Tie2 receptor proteins,allowing for stable blood vessel formation in affected tissue in the eyes and kidneys,which the company is testing in mid-stage clinical trials. Aerpio says it has preclinical evidence showing the drug\u2019s beneficial effects extend to a number of disease states including ARDS resulting from Covid-19 infections.",
    "numSites": "",
    "otherPartners": "Aerpio Pharmaceuticals Inc,Quantum Leap",
    "phase": "",
    "preferredName": "razuprotafib",
    "primaryCompletionDate": "",
    "productId": 613,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://sciencebusiness.technewslit.com/?p=39191",
      "https://www.globenewswire.com/news-release/2020/05/27/2039771/0/en/Aerpio-Pharmaceuticals-Inc-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Razuprotafib-for-Evaluation-in-the-I-SPY-COVID-Trial-for-the-Treatment-of-Acute-Respi.html"
    ],
    "sponsors": [
      {
        "sponsorId": "47c603698fd74b018b030979d7596f25a7f9a102",
        "sponsorName": "Aerpio Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "LAM-002A",
    "chemicalName": "apilimod",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "pyoung@ai-thera.com",
        "name": null,
        "notes": "",
        "phone": "4158608370",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "AI Therapeutics Inc.",
    "phase": "2",
    "preferredName": "apilimod",
    "primaryCompletionDate": "",
    "productId": 614,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04446377",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "New Haven",
        "country": "USA",
        "lat": 41.3163244,
        "lng": -72.92234309999999,
        "locationId": "3c8bbf40af9588348ee72dd41a39bc9d2c5d89fa",
        "name": "New Haven, CT 06520, USA",
        "state": "CT"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04446377#contacts",
      "https://adisinsight.springer.com/drugs/800043703"
    ],
    "sponsors": [
      {
        "sponsorId": "eec7529f9327cfeb8fa0e547aa52d04796843327",
        "sponsorName": "AI Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 31 Jan 2020 00:00:00 GMT",
    "studyStartDate": "Wed, 15 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "DUR-928",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "deborah.scott@durect.com ; julie.fergus@durect.com        ",
        "name": null,
        "notes": "",
        "phone": "4087771417",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "DUR928",
    "primaryCompletionDate": "",
    "productId": 615,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04447404",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Chicago",
        "country": "USA",
        "lat": 41.8781136,
        "lng": -87.6297982,
        "locationId": "fbaf06cd133bf6c895fa5a49a06af3ee91e808f0",
        "name": "Chicago, IL, USA",
        "state": "IL"
      },
      {
        "city": "Detroit",
        "country": "USA",
        "lat": 42.331427,
        "lng": -83.0457538,
        "locationId": "b79f8b30df2497a51975221a10b3a4c4851c41fe",
        "name": "Detroit, MI, USA",
        "state": "MI"
      },
      {
        "city": "Newark",
        "country": "USA",
        "lat": 40.735657,
        "lng": -74.1723667,
        "locationId": "75247dc58218d09ffbb9ca95442137b80d71dca7",
        "name": "Newark, NJ, USA",
        "state": "NJ"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://www.durect.com/dur-928/overview/",
      "https://www.biospace.com/article/releases/durect-corporation-announces-initiation-of-patient-recruitment-in-phase-2-safety-and-efficacy-study-of-dur-928-in-covid-19-patients-with-acute-liver-or-kidney-injury/",
      "https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4",
      "https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=5",
      "https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=6",
      "https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=7",
      "https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=8",
      "https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=9",
      "https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=10"
    ],
    "sponsors": [
      {
        "sponsorId": "16d4dbeba3798fe50eefb54803d0a296bb9520ed",
        "sponsorName": "Durect Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 01 Jan 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Tecfarin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently in phase 3 for treating patients with End Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Tecfarin",
    "primaryCompletionDate": "",
    "productId": 616,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/",
      "https://esperobio.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "3a9d2099cfa8e9dee05c02576fe34151aa3a054d",
        "sponsorName": "Espero Biopharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Interleukin-2",
    "chemicalName": "ILT101",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "Jean-michel.constantin@aphp.fr",
        "name": null,
        "notes": "",
        "phone": "3301421600",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Assistance Publique - H\u00f4pitaux de Paris",
    "phase": "2",
    "preferredName": "ILT101",
    "primaryCompletionDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "productId": 617,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04357444",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.856614,
        "lng": 2.3522219,
        "locationId": "b0a866eb290653a4466736d3babc6fa66234c084",
        "name": "Paris, France",
        "state": "IDF"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04357444#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "ccb2d316b0239e5a9b916549c4ebc0cc32112aa4",
        "sponsorName": "ILTOO Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sat, 01 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Nangibotide",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "covtrem@inotrem.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Nangibotide",
    "primaryCompletionDate": "Sun, 01 Mar 2020 00:00:00 GMT",
    "productId": 618,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04429334",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Nancy",
        "country": "FRA",
        "lat": 48.6839465,
        "lng": 6.1894724,
        "locationId": "d28ba0cf770d8c220cfcbda9f86d78167f2cc6c1",
        "name": "29 Avenue du Mar\u00e9chal de Lattre de Tassigny, 54035 Nancy, France",
        "state": "Grand Est"
      }
    ],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "704022b5f19f6408d4c855cfdc7fd3bb952dc2bf",
        "sponsorName": "Inotrem"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 01 Mar 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Inhibitor of Neutrophil Elastase,Isotretinoin",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "\tmahmoudramadan2051@yahoo.com",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": ["Egypt"],
    "countryCodes": ["EGY"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "",
    "otherPartners": "Damietta University",
    "phase": "2",
    "preferredName": "Inhibitor_of_Neutrophil_Elastase_Isotretinoin",
    "primaryCompletionDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "productId": 619,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04396067",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "EGY",
        "lat": 26.820553,
        "lng": 30.802498,
        "locationId": "0c5010eafdc6f084859e6e5aa933c88120049f80",
        "name": "Egypt",
        "state": null
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04396067#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "fd151515ae478f71dd5fdce169d883577fa21257",
        "sponsorName": "Kafrelsheikh University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 01 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Secukinumab",
    "chemicalName": "Cosentyx",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "begrambekova@ossn.ru ; yaorlova@mc.msu.ru",
        "name": null,
        "notes": "",
        "phone": "79854679273 ; 791651663002",
        "website": ""
      }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 08 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Combination",
    "notes": "Study compares COLchicine Versus Ruxolitinib and Secukinumab",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Cosentyx",
    "primaryCompletionDate": "",
    "productId": 620,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04403243",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Moscow",
        "country": "RUS",
        "lat": 55.755826,
        "lng": 37.6172999,
        "locationId": "a1b94a8d44ad80a9ccad02f5157703aa9cac61bc",
        "name": "Moscow, Russia",
        "state": null
      }
    ],
    "sources": [
      "https://www.cosentyx.com/",
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04403243#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "0dbbfcca49ab1d748bc20572875508a44075ee0a",
        "sponsorName": "Lomonosov Moscow State University Medical Research and Education Center"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 23 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Fri, 08 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Rayaldee",
    "chemicalName": "calcifediol",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Despite information that a phase 2 trial is happening,no information on clinical trials.com",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "calcifediol",
    "primaryCompletionDate": "",
    "productId": 621,
    "registryLink": "",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.opko.com/news-media/press-releases/detail/394/fda-authorizes-opko-health-clinical-trial-evaluating",
      "https://www.drugbank.ca/drugs/DB00146",
      "https://www.drugbank.ca/drugs/DB00147",
      "https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/"
    ],
    "sponsors": [
      {
        "sponsorId": "88c1753face32faae228509118d1afebd9cb9e06",
        "sponsorName": "Opko Health Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "AMY-101",
    "chemicalName": "",
    "conditionOrDisease": "ARDS",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Jul 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "is a C3 inhibitor",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "AMY101",
    "primaryCompletionDate": "Fri, 01 Jan 2021 00:00:00 GMT",
    "productId": 622,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04395456",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04395456#contacts",
      "https://www.amyndas.com/contact/"
    ],
    "sponsors": [
      {
        "sponsorId": "d8f6c93fd473eeeae66b037e34bdbf47207f50f6",
        "sponsorName": "Amyndas Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 01 Mar 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "RBT-9",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "covid19trials@renibus.com; sruiz@renibus.com\t",
        "name": null,
        "notes": "",
        "phone": "\t6822851733",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Frontier Scientific",
    "phase": "2",
    "preferredName": "RBT9",
    "primaryCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "productId": 623,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04364763",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Fort Worth",
        "country": "USA",
        "lat": 32.7554883,
        "lng": -97.3307658,
        "locationId": "b41afa35b480c2b3843f2f008f5b79cf44da4b70",
        "name": "Fort Worth, TX, USA",
        "state": "TX"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/",
      "https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "e5bd469344b4fe42c4f9a766c3ad7c046e92843d",
        "sponsorName": "Renibus Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Axatilimab",
    "chemicalName": "SNDX-6352",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "sfischer@syndax.com\t",
        "name": null,
        "notes": "",
        "phone": "7817959419",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 30 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "SNDX6352",
    "primaryCompletionDate": "Sun, 15 Nov 2020 00:00:00 GMT",
    "productId": 624,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04415073",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Scottsdale",
        "country": "USA",
        "lat": 33.4941704,
        "lng": -111.9260519,
        "locationId": "4bab31813b42601d9ecb4ab390665ca869163d51",
        "name": "Scottsdale, AZ, USA",
        "state": "AZ"
      },
      {
        "city": null,
        "country": "USA",
        "lat": 40.8447819,
        "lng": -73.8648268,
        "locationId": "c087dd724889171eca635293c6f51d6f1b33737a",
        "name": "The Bronx, NY, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://www.syndax.com/pipeline/",
      "https://clinicaltrials.gov/ct2/show/NCT04415073?recrs=a&type=Intr&cond=COVID-19&draw=14&rank=606",
      "https://www.bioworld.com/COVID19products",
      "http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB",
      "https://clinicaltrials.gov/ct2/show/NCT04415073",
      "https://clinicaltrials.gov/ct2/show/NCT04415073#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "95ca711e2f6e8ea27c70dff5cddb64337335931c",
        "sponsorName": "Syndax Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 15 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 30 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Zilucoplan",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "anja.delporte@uzgent.be; bart.lambrecht@ugent.be",
        "name": null,
        "notes": "",
        "phone": "003293320228",
        "website": ""
      }
    ],
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 22 May 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "9",
    "otherPartners": "University Hospital,Ghent",
    "phase": "2",
    "preferredName": "Zilucoplan",
    "primaryCompletionDate": "Thu, 20 May 2021 00:00:00 GMT",
    "productId": 625,
    "registryLink": "https://www.clinicaltrials.gov/ct2/show/NCT04382755",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Aalst",
        "country": "BEL",
        "lat": 50.9378101,
        "lng": 4.0409517,
        "locationId": "41f01b41f2fdac6a7f96bd54bb81d3e20cf08dd1",
        "name": "Aalst, Belgium",
        "state": "Flanders"
      },
      {
        "city": "Bruges",
        "country": "BEL",
        "lat": 51.209348,
        "lng": 3.2246995,
        "locationId": "0e245cc3ccf8ca67884c884d35f42714d67706a9",
        "name": "Bruges, Belgium",
        "state": "Flanders"
      },
      {
        "city": "Brussels",
        "country": "BEL",
        "lat": 50.8503396,
        "lng": 4.3517103,
        "locationId": "4e9cdebbc9850a46000b008e34b8eda2e12a8d85",
        "name": "Brussels, Belgium",
        "state": "Brussels"
      },
      {
        "city": "Ghent",
        "country": "BEL",
        "lat": 51.0543422,
        "lng": 3.7174243,
        "locationId": "548cfa20afa657f3467536c8f39bb8ca9053dd3c",
        "name": "Ghent, Belgium",
        "state": "Flanders"
      },
      {
        "city": "Ypres",
        "country": "BEL",
        "lat": 50.8492265,
        "lng": 2.8779388,
        "locationId": "280eb0dee7b27d94fadc2584996d956552533bba",
        "name": "Ypres, Belgium",
        "state": "Flanders"
      },
      {
        "city": "Li\u00e8ge",
        "country": "BEL",
        "lat": 50.6325574,
        "lng": 5.5796662,
        "locationId": "e39f3644fd0c352f85303ddbfd5752b831758b73",
        "name": "Li\u00e8ge, Belgium",
        "state": "Wallonia"
      },
      {
        "city": "Roeselare",
        "country": "BEL",
        "lat": 50.94990869999999,
        "lng": 3.1294471,
        "locationId": "6756327785dda01ec8ea0ce84cf2913f6eb9d9da",
        "name": "8800 Roeselare, Belgium",
        "state": "Flanders"
      },
      {
        "city": "Tongeren",
        "country": "BEL",
        "lat": 50.78419,
        "lng": 5.474489999999999,
        "locationId": "f7ccab2eff4e433570f72b82153de3f68591e69d",
        "name": "3700 Tongeren, Belgium",
        "state": "Flanders"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.clinicaltrials.gov/ct2/show/NCT04382755",
      "https://www.drugbank.ca/drugs/DB15636",
      "https://myastheniagravisnews.com/zilucoplan/",
      "https://www.ucb.com/our-science/pipeline"
    ],
    "sponsors": [
      {
        "sponsorId": "c7e43505cffbcf9841685fe24b4c5bb8df416c6f",
        "sponsorName": "UCB Pharma"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 20 Sep 2021 00:00:00 GMT",
    "studyStartDate": "Fri, 22 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Brequinar",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinical@clearcreekbio.com",
        "name": null,
        "notes": "",
        "phone": "(617) 765-2252",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 25 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "3",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "Brequinar",
    "primaryCompletionDate": "Sun, 20 Sep 2020 00:00:00 GMT",
    "productId": 626,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04425252",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Hartford",
        "country": "USA",
        "lat": 41.7545616,
        "lng": -72.6792339,
        "locationId": "9a6b133164f085ebb12032aaae4b6cd243a980a0",
        "name": "80 Seymour St, Hartford, CT 06106, USA",
        "state": "CT"
      },
      {
        "city": "Tampa",
        "country": "USA",
        "lat": 28.0670707,
        "lng": -82.41974019999999,
        "locationId": "898809dee0c66cd6a9882a1787581fd48788dd90",
        "name": "13330 USF Laurel Dr, Tampa, FL 33620, USA",
        "state": "FL"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 39.9805942,
        "lng": -75.1557376,
        "locationId": "c72f724509a4fb6f3444a3f59adcc578a06aa295",
        "name": "1801 N Broad St, Philadelphia, PA 19122, USA",
        "state": "PA"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04425252",
      "https://www.clearcreekbio.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "f5c984948f7e8d0795dcb6accb0b2bd27f1d75ca",
        "sponsorName": "Clear Creek Bio Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "studyStartDate": "Thu, 25 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Lanadelumab",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "roger.bruggemann@radboudumc.nl",
        "name": null,
        "notes": "",
        "phone": "0031243611111",
        "website": ""
      }
    ],
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "10",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "Lanadelumab",
    "primaryCompletionDate": "Tue, 01 Jun 2021 00:00:00 GMT",
    "productId": 627,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04422509",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "'s-Hertogenbosch",
        "country": "NLD",
        "lat": 51.6978162,
        "lng": 5.3036748,
        "locationId": "be5c63690a3c1ba89fa557cf1faa7d1ae72cbeaf",
        "name": "'s-Hertogenbosch, Netherlands",
        "state": "NB"
      },
      {
        "city": "Amsterdam",
        "country": "NLD",
        "lat": 52.3666969,
        "lng": 4.8945398,
        "locationId": "33624c23c17f5d26949c506ca477ff1efa426683",
        "name": "Amsterdam, Netherlands",
        "state": "NH"
      },
      {
        "city": "Arnhem",
        "country": "NLD",
        "lat": 51.9851034,
        "lng": 5.898729599999999,
        "locationId": "3c0d3ea7505940760c5d7070ff2125bb66134a9b",
        "name": "Arnhem, Netherlands",
        "state": "GE"
      },
      {
        "city": "Blaricum",
        "country": "NLD",
        "lat": 52.2726695,
        "lng": 5.248079499999999,
        "locationId": "dcabee67c18ef699c9869d9a2895de91ee1cb6bc",
        "name": "1261 Blaricum, Netherlands",
        "state": "NH"
      },
      {
        "city": "Breda",
        "country": "NLD",
        "lat": 51.5719149,
        "lng": 4.768323,
        "locationId": "f5768022dc5628ab08b7e314372479d2bbca37ef",
        "name": "Breda, Netherlands",
        "state": "NB"
      },
      {
        "city": "The Hague",
        "country": "NLD",
        "lat": 52.0704978,
        "lng": 4.3006999,
        "locationId": "8002f62952d555c02a8d0e807313a1002bc43c34",
        "name": "The Hague, Netherlands",
        "state": "ZH"
      },
      {
        "city": "Nijmegen",
        "country": "NLD",
        "lat": 51.8125626,
        "lng": 5.8372264,
        "locationId": "2d0fd3f7537be419e1e60c4e8d2fd9f3e97d5658",
        "name": "Nijmegen, Netherlands",
        "state": "GE"
      },
      {
        "city": "Tilburg",
        "country": "NLD",
        "lat": 51.560596,
        "lng": 5.0919143,
        "locationId": "6644605658d22f28374d684785e220ca950dc0d2",
        "name": "Tilburg, Netherlands",
        "state": "NB"
      },
      {
        "city": "Utrecht",
        "country": "NLD",
        "lat": 52.09073739999999,
        "lng": 5.1214201,
        "locationId": "deb377fb35f9ba7e5bf9ae5bc01148754ba4112a",
        "name": "Utrecht, Netherlands",
        "state": "UT"
      },
      {
        "city": "Zwolle",
        "country": "NLD",
        "lat": 52.5167747,
        "lng": 6.083021899999999,
        "locationId": "346aee25de1f9c21d26c5817703810569ef03002",
        "name": "Zwolle, Netherlands",
        "state": "Overste"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04422509",
      "https://www.takhzyro.com/",
      "https://www.ru.nl/english/"
    ],
    "sponsors": [
      {
        "sponsorId": "2535b4b541b25cc95cbd404bcf7c61d44c2d92d0",
        "sponsorName": "Radbout Univercity"
      },
      {
        "sponsorId": "31759effba9dd9037b4a5b2a4e1bf87cb0e4042b",
        "sponsorName": "Takeda"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 01 Aug 2021 00:00:00 GMT",
    "studyStartDate": "Thu, 25 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Pentoxifylline",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "mahmoud.samy@gop.usc.edu.eg",
        "name": null,
        "notes": "",
        "phone": "00201063340887",
        "website": ""
      }
    ],
    "countries": ["Egypt"],
    "countryCodes": ["EGY"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "Pentoxifylline",
    "primaryCompletionDate": "",
    "productId": 628,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04433988",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Shebeen El-Kom",
        "country": "EGY",
        "lat": 30.550334,
        "lng": 31.0106341,
        "locationId": "559458d8e4cc43c7d602695910b86031ab7f9c6e",
        "name": "Shebeen El-Kom, Qism Shebeen El-Kom, Shibin el Kom, Menofia Governorate, Egypt",
        "state": "Menofia Governorate"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04433988",
      "https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13733?af=R"
    ],
    "sponsors": [
      {
        "sponsorId": "a16bac5a1c4bf6f4e33b72f12986c8d936f2d5f2",
        "sponsorName": "Sadat City University"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Thu, 13 Aug 2020 00:00:00 GMT",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "SBI-101",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "brian.miller@sentienbiotech.com",
        "name": null,
        "notes": "",
        "phone": "781-361-9031",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "SBI101",
    "primaryCompletionDate": "Sat, 20 Feb 2021 00:00:00 GMT",
    "productId": 629,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04445220",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04445220",
      "https://sentienbiotech.com/product/",
      "https://sentienbiotech.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "da566f6dde9d880ea1d69769d90f4af25c5dadc0",
        "sponsorName": "Sentien Biotechnologies Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 20 Jul 2021 00:00:00 GMT",
    "studyStartDate": "Thu, 20 Aug 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "TL-895",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "jmei@teliospharma.com",
        "name": null,
        "notes": "",
        "phone": "650-542-0136",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "TL895",
    "primaryCompletionDate": "Tue, 20 Jul 2021 00:00:00 GMT",
    "productId": 630,
    "registryLink": "https://www.clinicaltrials.gov/ct2/show/NCT04419623",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.clinicaltrials.gov/ct2/show/NCT04419623"
    ],
    "sponsors": [
      {
        "sponsorId": "41bd7b0473a053c2df18cd85925146dcaf9ff2f7",
        "sponsorName": "Telios Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 20 Jul 2021 00:00:00 GMT",
    "studyStartDate": "Sat, 20 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Agent-797",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 02 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Agent797",
    "primaryCompletionDate": "",
    "productId": 631,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://agenusbio.com/pipeline/",
      "https://investor.agenusbio.com/2020-06-02-FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients",
      "https://agenusbio.com/inkt-allogeneic-cell-therapy/"
    ],
    "sponsors": [
      {
        "sponsorId": "70aae622d49d503de9e5605f93675daf07bb0646",
        "sponsorName": "Agenus Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "APL-9",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clinicaltrials@apellis.com",
        "name": null,
        "notes": "",
        "phone": "833-284-6361",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 26 May 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "APL9",
    "primaryCompletionDate": "Fri, 20 Nov 2020 00:00:00 GMT",
    "productId": 632,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04402060",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Miami",
        "country": "USA",
        "lat": 25.747314,
        "lng": -80.31765469999999,
        "locationId": "5f18442bb1f0e49d734c2e6f20dd54644a2d8a09",
        "name": "2500 SW 75th Ave, Miami, FL 33155, USA",
        "state": "FL"
      },
      {
        "city": "Louisville",
        "country": "USA",
        "lat": 38.2354572,
        "lng": -85.63263889999999,
        "locationId": "2efbd3139f6d88133c121e164ab55d5eb09b169e",
        "name": "4001 Dutchmans Ln, Louisville, KY 40207, USA",
        "state": "KY"
      },
      {
        "city": "Louisville",
        "country": "USA",
        "lat": 38.2153895,
        "lng": -85.7226919,
        "locationId": "1e5cbabccf3e07d9e67aa101b1b6ec0f79d182b3",
        "name": "One Audubon Plaza Dr, Louisville, KY 40217, USA",
        "state": "KY"
      },
      {
        "city": "Buffalo",
        "country": "USA",
        "lat": 43.0008093,
        "lng": -78.7889697,
        "locationId": "206ec8ecc47098542533b61fec20fa5a445d1d98",
        "name": "Buffalo, NY 14260, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://investors.apellis.com/news-releases/news-release-details/apellis-initiates-phase-12-study-apl-9-patients-severe-covid-19",
      "https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-will-commence-apl-9-program-control",
      "http://apellis.com/our-science/our-pipeline",
      "https://apellis.com/contact-us/",
      "https://clinicaltrials.gov/ct2/show/NCT04402060"
    ],
    "sponsors": [
      {
        "sponsorId": "19a5ec9e2f0b0179e97fd0d2eed9c23d8bc9ff25",
        "sponsorName": "Apellis Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Fri, 20 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Tue, 26 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "BX-U001",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "baylx@baylxinc.com",
        "name": null,
        "notes": "",
        "phone": "949-308-1952",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 04 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "ONGOING"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "BXU001",
    "primaryCompletionDate": "",
    "productId": 633,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells",
      "https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2",
      "https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells#:~:text=Irvine%2C%20CA%2C%20USA%2C%20June%2004%2C%202020%20--%20Baylx%2C",
      "%28hUC-MSC%29%20product%20in%20patients%20with%20Rheumatoid%20Arthritis%20%28RA%29."
    ],
    "sponsors": [
      {
        "sponsorId": "12e021f990b58f0c1d10bb15e82b486a26f92aa6",
        "sponsorName": "Baylx Inc"
      }
    ],
    "status": "On Hold",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 01 Sep 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "BAT-2020",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "BAT2020",
    "primaryCompletionDate": "Sat, 03 Oct 2020 00:00:00 GMT",
    "productId": 634,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04432766",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04432766",
      "https://www.biothera.com/"
    ],
    "sponsors": [
      {
        "sponsorId": "0ef1b6b8ccaf5de67fd274fb3286592880884373",
        "sponsorName": "BioThera Solutions"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 18 Jan 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "FSD-201",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 21 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Phase 1 demonstrated no serious adverse side effects and company plans to advance into a Phase 2a trail for COVID-19 treatment without mention of a start date",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "FSD201",
    "primaryCompletionDate": "",
    "productId": 635,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase",
      "https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379084&isReview=true"
    ],
    "sponsors": [
      {
        "sponsorId": "594be65a8371a5afc8037dcf3baf8df5ce31f8ea",
        "sponsorName": "FSD Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "TAK-981",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "globaloncologymedinfo@takeda.com",
        "name": null,
        "notes": "",
        "phone": "1-844-662-8532",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 22 May 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Intended for studying in subset of cancer patients with COVID-19",
    "numSites": "8",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "TAK981",
    "primaryCompletionDate": "Tue, 16 Feb 2021 00:00:00 GMT",
    "productId": 636,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "San Diego",
        "country": "USA",
        "lat": 32.8786467,
        "lng": -117.2230577,
        "locationId": "7a092973a489f9ec8dbb2ef9df1d074425cdf655",
        "name": "3855 Health Sciences Dr, La Jolla, CA 92037, USA",
        "state": "CA"
      },
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.363376,
        "lng": -71.0686521,
        "locationId": "ed8248051b6b3464b1ab752e5395715de5a96513",
        "name": "55 Fruit St, Boston, MA 02114, USA",
        "state": "MA"
      },
      {
        "city": "Detroit",
        "country": "USA",
        "lat": 42.3521598,
        "lng": -83.05730550000001,
        "locationId": "f976fa8b1d1356b3bb7be127f3a6a7b8092cae59",
        "name": "4100 John R St, Detroit, MI 48201, USA",
        "state": "MI"
      },
      {
        "city": "St Paul",
        "country": "USA",
        "lat": 44.955735,
        "lng": -93.09477299999999,
        "locationId": "5dad9ea34a92a6452961452d4bc08ec80eeba2d8",
        "name": "640 Jackson St, St Paul, MN 55101, USA",
        "state": "MN"
      },
      {
        "city": "Cleveland",
        "country": "USA",
        "lat": 41.5069941,
        "lng": -81.6056084,
        "locationId": "09dd02edeec7c0b4e5794bd319999961a34bc47e",
        "name": "11100 Euclid Ave, Cleveland, OH 44106, USA",
        "state": "OH"
      },
      {
        "city": "Philadelphia",
        "country": "USA",
        "lat": 40.0716804,
        "lng": -75.0912008,
        "locationId": "a474d21fa8393076deaeb2f098c2eaccefe88fa7",
        "name": "333 Cottman Ave, Philadelphia, PA 19111, USA",
        "state": "PA"
      },
      {
        "city": "Houston",
        "country": "USA",
        "lat": 29.7068146,
        "lng": -95.3971547,
        "locationId": "d3001c42b48ca12b20d91a9eecd9e4acc2d3740f",
        "name": "1515 Holcombe Blvd, Houston, TX 77030, USA",
        "state": "TX"
      },
      {
        "city": "Milwaukee",
        "country": "USA",
        "lat": 43.0412506,
        "lng": -88.0246804,
        "locationId": "88e7c8a4c306550bc7ecacff37c844af5456f811",
        "name": "9200 W Wisconsin Ave, Milwaukee, WI 53226, USA",
        "state": "WI"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3",
      "https://cancerres.aacrjournals.org/content/79/13_Supplement/3252",
      "https://www.fool.com/earnings/call-transcripts/2020/05/15/takeda-pharmaceutical-tak-q4-2019-earnings-call-tr.aspx"
    ],
    "sponsors": [
      {
        "sponsorId": "31759effba9dd9037b4a5b2a4e1bf87cb0e4042b",
        "sponsorName": "Takeda"
      },
      {
        "sponsorId": "045e824a5da5f72babae368754662beedb102779",
        "sponsorName": "Millenium Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 06 Oct 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 01 Oct 2018 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PL-8177",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Postive results in demonstrated in multiple preclinical inflammatory disease models and a lung injury model. IND is planned to be submitted in third quarter of 2020 and a Phase 2 clinical trial initiation in the fourth quarter of 2020.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PL8177",
    "primaryCompletionDate": "",
    "productId": 637,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html",
      "https://www.palatin.com/research-focus/inflammatory-disease/"
    ],
    "sponsors": [
      {
        "sponsorId": "b8857618611ee134961436d104fe230a1c93eb18",
        "sponsorName": "Palatin Technologies Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "R-107",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "also being used to treat ARDS",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "R107",
    "primaryCompletionDate": "",
    "productId": 652,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/"
    ],
    "sponsors": [
      {
        "sponsorId": "d16b517fd34d1c88b285851f141f1f513dcd7559",
        "sponsorName": "Kalytera Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "LYT-100",
    "chemicalName": "deupirfenidone",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "A deuterated analogue of pirfenidone -an approved drug for treatment of idiopathic pulmonary fibrosis. Currently in a Phase 1 trial to determine safety in healthy volunteers and patients with breast cancer-related upper limb secondary lumphoedema. There are plans to initiate a trail in third quarter of 2020 for treating non-critical patients with COVID-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "deupirfenidone",
    "primaryCompletionDate": "",
    "productId": 638,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection",
      "https://clinicaltrials.gov/ct2/show/NCT04243837?term=LYT-100&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "aa35972c3b3ff6b8976683f566db2d26a808a36f",
        "sponsorName": "Puretech Health plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "TY-027",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "justin@tychanltd.com ; anjalib@tychanltd.com",
        "name": null,
        "notes": "",
        "phone": "65 9002 5606 ; 65 9420 4576",
        "website": ""
      }
    ],
    "countries": ["Singapore"],
    "countryCodes": ["SGP"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 09 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "TY-027 showed full clearance of the virus in lab studies and demonstrated safety in preclincal studies,Currently in a Phase 1 trial with efficacy data expected to be available in the third quarter.",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "TY027",
    "primaryCompletionDate": "Tue, 20 Oct 2020 00:00:00 GMT",
    "productId": 639,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Singapore",
        "country": "SGP",
        "lat": 1.2809842,
        "lng": 103.8388793,
        "locationId": "f9f33288e3e5780e6e65dbaeadc94a3027d365f6",
        "name": "7 Outram Rd, Singapore 169608",
        "state": null
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.genengnews.com/covid-19-candidates/tychan-ty027/",
      "https://www.tychan.com/",
      "https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1"
    ],
    "sponsors": [
      {
        "sponsorId": "496163600d3ce1d2d068fd9e415b870246a0fb39",
        "sponsorName": "Tichan Pte Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Tue, 09 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Decidual stromal cells",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19 ",
    "contact": [
      {
        "email": "john.granton@uhn.ca ; jonas.mattsson@uhn.ca",
        "name": null,
        "notes": "",
        "phone": "416-340-4485; 416-946-4501",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 1",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 30 Jun 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "Decidual_stromal_cells",
    "primaryCompletionDate": "Wed, 06 Jan 2021 00:00:00 GMT",
    "productId": 640,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04451291#contacts",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Toronto",
        "country": "CAN",
        "lat": 43.6591496,
        "lng": -79.38801769999999,
        "locationId": "f97e59681e30c65a68ef22ee8066818dac20afa7",
        "name": "200 Elizabeth St, Toronto, ON M5G 2C4, Canada",
        "state": "ON"
      }
    ],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://clinicaltrials.gov/ct2/show/NCT04451291",
      "https://clinicaltrials.gov/ct2/show/NCT04451291#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "6c811bcaeb424eb454f36bda3cfbde712bb26ffd",
        "sponsorName": "University Health Network Toronto"
      },
      {
        "sponsorId": "acd37c2538b99b0058043071302b210fc68796ec",
        "sponsorName": "Oslo University Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 06 Jan 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 06 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "SARS-CoV-2 main protease inhibitors",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "The molecules were designed computationally using AI and preclinical optimization will lead to selection of lead candidates",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "SARSCoV2_main_protease_inhibitors",
    "primaryCompletionDate": "",
    "productId": 641,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "b2ef8bfd7ad33ad39c53f8cb90230b22f114c545",
        "sponsorName": "A2A Pharmaceuticals Inc"
      },
      {
        "sponsorId": "1fcffdacd8cdad3268381d1ba4404852f44e7fea",
        "sponsorName": "Laxai Life Sciences Pvt Ltd"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Human monoclonal antibodies (mAbCo19)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "The EU Malaria Fund announced funding for the development of the antibodies on 06/03/2020",
    "numSites": "",
    "otherPartners": "EU Malaria Fund",
    "phase": "",
    "preferredName": "Human_monoclonal_antibodies_mAbCo19",
    "primaryCompletionDate": "",
    "productId": 642,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.covidx.eu/mabco19",
      "https://www.businesswire.com/news/home/20200619005083/en/Italy-Beneficiary-EU-Malaria-Fund-Siena-Based-Achilles"
    ],
    "sponsors": [
      {
        "sponsorId": "9d5a1c4e0733cb70aab96efa202d8ccfbe4dd694",
        "sponsorName": "Achilles Vaccines srl"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Tempol",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Adamis is planning to apply for funding and work with the FDA to expedite testing.  Clinical trial material is curently available since Tempol is being tested in other clinical trials for other purposes.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Tempol",
    "primaryCompletionDate": "",
    "productId": 643,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol",
      "https://www.drugbank.ca/drugs/DB12449"
    ],
    "sponsors": [
      {
        "sponsorId": "88ad5addd85ff89d03e845d226fc5d550df79484",
        "sponsorName": "Adamis Pharmaceuticals Corp"
      },
      {
        "sponsorId": "d2795e3ee88c4be3d3d8cdb8d22d17048f6d25f0",
        "sponsorName": "Matrix Biomed Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AB-201 (rNAPc2)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "AB-201 is being developed as a potential treatment for COVID-related coagulopathy. It has undergone clinical testing through Phase 2 for anticoagulation. ARCA plans to file an IND application for COVID-19 in the third quarter of 2020 estimating late-stage clinical testing in the second half of 2020. A Phase 2B/3 clinical trial protocol is being developed for COVID-19 patients with elevated D-dimer levels.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AB201_rNAPc2",
    "primaryCompletionDate": "",
    "productId": 644,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html",
      "https://www.drugbank.ca/drugs/DB06552"
    ],
    "sponsors": [
      {
        "sponsorId": "9c13d33bd13132700e827beb6d905e4fd7881289",
        "sponsorName": "Arca Biopharm Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Xospata",
    "chemicalName": "gilteritinib",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "tyrosine kinase inhibitor",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "gilteritinib",
    "primaryCompletionDate": "",
    "productId": 645,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.drugbank.ca/drugs/DB12141",
      "https://www.astellas.com/en/contact-us"
    ],
    "sponsors": [
      {
        "sponsorId": "cb663fed483955b3dab4743f07b486955fed6169",
        "sponsorName": "Astellas Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ATR-002",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "MEK inhibitor",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "ATR002",
    "primaryCompletionDate": "",
    "productId": 646,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.genengnews.com/covid-19-candidates/atriva-therapeutics-atr-002/",
      "https://www.clinicaltrialsarena.com/news/atriva-therapeutics-covid-19-trial/",
      "https://www.globenewswire.com/news-release/2020/05/28/2039939/0/en/Atriva-Therapeutics-to-Develop-ATR-002-for-Treatment-of-Patients-with-COVID-19-in-Phase-II-Study.html",
      "https://www.atriva-therapeutics.com/14-news/96-news-phase2-2020"
    ],
    "sponsors": [
      {
        "sponsorId": "54e05d7f41524d6ae257f44e12f0540c0f86ca19",
        "sponsorName": "Atriva Therapeutics GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "TP-508",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "helps against blood clotting and other cardiovascular problems faced by COVID-19 patients",
    "numSites": "",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "TP508",
    "primaryCompletionDate": "",
    "productId": 647,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://chrysbio.com/chrysalis-biotherapeutics-receives-funding-from-the-national-institutes-of-health-for-covid-19-therapeutic-development/",
      "https://www.drugbank.ca/drugs/DB05309",
      "https://www.galvnews.com/news/free/article_31c2f715-0467-5348-89ef-fdd3a45b304d.html"
    ],
    "sponsors": [
      {
        "sponsorId": "079bc9b8c0c5b6efd67db7b7b9937c5c6eddb309",
        "sponsorName": "Chrysalis Biotherapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "digital drug discovery platform",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Delta_4_GmbH-648",
    "primaryCompletionDate": "",
    "productId": 648,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://delta4.ai/press-release-june-2020/"
    ],
    "sponsors": [
      {
        "sponsorId": "eaf144f7405b7c0fb9d8bc5a52c5be73bf8db412",
        "sponsorName": "Delta 4 GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "egg immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "customized immunoglobulins to inhibit infection",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "egg_immunoglobulins",
    "primaryCompletionDate": "",
    "productId": 649,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.prnewswire.com/in/news-releases/ignova-files-patent-application-on-antibody-against-covid-19-837978500.html",
      "https://ignova.com/ignova-files-patent-application-on-antibody-against-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "37e907f965e94c82c42432b138426dfa41608075",
        "sponsorName": "Ignova GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "plans to isolate antibodies from blood that can used to treat COVID-19 patients",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "primaryCompletionDate": "",
    "productId": 650,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.hospimedica.com/covid-19/articles/294783005/thermogenesis-announces-publishing-of-results-of-immunecytes-licensed-neutralizing-antibody-therapeutics-for-covid-19.html",
      "https://www.biospace.com/article/releases/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/"
    ],
    "sponsors": [
      {
        "sponsorId": "912ea5a364bc1ef18e2b2eccce53de667656b271",
        "sponsorName": "Immuncetye Life Sciences Inc"
      },
      {
        "sponsorId": "2d735c3d9d663fcc08e98c3576299ec02b7f8090",
        "sponsorName": "Thermogenesis Holdings Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "IMS-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "stem cell therapy,also being used to treat ARDS and pneumonia for COVID-19 patients",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IMS001",
    "primaryCompletionDate": "",
    "productId": 651,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.pharmaceutical-business-review.com/news/agex-therapeutics-imstem-biotechnology-sign-non-binding-letter-of-intent-regarding-investigational-msc-candidate-ims001-for-covid-19/",
      "https://www.bioworld.com/articles/435490-other-news-to-note-for-june-2-2020"
    ],
    "sponsors": [
      {
        "sponsorId": "fdae0c19faa2abbdaba4890b2003312afa5ebbf5",
        "sponsorName": "Imstem Biotechnology Inc"
      },
      {
        "sponsorId": "2af2b4cfdc7a01f1b1b30b7ed7d086ee3559a3f0",
        "sponsorName": "Agex Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "carragelose inhalation therapy",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStage": "Phase 1",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "sulfated polymer that comes from red seaweed,interacts with virus particles",
    "numSites": "",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "carragelose_inhalation_therapy",
    "primaryCompletionDate": "",
    "productId": 653,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/",
      "https://www.carragelose.com/en/mode-of-action",
      "https://www.pharmiweb.com/press-release/2020-04-28/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose-1",
      "https://www.marinomed.com/en/news/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose",
      "https://www.expresspharma.in/covid19-updates/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose/"
    ],
    "sponsors": [
      {
        "sponsorId": "a5ce72622018f447da2a5877aa50c4c0ba0596df",
        "sponsorName": "Marinomed Biotech Ag"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Dinaciclib",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "little information about this -- repurposed drug",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Dinaciclib",
    "primaryCompletionDate": "",
    "productId": 654,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296007/",
      "https://qbi.ucsf.edu/"
    ],
    "sponsors": [
      {
        "sponsorId": "35759a3021a327096a19d14e71986dd34642bd1c",
        "sponsorName": "Merck Sharp  Dohme Corp"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MNPR-101,Radioimmunotherapeutics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MNPR101_Radioimmunotherapeutics",
    "primaryCompletionDate": "",
    "productId": 655,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "87c57aa242a30221bb81157f5b54edf03f2f98e0",
        "sponsorName": "Monopar Therapeutics Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Oncolys_Biopharma_Inc-656",
    "primaryCompletionDate": "",
    "productId": 656,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "cd89286aaff544849e5b727d1488b979ee9334a1",
        "sponsorName": "Oncolys Biopharma Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Ranpirnase",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ranpirnase",
    "primaryCompletionDate": "",
    "productId": 657,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "5681cd5b349d3daab2eea51e5cc5ac1aef63b7a6",
        "sponsorName": "Orgenesis Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ORP-100S",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ORP100S",
    "primaryCompletionDate": "",
    "productId": 658,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "ceff146133490de22f886f48d17ff6a3a56b4909",
        "sponsorName": "Orpro Therapeutics Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "NET Inhibitor",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "NET_Inhibitor",
    "primaryCompletionDate": "",
    "productId": 659,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "b05b4b8ae97bbb19557f4e8cc0ef97728495eec7",
        "sponsorName": "Peel Therapeutics Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Pharnext_SA-660",
    "primaryCompletionDate": "",
    "productId": 660,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "8ef7261cae683e2f3ccfe5dbf762a36c5ef48adb",
        "sponsorName": "Pharnext SA"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "PTI-129",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PTI129",
    "primaryCompletionDate": "",
    "productId": 661,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "725f7a6352f55d2607a2fb6023f1ab491ab75bf1",
        "sponsorName": "Proteostasis Therapeutics Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "AS-1411",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AS1411",
    "primaryCompletionDate": "",
    "productId": 662,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "76359c6fac90eaaa53a84ee2d17a1e99bb0c3dee",
        "sponsorName": "Qualigen Therapeutics Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MAPK13-IN-1",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MAPK13IN1",
    "primaryCompletionDate": "",
    "productId": 663,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "06f23ad22f5f3f44778ea99cb2275d05e92ecac9",
        "sponsorName": "Quantitative Biosceinces Institute UCSF"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "SB203580",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "SB203580",
    "primaryCompletionDate": "",
    "productId": 664,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://www.bioworld.com/COVID19products"],
    "sponsors": [
      {
        "sponsorId": "06f23ad22f5f3f44778ea99cb2275d05e92ecac9",
        "sponsorName": "Quantitative Biosceinces Institute UCSF"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Silmitasertib",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Discovery",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Curbes RNA from proliferating,CK2 inhibitor",
    "numSites": "",
    "otherPartners": "Taiwan headquartered Senhwa Biosciences Inc,The University of California San Francisco\u2019s Quantitative Biosciences Institute",
    "phase": "",
    "preferredName": "Silmitasertib",
    "primaryCompletionDate": "",
    "productId": 665,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/senhwa-biosciences-silmitasertib-named-as-potential-covid-19-therapy/",
      "https://www.biospectrumasia.com/news/34/15848/senhwa-biosciences-nih-to-co-develop-covid-19-drug.html",
      "https://www.drugbank.ca/drugs/DB15408"
    ],
    "sponsors": [
      {
        "sponsorId": "1e9bcf520896b6caf986e652691d3a2891fa50d4",
        "sponsorName": "Senhwa Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "SFA-005",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Preventing cytokine release syndrome,currently being evaluated in animal model of ARDS",
    "numSites": "",
    "otherPartners": "Ben Franklin",
    "phase": "",
    "preferredName": "SFA005",
    "primaryCompletionDate": "",
    "productId": 666,
    "registryLink": "",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.businesswire.com/news/home/20200624005197/en/Melior-Discovery-Announces-Partnership-SFA-Grant-Directed",
      "https://www.sep.benfranklin.org/2020/06/18/ben-franklin-backs-founders-fighting-covid-19-and-its-effects/",
      "https://sfatherapeutics.com/",
      "https://www.sep.benfranklin.org/2020/06/18/ben-franklin-backs-founders-fighting-covid-19-and-its-effects/; https://www.businesswire.com/news/home/20200624005197/en/Melior-Discovery-Announces-Partnership-SFA-Grant-Directed"
    ],
    "sponsors": [
      {
        "sponsorId": "de3cdcce6919716bc3c5263ab68dcafb702af417",
        "sponsorName": "SFA Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Immunotherapy,StemVacs",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Based on activating universal donor immune systems so that upon injection they reprogram the bodies natural killer while also supressing lung inflammation",
    "numSites": "",
    "otherPartners": "Therapeutic Solutions Intl",
    "phase": "",
    "preferredName": "Immunotherapy_StemVacs",
    "primaryCompletionDate": "",
    "productId": 667,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.biospace.com/article/releases/therapeutic-solutions-international-submits-publication-on-stemvacs-preclinical-data-supporting-covid-19-indication/"
    ],
    "sponsors": [
      {
        "sponsorId": "b81dc519e12bb381185e293c3896855351179880",
        "sponsorName": "Therapeutic Solutions International Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "VAL-201",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["Ukraine"],
    "countryCodes": ["UKR"],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Treatment for hyperimmune response",
    "numSites": "",
    "otherPartners": "Collaboration with Oncolytika and Black Cat Bio",
    "phase": "",
    "preferredName": "VAL201",
    "primaryCompletionDate": "",
    "productId": 668,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.bioworld.com/COVID19products",
      "https://www.sharesmagazine.co.uk/news/market/6944114/ValiRx-enters-collaboration-to-develop-SARS-CoV2-treatment",
      "https://www.share-talk.com/valirx-plc-val-l-collaboration-agreement-signed/#gs.ae31u3"
    ],
    "sponsors": [
      {
        "sponsorId": "7a299b49f65120e5661f5ab2ae1784384d2d9225",
        "sponsorName": "Valirx plc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "AlloStim",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "axellaresearch@gmail.com;  thu@immunovative.com",
        "name": null,
        "notes": "",
        "phone": "1-732-630-9059; 1-619-227-4872",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 1",
    "indication": "Other",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Jul 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Protects against any type of viral infection and is designed for the elderly",
    "numSites": "1",
    "otherPartners": "Immunovative Therapies and Mirror Biologics",
    "phase": "1",
    "preferredName": "AlloStim",
    "primaryCompletionDate": "",
    "productId": 669,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04441047",
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.7127753,
        "lng": -74.0059728,
        "locationId": "2b662488252628020f275d46064d30dc77bb96d8",
        "name": "New York, NY, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04441047",
      "https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html"
    ],
    "sponsors": [
      {
        "sponsorId": "9ca3fdec10a2d19a058d21154ece1f6809409f21",
        "sponsorName": "Immunovative Therapies Ltd"
      },
      {
        "sponsorId": "85d779a6ca464033b3af98c970d768ab80229774",
        "sponsorName": "Mirror Biologics Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 06 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Oral Polio Vaccine (OPV)",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "a.fisker@bandim.org",
        "name": null,
        "notes": "Enrolling by invitation only",
        "phone": "245 966625316 ; 45 50570593",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Phase 4",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Global Virus Network",
    "phase": "4",
    "preferredName": "Oral_Polio_Vaccine_OPV",
    "primaryCompletionDate": "Sun, 20 Jun 2021 00:00:00 GMT",
    "productId": 670,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04445428",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "GNB",
        "lat": 11.803749,
        "lng": -15.180413,
        "locationId": "ca38023dd3444665019985419f11f26120420a98",
        "name": "Guinea-Bissau",
        "state": null
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6&rank=46",
      "https://biorender.com/covid-vaccine-tracker/details/v-CV15/-34",
      "https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6"
    ],
    "sponsors": [
      {
        "sponsorId": "57eec57daff4d3bbed859cb4ef877900baafee38",
        "sponsorName": "Bandim Health Project"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 20 Jun 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 20 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "IMM-101",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "cocallaghan@ctg.queensu.ca",
        "name": null,
        "notes": "",
        "phone": "613-533-6430",
        "website": ""
      }
    ],
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Jul 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Focused on strenghtening the immune system of cancer patients",
    "numSites": "",
    "otherPartners": "Canadian Cancer Society - BioCanRx - the Ontario Institute for Cancer Research - The Ottawa Hospital Foundation - The Ottawa Hospital Academic Medical Organization - ATGen Canada/NKMax - and Immodulon Therapeutics",
    "phase": "3",
    "preferredName": "IMM101",
    "primaryCompletionDate": "",
    "productId": 671,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04442048",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5&rank=40",
      "https://ichgcp.net/clinical-trials-registry/NCT04442048",
      "https://medicalxpress.com/news/2020-07-cancer-patients-covid-world-first-trial.html",
      "https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5"
    ],
    "sponsors": [
      {
        "sponsorId": "a8af43f60f0e421a43b632c90690329859938af5",
        "sponsorName": "Canadian Cancer Trials Group"
      },
      {
        "sponsorId": "9685c58f38205dfadb5310c4b73cf1f96b1475d5",
        "sponsorName": "Immodulon Therapeutics Ltd"
      },
      {
        "sponsorId": "430e04786b4eaafbfc9542951d4a766de2ab0e53",
        "sponsorName": "BioCan Rx"
      },
      {
        "sponsorId": "3f075ee81f66154e4daa236b5d862aaeefd3e70f",
        "sponsorName": "CCSRI"
      },
      {
        "sponsorId": "27fad021ac840435ee6b3db8a0d2315dbe481d1b",
        "sponsorName": "AtGen Canada Inc"
      },
      {
        "sponsorId": "1248fe2b31b83483e8d6a9ee3d24d336359d0669",
        "sponsorName": "ARCC"
      },
      {
        "sponsorId": "2d35d8fb47ee89b281e77116cdcc8d953016a76e",
        "sponsorName": "Ontario Institute for Cancer Research"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 31 Mar 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "RUTI Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "pjcardona@igtp.cat",
        "name": null,
        "notes": "",
        "phone": "34 93 033 0527 ext 6400",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "A therapeutic vaccine for tuberculosis indications",
    "numSites": "1",
    "otherPartners": "Collaboration with  University Institute for Primary Health Care Research Jordi Gol,clinical triai financed by The General Directorate of Research and Innovation in Health of the Government of Catalonia",
    "phase": "",
    "preferredName": "RUTI_Vaccine",
    "primaryCompletionDate": "",
    "productId": 672,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04453488",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "ESP",
        "lat": 40.46366700000001,
        "lng": -3.74922,
        "locationId": "a2ef04e82ab32ecc4f4e8d8f9da1f4a0b1fc8a38",
        "name": "Spain",
        "state": null
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3&rank=17",
      "http://biotech-spain.com/en/articles/archivel-s-ruti-vaccine-begins-clinical-trial-to-increase-the-immunity-of-healthcare-professionals-exposed-to-covid-19/",
      "https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3"
    ],
    "sponsors": [
      {
        "sponsorId": "b0962c2b93dc6086519ac8714873a08bdec5dcb8",
        "sponsorName": "Fundacio Institut Germans Trias i Pujol"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Fri, 10 Jul 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "Pre-Clinical Testing",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "ONGOING"
      }
    ],
    "moleculeType": "Other",
    "notes": "Using personalized vaccine technology previously created to fight cancer,work centered around manipulating mRNA to deliver a message to make parts of the coronavirus visible to the immune system,approach may provide protection against all future corona viruses",
    "numSites": "",
    "otherPartners": "Investment from Sam Altman",
    "phase": "",
    "preferredName": "Helix_Nanotechnologies_Inc-673",
    "primaryCompletionDate": "",
    "productId": 673,
    "registryLink": "",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [
      "https://www.helixnano.com/",
      "https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html",
      "https://www.genengnews.com/covid-19-candidates/helix-nanotechnologies/",
      "https://www.genengnews.com/covid-19-candidates/helix-nanotechnologies/; https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html"
    ],
    "sponsors": [
      {
        "sponsorId": "01ef7c5fd722bab5aa40806e22631d3b6f7a7563",
        "sponsorName": "Helix Nanotechnologies Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Infliximab",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "clawlor3@tuftsmedicalcenter.org",
        "name": null,
        "notes": "",
        "phone": "617-636-5000 ext 8897",
        "website": ""
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 01 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "TNF\u03b1 inhibitor therapy",
    "numSites": "1",
    "otherPartners": "Tufts Medical Center,NIH",
    "phase": "2",
    "preferredName": "Infliximab",
    "primaryCompletionDate": "",
    "productId": 674,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04425538",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Boston",
        "country": "USA",
        "lat": 42.3600825,
        "lng": -71.0588801,
        "locationId": "61fc866723a49eda123a79d7d6916f758f1fbd9e",
        "name": "Boston, MA, USA",
        "state": "MA"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04425538",
      "https://www.drugbank.ca/drugs/DB00065",
      "https://biorender.com/covid-vaccine-tracker/details/d-0080/ryoncil-remestemcel-l-allogenic-mesenchymal-stem-cells"
    ],
    "sponsors": [
      {
        "sponsorId": "806a8c2baa770636fe9a0bc6b58144d55ee4ae04",
        "sponsorName": "Tufts Medical Center"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Deferoxamine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Deferoxamine",
    "primaryCompletionDate": "",
    "productId": 675,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04333550"],
    "sponsors": [
      {
        "sponsorId": "c2754816106ca523c8d8464e63cc543e9a0d2213",
        "sponsorName": "Kermanshah University of Medical Sciences"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Puylmozyme",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Puylmozyme",
    "primaryCompletionDate": "",
    "productId": 676,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4"
    ],
    "sponsors": [
      {
        "sponsorId": "1dbdb628b7360e9e7fbdf8f15440a46587de4524",
        "sponsorName": "Acibadem University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Aspirin,clopidogrel,rivaroxaban,atorvastatin,omeprazole",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Aspirin_clopidogrel_rivaroxaban_atorvastatin_omeprazole",
    "primaryCompletionDate": "",
    "productId": 677,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/study/NCT04333407"],
    "sponsors": [
      {
        "sponsorId": "1a693dd5acf9f3ae07a65241da0b2f2102ed1377",
        "sponsorName": "Imperial College London"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Prazosin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Prazosin",
    "primaryCompletionDate": "",
    "productId": 678,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04365257"],
    "sponsors": [
      {
        "sponsorId": "a2061ed614e1cea96e01bbacea1c8e43eaf1c020",
        "sponsorName": "John Hopkins University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Etoposide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Etoposide",
    "primaryCompletionDate": "",
    "productId": 679,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04356690"],
    "sponsors": [
      {
        "sponsorId": "dd3995c1711a08d5f44869863581a63f4af7803b",
        "sponsorName": "Boston Medical Center"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Cyclosporine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Cyclosporine",
    "primaryCompletionDate": "",
    "productId": 680,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04412785"],
    "sponsors": [
      {
        "sponsorId": "20ef76f96c3905ce188bfac7757864ea5931ce71",
        "sponsorName": "University of Pennsylvania"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Sirolimus",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Sirolimus",
    "primaryCompletionDate": "",
    "productId": 681,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04341675"],
    "sponsors": [
      {
        "sponsorId": "9853a7e1f0cfc0e6d46583970b6858d7e3b7ad12",
        "sponsorName": "University of Cincinnati"
      },
      {
        "sponsorId": "1b9164e80e6eebf015de1a8aa6d9744d383d94d4",
        "sponsorName": "Thomas Jefferson University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Povidone-Iodine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PovidoneIodine",
    "primaryCompletionDate": "",
    "productId": 682,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04410159"],
    "sponsors": [
      {
        "sponsorId": "0347591bd41b20ca07b8da471b5ad2e0e1e4dbd4",
        "sponsorName": "Universiti Kebangsaan Malaysia Medical Centre"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Zanubrutinib",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Zanubrutinib",
    "primaryCompletionDate": "",
    "productId": 683,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04382586"],
    "sponsors": [
      {
        "sponsorId": "434ef2663aa327627ef0d2335c816613b5646c4f",
        "sponsorName": "BeiGene"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Azithromycin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Azithromycin",
    "primaryCompletionDate": "",
    "productId": 684,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04381962"],
    "sponsors": [
      {
        "sponsorId": "38652628acf1b84b92cad2bea1a82015a920b0c3",
        "sponsorName": "University of Oxford"
      },
      {
        "sponsorId": "531d5b28f1f18f219741627c0f2a1e09d355e46a",
        "sponsorName": "Pfizer"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Enoxaparin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Enoxaparin",
    "primaryCompletionDate": "",
    "productId": 685,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04427098",
      "https://clinicaltrials.gov/ct2/show/NCT04366960"
    ],
    "sponsors": [
      {
        "sponsorId": "b98f61dc065866ca7b9c59da5a25a1c783028204",
        "sponsorName": "Azienda Ospedaliera Universitaria di Bologna Policlinico S Orsola Malpighi"
      },
      {
        "sponsorId": "6fd50186f702be2b011978a01b2681d8494bb38c",
        "sponsorName": "Niguarda Hospital"
      },
      {
        "sponsorId": "bac83d38f998ece71d1a88997387e0123a35d365",
        "sponsorName": "University Hospital Geneva"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Levamisole,formoterol,budesonide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Levamisole_formoterol_budesonide",
    "primaryCompletionDate": "",
    "productId": 686,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04331470"],
    "sponsors": [
      {
        "sponsorId": "169fcfe8011dadfe7b87f08c9ab8e63c8f10f1b0",
        "sponsorName": "Fasa University of Medical Sciences"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "MSTT1041A",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MSTT1041A",
    "primaryCompletionDate": "",
    "productId": 687,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04386616"],
    "sponsors": [
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "UTTR1147A",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "UTTR1147A",
    "primaryCompletionDate": "",
    "productId": 688,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04386616"],
    "sponsors": [
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "metenkefalin,tridecactide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "metenkefalin_tridecactide",
    "primaryCompletionDate": "",
    "productId": 689,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04374032"],
    "sponsors": [
      {
        "sponsorId": "3e0a4169cedbfca56363d1777ac5493edf56ed33",
        "sponsorName": "Bosnalijek DD"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Melatonin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Melatonin",
    "primaryCompletionDate": "",
    "productId": 690,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04409522"],
    "sponsors": [
      {
        "sponsorId": "00b2d29bf7b45cc1c59c38b5a33f94d0f62c2818",
        "sponsorName": "Baqiyatallah Medical Sciences University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Iloprost",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Iloprost",
    "primaryCompletionDate": "",
    "productId": 691,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04420741"],
    "sponsors": [
      {
        "sponsorId": "3e34a11c6c1d9a73c04130f5f4a376615cbe7117",
        "sponsorName": "Rigshospitalet"
      },
      {
        "sponsorId": "3f2cf252bd7183f751952ba8b138339621c9fbdc",
        "sponsorName": "Hamad Medical Corporation"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Progesterone",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Progesterone",
    "primaryCompletionDate": "",
    "productId": 692,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04365127"],
    "sponsors": [
      {
        "sponsorId": "810a11cfef19294172551c5c929f93ca1fbf010f",
        "sponsorName": "IBSA Institut Biochimique SA"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Bacille Calmette-Gu\u00e9rin (BCG)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      {
        "email": "nigel.curtis@rch.org.au",
        "name": null,
        "notes": "",
        "phone": "",
        "website": ""
      }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Bacille_CalmetteGu\u00e9rin_BCG",
    "primaryCompletionDate": "",
    "productId": 693,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04327206",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04327206"],
    "sponsors": [
      {
        "sponsorId": "25c88e3eb4d93b08b56cb1cb400c834d542cbee4",
        "sponsorName": "Murdoch Childrens Research Institute"
      },
      {
        "sponsorId": "370728988e10a6f311c1f384a3cb85477753b1a2",
        "sponsorName": "TASK Applied Science"
      },
      {
        "sponsorId": "1a862ddc71a8eb4c93961805a869c775316c9c3a",
        "sponsorName": "Texas AM University"
      },
      {
        "sponsorId": "2dd4e69fcd3ebe36b954676861c245a30a347d30",
        "sponsorName": "UMC Utrecth"
      },
      {
        "sponsorId": "15efcaf1de08b9cb2b76f392d4957714c2609c4c",
        "sponsorName": "Radboud University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Tigerase",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Tigerase",
    "primaryCompletionDate": "",
    "productId": 694,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04459325"],
    "sponsors": [
      {
        "sponsorId": "99634b02a898f433bdd576736a09577778a6144d",
        "sponsorName": "AO GENERIUM"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "N-acetylcysteine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nacetylcysteine",
    "primaryCompletionDate": "",
    "productId": 695,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04374461"],
    "sponsors": [
      {
        "sponsorId": "c576f01fc28e684ff10c286a469e1a66ad86244c",
        "sponsorName": "Memorial Sloan Kettering Cancer Center"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Melphalan",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Melphalan",
    "primaryCompletionDate": "",
    "productId": 696,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04380376"],
    "sponsors": [
      {
        "sponsorId": "de240dedbb333ee63330c2e0ea844b8d8eab0384",
        "sponsorName": "Federal State Budgetary Institution  Pulmonology Scientific Research Institute"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "DFV890",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DFV890",
    "primaryCompletionDate": "",
    "productId": 697,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04382053"],
    "sponsors": [
      {
        "sponsorId": "958604794b99b1af30fcaaf34a66324bbc90348d",
        "sponsorName": "Novartis Pharmaceuticals"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Fluoxetine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Fluoxetine",
    "primaryCompletionDate": "",
    "productId": 698,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04377308"],
    "sponsors": [
      {
        "sponsorId": "9326f44d8c17be59503fdab91614bc83c4cd631b",
        "sponsorName": "University of Toledo Health Science Campus"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Clazakizumab",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Clazakizumab",
    "primaryCompletionDate": "",
    "productId": 699,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04348500"],
    "sponsors": [
      {
        "sponsorId": "e5b332c4009ba58797ec42566d7cf563aabdc215",
        "sponsorName": "CedarsSinai Medical Center"
      },
      {
        "sponsorId": "491682d08f8b84eaabfc2121e730b32aa0da34d4",
        "sponsorName": "Johns Hopkins University"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Defibrotide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Defibrotide",
    "primaryCompletionDate": "",
    "productId": 700,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04348383"],
    "sponsors": [
      {
        "sponsorId": "7a22957f1b52dec631aa77a48e9b62a663c72aea",
        "sponsorName": "Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "JS016",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "JS016",
    "primaryCompletionDate": "",
    "productId": 701,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04441918"],
    "sponsors": [
      {
        "sponsorId": "d069f9390b3d2a799efdba5329c0b415dd610a4b",
        "sponsorName": "Shanghai Junshi Bioscience Co Ltd"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "GLS-1200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "GLS1200",
    "primaryCompletionDate": "",
    "productId": 702,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04408183"],
    "sponsors": [
      {
        "sponsorId": "a16b70b82bdd9b5e61c50e750862a8851ee80507",
        "sponsorName": "GeneOne Life Science"
      },
      {
        "sponsorId": "72a5f6c42a6c39ea891ecb24d22128fd281d0e18",
        "sponsorName": "Inc"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "Garadacimab",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Garadacimab",
    "primaryCompletionDate": "",
    "productId": 703,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04409509"],
    "sponsors": [
      {
        "sponsorId": "55f0aa800f25c9093f14e24ae7f37b8f48615a59",
        "sponsorName": "CSL Behring"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "",
    "brandName": "ArtemiC",
    "chemicalName": "",
    "conditionOrDisease": "",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": [""],
    "countryCodes": [""],
    "currentStage": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ArtemiC",
    "primaryCompletionDate": "",
    "productId": 704,
    "registryLink": "",
    "repurposed": "",
    "siteLocations": [],
    "sources": ["https://clinicaltrials.gov/ct2/show/NCT04382040"],
    "sponsors": [
      {
        "sponsorId": "fb1a448d595002a76acc688e10e55f9b1bc11137",
        "sponsorName": "MGC Pharmaceuticals doo"
      }
    ],
    "status": "",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "CERC-002",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "jwilkins@cerecor.com",
        "name": null,
        "notes": "",
        "phone": "6104575095",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04412057"
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Sun, 28 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 02 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "CERC002",
    "primaryCompletionDate": "Thu, 01 Oct 2020 00:00:00 GMT",
    "productId": 705,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04412057",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Fayetteville",
        "country": "USA",
        "lat": 35.0317932,
        "lng": -78.93509499999999,
        "locationId": "103638c89920a94e93548536e47ce75c55ecc0a5",
        "name": "1638 Owen Dr, Fayetteville, NC 28304, USA",
        "state": "NC"
      },
      {
        "city": "Fayetteville",
        "country": "USA",
        "lat": 35.0291834,
        "lng": -78.9239623,
        "locationId": "2966fc12334e81310c18f62a278016b1a2dd8dd4",
        "name": "1841 Quiet Cove Suite 2, Fayetteville, NC 28304, USA",
        "state": "NC"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04412057",
      "https://ir.cerecor.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in",
      "https://clinicaltrials.gov/ct2/show/study/NCT04412057",
      "https://www.cerecor.com/resources/related-publications/cerc-002-publications",
      "https://www.cerecor.com/pipeline"
    ],
    "sponsors": [
      {
        "sponsorId": "52b90346e93819a6411f86d06609490e4214e09b",
        "sponsorName": "Aevi Genomic Medicine LLC"
      },
      {
        "sponsorId": "494058da7e8f7b7a41aee4e24ceb5ea1567e8aee",
        "sponsorName": "Cerecor"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 01 Nov 2020 00:00:00 GMT",
    "studyStartDate": "Tue, 02 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "BMS-986253",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "cancerclinicaltrials@cumc.columbia.edu",
        "name": null,
        "notes": "",
        "phone": "2123425162",
        "website": "https://clinicaltrials.gov/ct2/show/record/NCT04347226"
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Drug indication for solid tumor,COVID-19,and hematological malignancy",
    "numSites": "1",
    "otherPartners": "Bristol-Myers Squibb",
    "phase": "2",
    "preferredName": "BMS986253",
    "primaryCompletionDate": "Wed, 01 Sep 2021 00:00:00 GMT",
    "productId": 706,
    "registryLink": "https://clinicaltrials.gov/ct2/show/record/NCT04347226",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "USA",
        "lat": 40.8417567,
        "lng": -73.9419848,
        "locationId": "687c1be40bc7f5a8d237a564c504d3088733f25e",
        "name": "650 W 168th St, New York, NY 10032, USA",
        "state": "NY"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04347226",
      "https://clinicaltrials.gov/ct2/show/record/NCT04347226",
      "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-8-monoclonal-antibody-humax-il8",
      "https://clinicaltrials.gov/ct2/show/study/NCT04347226"
    ],
    "sponsors": [
      {
        "sponsorId": "930d83a6a56629a85b56e48193bd300b9cb6c258",
        "sponsorName": "BristolMyers Squibb"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 01 Sep 2022 00:00:00 GMT",
    "studyStartDate": "Wed, 15 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Anluohuaxian",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "john131212@sina.com",
        "name": null,
        "notes": "",
        "phone": "13911405123",
        "website": "https://clinicaltrials.gov/ct2/show/record/NCT04334265"
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 1",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "9",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Anluohuaxian",
    "primaryCompletionDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "productId": 707,
    "registryLink": "https://clinicaltrials.gov/ct2/show/record/NCT04334265",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Fuyang Shi",
        "country": "CHN",
        "lat": 33.164296,
        "lng": 115.628262,
        "locationId": "dd274622ffd92fae48dc2fd994378c556986a395",
        "name": "Wenming Rd, Taihe Xian, Fuyang Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CHN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "82f2837fa98bceff46a0dd7695d73e284612bd61",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "4ebbcedc0337a8cd74ef073a06634ce29adb5857",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "94b0d97f3a89874e49d89e36aba7adca7e5bb613",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "f4e5f87d9b958163ccb7eacbca85f606e3301a1f",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "454ebc74f94359dd68008d4d4fa26070d4c8b700",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "90efe53a54e9406c789671c03062d089ea68dda3",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CHN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "c595ae2160c1b86c2b9c3542beeab75db5f82fbf",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wenzhou",
        "country": "CHN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "0f2a2808c2579a3fc991c179fc683179b0085f25",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04334265",
      "https://clinicaltrials.gov/ct2/show/record/NCT04334265",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/",
      "https://clinicaltrials.gov/ct2/show/study/NCT04334265",
      "https://clinicaltrials.gov/ct2/show/study/NCT04334265#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "Wed, 01 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Polyoxidonium",
    "chemicalName": "azoximer bromide",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "dodonovns@petrovax.ru",
        "name": null,
        "notes": "",
        "phone": "7 (495)7307545 ext 125",
        "website": "https://clinicaltrials.gov/ct2/show/record/NCT04381377"
      }
    ],
    "countries": ["Russian Federation"],
    "countryCodes": ["RUS"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 29 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 29 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Azoximer bromide acts as an immune adjuvent.",
    "numSites": "12",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "azoximer_bromide",
    "primaryCompletionDate": "Thu, 01 Apr 2021 00:00:00 GMT",
    "productId": 708,
    "registryLink": "https://clinicaltrials.gov/ct2/show/record/NCT04381377",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Barnaul",
        "country": "RUS",
        "lat": 53.3497499,
        "lng": 83.78357369999999,
        "locationId": "5fe37092d22d89b5996e526c8eb3981388c7c582",
        "name": "Barnaul, Altai Krai, Russia",
        "state": "Altai Krai"
      },
      {
        "city": "Moscow",
        "country": "RUS",
        "lat": 55.755826,
        "lng": 37.6172999,
        "locationId": "eebb362344a95796374923a397ea36913ce1026c",
        "name": "Moscow, Russia",
        "state": null
      },
      {
        "city": "Moscow",
        "country": "RUS",
        "lat": 55.755826,
        "lng": 37.6172999,
        "locationId": "a1db0539155edd476924b05ae414c18631752ef8",
        "name": "Moscow, Russia",
        "state": null
      },
      {
        "city": "Moscow",
        "country": "RUS",
        "lat": 55.755826,
        "lng": 37.6172999,
        "locationId": "c74a2cfeeaf019e9389b16a8898715ed6547a4bd",
        "name": "Moscow, Russia",
        "state": null
      },
      {
        "city": "Moskva",
        "country": "RUS",
        "lat": 55.7497603,
        "lng": 37.3897148,
        "locationId": "e92ef8ee2e3e2b8e4444834445a953e8351923df",
        "name": "Marshala Timoshenko Ulitsa, 15, Moskva, Russia, 121359",
        "state": null
      },
      {
        "city": "Moscow",
        "country": "RUS",
        "lat": 55.755826,
        "lng": 37.6172999,
        "locationId": "3d1ff9e062ba8d443a340fd1e5f73e11cf8d32d5",
        "name": "Moscow, Russia",
        "state": null
      },
      {
        "city": "Moscow",
        "country": "RUS",
        "lat": 55.755826,
        "lng": 37.6172999,
        "locationId": "411501580c7e72cb61fdef650a28a957d47e2844",
        "name": "Moscow, Russia",
        "state": null
      },
      {
        "city": "Nizhny Novgorod",
        "country": "RUS",
        "lat": 56.3268684,
        "lng": 44.0058793,
        "locationId": "62b5fb7b2c2bcff3c6dfaa34829fbe4d18565e27",
        "name": "Nizhny Novgorod, Nizhny Novgorod Oblast, Russia",
        "state": "Nizhny Novgorod Oblast"
      },
      {
        "city": "Orenburg",
        "country": "RUS",
        "lat": 51.7562809,
        "lng": 55.105858,
        "locationId": "090d3efaa5977f74cf8db7a4e31404bd9ac6af35",
        "name": "Sovetskaya Ulitsa, 6, Orenburg, Orenburgskaya oblast', Russia, 460000",
        "state": "Orenburgskaya oblast'"
      },
      {
        "city": "\u0421\u041f\u0411",
        "country": "RUS",
        "lat": 59.9645655,
        "lng": 30.3206798,
        "locationId": "588bfd62aae4ca6e2eb1981a81014ed880dde8bb",
        "name": "Ulitsa L'va Tolstogo, 6-8, Sankt-Peterburg, Russia, 197022",
        "state": null
      },
      {
        "city": "Vladimir",
        "country": "RUS",
        "lat": 56.1428026,
        "lng": 40.3895795,
        "locationId": "84aba3fcf2806970ef8e21738ed5c7b404d7b7bc",
        "name": "Vladimir, Vladimir Oblast, Russia",
        "state": "Vladimir Oblast"
      },
      {
        "city": "Yaroslavl'",
        "country": "RUS",
        "lat": 57.6244343,
        "lng": 39.89681849999999,
        "locationId": "507c1bc8817f88ea54d4df297d5771914f3f78a7",
        "name": "Revolyutsionnaya Ulitsa, 5, Yaroslavl', Yaroslavskaya oblast', Russia, 150000",
        "state": "Yaroslavskaya oblast'"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04381377",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892947/",
      "http://www.freepatentsonline.com/EP0789586.html",
      "https://clinicaltrials.gov/ct2/show/record/NCT04381377"
    ],
    "sponsors": [
      {
        "sponsorId": "c5dc6c359bcfbbbf78636c3fcd382827683e015e",
        "sponsorName": "NPO Petrovax"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Thu, 01 Apr 2021 00:00:00 GMT",
    "studyStartDate": "Wed, 29 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Sevoflurane",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "martin.schlaepfer@usz.ch",
        "name": null,
        "notes": "",
        "phone": "41442554690 ext 41442554690",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04355962"
      }
    ],
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStage": "Phase 3",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 23 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Sevoflurane",
    "primaryCompletionDate": "Wed, 31 Mar 2021 00:00:00 GMT",
    "productId": 709,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04355962",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Z\u00fcrich",
        "country": "CHE",
        "lat": 47.3766158,
        "lng": 8.549177499999999,
        "locationId": "a80ca900b8f3f3aab43731cb13f674f6593c9b28",
        "name": "R\u00e4mistrasse 100, 8091 Z\u00fcrich, Switzerland",
        "state": "ZH"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04355962",
      "https://www.drugbank.ca/drugs/DB01236"
    ],
    "sponsors": [
      {
        "sponsorId": "ae69a5c6de79a7259c3019a496c3a8f6b2b42a8e",
        "sponsorName": "University of Zurich"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 31 Mar 2021 00:00:00 GMT",
    "studyStartDate": "Thu, 23 Apr 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Budesonide",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "mdaval@for.paris",
        "name": null,
        "notes": "",
        "phone": "0148036870",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04361474"
      }
    ],
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStage": "Phase 3",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 15 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 18 Jun 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "This study specifically investigates treatments for olfaction disorders which may be caused or related to COVID-19.",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Budesonide",
    "primaryCompletionDate": "Tue, 18 May 2021 00:00:00 GMT",
    "productId": 710,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04361474",
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Paris",
        "country": "FRA",
        "lat": 48.8824675,
        "lng": 2.3528824,
        "locationId": "1767bd1185c4b9c3a6d9806358b16eaddccfec0a",
        "name": "2 Rue Ambroise Par\u00e9, 75010 Paris, France",
        "state": "IDF"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04361474",
      "https://www.drugbank.ca/drugs/DB01222",
      "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001667-85/FR"
    ],
    "sponsors": [
      {
        "sponsorId": "09a311388d29aefc82ca5a5df8f232b0444f9d85",
        "sponsorName": "Fondation Ophtalmologique Adolphe de Rothschild"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Tue, 25 May 2021 00:00:00 GMT",
    "studyStartDate": "Mon, 18 May 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Abidol hydrochloride",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "qning@vip.sina.com",
        "name": null,
        "notes": "",
        "phone": "8613971521450",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04254874"
      }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 4",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "Abidol_hydrochloride",
    "primaryCompletionDate": "Mon, 01 Jun 2020 00:00:00 GMT",
    "productId": 711,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04254874",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CHN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "c0bc23bc361e660c0e85e78769a03b6c9f9cdc73",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04254874",
      "https://www.drugs.com/international/abidol.html",
      "https://clinicaltrials.gov/ct2/show/study/NCT04254874",
      "https://www.medrxiv.org/content/10.1101/2020.03.16.20034934v1.full.pdf"
    ],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Wed, 01 Jul 2020 00:00:00 GMT",
    "studyStartDate": "Sat, 01 Feb 2020 00:00:00 GMT",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Veru-111",
    "chemicalName": "",
    "conditionOrDisease": "Respiratory Distress Syndrome",
    "contact": [
      {
        "email": "gbarnette@verupharma.com",
        "name": null,
        "notes": "",
        "phone": "9194263611",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04388826"
      }
    ],
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStage": "Phase 2",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 18 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 12 Jun 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 18 Jun 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "The therapeautic approach of this drug is both antivial and anti-inflammatory",
    "numSites": "5",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Veru111",
    "primaryCompletionDate": "Thu, 30 Jul 2020 00:00:00 GMT",
    "productId": 712,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04388826",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Scottsdale",
        "country": "USA",
        "lat": 33.4883996,
        "lng": -111.9229949,
        "locationId": "aa01aa9ac967926ade3e5ba1e9589cb4f015395e",
        "name": "7400 E Osborn Rd, Scottsdale, AZ 85251, USA",
        "state": "AZ"
      },
      {
        "city": "St Louis Park",
        "country": "USA",
        "lat": 44.9300754,
        "lng": -93.3619384,
        "locationId": "864d7aebb4d236ac02c250c6b1be3cb2268c4713",
        "name": "6500 Excelsior Blvd, St Louis Park, MN 55426, USA",
        "state": "MN"
      },
      {
        "city": "St Paul",
        "country": "USA",
        "lat": 44.9561719,
        "lng": -93.0944148,
        "locationId": "1bc3b3859f4c2f649e29fbfa02a1a9678b6c1b39",
        "name": "640 Jackson St, St Paul, MN 55101, USA",
        "state": "MN"
      },
      {
        "city": "North Las Vegas",
        "country": "USA",
        "lat": 36.1951782,
        "lng": -115.1228081,
        "locationId": "eebc5cadb16197e195079d4049a3e764268008c0",
        "name": "1409 E Lake Mead Blvd, North Las Vegas, NV 89030, USA",
        "state": "NV"
      },
      {
        "city": "Vineland",
        "country": "USA",
        "lat": 39.4454545,
        "lng": -75.05814889999999,
        "locationId": "6c75b4ed8c0cfffcac66a1537613a67d9c054d07",
        "name": "1505 W Sherman Ave, Vineland, NJ 08360, USA",
        "state": "NJ"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04388826",
      "https://www.globenewswire.com/news-release/2020/05/05/2027535/0/en/Veru-Reports-Positive-Clinical-Results-from-VERU-111-Phase-1b-2-Trial-in-Men-with-Metastatic-Castration-Resistant-Prostate-Cancer-Advancing-to-Pivotal-Phase-3-Clinical-Program.html#:~:text=VERU%2D111%20is%20an%20oral",
      "agents%20(abiraterone%20or%20enzalutamide).",
      "https://verupharma.com/pipeline/veru-111-for-covid-19/"
    ],
    "sponsors": [
      {
        "sponsorId": "222246536520b7e6a444b51878b5703278765b2c",
        "sponsorName": "Venu Inc"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 30 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Thu, 18 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "No",
    "brandName": "Escin",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "gallelli@unicz.it",
        "name": null,
        "notes": "",
        "phone": "3339245656 ext 3339245656",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04322344"
      }
    ],
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 06 Jan 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Escin",
    "primaryCompletionDate": "Tue, 30 Jun 2020 00:00:00 GMT",
    "productId": 713,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04322344",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Catanzaro",
        "country": "ITA",
        "lat": 38.8686453,
        "lng": 16.5788521,
        "locationId": "0dda7e51d447aafe24f3968d90ff9e9c8a2d5e5e",
        "name": "Viale Europa, 88100 Catanzaro CZ, Italy",
        "state": "Calabria"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04322344",
      "https://www.drugbank.ca/drugs/DB13195",
      "https://web.unicz.it/it/news/85621/il-prof-luca-gallelli-in-collaborazione-con-il-gruppo-cinese-di-farmacologia-di-yantai-university-ha-pubblicato-la-review-severe-acute-lung-injury-related-to-covid-19-infection-a-review-and-the-possible-role-for-escin-su-j-of-clinical-pharmacolog",
      "https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "030d3cf98fce31a3c73af6370ea8080c49752897",
        "sponsorName": "University of Catanzaro"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Sun, 30 Aug 2020 00:00:00 GMT",
    "studyStartDate": "Mon, 23 Mar 2020 00:00:00 GMT",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "VPM1002,Bacillus Calmette-Gu\u00e9rin (BCG)",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      {
        "email": "grode@vakzine-manager.de",
        "name": null,
        "notes": "This is a repurposed BCG vaccine, not a new COVID-19 vaccine",
        "phone": "49 (0)511 169908-14",
        "website": "https://clinicaltrials.gov/ct2/show/NCT04435379"
      }
    ],
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStage": "Phase 3",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 17 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 18 Jun 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ONGOING"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "5",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "VPM1002_Bacillus_CalmetteGu\u00e9rin_BCG",
    "primaryCompletionDate": "Mon, 31 May 2021 00:00:00 GMT",
    "productId": 714,
    "registryLink": "https://clinicaltrials.gov/ct2/show/NCT04435379",
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Hannover",
        "country": "DEU",
        "lat": 52.3835661,
        "lng": 9.804956899999999,
        "locationId": "4935813459f5024692d78f146142748efe852835",
        "name": "Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany",
        "state": "NDS"
      },
      {
        "city": "EF",
        "country": "DEU",
        "lat": 50.9750233,
        "lng": 11.0195683,
        "locationId": "6d30f0973152db89fd889e61430d893b17cbcdd2",
        "name": "Mainzerhofpl. 14, 99084 Erfurt, Germany",
        "state": "TH"
      },
      {
        "city": "Berlin",
        "country": "DEU",
        "lat": 52.5023604,
        "lng": 13.307609,
        "locationId": "e71e0bb68f9da164f4d959fa42ba1b2a62204ce0",
        "name": "Wilmersdorfer Str. 79/2. OG, 10629 Berlin, Germany",
        "state": "Berlin"
      },
      {
        "city": "Berlin",
        "country": "DEU",
        "lat": 52.5033061,
        "lng": 13.3429489,
        "locationId": "7d54673c88316f3b4e19baf222a3f03cd245c129",
        "name": "Ansbacher Str. 17, 10787 Berlin, Germany",
        "state": "Berlin"
      },
      {
        "city": "Hamburg",
        "country": "DEU",
        "lat": 53.57982,
        "lng": 9.975249999999999,
        "locationId": "c56730ef8cb9e2a61fe5300b59d375ada23a0e9f",
        "name": "Hoheluftchaussee 18, 20253 Hamburg, Germany",
        "state": "HH"
      }
    ],
    "sources": [
      "https://clinicaltrials.gov/ct2/show/NCT04435379",
      "https://clinicaltrials.gov/ct2/show/record/NCT04435379",
      "https://www.drugbank.ca/drugs/DB05089",
      "https://www.precisionvaccinations.com/vaccines/vpm1002-tuberculosis-vaccine",
      "https://clinicaltrials.gov/ct2/show/study/NCT04435379",
      "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001675-33/DE",
      "https://clinicaltrials.gov/ct2/show/study/NCT04435379#contacts",
      "https://clinicaltrials.gov/ct2/show/NCT04435379#contacts"
    ],
    "sponsors": [
      {
        "sponsorId": "711c49a1ef9689688c2b88527c81dc01498bf2c8",
        "sponsorName": "Vakzine Projekt Management GmbH"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "Mon, 31 May 2021 00:00:00 GMT",
    "studyStartDate": "Thu, 18 Jun 2020 00:00:00 GMT",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "acceptsHealthySubjects": "Yes",
    "brandName": "Innactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "contact": [
      { "email": "", "name": null, "notes": "", "phone": "", "website": "" }
    ],
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStage": "Phase 2",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "1/2",
    "preferredName": "Innactivated_Vaccine",
    "primaryCompletionDate": "",
    "productId": 715,
    "registryLink": "http://www.chictr.org.cn/showproj.aspx?proj=53003",
    "repurposed": "New",
    "siteLocations": [],
    "sources": [
      "https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving",
      "http://www.chictr.org.cn/showproj.aspx?proj=53003"
    ],
    "sponsors": [
      {
        "sponsorId": "3bd129a36a22b99edf40b395c2fad7b78193bda9",
        "sponsorName": "Sinopharm"
      },
      {
        "sponsorId": "e1992462e6978a6ef1bdee8a86f7d513222c1ad6",
        "sponsorName": "Beijing Institute of Biological Products"
      },
      {
        "sponsorId": "d8671bd89373ad829344fa7eb484819909f5301a",
        "sponsorName": "China National Biotec Group"
      }
    ],
    "status": "Ongoing",
    "studyCompletionDate": "",
    "studyStartDate": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  }
]
